INVESTIGATION OF NOVEL CATALYTIC TRANSFORMATIONS USING BIO-HYBRID AND TRANSITION METAL CATALYSIS by Cattoen, M
  
School of Biological and Chemical Sciences 
 
 
 
 
 
INVESTIGATION OF NOVEL CATALYTIC TRANSFORMATIONS USING 
BIO-HYBRID AND TRANSITION METAL CATALYSIS 
 
 
 
 
Martin Cattoen 
 
 
Advisor: Dr Stellios Arseniyadis 
 
 
Submitted in partial fulfilment of the requirements of the Degree of Doctor of Philosophy 
 
 
2019  
  
 
2 
 
  
  
 
3 
Declaration 
 
I, Martin Pierre Cattoen, confirm that the research included within this thesis is 
my own work or that where it has been carried out in collaboration with, or supported 
by others, that this is duly acknowledged below and my contribution indicated. 
Previously published material is also acknowledged below. 
I attest that I have exercised reasonable care to ensure that the work is original, 
and does not to the best of my knowledge break any UK law, infringe any third party’s 
copyright or other Intellectual Property Right, or contain any confidential material. 
I accept that the College has the right to use plagiarism detection software to 
check the electronic version of the thesis. 
I confirm that this thesis has not been previously submitted for the award of a 
degree by this or any other university. 
The copyright of this thesis rests with the author and no quotation from it or 
information derived from it may be published without the prior written consent of the 
author. 
 
Signature: Martin Cattoen 
 
 
Date: 15/08/2019 
 
Details of collaboration and publications: 
The research described in chapter 3 was produced in collaboration with Dr 
Laurent El Kaim's group at ENSTA ParisTech, France and has been partially published.[1] 
Additional work not discussed in the thesis has been published.[2,3] 
 
 
 
 
 
 
 
  
 
4 
  
  
 
5 
Abstract 
 
This thesis is focused on the development of new catalytic tools to access 
complex structural scaffolds with a special emphasis given to heterocyclic compounds. 
The first chapter presents our work in the field of DNA-based asymmetric 
catalysis. After presenting how the DNA double-helix has been leveraged to promote 
and control various asymmetric transformations during the last decade, our efforts to 
extend this concept to new transformations are described. The behaviour of several 
processes was investigated, including a 1,3-dipolar cycloaddition, a Nazarov 
electrocyclisation, a conjugate silylation of enones and a propargylative 
dearomatisation. The chapter concludes with synthetic studies towards the 
asymmetric preparation of endiandric acid A. 
The second chapter is focused on the implementation of an enantioselective 
Michael addition/retro-Dieckmann sequence to the formation of a-functionalised 
alkenyl nitriles and related compounds, using both a bio-hybrid and a more traditional 
Lewis acid-catalysed approach. An introduction gives a brief overview of the various 
methods reported in the literature that allow a straightforward access to diversely 
substituted acrylic derivatives, emphasizing on the appeal of the 
tetrahydrothiophenone scaffold as an a-acrylate anion surrogate. Our results on the 
optimisation of a new enantioselective approach are then presented, followed by a 
discussion of the reaction’s scope. Finally, prospective studies on a potential 
application of our strategy to the synthesis of chromanes are described. 
The third chapter dwells on the preparation of phosphonated heterocycles, 
which hold a considerable biological interest. Building upon our group's previous work 
in the field of palladium-catalysed allylic alkylation, a straightforward and atom-
economic retrosynthetic approach was devised. We first developed a two-step 
synthesis of a-allyloxy phosphonate derivatives starting from the corresponding 
aldehydes. A subsequent ring-closing metathesis eventually delivered a set of 
oxygenated heterocycles. An investigation of potential late-stage functionalisations of 
the resulting products concludes the chapter. 
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“The first principle is that you must not fool yourself and you are the easiest 
person to fool.” 
― Richard P. Feynman 
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1. Investigation of the applicability of DNA-based catalytic 
systems to new asymmetric reactions 
1.1. Introduction to ds-DNA/copper(II) catalytic systems  
1.1.1. Biocatalysis and the emergence of DNA catalytic systems 
The control of the selectivity in organic reactions has long been a central 
challenge of the field. In the last decades, the control of the absolute configuration of 
chiral molecules has taken a growing importance due to its significance when dealing 
with the biological world, for instance during the preparation of pharmaceuticals and 
agrochemicals. Hence, it should come as no surprise that nature's chirality itself has 
been harnessed as a tool to provide enantioenriched compounds. 
Historically, enantiopure substrates have been isolated from the wild to be 
used as starting materials in the chemical industry; however, this entails the expansive 
production of bulk quantities and limits the scope of available materials. 
Unsurprisingly, it is more desirable to develop asymmetric reactions that transform 
cheaper, more versatile prochiral substrates into enantioenriched products using a 
minute amount of chiral inductor. To this end, chemists have engineered a number of 
synthetic systems based on ever more elaborate chiral catalysts, including metal 
complexes and organocatalysts. Yet, they still struggle to rival with the astounding 
machinery of enzymes, whose precise control of the molecular environment provides 
high enantioselectivities. Biohybrid catalysis, which merges catalytically active metals 
with the intricate structure of proteins, has thus emerged as a fertile tool to develop 
regio-, stereo- and enantiospecific reactions, starting in the late 1970s.[4,5] In a seminal 
example, Whitesides et al. used avidin to direct the stereochemical outcome of a 
rhodium-catalysed hydrogenation by binding the active metallic site to the protein 
using a biotin derivative (Scheme 1).[6] The initially modest selectivity (44% ee) was 
later improved through a combination of chemical optimisation and genetic 
engineering.[7] 
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Developments in the field have led to reports of ever more complex 
transformations, including valuable carbon-carbon bond forming reactions.[8] In this 
context, Colonna and co-workers showed in a 1988 study that bovin serum albumin 
could promote intermolecular Diels-Alder cycloadditions, albeit in modest ees of up to 
38%.[9] This early observation prompted Reetz et al. to investigate the cyclisation 
between azachalcone 1 and cyclopentadiene 2 in the presence of a biohybrid 
albumine/copper(II) catalytic complex, which gave the adduct 3 in an excellent ee of 
93% and a high endo/exo ratio of 96:4 (Scheme 2).[10]  
 
The versatility of enzyme-based biohybrid catalysis continues to be 
expanded.[11] This approach has eventually inspired the development of 
supramolecular systems that attempt to mimic the well-defined microenvironment of 
enzymes, including cyclodextrins and cage molecules.[12] Through a combination of 
specific interactions, pre-organisation of the supramolecular catalyst and an increase 
in the effective molarity of the reactants, this concept has proven a fertile ground for 
the control of selectivity. Ultimately, the interactions are highly dependent on the 
scaffold used during the process, encouraging the study of various types of structures.  
Despite its ubiquity in living systems, DNA was only recently leveraged to 
provide a chiral environment around a transition metal catalyst. Hence, the 
4
S
NH
HN
O
H
H N
P
Rh
P Ph
Ph
Ph
PhO
Scheme 1. Asymmetric hydrogenation based on the chiral environment provided by avidin
CO2H
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O
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O
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Scheme 2. Diels-Alder reaction controlled by an albumine metalloenzyme
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1 3
(ee = 93%
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N
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attachment of a copper(II) centre to the chiral double-helix of DNA enabled Roelfes 
and Feringa to induce decent levels of enantioselectivity in the Diels-Alder 
cycloaddition between azachalcone 1 and cyclopentadiene 2. Using an aqueous 
solution of commercial DNA extracted from salmon testes (st-DNA), the bridged 
product 3 was obtained with ees of up to 53% and endo/exo ratios superior to 90:10 
(Scheme 3). Since then, the broad availability of natural and synthetic oligonucleotides 
has allowed the exploration of various binding modes between the DNA and the metal, 
as well as the application of DNA-based catalysts to other reaction manifolds.[13–16] 
  
 
1.1.2. Catalyst structure and ligation modes 
A DNA sequence is a biopolymer constituting of a thread of monomers, the 
nucleotides, which are in turn constructed from a phosphate group, a deoxyribose 
sugar and one of four nucleobases: adenine (A), guanine (G), thymine (T) and cytosine 
(C) (Figure 1). Subsequent nucleotides are attached by a 3'- to 5'-phosphate diester 
link, which is stable enough to sustain over 108 nucleotides in a single strand of 
chromosome. Hence, a given oligonucleotide is defined by the sequence of its 
nucleobases, while its chirality stems from that of the D-deoxyribose. The secondary 
structure of DNA arises from the pairing of adenine with thymine and guanine with 
cytosine through hydrogen bonding, and the p-p interactions between the resulting 
base-pairs. These interactions induce the assemblage of two complementary strands 
of DNA to form a double-stranded DNA, which usually adopts a double-helix shape. 
The precise conformation of the helix depends on both the exact sequence of base-
pairs and the experimental conditions, with two main families designated as the 
Scheme 3. First Diels-Alder reaction controlled by a DNA-based catalyst
MOPS buffer (pH 6.5)
5 °C
Cu(NO3)2, ligand (20 mol%)
st-DNA
1 32
R
O
N +
3a
(ee up to 48%
endo/exo = 98:2)
3b
(ee up to –47%
endo/exo = 88:12)
3c
(ee up to –53%
endo/exo = 91:9)
R
O
N
O
N
O
N
O
N
MeOO2N
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A-form and the B-form, the latter being the most common. The hydration also plays a 
major role in stabilizing the scaffold and water molecules can be highly ordered around 
the DNA.[17]  
 
DNA-based catalysts usually require an achiral co-factor to promote the desired 
transformation, similar to enzyme-based biohybrid catalysis. The key is to ensure that 
the reaction takes place in the vicinity of the helix to enable chiral discrimination. To 
this end, the co-factor can be anchored to the DNA in a supramolecular or covalent 
fashion. Generally, small-molecule supramolecular interactions with DNA include 
electrostatic interactions with the negatively charged phosphate backbone, external to 
the helix and non-directional (Figure 2.A); intercalation of aromatic ring systems 
between base-pairs, via p-p stacking (Figure 2.B); and groove-binding, relying on the 
affinity between the molecule and the edges of base-pairs in either of the grooves of 
the oligonucleotide (Figure 2.C). Conversely, covalent linking consists in the insertion 
of a functional group onto the DNA through a modified nucleotide (Figure 2.D). In the 
context of catalysis, the metal co-factor is chelated by a ligand, which in turn is linked 
to DNA in one of the ways described above.  
Broadly speaking, supramolecular interactions allow the straightforward 
construction of modular catalytic complexes, thus providing an experimentally 
convenient platform to explore diverse structural features. However, those assemblies 
are too labile to allow the precise control of the position of the co-factor. In contrast, 
Figure 1. Core structural features of DNA
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the site-specificity of covalent links enables the formation of bespoke catalysts, but 
this entails the synthesis of modified oligonucleotides, which makes the approach 
costlier and more time-consuming. As a result, the supramolecular approach 
dominated the field at the beginning. 
 
 
1.1.3. Intercalative binding 
The first system developed by Roelfes and Feringa for a [4+2] addition relied on 
a supramolecular approach through a family of ligands L1-L4 that contain a strongly 
intercalative acridine moeity,[18] an alkyl spacer and a diamine copper-chelating moeity 
(Figure 3.A). A notable result of this early study was the inverse correlation between 
the selectivity and the length of the spacer, which suggested the importance of 
keeping the co-factor close to the DNA helix. Building on this observation, a second 
generation of polypyridyl ligands L5-L10 that combine the chelating and intercalating 
moeities was found to provide high conversions (more than 80%) and improved 
selectivities, with ees reaching 73% (Scheme 3).[19]  
H3N
A. Electrostatic C. Groove-binding
(left: minor groove, right: major groove)
B. Intercalative D. Covalent
Figure 2. Binding modes between DNA and small molecules
Na
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The intercalating ligands have been found to be the most selective for various 
copper-catalysed transformations. In particular, the first asymmetric syn-hydration of 
α,β-unsaturated 2-acylimidazoles 4 was reported by Roelfes and Feringa using L1, 
yielding b-hydroxyketones 5 with ees of up to 72% at 55% conversion (Scheme 4.A).[20] 
Further, a Cu(NO3)2/L6/st-DNA system managed to trigger the intramolecular 
cyclopropanation of diazoketones 6, yielding bicycle 7 in high selectivities (ee = 83% for 
a 46% yield), via a copper(I) co-factor generated in situ (Scheme 4.B).[21] The latter 
milestone constitutes the earliest example of a co-factor acting as a transition metal 
instead of a Lewis acid in DNA-based biohybrid catalysis. In both cases, the 
intercalating binding was instrumental in ensuring a better control of the catalytic 
pocket and particularly of the accessibility of water molecules. Moreover, the synthetic 
availability of the corresponding ligands provides a relatively inexpensive way to 
explore various reaction systems as well as other reaction parameters. Hence, the 
intercalative approach remains a mainstay of DNA-based asymmetric catalysis. 
Figure 3. Notable intercalative ligands used in DNA-mediated catalysis
N
H
N N
N
L1 (n = 2)
L2 (n = 3)
n
NN
N N
R
R
L5 (R = H)
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MeO OMe
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N N
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L3 (n = 2)
L4 (n = 3)
n
NN
N N
L7
B. Second generation ligands
A. First generation ligands
N
N
R
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N
N
L10L8 (R = H)L9 (R = Me)
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1.1.4. Groove-binding anchoring 
In addition to the intercalative sites between base-pairs, ds-DNA provides two 
grooves between the ridges of the helix. The major and minor grooves have distinct 
electrostatic properties, hydrogen-bond sites and steric characteristics. For instance, in 
the classic B-type helix, the successive strands are separated by 22 Å in the major 
groove and 12 Å in the minor groove. Small molecules can interact with the moieties 
on the edges of the protruding bases, and usually adopting a crescent shape around 
the helix. In particular, groove-binders are often preferentially found in the minor 
groove, due to better van der Vaals contacts. The binding affinity can also show a 
stronger correlation to the precise sequence of base-pairs than intercalative small 
molecules.[17] In catalysis, groove-binding ligands display an impressive ability to direct 
the stereochemical outcome. In the prototypical copper-catalysed Diels-Alder 
cycloaddition, bipyridine-based ligands L11-L13 provided adducts with ees up to 99% 
and conversions of more than 80% (Figure 4). Beside the selectivity, a notable increase 
Scheme 4. Reactions mediated by DNA/intercalative ligands/Cu(II) systems
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of the reaction rate was observed under this binding mode, which makes it more 
attractive than the intercalative alternative.[19]  
Despite their strong credentials in catalysis, these ligands were initially 
assumed to bind DNA through intercalation, without strong experimental evidence. 
Several techniques have been developed to shed light on DNA/small molecules 
complexes, including X-ray crystallography, circular and linear dichroism, EPR, Raman 
and UV/vis spectroscopy and DNA melting curves; however, competing methods 
sometimes lead to unclear or contradictory conclusions and extensive analysis is 
warranted to uncover the precise mode of interaction.[22] In 2015, comprehensive 
experiments revealed that unlike first-generation ligands, L11-L12 behave as groove-
binders.[23,24] Importantly, the authors found that the latter have a more dynamic and 
flexible binding than the former, which allows the complex to adopt the more selective 
orientation and therefore accounts for its higher selectivity. 
 
The new ligands, especially the most selective L12, were rapidly applied to 
other reaction manifolds, starting with the Michael addition of malonate 8a and 
nitromethane 8b on α,β-unsaturated 2-acylimidazoles 4 (Scheme 5.A).[25] The 
products 9 were obtained with high selectivities (up to 99% and 94% ee respectively). 
The conversions were high as well (up to 100% and 70%), thanks in part to a 
substantial acceleration of the reaction rate. The reaction was extended to 
cyanoacetates by Li and co-workers, showcasing the tolerance of the reaction to 
various nucleophiles.[26] Then, Roelfes et al. showed that the same α,β-unsaturated 
2-acylimidazoles substrates 4 were able to undergo Friedel-Crafts alkylation by 
indoles 10 to provide the 1,4-addition products 11 with full conversions and high 
selectivies (up to 83% ee) under similar conditions (Scheme 5.B).[27] An intramolecular 
version was also reported by the Sugiyama group, providing access to tricyclic 
Figure 4. Groove-binding ligands used in DNA-mediated catalysis
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derivatives.[28] The broad ability of DNA-based catalysts to mediate conjugate additions 
is quite remarkable, considering that only a few examples of non-DNA-based 
alternatives have been described in water. 
 
Later, Roelfes and colleagues expanded the Friedel-Crafts alkylation of 
2-acylimidazoles to a-methyl analogue 12 (Scheme 6.A).[29] This deceptively small 
change in structure led to a fundamentally different challenge as the 
enantiodetermining step here is the protonation of the enolate intermediate, a 
transformation of heightened difficulty in water due to the large availability of 
protons. Regardless, products 13 were obtained in moderate to high ees (up to 84%) 
and high yields in the presence of the st-DNA/L12/Cu catalyst, thanks to an impressive 
rate acceleration (up to 990-fold). Finally, the same group provided the first example 
of a kinetic resolution using a DNA-based catalyst (Scheme 6.B). Specifically, the 
hydrolytic opening of pyridyloxiranes 14 furnished diols 15 in up to 63% ee at 74% 
conversion (s = 2.7).[30] This plethora of reactions secured the position of L12 as the 
staple ligand in DNA-based catalysis, though it is by no means the only groove-binder 
available. 
Scheme 5. Conjugate additions mediated by DNA/groove-binding ligands/Cu(II) systems
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Lately, more specific ligands L14-L17 were developed in our group, based on 
the known minor groove binder Hoechst 33258 (Figure 4).[31] This ligand preferentially 
binds to A·T rich sequences in an isohelical fashion, through hydrogen bonds between 
the benzimidazole and the hydrogen-bond acceptors on thymine and adenine, as 
shown by X-ray crystal structures. However, thermodynamics measurements have 
demonstrated that the driving force for complexation is the transfer of the Hoechst 
ligand from the bulk water to the hydrophobic groove-binding site.[17] Turning to 
catalysis, moderate selectivities were obtained when using derivatives L14-L17 to the 
Friedel-Crafts alkylation (ees up to 47%), and a detailed study showed that careful 
design of the ligand structure allows one to target specific oligonucleotides. This 
milestone opened the door to a structure-based development of groove-binding 
ligands. 
 
1.1.5. Covalent attachment 
As we have seen, a number of structurally diverse ligands have been used to 
anchor the chiral DNA scaffold to the active catalytic co-factor. Across the course of 
those studies, experiments with short, synthetic DNA strands also showed that the 
oligonucleotide's structure and properties impacted the selectivity of the reaction. 
Scheme 6. Other applications of DNA/groove-binding ligands/Cu(II) systems
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Nonetheless, regardless of the precise binding mode (groove-binding or intercalating), 
the different sites available for the co-factor compete and cannot be easily 
distinguished. In order to delve into the deeper mechanistic factors that relate the 
oligonucleotide structure to the reaction outcome, more controlled strategies were 
envisioned based on covalently attaching the ligand to a chosen site on the DNA. In 
other words, the oligonucleotide sequence is turned into a customised ligand. 
The synthesis of tailored oligonucleotide sequences presents a significant 
challenge, but its applications cover various domains from catalysis to diagnosis and 
therapy to nanotechnology.[32] In catalysis, Kamer et al. initially used a single modified 
nucleotide L18 incorporating a phosphine group to act as an asymmetric ligand in a 
palladium-catalysed allylic alkylation, generating the desired amine 16 in ees up to 80% 
in THF (Scheme 7.A).[33] Unfortunately, this work was not extended to longer 
sequences or aqueous conditions. Jäschke and co-workers developed an 
oligonucleotide bearing a pendant diene (ON1) to form a well-defined iridium 
complex. This catalyst was able to induce an allylic amination and afford 17, albeit with 
a low selectivity (ee up to 27%) (Scheme 7.B).[34] Despite their shortcomings, these two 
examples showed that DNA biohybrid catalysis can use metals other than copper. 
 
Turning back to copper catalysis, Roelfes and co-workers incorporated a 
bipyridine moiety to the 5' terminal phosphate end of an oligonucleotide sequence 
(ON2a), which was then combined with a termination sequence (ON3) and template 
sequence (ON4) to form a modular duplex that surrounds the catalytic centre 
Scheme 7. Reactions catalysed by modified nucleotides systems
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(Scheme 8). This tactic allowed the canonical Diels-Alder reaction to proceed with ees 
as high as 93% at 71% conversion, a significant improvement on the supramolecular 
approach.[35] Once again, the best selectivity was obtained with a shorter linker 
between the bipyridine and the DNA backbone, highlighting that proximity to the helix 
is paramount. 
 
Expanding on Roelfes' strategy, Sugiyama et al. later introduced a family of 
oligonucleotides that contain either an in-strand bipyridine ligand (ON5) or a non-
chelating spacer (ON6), in place of a nucleotide (Scheme 9.A). When applied to a 
Michael addition, their experiments shed light on the influence of the neighbouring 
nucleobases on the selectivity outcome (ees ranging from 6% to 84%).[36] More 
importantly, a ligand-free system was able to yield the Diels-Alder adduct with high 
selectivity (97% ee) by complexation of the copper co-factor to a cytosine in a catalytic 
pocket formed with a propyl spacer ON6c.[37] Hence, the replacement of a nucleobase 
by a synthetic moiety to create a tailored catalytic pocket around the DNA helix was 
validated as an efficient tactic. 
Building on these endeavours, our group recently developed a more versatile 
method to access modified oligonucleotides (Scheme 9.B). Using automated 
oligonucleotide synthesis technology, a general precursor ON8 was prepared with one 
nucleobase replaced by a new amine building block. From there, any ligand bearing a 
carboxylic acid moiety can be incorporated via an amide coupling under optimised 
conditions to deliver a functionalised DNA sequence such as ON9a-c, which feature a 
Scheme 8. Covalent anchoring of a bypyridine ligand for the Diels-Alder reaction
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bipyridine moiety. The application of several families of such oligonucleotides is 
currently under investigation in the group. 
Concurrently, the Carell group also attempted to attach other types of ligands 
by designing a series of oligonucleotides featuring pyrazole-phenol moieties, which 
mimic the strongly chelating salen derivatives. A tight binding of copper ions was 
observed and the Diels-Alder model reaction proceeded in full conversion but with 
modest enantioselectivities (ee up to 39%).[38] 
 
The covalent introduction of a chelating group within a DNA sequence has 
demonstrated its utility both as a probe to test new reactions and as a synthetically 
relevant approach to reach higher selectivities. Indeed, by providing a catalytic pocket 
inside or in close proximity to the helix, synthetic oligonucleotides can outperform 
supramolecular complexes, as recently disclosed by our group in a study of the Friedel-
Crafts alkylation/asymmetric protonation cascade.[39] While their higher cost of 
synthesis still hinders them in superseding natural DNA extracts, the situation is bound 
to evolve with the development of more modular methods to integrate ligands in 
bespoke oligonucleotides. 
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1.1.6. Practical considerations 
The variation of the binding mode between the metallic co-factor and the 
oligonucleotide scaffold offers unlimited avenues of exploration to design new 
catalysts. The two classes of ligand anchoring provide complementary strategies: on 
the one hand, the more affordable and easily prepared supramolecular complexes 
allow a rapid screening of conditions; on the other hand, functionalised 
oligonucleotides can deliver a more controlled environment and an improved 
selectivity. Yet, for a given DNA sequence and/or ligand, a number of additional 
parameters can play a vital role, including the temperature, the concentration, the 
co-solvents, the pH, the buffer composition and the additives. Fortunately, DNA-based 
reactions can be conducted on minute amounts (micromolar scale), which allows one 
to explore a broad set of conditions in parallel. 
Upon addition of co-solvents in the reaction mixture, notable effects were 
observed by Roelfes et al.[40] Reactions were broadly tolerant of polar solvents (such as 
MeOH, EtOH, MeCN, DMSO) in contrast to more hydrophobic solvents (such as THF or 
CH2Cl2), with the latter leading to a sharp decrease in selectivity and yield. In the case 
of the Diels-Alder reaction, up to 33% v/v of organic solvent was compatible with the 
cycloaddition; however, the reaction rate dropped due to a reduction of the well-
documented water accelerating effect in such cycloadditions.[41] Conversely, the 
Friedel-Crafts alkylation and Michael addition could not handle more than 10% v/v, but 
the reaction was found to go faster. Co-solvents afford the useful opportunity to run 
the reaction at lower temperature, thanks to a decrease of the melting point. 
Pleasantly, a favourable effect on the selectivity ensued when the process was 
conducted at –18 °C instead of 5 °C, with the ee climbing from 83% to 90%. In a similar 
approach, the Zhao group found that other additives such as glymes, deep eutectic 
solvents (DES) and ionic liquids have a positive influence on the enantioselectivity of 
the reaction.[42] Interestingly, such co-solvents allowed the reactions to be carried out 
at higher temperatures (r.t. instead of 5 °C) with a minimal erosion of the selectivity. 
Besides the modulation of selectivity, a small amount of organic solvent can be 
required to ensure the dissolution of the substrates.[43] The above shows that additives 
constitute an important tool in DNA-based catalysis. 
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The pH of the reaction is another parameter which may require optimisation 
through an adequate choice of buffer. MOPS and MES buffers are often used since 
they do not bind to copper and cover a useful range of pH (respectively 5.5-6.7 and 
6.5-7.9),[44] though alternatives such as a phosphate buffer have been reported as 
well. Shifting the pH by only one point can have measurable effects that are difficult to 
rationalise. For instance, when shifting the pH from 7.5 to 5.5, the selectivity of the 
Michael addition evolved by a few points: when using nitromethane as the 
nucleophile, the ee decreased from 85 to 74%; when using dimethyl malonate instead, 
the ee increased from 90% to 95%.[45] A study of a Diels-Alder catalytic system found a 
similar influence of the pH on selectivity.[38] More drastically, in the case of the 
conjugate addition/protonation of a-substituted enones, the ee plummeted from 84% 
to 19% when increasing the pH from 5.0 to 7.5.[29] It can therefore be worthwhile to 
probe the influence of the pH on DNA-catalysed reactions. 
Having considered the parameters at work in oligonucleotide-based catalysis, it 
must be noted that various tools have been built to ensure a streamlined application 
of the concept. While the discovery and optimisation of new reactions can be realised 
on the micromolar scale, preparative scale reactions were also conducted on the 
millimolar scale early on, and the catalyst was shown to be recyclable without any 
erosion of the selectivity.[25] A landmark in scalability was achieved with the 
elaboration of solid-supported DNA catalysts. The idea was first put into practice by 
Sugiyama and co-workers who used ammonium functionalised silica beads to form a 
tight complex with commercial st-DNA 18 based on electrostatic interactions. This 
system provided satisfactory levels of selectivity in the canonical Diels-Alder reaction 
(94% ee compared to 99% with pure st-DNA) and could be recycled at least ten times 
by a simple solvent wash without loss of selectivity (Scheme 10.A).[46] The same group 
subsequently developed a more selective supported-DNA complex 19 by replacing the 
silica beads with silicate, which furnished ees up to 99% in the Diels-Alder 
(Scheme 10.B).[47] Our group has also reported on the behaviour of a commercial 
cellulose-bound supported DNA catalyst 20 (Scheme 10.C). The material, which is 
formed by covalently linking the cellulose to nucleophilic groups of the DNA,[48] 
afforded high selectivies in the Michael addition and Friedel-Crafts reaction (up to 
97% ee). A filtration was sufficient to recover the catalyst, and no erosion of the 
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selectivity was observed after ten cycles. In addition, the catalyst was readily 
integrated in a continuous-flow process to provide the Michael adduct in 80% ee at the 
mmol scale.[43] All in all, these benchmark supported-catalysts firmly improve the 
scalability of DNA-based reactions. 
 
 Another general challenge in asymmetric catalysis lies in the inversion of 
selectivity. Some solutions have been found in this field by switching the ligand, but 
each case is heavily reaction-dependent and the selectivity reversal is only partial.[34,49] 
A more reliable and conceptually straightforward strategy consists in using mirror-
image DNA. Our group showed that by using a non-natural L-oligonucleotide sequence, 
opposite ees were obtained compared to the corresponding natural D-DNA 
sequence.[50] Although this tactic requires synthetic oligonucleotides, the simple switch 
of the helix orientation permits access to either enantiomers at will. Most importantly, 
this strategy also allows to study potential non-linear effects using enantiomeric 
mixtures of specific sequences. 
As we have seen, DNA-based catalytic systems are influenced by numerous 
factors and wide avenues of research are open to extend its applications. 
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1.1.7. Future developments 
The success of DNA-based catalysis in mediating a variety of asymmetric 
reactions with high selectivities and the large number of competing tactics to exert 
control on their outcome suggest untapped applications abound. For instance, while 
much of the field of oligonucleotide-based catalysis has focused on DNA, Hennecke's 
group[51] and ours[52] recently showed that RNA can also induce a chirality transfer in a 
similar fashion, albeit in modest selectivity so far (ee up to 54%). Excitingly, using DNA 
as the sole catalyst without even relying on a metallic co-factor has emerged as a 
viable possibility. In 2017, Wagenknecht et al. disclosed a photochemical [2+2] 
cycloaddition mediated by the modified DNA sequence ON10, which incorporates a 
benzophenone photosensitiser, though ees did not exceed 28% (Scheme 11.A).[53] Our 
group has been engaged in similar investigations, culminating in the synthesis of 
dictazole B 21 via a biomimetic [2+2] photocycloaddition templated by st-DNA 
(Scheme 11.B).[54] Even if ees were very low (7%), the achievement is remarkable given 
that the reaction does not even occur in solution in the absence DNA. The exploration 
of the reaction space available to DNA-based catalysts is just in its infancy and begs for 
further applications to new synthetic targets. 
 
 
  
Scheme 11. DNA catalysis without metallic co-factor
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1.2. [3+2] cycloaddition of nitrile oxides with electron-poor 
alkenes 
In the course of our studies on the applicability of DNA-based catalysis to new 
transformations, the cycloadditions of 1,3-dipoles caught our attention. Since the early 
work of Huisgen and co-workers, [3+2]-cycloadditions have become a cornerstone of 
synthetic chemistry, owing to the broad scope of 1,3-dipoles and dipolarophiles 
available and the variety of accessible structures.[55,56] While several dipoles were 
considered in our group’s endeavours, we were particularly attracted to nitrile oxides 
as precursors to isoxazoline derivatives. Encouragingly, this class of 1,3-dipolar 
cycloadditions had previously been shown to proceed in water,[57,58] including using 
ribozymes as catalyst.[59] 
Most nitrile oxides tend to dimerise easily; hence, they are generally formed in 
situ from either oxime halides or nitroalkanes. The former are conveniently obtained 
from aldehydes after formation of the oxime followed by halogenation. A wealth of 
conditions has been reported for the subsequent dehydrohalogenation of the oxime 
halide to the nitrile oxide, mostly relying on basic conditions or on a transition-metal 
promoter.[56] More recently, Kittakoop et al. managed to effect this transformation in 
high yields in an aqueous medium at pH 4–6, a tactic that begged to be tested in the 
presence of a DNA-based catalyst.[58] Hence, we started our study with commercial 
oxime 22, which was converted to oxime chloride 23 in 54% yield [NCS, pyridine, 
CHCl3], the direct precursor of nitrile oxide 24 (Scheme 12.A). Turning to the 
dipolarophilic partner, we anticipated that enone 4a would readily participate in the 
desired cycloaddition, having been extensively used in DNA biohybrid catalysis. Indeed, 
the 2-acylimidazole moiety provides an efficient handle for complexation to the metal 
co-factor.[60] Furthermore, this functional group affords interesting 
post-functionalisation opportunities as it can be readily converted to aldehydes, esters 
or ketones in high yields.[60–63] 
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To our satisfaction, upon exposure of oxime chloride 23 to dipolarophile 4a, the 
expected isoxazoline 25 was successfully obtained in conditions compatible with 
standard DNA-based catalytic systems [phosphate buffer, pH 6] in an unoptimised 
yield of 24% (Scheme 12.A). Although steric factors often control the approach of the 
dipolarophile towards the nitrile oxide, in this case the regioselectivity is probably best 
explained by the frontier molecular orbitals. For electron-poor alkenes like 4a, as 
described by Fleming, the frontiers orbitals have close energy levels and thus do not 
clearly favour one regioisomer a priori.[64] In this model, the obtention of 26, resulting 
from the interaction between the LUMO of the dipole and the HOMO of the alkene, 
suggests that the catalyst is more likely bound to nitrile oxide 27, resulting in a 
lowering of its LUMO (Scheme 12.B). Turning to stereochemistry, the trans relationship 
between the substituents is imposed by the (E) configuration of starting olefin 4a and 
was confirmed by 1H NMR coupling constants. The absolute stereochemistry of 25 was 
not assigned.1 
Next, we attempted to conduct the reaction in the presence of the 
supramolecular catalytic complex formed from st-DNA, Cu(NO3)2 and the minor-groove 
binder L12. Various parameters were explored, including the buffer, the pH, the 
reagents' stoichiometry, the catalyst loading and the use of organic co-solvents 
(Table 1). As expected, control experiments without copper and/or DNA confirmed 
 
1 All stereochemistry indicated from this point forward are relative. 
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that the reaction could take place in the absence of the metal (Table 1, entries 1-3). In 
the presence of the st-DNA/L12/Cu catalyst, an enhancement in the conversion of 4a 
to 25 was observed, but the product was obtained in a low ee of 4% (Table 1, entry 4). 
Exploring a range of pH led to a slight increase in conversion, especially in a more 
acidic medium, but unfortunately not in selectivity (Table 1, entries 5-13). The lower 
conversion to the desired product in more basic conditions is consistent with the work 
of Kittakoop et al., probably due to a less favoured formation of the intermediate 
nitrile oxide 24. We then tried to use a stoichiometric amount of catalyst, to no 
significant avail, as the ee did not exceed 13% (Table 1, entries 14-15). The addition of 
organic co-solvents such as DMF or acetone (10% v/v) caused a slight improvement in 
selectivity, albeit the best ee (28%) was obtained at a suboptimal conversion as shown 
by the 4a/25 ratio (Table 1, entries 16-21). 
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The main issue at this juncture was the formation of the hydrated product 5a, 
which is catalysed by Cu/st-DNA complexes (Scheme 13).[20] Indeed, HPLC analysis 
showed that 4a underwent hydration at a much faster rate than the cycloaddition with 
the nitrile oxide; this trend was more pronounced when a stoichiometric amount of 
copper was used. To bypass this undesired pathway, we conducted the reaction with 
an excess of oxime 23 (10 equiv.), but this did not improve the outcome. Conversely, 
no attempt was made to conduct the reaction with intercalative ligands given that 
they tend to promote the formation of 5a even more efficiently than L12. 
Table 1. Screening of conditions for the [3+2] cycloadditionb
11 6.5
12 6.9
aRelative stereochemistry based on 1H NMR J-couplings. bAll reactions were run on a 0.6 µmol scale at a 
final concentration of 1 mM. c10% v/v. dAbsorption at 280 nm measured by HPLC. eee of 25 determined 
by chiral HPLC analysis and reproductible within ±3%. Sign chosen arbitrarily to indicate the relative 
stereochemistry. fControl experiment run without st-DNA.
9 6.5
10 6.1
17 7.5
15 7.5
16 6.5
14 6.5
Entry pH eee (%)Ratio 4a:25:5ad
Aqueous buffer
r.t., 24 h
Cu(NO3)2 (x mol%)
L12 (1.2 x mol%)
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+
30 mol%
30 mol%
30 mol%
30 mol%
100 mol%
100 mol%
100 mol%
[Cu] loading
100 mol%
20 7.5
21 8.5
100 mol%
100 mol%
MES
PIPES
PIPES
PIPES
MOPS
MOPS
MOPS
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MOPS
MOPS
TRIS
6.5
5 7.0
6 7.5
2f
3 6.5
4 6.5
18 8.5
8 6.0
7 5.5
30 mol%
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30 mol%
30 mol%
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6.51f 0 mol%MOPS
6.519 100 mol%MOPS
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57:43:0
6:35:59
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6:23:71
7:33:60
4:22:74
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At this stage, we decided to change our tactic and swap dipolarophiles. Instead 
of incorporating a chelating moiety susceptible to undergo side-reactions, we hoped to 
promote the cycloaddition of a carbon-rich alkene by relying on hydrophobic effects. 
Indeed, it has been shown that hydrophobic environments are created around the 
base pairs of DNA, playing a role in RNAzymes[65] and DNA-based catalysts.[66,67] On this 
basis, we conducted a series of experiments on the annulation of indene 28 with 
previously used benzonitrile oxide 24 (Scheme 14). 
 
A racemic sample of isoxazoline 29 was prepared under conditions used 
previously [phosphate buffer, pH 6, 33%]. Regrettably, upon switching to DNA-based 
conditions, low enantioselectivities were obtained even when using organic co-
solvents (maximum 12% ee). More worryingly, control experiments showed that the 
presence of copper did not seem to impact the conversion. 
With the challenge posed by the inactivity of the copper catalyst compared to 
the uncatalysed background reaction, we feared that this cycloaddition was not suited 
to our DNA-based system. Interestingly, a recent study by Cossío and co-workers 
reported a 1,3-dipolar cycloaddition in the presence of DNA, but this system relied on 
a double-helix distorted by a heterobimetallic Pt(II)/Cu(II) complex and furnished the 
product in low yields (10%) and no enantioselectivity, while no conversion was 
observed in the absence of Pt.[68] Thus, at that point, we decided to cut our losses and 
examine a different reaction.  
Scheme 14. Cycloaddition of benzonitrile oxide with indene 26
aRelative stereochemistry based on 1H NMR J-couplings and literature assignment.
MOPS, pH 6.5
r.t., 24 h
low conversion
Cu(NO3)2 (30 mol%)
L12 (38 mol%)
st-DNA
23
+
27a
(ee up to 13%)
N
Ph
HO
Cl
NO
Ph
26
H
H
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1.3. Nazarov cyclisation 
The Nazarov cyclisation, in effect the 4p-electrocyclisation of divinylketones 
and related systems (Scheme 15), had roused our interest due to its widespread use in 
the synthesis of cyclopentenones.[69] In addition, the intermediates can be trapped in a 
number of ways, making the Nazarov reaction useful to access more exotic 
scaffolds.[70–72] A number of asymmetric approaches have been reported since 2003, 
mostly based on Lewis acid catalysis.[73–77] It is also worth noting that a Nazarov 
cyclisation has been described in an aqueous medium.[78]  
 
In collaboration with Dr David Lebœuf (Université Paris-Sud, France) who kindly 
provided a number of divinyl ketones, we attempted to trigger the electrocyclisation of 
indoles 30 and 31, cyclohexene 32 and pyran 33 (Figure 5). These substrates have been 
used extensively in Nazarov cyclisations and related transformations, thanks to a 
favourable polarisation of the p-system induced by suitably placed electron-
withdrawing and -donating groups.[79,80] Furthermore, 30, 31 and 33 are susceptible to 
bidentate coordination with a Lewis acid catalyst.[74] Indeed, the divinyl ketones were 
readily converted to the racemic cyclisation products under standard conditions 
[Sc(OTf)3 (20 mol%), DCE, 90 °C, 43-98%]. Control experiments also confirmed that the 
reaction proceeds upon switching the solvent to water. 
 
An extensive screening of DNA-based conditions was then conducted, starting 
with substrates 30 and 31 (Table 2). No formation of the desired cyclopentenones 34 
and 35 was observed under a range of pH; in fact, the starting ketone remained stable 
under the conditions (Table 2, entries 1-4). The situation was unchanged upon addition 
Scheme 15. General mechanism of the Nazarov cyclisation
O OH
H
OH
4π
conrotatoryLewis or
Bronsted acid
O
B
Figure 5. Divinyl ketones considered in this study
H
N
O
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of organic co-solvents, whether protic (MeOH, EtOH), polar aprotic (MeCN, DMF, 
DMSO) or apolar (dioxane) (Table 2, entries 5-10). Switching the source of copper to 
more dissociated complexes such as Cu(OTf)2 or Cu(ClO4)2 or even scandium triflate did 
not improve the outcome (Table 2, entries 11-16). Finally, an attempt to alter the 
binding mode of the copper centre to the ds-DNA by using different ligands, including 
intercalative L5, L8 and L10, remained fruitless (Table 2, entries 17-21). 
 
Still optimistic, we carried on our investigation by trying to promote the 
cyclisation of 32 and 33 to cyclopentanone 36 and cyclopentenone 37 respectively 
(Table 3). Not unexpectedly, the less activated substrate 32 failed to react under 
Table 2. Screening of conditions for the Nazarov cyclisationb
-
-
MeCN
DMF
-
EtOH
MeOH
-
-
-
-
-
-
-
-
-
-
-
dioxane
DMSO
11 7.0
12 7.0
aRelative stereochemistry based on 1H NMR J-couplings and literature assignment. bAll reactions were 
run on a 0.6 µmol scale at a final concentration of 1 mM. c10% v/v. dBased on HPLC analysis.
9 7.0
10 7.0
16 7.0
14 7.0
15 7.0
13 7.0
Entry pH ResultdLigand
Aqueous buffer, r.t., 3 d
Metal (30 mol%), ligand (38 mol%), st-DNA
28 (R = CO2Me)
29 (R = H)
Co-solventc
19 7.0
20 7.0
MOPS
MOPS
MOPS
MOPS
MOPS
MOPS
MOPS
Buffer
MOPS
MOPS
MOPS
6.1
5 7.0
6 7.0
2
3 7.9
4 9.0
17 7.0
8 7.0
7 7.0
PIPES
MOPS
TRIS
MOPS
MOPS
MOPS
MOPS
MOPS
7.01 MOPS
7.018 MOPS
L12
L12
L12
L12
L12
L12
L12
L12
L5
L8
L12
L12
L12
L12
L12
L12
L12
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
L12 No conversion
L10
L12
Metal source
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
CuCl2
Cu(OAc)2
Sc(OTf)3
CuF2
Cu(ClO4)2
Cu(OTf)2
Cu(NO3)2
Cu(NO3)2
H
N
O
R
Ph
HN
O
Ph
R
-21 7.0 MOPS No conversionL13Cu(NO3)2
32 (R = CO2Me)a
33 (R = H)
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similar conditions (Table 3, entries 1-4). In the case of pyran 33, which usually engages 
more readily in Nazarov cyclisations, no desired cyclisation product was formed either 
(Table 3, entries 5-8). 
 
 As a last resort, we decided to test the reaction under harsher conditions, 
namely at an elevated temperature. To this end, we replaced commercial st-DNA with 
synthetic ON9c, which covalently incorporates a pendant bipyridine ligand (Table 4). 
This oligonucleotide conjugate, prepared in our laboratory, hybridizes with 
complementary strands to form stable helixes, as shown by their relatively high 
melting temperature of 50-52 °C (unpublished results). However, testing the 
cyclisation of 33 at 50 °C with ON9c and DNA counter-strand ON6c bearing a C3 spacer 
opposing the bipyridine ligand did not change the outcome compared to the previous 
approach (Table 4, entry 1). Using the analogous RNA counter-strand ON6c' (Table 4, 
entry 2), or forgoing the counter-strand altogether (Table 4, entry 3) gave similar 
results. At this juncture, the inability of our catalytic system to trigger the desired 
reaction convinced us to focus our efforts on yet another application. 
Table 3. Screening of conditions for the Nazarov cyclisationc
1 7.0
2 7.0
aRelative stereochemistry based on X-ray structure of a close analogue. bRelative stereochemistry based 
on literature assignment. cAll reactions were run on a 0.6 µmol scale at a final concentration of 1 mM. 
dBased on HPLC analysis.
4 7.0
3 7.0
Entry pH ResultdLigand
Aqueous buffer
r.t., 3 d
Metal (30 mol%)
Ligand (38 mol%)
st-DNA
30
7 7.0
8 7.0
MOPS
MOPS
MOPS
MOPS
Buffer
MOPS
MOPS
5 7.0 MOPS
7.06 MOPS
L12
L12
L12
L12
L12 No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
No conversion
L12 No conversion
L12
L12
34a
Metal source
Cu(ClO4)2
Cu(NO3)2
Sc(OTf)3
Cu(OTf)2
Cu(OTf)2
Sc(OTf)3
Cu(ClO4)2
Cu(NO3)2
O
Ph
O
PhMe
Aqueous buffer
r.t., 3 d
Metal (30 mol%)
Ligand (38 mol%)
st-DNA
31 35b
O
O
Ph
O
Ph
OCO2Me
CO2Me
Substrate
30
30
30
30
31
31
31
31
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1.4. Silylation of enones 
Given the extensive applications of DNA-based catalysts in promoting 
1,4-additions on enones, we envisioned the formation of carbon-silicon bonds through 
a similar process. Organosilicon derivatives are commonly used in organic chemistry 
and materials science. In synthesis, they are useful intermediates owing to the 
properties of silyl groups to exert steric and electronic control over reactions occurring 
in its vicinity,[81] and to engage in valuable transformations such as oxidation into 
alcohols,[82] metal-catalysed cross-couplings[83] or Brook rearrangement.[84,85] As a 
result, a number of methods have emerged to build carbon-silicon bonds; among 
those, the catalysed activation of silicon-heteroatom bonds has met with frank 
success.[86] 
Several activation modes of silicon-boron derivatives in particular have been 
used to trigger the silylation of unsaturated bonds.[87] In the last decade, several 
groups introduced protocols relying on the conjugate addition of commercially 
available dimethylphenylsilyl-pinacolatoboron 38 onto enones 39. For instance, in a 
seminal work, Oestreich et al. used a rhodium catalyst to install b-silyl groups in an 
asymmetric fashion.[88,89] Later, the Hoveyda group elaborated a copper(I)-catalysed 
approach and ultimately developed a metal free, NHC-mediated activation of the Si-B 
bond to the same end.[90,91] Concurrently, the emergence of more environmentally-
friendly alternative strategies based on copper(II) catalysts culminated in an 
asymmetric conjugate addition in water developed by Kobayashi and co-workers, who 
Table 4. Screening of conditions for the Nazarov cyclisation using synthetic oligonucleotidesa
1 ON6c = 3'-CGGTCG-C3-CTGGC-5' (DNA)
2 ON6c' = 3'-CGGUCG-C3-CUGGC-5' (RNA)
aAll reactions were run on a 0.1 µmol scale at a final concentration of 1 mM. bBased on HPLC analysis.
4
3 No counter strand
Entry Counter strand (DNA or RNA) Resultb
No conversion
No conversion
No conversion
No conversion
MOPS buffer, pH 7.0
50 °C, 24 h
Cu(OTf)2 (20 mol%)
ON9c, Counter-strand
31 35
O
O
Ph
CO2Me
DNA sequence
ON9c = 5'-GCCAGC-bipyC3-GACCG-3'
ON9c = 5'-GCCAGC-bipyC3-GACCG-3'
ON9c = 5'-GCCAGC-bipyC3-GACCG-3'
O
Ph
O
CO2Me
No DNA No DNA
ON9c R =
R
OO
NH
O
N N
bipyC3
ON6c R = H
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achieved ees up to 96% (Scheme 16.A).[92,93] The mechanism likely entails the 
activation of boron by water, which facilitates transmetalation with copper. The 
resulting copper-silicon complex can then undergo a conjugate addition onto reactive 
double bonds (Scheme 16.B).[87] These latter contributions encouraged us to examine 
the adaptability of the reaction to DNA-based conditions. 
 
Assuming that the chiral environment would be controlled via the coordination 
of copper to the silicon atom derived from 38, we selected cyclopentenone 40 as a 
model substrate for our studies. An reference sample was prepared in 82% yield in 
aqueous conditions adapted from Kobayashi, using Cu(acac)2 and achiral ligand L11. 
With the racemate in hand, we turned to commercial st-DNA systems (Table 5). Our 
first screening examined whether the reaction proceeded around neutral pH 
(6.5 to 7.5). Given that the nucleophile sometimes has to be present in large excess in 
comparable DNA-based conjugate additions, we tested variable amounts of silyl 
donor 38. Indeed, a high conversion was observed when using a large excess of 
5.0 equiv. of 38, but the product was racemic (Table 5, entries 1-3). Slightly more 
heartening ees of 6-7% were obtained with 1.2 equiv.; nonetheless, the conversion 
was limited by the formation of unidentified by-products visible by HPLC analysis 
Scheme 16. Silyl conjugate addition using a copper (II) catalyst
Cu(acac)2 (5 mol%)
L19 (5 mol%)
Me2PhSi B(pin)
36
+
R1
O
R2
37
R1, R2 = alkyl, aryl
R2
O
R1
yield up to 95%
(ee up to 96%)
SiPhMe2
H2O, r.t. N
N
OH
OH
t-Bu
t-Bu
L19
A. Literature precedent
B. Catalytic cycle
Cu•L19
37
Me2PhSi
OH2
O
O
BMe2PhSi B(pin) HO B(pin), H
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O
R2
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R2
SiPhMe2
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O
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H2O
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(Table 5, entries 4-6). In an attempt to reduce the occurrence of side-reactions, we 
lowered the concentration, but unfortunately, there was no conversion under these 
conditions (Table 5, entry 7). Significantly higher concentrations resulted in turning the 
solution into a hydrogel due to the large amount of DNA. Therefore, we elected to 
keep a large excess of 38 when testing other copper sources and ligands. Changing the 
metal had no influence on the outcome: as previously, high amounts of the racemic 
b-silyl 41 were obtained with CuCl2, CuF2, Cu(OTf)2 and Cu(OAc)2 (Table 5, 
entries 8-11). The results were comparable when using either intercalative ligands L5 
and L8 or groove-binding ligands L11 and L13. The lack of chiral induction under those 
conditions forced us to alter our approach, and we next attempted to use a covalent 
anchoring strategy. 
 
Synthetic sequence ON9c was selected as a benchmark, and we first used the 
complementary strand ON6c featuring a C3 spacer to form the DNA duplex. When 
using 1.2 equiv. of 38, we observed no conversion (Table 6, entries 1-3). Upon 
Table 5. Screening of conditions for silylative conjugate additiona
7.5
7.5
7.5
7.5
6.5
6.5
a Reactions were run on a 10 µmol scale. bBased on HPLC analysis.
9
7.0
10
7.0
Entry ResultbLigand
MOPS buffer, r.t., 3 d
Copper (5 mol%), ligand (6 mol%), st-DNA
Concentration 38 pH
5.0
5.0
Equiv. 36
7.5
5
7.5
6
8.3 mM
2
3
8.3 mM
4
8.3 mM
8
8.3 mM
7
8.3 mM
8.3 mM
8.3 mM
5.0
5.0
1.2
1.2
1.2
5.0
1.2
8.3 mM
1 5.0 L12
L12
L12
L12
L12
L12
L12
L12
L12
L12
Good conversion
Good conversion
Good conversion
Limited conversion, messy
Limited conversion, messy
Good conversion
Good conversion
Limited conversion, messy
Good conversion
No desired product
39
Copper source
Cu(NO3)2
Cu(NO3)2
CuCl2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(OTf)2
CuF2
0.8 mM
8.3 mM
38
O
SiPhMe236
+
O
11 5.0 7.58.3 mM L12 Good conversionCu(OAc)2
7.5
13
14
5.0
5.0 7.5
7.58.3 mM
8.3 mM
12 5.08.3 mM L8
L10
L11
Good conversion
Good conversion
Good conversionCu(NO3)2
Cu(NO3)2
Cu(NO3)2
15 5.0 7.58.3 mM L13 Good conversionCu(NO3)2
Me2PhSi B(pin)
<1
<1
eeb (%)
<1
<1
6
1
7
<1
N/A
<1
<1
<1
<1
<1
<1
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increasing the amount of 38 to 5.0 equiv., some silylated product 41 was formed, but 
competitive reactions led to a complex mixture as assessed by HPLC, and only slightly 
higher ees of up to 24% were obtained compared to the supramolecular approach 
(Table 6, entries 4-6). Next, we changed the counter-strand to RNA sequences ON6c' 
or ON11 but these slightly different complexes did not improve the outcome (Table 6, 
entries 7-8). At this stage, neither the enantioselectivity nor the chemoselectivity were 
deemed promising enough to justify a continued investigation of the reaction. 
 
 
1.5. Propargylation of phenols 
The alkyne moiety still stands as a central workhorse of synthetic chemistry, 
given that it provides a handle for a broad variety of transformations; yet, it remains 
an unseen feature in the landscape of DNA biohybrid catalysis. Historically, the 
Nicholas reaction established propargylic alcohol derivatives as straightforward 
precursors to chiral propargylic compounds, prompting research into more 
environmentally friendly alternatives that forgo the use of stoichiometric amounts of 
Co2(CO)8.[94] A number of transition metals have since been described to catalyse the 
formation of propargyl cation intermediates, which can subsequently react with 
Table 6. Screening of conditions for silylative conjugate addition using a covalent anchoringa
7.5
7.5
7.5
7.5
6.5
6.5
aReactions were run on a 2.5 µmol scale at 8.3 mM. ON9c = 5'-GCCAGC-(bipyC3)-GACCG-3'.
bBased on HPLC analysis.
7.0
7.0
Entry Resultb
MOPS buffer, r.t., 3 d
Cu(NO3)2 (2 mol%)
ON9c, Counter-strand
Counter strand (DNA or RNA) pHEquiv. 36
5
6
2
3
4
ON6c = 3'-CGGTCG-C3-CTGGC-5' (DNA)
8
ON6c = 3'-CGGTCG-C3-CTGGC-5' (DNA)
7
ON6c = 3'-CGGTCG-C3-CTGGC-5' (DNA)
ON6c = 3'-CGGTCG-C3-CTGGC-5' (DNA)
ON6c = 3'-CGGTCG-C3-CTGGC-5' (DNA)
1.2
1.2
5.0
5.0
5.0
5.0
5.0
ON11 = 3'-CGGTCG-U-CTGGC-5' (RNA)
1 1.2 No desired product
Limited conversion, messy
Limited conversion, messy
No desired product
No desired product
Limited conversion, messy
Limited conversion, messy
Limited conversion, messy
39
ON6c' = 3'-CGGTCG-C3-CTGGC-5' (RNA)
ON6c = 3'-CGGTCG-C3-CTGGC-5' (DNA)
O
SiPhMe236
+
O
38
ON9c R =
R
OO
NH
O
N N
bipyC3
ON6c R = H
Me2PhSi B(pin)
N/A
N/A
N/A
18
N/A
24
11
N/A
eeb (%)
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nucleophiles to build new carbon-carbon and carbon-heteroatom bonds.[95] In 
particular, highly enantioselective propargylic substitutions were disclosed with 
copper, though only a small number of efficient chiral ligands have been reported.[96] 
The earliest asymmetric reactions described in 2008 relied on amine nucleophiles;[97,98] 
more recently, carbon nucleophiles such as phenols and indoles have been used in 
Friedel-Crafts acylations and dearomatisation reactions, especially by Hu et al.[99–102]. 
Hence, we were encouraged to pursue the activation of propargylic derivatives by 
DNA-based copper catalysts. 
Aromatic hydrocarbons are some of the most common feedstock chemicals, 
and as such they have been used extensively to rapidly access complex structures. In 
particular, they have been leveraged with great success in dearomatisation processes 
to build carbon-carbon bonds in an enantioselective fashion, as shown by countless 
total syntheses.[103,104] Inspired by a recent report from Hu's group,[101] we examined 
the conversion of propargylic acetate 42 and commercially available phenol 43 to 
alkyne 44 (Scheme 17.A). The reported conditions struck us as quite favourable to 
standard DNA-based catalysis: several sources of copper(II) are compatible with the 
reaction and the basic, protic reaction medium (MeOH, NEt3) suggests feasibility in 
water. Turning to mechanistic considerations, the putative catalytic cycle starts with 
the copper/triple-bond p-complex 45, which after deprotonation of the acetylenic 
proton yields copper acetylide 46 (Scheme 17.B). The elimination of the acetate gives 
the stabilized copper-allenylidene 47. This electrophilic intermediate then undergoes 
nucleophilic attack to form acetylide 48. Finally, hydrolysis releases the propargylic 
product 44. We anticipated that the reactive copper complex 47 could be sufficiently 
integrated in the DNA scaffold to ensure an efficient chirality transfer. Furthermore, 
hydrophobic interactions make the reaction more likely to proceed in close proximity 
to the oligonucleotide duplex with aromatic hydrocarbon 43 than with a more polar 
nucleophile such as an amine.  
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We started our study by preparing acetate 42 from the corresponding alcohol 
in 88% yield [Ac2O, Et3N, DMAP in CH2Cl2]. An attempt to convert the later to racemic 
product 44 using Cu(OTf)2/L11 as a catalyst failed, and we eventually obtained the 
desired product in 40% yield and 30% ee using an enantiopure chiral bis(oxazoline) as 
ligand [43, Et3N in MeOH] (see experimental part for details). 
Turning to DNA-based conditions, we initially engaged propargylic acetate 42 in 
the presence of 1.2 equiv. of phenol 43 and a standard st-DNA/L12/Cu(NO3)2 catalyst 
in increasing loading from 10 mol% to 100 mol% (Table 7, entries 1-4), but the 
substrates were unreactive. An exploration of the pH range (5.5 to 8.5) was attempted, 
without any positive result (Table 7, entries 5-7). Upon increasing the amount of the 
nucleophile 43, we were pleased to see the formation of the desired product 44; 
however, even with 5.0 equiv. of phenol, the conversion was low (<5%) as assessed by 
HPLC, and the product was obtained as a racemate (Table 7, entries 8-10). 
Concurrently, we tried to conduct the reaction in the presence of polar co-solvents 
(10 %v/v). Interestingly, all the solvents tested (MeOH, EtOH, i-PrOH, MeCN) led to the 
formation of dearomatised product 44, but only in minute amounts (Table 7, 
Scheme 17. Asymmetric catalytic propargylic dearomatisation of phenols
Cu(OTf)•½C6H6 (5 mol%)
L18 (5 mol%)
(±)-40
OAc
Ph
+
41 42
91% yield
(99% ee)
Et3N (1.2 equiv)
MeOH
-20 °C
Ph2P
L20
N Ph
N
Ph
OH
MeO
OMeMeO
O
MeO
OMeMeO
OAc
Ph
40
OAc
Ph
43
Cu•L20 OAc
Ph
Cu•L2044
Ph
Cu•L20
45
•Ph • Cu•L20
45'
OH
MeO
OMeMeO
Ph
O
MeO
OMeMeO
Ph
O
MeO
OMeMeO
Cu•L20
Cu•L20
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A. Prototypical reaction
B. Catalytic cycle
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entries 11-14). An outstanding result was obtained with HFIP, a strongly polar solvent 
prone to stabilise cationic intermediates,[105] as the conversion reached 60% (Table 7, 
entry 15). Yet, the reaction proceeded with no enantioselectivity, suggesting that HFIP 
may catalyse the reaction outside the DNA scaffold. 
 
While unsatisfactory, these results encouraged us to experiment with other 
copper complexes and ligands. When Cu(NO3)2 was replaced by Cu(OTf)2 or Cu(SbF6)2, 
low conversions were observed, and an ee of 10% was obtained with the latter 
complex (Table 8, entries 1-2). Turning to the influence of the ligand, L10 failed to 
deliver any product, while L13 showed an enhanced selectivity (ee = –21%) but a 
limited activity (Table 8, entry 3-4). More interestingly, the intercalative ligands L5 and 
L8 displayed a similar enantioselectivity (ee = 29%) and slightly better conversions 
(Table 8, entries 5-6). Therefore, we elected to conduct more experiments with the 
L12/Cu(NO3)2, L5/Cu(OTf)2 and L8/Cu(SbF6)2 systems. A series of tests at different pH 
Table 7. Screening of conditions for propargylic dearomatisationa
7.5
8.5
7.5
1.2 100:0
7.5
6.5
aReactions were run on a 0.5 µmol scale at 0.8 mM. b10% v/v cDetermined by HPLC analysis after 
calibration. dBased on HPLC analysis. Sign chosen arbitrarily to indicate the relative stereochemistry. 
eHFIP: hexafluoroisopropanol
9
5.5
10
7.5
Entry Ratio 40:42cCo-solventb
Aqueous buffer, r.t., 3 d
st-DNA
Cu(NO3)2 (y mol%), L12 (1.2 y mol%)
[Cu] loading
-
pH
5.0
5.0
Buffer
7.5
5
7.5
6
100 mol%
2
3
100 mol%
MOPS
30 mol%
8
50 mol%
7
100 mol%
100 mol%
100 mol%
MOPS
MOPS
4
MES
MOPS
5.0
TRIS
100 mol%
1 MOPS -
-
-
-
-
-
-
-
-
100:0
100:0
>95:5
100:0
100:0
100:0
100:0
100:0
100:0
Equiv. 41
1.2
1.2
2.0
1.2
1.2
1.2
1.2
5.0
3.0
100 mol%
10 mol%
11 5.07.5100 mol% MeOH >95:51.2
7.5
13
14
5.0
5.07.5
7.5100 mol%
100 mol%
12 5.0100 mol% EtOH
i-PrOH
MeCN
>95:5
>95:5
>95:51.2
1.2
1.2
15 5.07.5100 mol% HFIPe 40:601.2
7.5
42
Ph
O
MeO
OMeMeO
40
OAc
Ph
+
41 (x equiv.)
OH
MeO
OMeMeO
N/A
eed (%)
N/A
N/A
-2
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
2
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showed that no reaction occurred under more acidic (pH 6.0, MES buffer) or basic 
(pH 9.0, TRIS buffer) conditions (Table 8, entries 7-12). However, at pH 8.2 (HEPES 
buffer), higher conversions were obtained and an optimal ee of 29% was attained with 
L8 (Table 8, entries 13-15). Unfortunately, when combining Cu(SbF6)2 as the metal 
source and L8 as the ligand, no improvement was observed (Table 8, entries 16-17). A 
last attempt was also made to use HFIP as an additive, but as previously, the product 
was obtained in low ees (Table 8, entries 18-20). 
 
Despite the heartening improvements seen at pH 8.2, the desired product's 
yield increase was concomitant with the appearance of new by-products on HPLC. This 
new development was not entirely unanticipated, as a number of competitive reaction 
Table 8. Screening of conditions for propargylic dearomatisationa
7.5
N/A
N/A
N/A
N/A
>95:5
29
9
L8
6.0
Cu(SbF6)2
aReactions were run on a 0.5 µmol scale at 0.8 mM. b10% v/v cDetermined by HPLC analysis after 
calibration. dBased on HPLC analysis. Sign chosen arbitrarily to indicate the relative stereochemistry. 
eHFIP: hexafluoroisopropanol
9
11
Entry Ratio 40:42cCo-solvent
Aqueous buffer, r.t., 3 d
st-DNA
copper (100 mol%), ligand (120 mol%)
8.2
7.5
-
MES
L8
Ligand
5
L5
6
TRIS
2
3
100:0-
8
7
Buffer
Cu(NO3)2
HEPES
100:0
4 MOPS
1 -
-
-
-
-
-
100:0
-
91:9
-
93:7
74:26
89:11
100:0
100:0
L5
Cu(SbF6)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
MES
Cu(SbF6)2
Cu(OTf)2
Copper source
L12
L10
L13
L5
L8
MOPS
MOPS
MOPS
MOPS
MES
6.0
L8 100:0
MOPS
12
L12
-TRIS
L12
Cu(NO3)2
Cu(NO3)2
9.0Cu(NO3)2
pH
56:44
70:30
15
18
-
-
14
7.5
7.5
L5
HFIPe 74:26
7.5
7.5
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L12
Cu(NO3)2
8.2
6.0
7.5
42
Ph
O
MeO
OMeMeO
40
OAc
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+
41 (1.2 equiv.)
OH
MeO
OMeMeO
- 86:1413 Cu(SbF6)2 HEPESL12 8.2
-21
eed (%)
1
9.0
14
29
10
N/A
N/A
Cu(NO3)2
Cu(NO3)2
8
13
10 - 100:0Cu(SbF6)2 TRISL12 9.0 N/A
Cu(NO3)2 7.5
Cu(NO3)2 7.519 HFIPe >95:5MOPSL5
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2
3
15L8 >95:516 -MOPS7.5Cu(SbF6)2
0L8 HEPES 91:917 -8.2Cu(SbF6)2
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pathways can occur once the electrophilic copper-allenylidene 47 is generated. For 
instance, an O-alkylation of the phenol can take place, though electron-rich phenols 
such as 43 have been reported to prefer Friedel-Crafts alkylation.[100] There is also the 
possibility that a Friedel-Crafts occurs on the 2 position, as described in the initial 
report of the reaction,[101] and of course a reaction with water cannot be ruled out. 
These considerations prompted us to study the behaviour of propargylic 
acetate 42 when the nucleophile is replaced by commercial 3,5-disubstitued phenol 49 
as, in the absence of the 4-substituent, we expected the formation of the Friedel-
Crafts product 50 to be more favoured. A reference sample was prepared under the 
conditions used for the preparation of 44 [42, 49, Et3N, Cu(OTf)2, chiral bis(oxazoline), 
MeOH, 88% yield, 14% ee]. Next, a series of experiments was conducted under 
DNA-based conditions comparable to those used for the dearomatisation, with a rapid 
survey of the pH, the copper source and the ligand. However, no Friedel-Crafts 
alkylation occurred, even when using Cu(SbF6)2, L5 or L8 which were relatively 
successful for the dearomatisation (Table 9). Those observations suggested that other 
undesired reactions such as an O-alkylation or a hydration were more likely to take 
place.  
 
Table 9. Screening of conditions for propargylic Friedel-Craftsa
Cu(SbF6)2 7.5
MOPS
aReactions were run on a 0.5 µmol scale at 0.8 mM. bBased on HPLC analysis.
9
10
Entry ResultbEquiv. 47
Aqueous buffer, r.t., 3 d
st-DNA
copper (100 mol%), ligand (120 mol%)
L12
Ligand
5
6
2
3
8
7
Buffer
1.2
MOPS
No desired product
4
1 1.0
1.2
2.0
1.2
1.2
1.2
L8
Cu(OTf)2
No desired product
1.2
No desired product
No desired product
No desired product
No desired product
1.2
No desired product
No desired product
1.2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
Cu(NO3)2
No desired product
Cu(NO3)2
Cu(NO3)2
Copper source
L12
L12
L12
L12
MOPS
MOPS
MOPS
MES
No desired product
TRIS
7.5
Cu(NO3)2
MOPS
L12
Cu(NO3)2
L12
MOPS
MOPSL12
L5
pH
7.5
7.5
6.5
5.5
7.5
7.5
9.0
7.5
Ph
OH
MeO OMe
40
OAc
Ph
+
47 (x equiv.)
OH
MeO OMe
48
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Given the unsolved challenges of the propargylative dearomatisation and the 
fact that a Friedel-Crafts propargylation seemed even more difficult to promote, we 
did not pursue the optimisation of this project further. 
 
1.6.  An asymmetric approach towards the endiandric acids  
1.6.1. Biosynthetic origin and previous syntheses 
The bulk of research into new DNA catalytic systems has been reaction-driven 
rather than target-oriented, yet the ability of the DNA scaffold to template truly 
unique reaction pathways has been demonstrated with the biomimetic synthesis of 
dictazole B and analogues thereof.[54] Often, natural products offer an inspiration to 
tackle particular structures, and we therefore became interested in the endiandric acid 
family of natural products, which derive from simple tetraenes through a pericyclic 
cascade proposed by Black and Banfield upon isolation in 1980 (Scheme 18).[106] For 
instance, endiandric acid A arises from precursor 51, which undergoes an 8π 
conrotatory electrocyclisation to cyclooctatriene 52, followed by a 6π disrotarory 
electrocyclisation to 53; finally, an intramolecular Diels-Alder delivers the structurally 
complex tetracyclic framework 54. Since then, a number of natural products have been 
found to stem from similar pericyclic sequences, including the SNF4435 family and the 
shimalactones.[107–111] Unlike most natural products, which are formed as secondary 
metabolites by chiral enzymes and are thus found in the wild as optically active 
compounds, many derivatives arising from pericyclic transformations of achiral 
polyenic precursors have been isolated as racemates.[112] 
 
  
 
52 
 
Despite the existence of numerous synthetic targets arising from tetraenes, 
there has been a lack of methods to effect carbocyclic electrocyclisations in an 
asymmetric fashion. Indeed, most of the efforts in asymmetric electrocyclisations have 
focused on heterocyclic substrates, such as the Nazarov cyclisation,[113] and some 
limited results have been reported on enantioselective 6π carbocyclisations.[114] We 
viewed this lack of precedent as an opportunity to expand the field of DNA biohybrid 
catalysis and anticipated that during the initial 8π electrocyclisation process, the 
tetraene could potentially fit between the base pairs, given that the helical transition 
state has a pitch of about 3 Å (Figure 6).[115,116] While thrilled by the possibility that a 
mere template effect would favour the desired conformation and be efficient enough 
to exert stereochemical control, we also considered fall-back options. We envisioned 
the temporary attachment of a DNA-complexing ligand onto the endiandric acid 
precursor's scaffold, in a manner akin to a directing group. For instance, the carboxylic 
acid present on all members of the endiandric family could be used as a handle to 
introduce a groove-binding or intercalating moiety via an ester bond. Putatively, 
linkers of varying length could be incorporated between the tetraene and the DNA 
Scheme 18. Endiandric acids
A. Representative members of the endiandric acids family
HO2C
H
H
H
H
H
H
Endiandric acid CEndiandric acid A Endiandric acid E
Ph
H
H
H
CO2H
PhH
H HH
H
CO2H
Ph
H
B. Pericyclic biosynthesis as proposed by Black and Banfield
H
H
H
CO2H
PhH
H
HH
H CO2H
Ph
CO2HPh
CO2HPh
(±)-Endiandric acid A (52)(E,Z,Z,E)- or (Z,Z,Z,Z)-tetraene 49
8π conrotatory
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[4+2]
H
51
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binder. With these considerations in mind, we examined the available retrosynthetic 
pathways. 
 
The Woodward-Hoffmann rules indicate that the thermally allowed formation 
of the endiandric acids may proceed from one of two tetraenic structures, either the 
(E,Z,Z,E)- or the (Z,Z,Z,Z)-tetraene.[117] Early observations on decatetraene showed that 
the cyclisation of the (E,Z,Z,E)-isomer occurs at –10 °C, wheras the (Z,Z,Z,Z)-analogue 
requires heating to 65 °C.[118] Accordingly, the first synthesis of the endiandric acids, 
accomplished by Nicolaou et al. in 1982, entailed the preparation of diene diyne 55 
which was semi-hydrogenated using Lindlar's catalyst to afford the key 
(E,Z,Z,E)-tetraene 56. At this stage, the tetraene spontaneously underwent 8π/6π 
electrocyclisation at room temperature to deliver endiandric acid E methyl ester 57, 
which upon heating to 100 °C was converted to endiandric acid A methyl ester 58 
through an intermolecular Diels-Alder reaction (Scheme 19.A).[119–122] These landmark 
studies confirmed the power of electrocyclisations to deliver complex carbocyclic 
compounds both in the laboratory and in the wild. Conversely, the propensity of 
(Z,Z,Z,Z)-tetraenes to deliver the same tetracyclic framework was only evaluated by 
Sherburn and co-workers in 2015.[123] Their strategy features the formation of tetrayne 
precursor 59, which after extensive experimentation could be reduced to the 
corresponding (Z,Z,Z,Z)-tetraene 60 using Rieke zinc in an ethanol/THF mixture. In 
contrast to the (E,Z,Z,E)-tetraene, (Z,Z,Z,Z)-60 required heating to 100 °C to undergo 
the thermal electrocyclisation/cycloaddition process and deliver the fully-formed 
endiandric framework of intermediate 61. A two-step deprotection/oxidation 
sequence completed the synthesis of endiandric acid A (54). The observation that 
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Figure 6. Transition structure of cyclooctatriene, reproduced from reference [115]
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(E,Z,Z,E)-tetraenes cannot be isolated at room temperature convinced us that a 
catalysed process would have to be based on a more stable (Z,Z,Z,Z)-derivative.  
  
 
1.6.2. Preparation of tetrayne precursors to the endiandric acids 
In addition to furnishing the desired (Z,Z,Z,Z)-tetraene configuration, Sherburn's 
approach is particularly appealing as it allows a modular access to structurally diverse 
tetraenes (Scheme 20). Indeed, a retrosynthetic analysis suggested that the fully 
substituted tetrayne 59 could be assembled from a nucleophilic tetrayne 62 and 
electrophilic synthon 63. With this route, the variation of the electrophile at a late-
stage of the synthesis provides access not only to endiandric acid A but also to the 
Scheme 19. Landmark syntheses of endiandric acids
A. Synthesis by Nicolaou via a (E,Z,Z,E)-tetraene
B. Synthesis by Sherburn via a (Z,Z,Z,Z)-tetraene
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H
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(±)-Endiandric acid A methyl ester (56) 
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(E,Z,Z,E)-tetraene 54
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6π dis.
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CO2Me
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(±)-Endiandric acid E methyl ester 55
H2, Pd/BaSO4
quinoline
CH2Cl2, 25 °C
[4+2]
Toluene
100 °C
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Tetrayne 57 (Z,Z,Z,Z)-tetraene 58Ph
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H
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H
H
H
CO2H
PhH
H
(±)-Endiandric acid A (52)
19% from tetrayne 57
2) TPAP, NMO
    CH3CN, H2O
OTBS
(±)-59
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related kingianic acid E and kingianin A, D and F.[123] The intermediate tetrayne would 
in turn arise from a cross-coupling between two suitable diynes 64 and 65. Given that 
long polyynes tend to become unstable unless capped by large steric groups, it was 
important to protect the structure with a silyl group.[124,125]  
 
A bromide was selected as the electrophilic parter and was prepared following 
Sherburn's report (Scheme 21). Commercial cinnamaldehyde 66 was subjected to a 
Wittig olefination [Ph3PC(H)CO2Et, CH2Cl2, 79%] followed by the reduction [DIBAL-H, 
CH2Cl2, 0 °C, 84%] of the resulting ester to afford allylic alcohol 67, which was 
brominated to the corresponding allylic bromide 68 [PBr3, Et2O, 0 °C, 87%].  
 
In parallel, the synthesis of the tetrayne building block started with the 
formylation of commercially available terminal alkyne 69 [n-BuLi, THF, then 
4-methylmorpholine, 76%] (Scheme 22). The resulting aldehyde 70 was converted to 
diynyl bromide 65 by a one-pot Colvin homologation/bromination sequence [n-BuLi, 
trimethylsilyldiazomethane, THF, then n-BuLi, NBS, 59%]. Bromide 65 was then treated 
with diynyl zincate 71 (generated in situ from the bis-TMS precursor 64) in a Negishi 
coupling [PdCl2(dppf) (5 mol%), THF/toluene, 56%]. Finally, the resulting TMS-capped 
tetrayne 72 was subjected to a sequential mono-desilylation [K2CO3, MeOH, 
0 °C]/Cu-catalysed alkylation using bromide partner 68 [t-BuMgCl, THF, then 68, 
CuI (15 mol%)] to yield tetrayne 59 (28% from 68).  
Ph
TBSO TBSO
Ph 61
TMSTMS
TBSO
Br+
6362
57 60
Scheme 20. Retrosynthesis of tetrayne intermediate
Scheme 21. Preparation of electrophile 66
Ph Ph
OH
PBr3
Et2O, 0 °C
87%
1) Ph3PC(H)CO2Et
    CH2Cl2, r.t.
2) DIBAL-H
    CH2Cl2, 0 °C
    66% (2 steps)64 65 66
O Ph
Br
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The previous sequence furnished amounts of tetrayne 59 on the order of 
100 mg, and we anticipated the need for a more efficient access to this intermediate in 
order to provide key tetraene 60 in sufficient quantities for a study of DNA conditions 
and subsequent scale-up. To this end, we considered a more convergent route where 
59 would be assembled from diynes 73 and 74 via an sp-sp cross-coupling 
(Scheme 23). In turn, diyne 74 would be prepared from the previously used 
electrophile 68 and commercial diyne 64. Concurrently, 73 can be obtained from 
alkyne 69 by a formylation/Seyferth-Gilbert sequence as before, but we looked for 
more practical conditions that would avoid n-BuLi or TMS-diazomethane.  
 
An experimentally straightforward synthesis of 74 started from 
but-3-yn-1-ol 75, which was first converted to bromide 76 [NBS, AgNO3 (15 mol %), 
Acetone, 86%]. The latter was then engaged in a Cadiot-Chodkiewicz coupling with 
TMS-acetylene 77 [CuI (10 mol %), piperidine] to afford TMS-protected diyne 78 in 75% 
yield (Scheme 24.A). 
TBSO
TMS
OHC
TBSOTBSO THF, -78 °C
76%
n-BuLi
then
4-formylmorpholine Br
TBSO
6867
TMSC(Li)N2
THF, -78 °C to r.t.
then n-BuLi, NBS
-78 °C to r.t.
59% 63
69
PdCl2(dppf)
    (5 mol %)
THF, toluene
r.t.
56%
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1) K2CO3
    MeOH, 0 °C
2) t-BuMgCl, THF, 40 °C
    then 66 (0.52 equiv)
    CuI (15 mol %), 50 °C
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57
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Scheme 22. Preparation of the tetrayne precursor
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Scheme 23. Second approach to the tetrayne precursor
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Later, the publication of a Glaser-Hay-type copper-catalysed heterocoupling of 
terminal alkynes prompted us to attempt the direct sp-sp cross-coupling of 
commercial butynol 75 with TMS-acetylene 77 [Cu(0) (5 mol%), TMEDA (20 mol%), 
CHCl3/dioxane 3:1, 50 °C, air],[126] however no conversion was observed. Inspired by 
the initial report, we replaced 77 with 2-methylbut-3-yn-2-ol 79, and with this 
protecting group the desired diyne 80 was obtained in 66% yield (Scheme 24.B). 
Treatment under basic conditions would eventually furnish the free diyne 74. 
 
Conversely, the alkylation of bis-TMS diyne 64 with bromide 68 proved 
problematic (Table 10). First, we attempted to treat the diynyl lithiate derivative with 
68 in a THF/HMPA mixture,[127] but these conditions resulted in a complex mixture as 
shown by 1H NMR and flash chromatography failed to provide the desired product 73. 
Next, we tried to generate the diynyl zincate 71 and use a copper iodide catalyst, 
similar to the conditions used for the coupling of 68 with tetrayne 59, but again a 
complex mixture was obtained.[123] Finally, Negishi coupling conditions reported for a 
similar diyne functionalisation were used;[128] yet, intractable products were obtained 
in this case. While hoping that a careful tweaking of the experimental protocol would 
solve the problem, we decided at this juncture to delay further optimisation of the 
synthesis of 59, and embarked on the preparation of simpler tetraynes to be used as 
model substrates.  
Scheme 24. Alternative approaches to diyne 72
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A. Diyne formation via a Cadiot-Chodkiewicz coupling
B. Diyne formation via a Glaser-Hay heterocoupling
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1.6.3. Preparation of tetraene model substrates 
As mentioned previously, the limited amounts of endiandric acid precursor 59 
and the challenges of the tetrayne semi-hydrogenation prompted us to prepare more 
accessible model substrates to optimise the sequence. Symmetrical tetraene 81 would 
stem from the reduction of tetrayne 82, which would itself be generated through the 
homocoupling of diyne 83 (Scheme 25). Ultimately, the latter would be prepared from 
84 through a two-step sequence already established for the free alcohol (Scheme 24). 
 
Applying this strategy to the unprotected alcohol (R = H), we engaged diyne 78 
in a Glaser coupling [CuCl, DMF, 60 °C, air] and obtained the symmetrical tetrayne 85 
in 83% yield (Scheme 26.A). This substrate was found to be unstable and had to be 
used quickly, as it degraded to intractable products after a few days in the freezer and 
in a matter of hours at room temperature. We also prepared a silyl ether analogue 
following a similar sequence, starting with commercial alkyne 69 (R = TBS). A 
comparable bromination [NBS, AgNO3 (15 mol %), acetone, 94%]/Cadiot-Chodkiewicz 
coupling [77, CuI (10 mol %), piperidine, 76%] sequence furnished diyne 86 
(Scheme 26.B). However, the direct homocoupling of this protected compound [CuCl, 
DMF, 60 °C, air] delivered tetrayne 87 in only 26% yield. To our delight, a simple 
Table 10. Attempted preparation of diyne 72
THF
-78 °C
MeLi•LiBr
Conditions
Entry Conditions Result
ZnCl2, then 66, CuI (30 mol %), 50 °C2
3 ZnCl2, then 66, PdCl2(dppf) (5 mol%), 50 °C
66, HMPA, r.t.1 Complex mixture
Complex mixture
Intractable products
66
Ph
Br
Ph
TMS
TMSTMS
62
Li•LiBrTMS
72
Scheme 25. Retrosynthesis of a symmetrical model tetraene
OR
79
RO
80 81 82
ROOR RO RO
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removal of the TMS group by methanolysis [K2CO3, MeOH] followed by a Glaser 
coupling in the conditions used before [CuCl, DMF, 60 °C, air] yielded tetrayne 87 in 
91% over two steps. 
 
With tetraynes 85 and 87 in hand, a cis-selective semi-hydrogenation was the 
last step before the crucial pericyclic sequence; unfortunately, Sherburn’s Rieke zinc 
reduction failed to furnish the desired tetraenes. Repeated attempts with various 
conditions consistently led to a complex mixture of olefinic compounds; 1H and 13C 
NMR showed the presence of geometric isomers and over-reduction products 
(Table 11). Chromatography on silica gel did not afford the pure (Z,Z,Z,Z)-tetraene, 
even when silver nitrate was used as an additive to help with the resolution of 
isomeric alkenes.[129] Eventually, we also treated 85 with Lindlar's catalyst, but 
unsurprisingly, over-reduction was encountered again under those conditions 
(Table 11, entry 6). 
Scheme 26. Synthesis of model tetraynes
air, 60 °C
83%
CuCl, DMF2 steps, 65%
see scheme 24
A. Preparation of model tetrayne with free alcohols
B. Preparation of model tetrayne with TBS-protected alcohols
air, 60 °C
26%
CuCl, DMF
1) NBS
    AgNO3 (15 mol%)
    Acetone, r.t.
2) 
     CuI (10 mol%)
     Piperidine, 0 °C
     71% (2 steps)
TMS
75 1) K2CO3
    MeOH
2) CuCl, DMF
    air, 60 °C
    91% (2 steps)
73
HO
76
HO
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83
HOOH
67
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In the end, when impure samples of the tetraenes were heated in toluene 
[120 °C] to trigger the thermal electrocyclisation cascade, trace amounts of the 
putative electrocyclisation adducts 88 were detected by 1H NMR (Scheme 27). 
However, the complexity of the mixture precluded a monitoring of the reaction by 
HPLC and we decided to reconsider our strategy. 
 
 
1.6.4. Perspectives 
Our investigations showed that Sherburn's approach to (Z,Z,Z,Z)-tetraene 
precursors of endiandric-type tetracycles is indeed versatile, given that a vast number 
of diversely decorated tetraynes can be obtained quickly after a judicious choice of 
sp-sp cross-coupling reactions. However, as observed by other researchers, the 
controlled semi-hydrogenation of polyynes is a challenging transformation,[130,131] and 
in our hands the Rieke zinc system used by Sherburn et al. did not cleanly afford the 
required tetraenes. Arguably, a more extensive survey of experimental conditions 
Table 11. Attempted preparation of 79
Entry Conditions Products
Rieke zinc (170 equiv.), THF/EtOH, 0 °C, 15 h2
3 Rieke zinc (50 equiv.), THF/EtOH, 0 °C, 15 h
Rieke zinc (170 equiv.), THF/EtOH, 0 °C, 15 h1 Geometrical isomers and over-reduction
Geometrical isomers and over-reduction
Geometrical isomers and over-reduction
OR
79
RO
Conditions
Rieke zinc (30 equiv.), THF/EtOH, 0 °C, 1 h5
6 Lindlar's catalyst, quinoline, H2, EtOAc, r.t., 15 h
Rieke zinc (30 equiv.), THF/EtOH, 0 °C, 1 h4 Geometrical isomers and over-reduction
Geometrical isomers and over-reduction
Over-reduction
Substrate
83 (R = H)
85 (R = TBS)
85 (R = TBS)
83 (R = H)
83 (R = H)
85 (R = TBS)
80
ROOR
RO ORH H
86
traces
Scheme 27. Thermal electrocyclisation of crude tetraenes
120 °C, Toluene
ORRO
79
24 h
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should enable the isolation of sufficient amounts of tetraene to finish the desired 
pericyclic sequence in a thermal fashion. Yet, the fruitful adaptation of the protocol to 
DNA-based catalysis requires the availability of the starting material and the reference 
racemic product in high purity, which stands as a much more daunting challenge. Even 
according to Sherburn's report, small amounts of undesired geometrical isomers are 
present after the semi-hydrogenation and tetraenes were usually engaged in the 
thermal pericyclic cascade without delay to avoid (Z/E) isomerisation; moreover, the 
tetraene mixture was found difficult to analyse by HPLC. These considerations led us to 
look for a more controlled synthesis of the necessary (Z,Z,Z,Z)-tetraene structure. 
Therefore, we considered palladium-catalysed sp2-sp2 cross-couplings, which 
have been reliably used to prepare conjugated polyenes in a stereocontrolled fashion, 
including (Z,Z,Z)-trienes.[132] In the last few years, Burke and co-workers reported an 
iterative cross-coupling strategy for the construction of polyenic structures. 
Bifunctional haloalkenyl MIDA boronates such as 89 can undergo a Suzuki-coupling 
with boronic acid 90, and a subsequent hydrolysis of the MIDA boronate yields boronic 
acid 91; the procedure can be repeated at will to access various polyenes 
(Scheme 28).[133–135] Alternatively, the MIDA boronate can be directly converted to the 
iodide derivative in a one-pot procedure. In 2016, this method was applied to generate 
an (E,Z,Z,E)-tetraene during the synthesis of an endiandric acid derivative.[136] 
 
Inspired by this report, we imagined the preparation of a (Z,Z,Z,Z)-isomer using 
building block 89 (Scheme 29). A generic (Z,Z,Z,Z)-tetraene 92 would result from the 
coupling of (Z,Z)-dienyl MIDA boronate 93 and (Z,Z)-dienyl halide 94, itself derived 
from the corresponding MIDA boronate. Both of those dienes would be obtained via a 
Suzuki coupling between 89 and the relevant boronic acids 95 and 96. This approach is 
potentially applicable to both a symmetrical model tetraene (if R = CH2OTBS) or a more 
complex precursor such as 59. 
Scheme 28. Burke's iterative cross-coupling strategy for the synthesis of conjugated polyenes
B
O
O O
O
MeN
X
(MIDA)B
B(OH)2
R
(MIDA)B
RSuzukicoupling
+
Hydrolysis
(HO)2B
R
87 88 89 B(MIDA)
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While the stability of the fully formed (Z,Z,Z,Z)-tetraene may still present a 
challenge, this route might offer a way around the problematic cis-selective semi-
hydrogenation of tetraynes for future endeavours in this project. 
  
Scheme 29. Iterative cross-coupling decomposition of (Z,Z,Z,Z)-tetraenes
R OTBS
90
R
B(MIDA) X
OTBS
R
B(OH)2 (HO)2B
OTBS
B(MIDA)
X X
(MIDA)B
91 92
93 94
87 87
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2. Asymmetric transformations of a-acrylate anions surrogates 
2.1. Approaches for the a-functionalisation of acrylic derivatives 
 
Acrylic moieties and other electron-poor alkenes such as alkenyl nitriles are a 
common feature of organic synthesis (Figure 7). For example, simple acrylates are 
widely used as reactive building blocks, as demonstrated by their success in the 
polymer industry.[137] While the smaller derivatives can present toxicity hazards,[138] 
acrylic moieties have been fruitfully incorporated in bioactive compounds as well.[139] 
For instance, the anti-cancer covalent inhibitor ibrutinib includes an acrylamide 
group.[140,141] Teriflunomide, an immunomodulator used against multiple sclerosis, 
incorporates a cyanoacrylate fragment,[142] while the anti-retroviral drug rilpivirine 
displays an alkenyl nitrile (Figure 8).[143] In fact, evidence suggests that an additional 
a-substituent on the acrylic moiety reduces toxicity.[144] Therefore, new methods to 
functionalise these derivatives are desirable. 
 
In addition to the adjustment of a small-molecule's characteristics, acrylate 
groups and their analogues are versatile intermediates thanks in large part to the high 
Figure 7. Commonly encountered acrylic derivatives, and annual production when available
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Figure 8. Pharmaceuticals incorporating acrylic derivatives
O
HN
F
F
F
N
HO
Ibrutinib
Anti-cancer
Teriflunomide
Active against multiple sclerosis
O
N
N
N
O
N
N
NH2
Rilpivirine
Active against HIV
N
N
N
H
NHN N
  
 
64 
reactivity of the polarised double bond (Scheme 30). Among their most common 
applications to the formation of carbon-carbon bonds, they readily behave as 
dienophiles in Diels-Alder and other cycloadditions;[145] they can undergo conjugate 
addition on the electrophilic b-position of the alkene as well nucleophilic activation of 
the a-position, such as in Morita-Baylis-Hillman-type reactions.[146] Asymmetric 
versions of these transformations are well documented, allowing the construction of 
structurally complex scaffolds. Acrylates can also selectively engage in olefin cross-
metathesis reactions,[147] and alkenyl nitriles have been used in the synthesis of 
numerous heterocycles, including purines, pyrimidines, pyrazines, imidazoles and 
porphyrazines.[148] Furthermore, asymmetric hydrogenations of multisubstituted 
acrylates have met with widespread success, becoming one of the primary industrial 
way to generate chiral centres in an enantioselective fashion.[149] Finally, the electron-
withdrawing group can undergo further transformations: carbonyls constitute a 
flexible electrophile and nitriles are direct precursors to amines and other nitrogen-
containing groups. 
 
A retrosynthetic analysis of an a-functionalised acrylate 97 suggests its 
formation can be accomplished from diverse building-blocks (Scheme 31). A first path 
(path a) involves the a-olefination of a nitrile or a carbonyl 98 with an appropriate 
partner 99. A second approach (path b) consists in the a-alkylation of a preformed 
acrylic derivative 100. A third alternative (path c) would rely on the hydro- or carbo-
cyanation of an alkyne precursor 101. More exotic solutions have been explored, such 
as the dehydrogenation of an alkyl precursor 102 (path d) and the activation of a 
Csp2-H bond to introduce a carbonyl, carboxylic or nitrile group onto an alkene 103 
(path e). 
Scheme 30. Common synthetic transformations of acrylic derivatives
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Historically, path a (Scheme 32) was available through the Knoevenagel 
condensation, but substrates were usually limited to strongly electron-withdrawing 
substituents (R1 = EWG); some examples using aryl precursors have been reported.[150] 
Alkyl substituents have been introduced at the a-position using decarboxylative 
versions, such as the Galat reaction.[151] More general olefination methods have been 
applied to acrylic derivatives: the aldol reaction (or the related direct condensation of 
acetonitrile with carbonyls for the formation of alkenyl nitriles) is a standard route to 
access acrylic derivatives despite issues in the control of selectivity, and the Wittig, 
Horner-Wadsworth-Emmons and Peterson olefinations remain some of the most 
established synthetic routes to such compounds.[152–155] Yet, these tactics require 
harsh reaction conditions and usually generate significant amounts of waste. Over the 
last few years, promising methods relying on the catalytic dehydrogenation of alcohols 
by ruthenium or manganese complexes have allowed the direct a-olefination of 
nitriles with alcohols.[156,157] 
 
Scheme 31. Main retrosynthetic approaches towards α-acrylic derivates
R1 EWG
95
R2
R1 EWG
97
G
path a path b
path c
R2
olefination α-alkylation
98
R2
99
96
G1
101
G2
R1 EWG
100
R2
path d path e
R1
R2
EWG
Scheme 32. Formation of α-acrylic derivates via olefination (path a)
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Turning to path b, the a-alkylation of an acrylic derivative can theoretically be 
achieved via an a-acrylate cation or an a-acrylate anion reacting with the 
corresponding nucleophile or electrophile, respectively (Scheme 33.A). The former 
umpolung strategy has been independently explored by Corey, Fuchs and Stork, who 
used a,b-epoxyketones derivatives as a latent equivalent for the a-acrylate  
cation.[158–160] Nonetheless, these routes require a convoluted prefunctionalisation of 
the substrates (Scheme 33.B). 
 
In contrast, the a-acrylate anion is virtually impossible to obtain without using 
protecting groups and prefunctionalisation as the a-acrylate bromide, under cryogenic 
conditions [t-BuLi, -78 °C].[161–163] However, this tactic has been difficult to generalize 
and the substrate scope remains limited. To circumvent this limitation, some groups 
have relied on the palladium-catalysed cross-coupling of a-acrylate halides.[164,165] 
Subtler strategies rest on the generation of a transient a-acrylate anion 
surrogate. The most ubiquitous example is the Morita-Baylis-Hillman reaction, 
catalysed by amines or phosphines, which enables the formal addition of a-acrylate 
anions on carbonyls (Scheme 34.A).[146,166] Consequent efforts have been focused on 
this reactivity, including asymmetric versions;[167] nonetheless, it has been difficult to 
expand the electrophilic partners beyond carbonyls and related imines derivatives. 
More recently, Scheidt et al. showed that silyloxyallenes behave as latent a-acrylate 
anions (Scheme 34.B).[168–170] When treated with a Lewis acid, they react efficiently 
with aldehydes, ketones and imines in a manner akin to the Mukaiyama aldol addition, 
delivering Morita-Baylis-Hillman-type products in high yields. Unlike the latter 
reaction, this approach provides access to b-substituted acrylates; however, it has not 
been generalised to other types of electrophiles. 
Scheme 33. α-functionalisation of acrylic derivatives
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E
EWG EWGEWG
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Nu EWG
A. General strategies
B. Implementation through α-acrylate cation surrogates (Corey et al., Fuchs et al., Stork et al.)
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Conversely, Baraldi and co-workers demonstrated that 4-substituted 
tetrahydrothiophenones 104 (THTs) react like latent a-acrylate anions with various 
halides 105.[171–174] Indeed, in the presence of K2CO3 in refluxing acetone, alkylation 
products 106 are obtained in moderate to satisfactory yields (29–77%). Upon exposure 
to aqueous NaOH and formation of reactive intermediate 107, the THT ring can then 
be cleaved in a reverse Dieckmann/Michael reaction to furnish a-alkylated 
acrylates 108 (Scheme 35). While the method does require prefunctionalisation of the 
acrylate by a sequential Michael addition/Dieckmann annulation, the alkylation/ring-
cleavage sequence can be performed in a one-pot fashion under relatively mild 
conditions. Later, the reaction scope relative to electrophiles was expanded to Michael 
acceptors. 
 
The formation of acrylates from alkyne precursors, following path c, was 
initiated in the 1980s with the nickel-catalysed hydrocyanation of silylalkynes 
(Scheme 36).[175,176] More general conditions were later developed by Nakao and 
Hiyama who realised the carbocyanation of alkynes using a nickel catalyst.[177,178] More 
recently, a rhodium-catalysed anti-Markovnikov hydrocyanation of terminal alkynes 
was disclosed by Ritter et al., but the approach was not extended to disubstituted 
alkynes and no a-functionalised alkenyl nitriles were obtained.[179] The 
hydroformylation of alkyne has also been studied, but overreduction and lack of 
Scheme 34. Formation of α-hydroxyacrylic derivates
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Scheme 35. Tetrahydrothiophenones as α-acrylate anion surrogates
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regioselectivity remain significant limiting factors.[180] As a result and despite a high 
theoretical atom-economy, this route has met with limited success.  
 
Path d, the a,b-dehydrogenation of carbonyls derivatives to generate enones, 
has been used in countless instances, and several protocols have been the subject of 
thorough investigations, including an IBX-mediated oxidation,[181] the Saegusa 
oxidation,[182] and various methods involving the introduction of a suitable leaving 
group followed by its elimination, thermally-induced or catalysed. It is worth 
mentioning that a few similar reactions have been reported for nitriles, though the 
body of work is not nearly as large as for the formation of enones. However, this 
strategy generally does not allow the formation of a-substituted derivatives. 
While traditionally more difficult to achieve, the direct C–H functionalisation of 
alkenes, path e, has emerged as a promising strategy, with TMSCN used as a 
nucleophilic source of nitrile. The Engle and Studer groups recently reported catalytic 
systems for the oxidative cyanation of alkenes (Scheme 37).[183,184] This tactic would be 
most useful for the late-stage diversification of acrylates and alkenyl nitriles of 
interest. 
 
In addition to these main strategies, a few more original efforts have been 
reported, including oxidative protocols. For instance, Jiao and co-workers developed 
an iron-catalysed Csp2–H activation process that converts allyl groups to the 
corresponding alkenyl nitriles.[185] Another interesting synthesis of aryl and alkenyl 
nitriles via the oxidation of alcohols in the presence of ammonia, mediated by a 
Scheme 36. Formation of α-acrylic derivates via hydro- or carbocyanation (path c)
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Scheme 37. Formation of α-acrylic derivates via C-H activation (path e)
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ruthenium catalyst, was developed by the Mizuno group.[186] But despite the existence 
of multiple alternatives to build acrylic derivates, the variety of accessible products 
remains limited.  
Another limitation of the different methods available to prepare acrylic 
derivatives lies in the construction of stereocenters in a controlled fashion. This 
consideration directed our interest towards the a-acrylate anion surrogate approach 
pioneered by Baraldi and co-workers. At the time, this tactic was employed with a 
limited range of electrophiles, and the reaction was mediated by a weak base. Hence, 
we aimed to expand the reaction to prochiral electrophiles 109, which would be 
selectively alkylated by a THT acrylic equivalent 104 in the presence of a suitable chiral 
catalyst. The subsequent intermediate 110 would ultimately provide the 
enantioenriched acrylate 111 after the retro-Dieckmann fragmentation of the THT ring 
(Scheme 38). This unprecedented asymmetric a-functionalisation of acrylate 
derivatives is particularly relevant thanks to its potential to furnish all-carbon 
stereocentres, a substitution pattern inaccessible through the Morita-Baylis-Hillman 
reaction and similar approaches. 
 
  
Scheme 38. Plan for the asymmetric synthesis of α-acrylates derivatives
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2.2. Initial investigations of the a-functionalisation of acrylic 
derivatives using DNA-based catalysis  
While a vast number of prochiral electrophiles can potentially be used as 
partners for the THT a-acrylate anion surrogates, we were inspired by our related 
studies in the field of DNA-based catalysis. Hence, given their advantageous reactivity 
in asymmetric conjugate additions, we elected to use a,b-unsaturated acylimidazole 
substrates 4. Upon alkylation with THT 104, enantioenriched intermediate 112 would 
be formed, and hydrolytic cleavage would yield a-functionallised acrylate 113 
(Scheme 39).  
 
THT substrates bearing a b-substituent (R ≠ H) could present selectivities issues 
in the formation of intermediate 112, and eventually lead to a mixture of the (E) and 
(Z) geometrical isomers of acrylate 113. Conversely, if R = H, the diastereoselectivity of 
the first step would be immaterial inasmuch as the a-carbon's configuration is 
removed after ring cleavage, although each intermediate diastereomer could have 
different ee. As a result, we set out to develop the reaction using commercial 
cyano-THT 114, first reported in the preparation of alkenyl nitriles by Baraldi et al. in 
1985, as the a-acrylate anion surrogate.[174] We chose b-methyl enone 4a as a 
representative acylimidazole substrate. The racemic Michael adduct 115a was 
prepared in 60% yield as a single diastereomer using a copper catalyst [Cu(NO3), 
L12 (20 mol%), DMF], and the alkenyl nitrile 116a was obtained in 48% yield in a one-
pot operation [K2CO3, DMF] (Scheme 40). 
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Scheme 39. General strategy for the conjugate addition of α-acrylate anion surrogates
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Having confirmed the reactivity of 4a with THT a-acrylate anion surrogates, we 
started to study the conjugate addition under DNA-compatible conditions.2 To our 
delight, alkenyl nitrile 116a was directly observed upon HPLC analysis of the crude 
reaction mixture. Interestingly, the aqueous buffer used as solvent was sufficient to 
trigger the in situ retro-Dieckmann fragmentation of intermediate THT 115a. After an 
extensive screening, a modest ee of 31% was obtained for a 50% yield (Scheme 41). 
 
Unfortunately, as was the case for the 1,3-dipolar cycloaddition between 
enone 4a and nitrile oxides (chapter 1.2), the undesired hydration of the enone was a 
major competitive pathway to the formation of the desired product. Therefore, 
despite our long-standing interest in DNA-based catalysis and the effectiveness of 
conducting the Michael addition and retro-Dieckmann ring cleavage in one-pot 
fashion, we started to explore more traditional catalytic systems to effect the 
transformation. 
  
 
2 DNA-based conditions were investigated by Nicolas Duchemin and will not be detailed in this thesis. 
O
Me
Scheme 41. Model Michael addition/retro-Dieckmann using DNA-based catalysis
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2.3. Asymmetric 1,4-additions on a,b-unsaturated carbonyls 
While biohybrid catalytic systems are on the rise, chemists have long relied on 
bespoke small-molecules to trigger reactions and exert stereocontrol. The Michael 
addition is no exception: indeed, since its discovery more than a century ago, it has 
become an essential part of the organic synthesis toolkit.[187] In the first 
enantioselective version of the reaction, reported in 1975, the 1,4-addition of 
nitroalkane 117 onto enone 118 was mediated by quinine 119, allowing the formation 
of ketone 120 in 56% ee (Scheme 42).[188] Various organocatalysts and transition metal 
catalysts have been developed since then.[189,190] Having already confirmed the ability 
of a copper-based catalyst to mediate our model reaction using DNA as the chiral 
inductor, we decided to focus on Lewis acid catalysis. 
 
Bis(oxazoline) derivatives, sometimes known as BOX ligands, stand as one of 
the most reliable family used in copper-catalysed conjugate additions. Inspired by 
vitamin B12 and earlier oxazoline ligands such as L21, they were introduced 
by Nishiyama in 1989 for the rhodium-catalysed hydrosilylation of ketones.[191] They 
rapidly rose to prominence thanks to their ease of synthesis, with both enantiomers 
available, and the accessibility of numerous bespoke analogues which in turns offer a 
notable flexibility when optimising new processes (Figure 9).[192,193] Further, their 
C2-symmetry makes them more likely to produce high selectivities thanks to the 
halving of possible diastereomeric transition states.[194] In fact, the bis(oxazoline) 
framework has found so many applications from cycloadditions to oxidations to 
cyclopropanations that they can be considered a privileged structure.[195] 
The most frequently used BOX ligands are formed by two 2-oxazoline rings 
linked by a methylene spacer at the 2-position (L22-L29). The spacer can be 
functionalised by groups of various sizes (L23-L25). The 4- and sometimes 5- position 
of the oxazolines are also substituted, conferring its chirality to the ligand. This 
framework leads to the formation of six-membered metal chelates, with the face-
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Scheme 42. First enantioselective Michael addition
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selective ring substituents in close proximity to the centre of the complex and the 
newly created chiral centre. The core oxazolines may also be linked directly together, 
which results in five-membered metal complexes. Conversely, larger spacers can be 
used, such as a pyridine (L30-L32, henceforth reference to as PyBOX) or a bypiridine 
(L33, BipyBOX). More exotic linkers have also been explored to restrain the 
conformation in specific ways.[192] 
 
The behaviour of those ligands in conjugate additions was pioneered by 
Bernardi et al. who demonstrated that copper/BOX complexes can promote the 
Mukaiyama Michael addition of enolsilanes on a,b-unsaturated carbonyls.[196] Later, 
the reaction was extensively investigated and the stereoselectivity significantly 
improved (ees > 90%) by Evans and co-workers (Scheme 43.A).[197–200] The Jørgensen 
group also obtained excellent selectivities in the Friedel-Crafts acylation of 
a,b-unsaturated esters (Scheme 43.B).[201,202] Using similar catalytic complexes, the 
same group realised the asymmetric Michael addition of 1,3-dicarbonyl and enamine 
nucleophiles.[203] However, the successful application of Cu/BOX catalysts is not a 
given: some groups have attempted to use them in the Michael additions of b-
ketoesters and enones, only to obtain the products in negligible ees.[204] This type of 
transformation was only achieved in high selectivities by Nagorny et al. recently 
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(Scheme 43.C).[205] Aside from carbon nucleophiles, the formation of carbon–
heteroatom bonds has also been implemented using amines and carbamates, albeit in 
somewhat lower selectivities.[206–208] 
 
The efficacy of BOX ligands in asymmetric catalysis is not restrained to copper. 
As most of the applications described above rely on the Lewis acidity of the metal, 
similar complexes have been studied, including zinc, nickel, magnesium, calcium, 
scandium and other rare earths.[193] For instance, scandium has met with much 
success, although it is generally more efficient when coupled to PyBOX ligands such as 
L30-L32. After being introduced independently by Desimoni and Evans in 2001,[209,210] 
the latter's group obtained convincing results (ees > 90%) in the Friedel-Crafts 
alkylation of a,b-unsaturated carbonyls.[62,211,212] More recently, high yields and 
enantioselectivities were also reported in the Mukaiyama-Michael reaction, including a 
vinylogous version by Singh et al.[213,214] Nowadays, copper/BOX complexes remain a 
staple choice, but alternative metals are routinely screened when the latter fail to 
deliver satisfactory yields and selectivities.  
The BOX structure's track-record as a source of chiral induction in transition 
metal catalysed 1,4-additions convinced us to focus on this ligand class; conveniently, 
many are commercially available. With this in mind, we embarked on the investigation 
of various experimental parameters. 
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2.4. Development of an enantioselective Michael addition/retro-
Dieckmann sequence 
2.4.1. Copper mediated Michael addition 
While the choice of Lewis acid is a foremost consideration, we initially elected 
to focus on copper-based conditions due to the limited success of our DNA-based 
copper catalyst. To our delight, early experiments showed that the Michael addition 
proceeded smoothly in the presence of Cu(OTf)2 (10 mol%) in methylene chloride. 
Conveniently, the adduct was obtained essentially as a single diastereomer as drs were 
superior to 95:5 (indicated by HPLC and 1H NMR analysis). Pleasingly, our first attempts 
to use chiral BOX ligands yielded 115a in decent ees. Early experiments confirmed that 
the preformation of the catalytic complex requires stirring for at least 30 min to ensure 
the highest possible enantioselectivity, consistent with early studies of this catalyst 
class.[215] In addition, to reduce the risk of moisture impacting the reaction by 
deactivating the copper, care was taken to dry the catalyst and ligand under high-
vacuum prior to solvent addition. 
Therefore, we embarked on an optimisation based on yield (measured by NMR 
using CH2Br2 as an internal standard) and enantiomeric excess (measured by chiral 
HPLC). We started with a survey of ligands and, given the major influence that the 
solvent can hold on this type of reaction, we elected to screen a set of commercial 
oxazolidines in both CH2Cl2 and toluene (Table 12). Reactions run in the former 
demonstrated that decent to high yields could be obtained across the board 
(generally, 59–89%), but selectivity was more challenging to achieve (Table 12, 
entries 1-12). For instance, non-C2-symmetric oxazoline L21 gave the product in 89% 
yield but with a mediocre ee of 30% (Table 12, entry 1). Likewise, PyBOX and BipyBOX 
ligands L30-33 failed to afford acceptable ees (10–31%, Table 12, entries 10-12). Some 
of the BOX derivatives did not do better, especially the 4-tert-butyl derivatives L22 and 
L23 (ee = 10-14%), and the 4-benzyl L28 (ee = 24%). In contrast, BOX L26-27 and L29, 
incorporating an i-propyl, a phenyl or a bridged indane, provided the Michael adduct 
with high selectivities (71-93%, Table 12, entries 6, 7, 9). Comparatively, ligands with a 
bulky spacer such as L24 and L25 gave lower ees than their methylidene or 
isopropylidene analogues (Table 12, entries 4-5). These results clearly point to the 
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4-phenyl derivative L27 as the frontrunner, with 115a obtained in 93% ee, albeit in a 
somewhat lower yield of 59%. 
In the case of the reactions run in toluene, complete conversion of 4a usually 
took longer to reach, with a two- to ten-fold increase of the reaction time, and lower 
yields were observed in most cases. This is probably linked to the lower solubility of 
the ligand and the resulting catalytic complex. For instance, the reaction with 
oxazoline L21 could not be run due to the very poor solubility of the ligand (Table 12, 
entry 13). Nevertheless, some similarities with CH2Cl2 stand out: PyBOX and BipyBOX 
L30-33 again induced a low selectivity (ee = 6-21%, Table 12, entries 22-24) as well as 
4-tert-butyl BOX L22 and L23 (ee = 6-16%, Table 12, entries 14-15). The other BOX 
derivatives gave the product in decent ees (65-84%, Table 12, entries 16-21). Most of 
the ligands actually performed better in toluene than CH2Cl2, except surprisingly L27 
(75% instead of 93% ee). Overall, the bridged indane L29 was the most selective in 
toluene, affording 115a in 84% ee and a high 77% yield. 
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The ligand survey showed that the BOX framework is instrumental to reach 
high selectivities compared to other oxazoline-based structures, hinting at the 
importance of the six-membered copper chelate. A second important factor is 
underlined by the inverse correlation between the steric bulk of the ligand's blocking 
group and the chiral induction. This trend suggests a more fundamental challenge to 
exert stereocontrol in this reaction, which results in the formation of a new quaternary 
Table 12. Initial screening: ligands and solventsa
11 L32
12 L33
aAll reactions were run on a 0.27 mmol scale at a concentration of 0.1 M.bNMR yield using CH2Br2.
ND = not determined. cDetermined by chiral HPLC analysis.
9 L29
10 L30
Entry Ligand eec (%)Yieldb (%)
Solvent
0 °C
Cu(OTf)2 (10 mol%)
Ligand (11 mol%)
4a
+
10 min
1 h
1 h
24 h
Reaction time
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
Solvent
L22
5 L25
6 L26
2
3 L23
4 L24
8 L28
7 L27
30 min
24 h
10 min
10 min
5 min
24 h
30 min
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
112 (1.1 equiv.)
L211 30 minCH2Cl2 89
ND
ND
72
63
88
59
ND
75
66
83
84
30
10
13
74
31
60
71
10
14
45
24
93
O
MeN
N
Me
SO
CNO Me
113a
N
N
Me
S
O
CN
23 L32
24 L33
21 L29
22 L30
2 h
3 h
3 h
90 min
Toluene
Toluene
Toluene
Toluene
L22
17 L25
18 L26
14
15 L23
16 L24
20 L28
19 L27
3 h
3 h
2 h
90 min
30 min
24 h
60 min
Toluene
Toluene
Toluene
Toluene
Toluene
Toluene
Toluene
L2113 N/AToluene 0
ND
ND
76
46
69
66
72
77
ND
ND
ND
N/A
8
21
84
6
79
65
6
16
70
67
75
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centre: the approach of the substrate must be tightly controlled, but at the same time 
the catalytic centre has to remain accessible in a sterically demanding environment. 
At this stage, we turned our attention to other experimental parameters, while 
still considering both L27 and L29. Starting with L29, which had more room for 
improvement in terms of selectivity but gave the product in higher yield, we tried 
various solvents (Table 13, entries 1-8). Some of the most common choices with 
Cu/BOX catalysts, such as Et2O and acetonitrile, gave low yields and ees, while 
chloroform fared little better. Methanol, while enabling the formation of the product 
in 81% yield, also led to a mediocre selectivity (ee = 44%). Solvents more similar to 
toluene, such as m-xylene, THF or 1,4-dioxane also gave similar results (yields of 
57-72%, ees in the 76–81% range), but none could outperform it. Continuing our 
survey in toluene, we tried to use HFIP as an additive, but its influence on the outcome 
was detrimental (ee = 70%, Table 13, entry 9). A slow addition of nucleophile 114 over 
30 min (using a syringe pump) was detrimental as well (ee = 78%, Table 13, entry 10). 
Next, we studied the influence of the catalyst loading: lowering it to 5 mol% instead of 
10% led to a noticeable plunge in yield and selectivity, whereas increasing it to 20 
mol% was slightly beneficial (yield of 84% and ee = 86%, Table 13, entries 11-12). While 
the catalyst was barely soluble in toluene at this stoichiometry, sonicating the catalyst 
mixture prior to adding the substrate had no impact (Table 13, entry 13). Increasing 
the amount of nucleophile did not improve the yield and had a negative effect on the 
enantioselectivity (Table 13, entries 14-15). Switching from copper triflate to copper 
hexafluoroantimonate also resulted in lower yields and ees (Table 13, entry 16). 
Finally, the influence of the temperature was assessed (Table 13, entries 17-18). Not 
unexpectedly, at r.t., the product was obtained in lower ee (58%). At –20 °C, the ee 
remained the same as that obtained at 0 °C (86%), however the reaction took much 
longer to reach completion (16 h). 
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After this extensive survey of conditions based on L29, we turned back to L27, 
which had furnished 115a with a better ee of 93% (Table 14). Upon switching the 
solvent to THF or CHCl3, the yield and selectivity plummeted, confirming CH2Cl2 as 
optimal for this ligand (Table 14, entries 3-4). Given the high performance of this 
Cu(OTf)2/L27/CH2Cl2 system, we next examined the influence of various additives on 
the reaction, and found that an equimolar quantity of ethanol was well tolerated 
(ee = 90%, Table 14, entry 5). Interestingly, this experiment suggests that substrates 
bearing a free hydroxyl group should be compatible. Conversely, the addition of 
triethylamine reduced both the yield and the selectivity of the reaction (ee = 21%), 
probably due to an expected poisoning of the catalyst (Table 14, entry 6). Finally, we 
Table 13. Further screening of conditions using L29a
Toluene 20 mol%
9
10
aAll reactions were run on a 0.27 mmol scale at a concentration of 0.1 M, using 1.1 equiv. of ligand 
relative to Cu(OTf)2. bNMR yield using CH2Br2. ND = not determined. cDetermined by chiral HPLC 
analysis.
12
13
Entry eec (%)Yieldb (%)
Solvent
0 °C
Cu(OTf)2
L29
4a
+
-
30 min sonication
with 1 eq. HFIP
addition of 112 over 30 min
Other variation from conditions
11
1
-
-
112 (1.1 equiv.)
77
53
84
83
ND
57
70
78
86
86
78
84
O
MeN
N
Me
SO
CNO Me
113a
N
N
Me
S
O
CN
Toluene
Toluene
10 mol%
5 mol%
Solvent
Toluene
Toluene
Toluene
Toluene
Copper charge
20 mol%
20 mol%
18 reaction run at -20 °C 52 86
10 mol%
10 mol%
5
4
-
-
3 - 47
81
23
44
60
58MeCN 10 mol%
CHCl3
MeOH
10 mol%
10 mol%
7
8
-
-
6 - 57
86
72
78
81
76m-Xylene 10 mol%
Dioxane
THF
10 mol%
10 mol%
14 with 1.5 equiv. of 112 57 68Toluene 20 mol%
15 with 2.0 equiv. of 112 57 58Toluene 20 mol%
17 reaction run at r.t. 57 58Toluene 20 mol%
2 - 21 30Et2O 10 mol%
Toluene 20 mol%16 Cu(SbF6)2 instead of Cu(OTf)2 44 68
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prepared the Cu(OTf)2L27 complex and confirmed that it gives 115a in essentially the 
same yield and selectivity as when adding Cu(OTf)2 and the ligand separately (Table 14, 
entry 7).[216] The preformation of the catalytic complex is particularly convenient 
experimentally, given that L27 is a waxy solid difficult to weigh out, whereas 
Cu(OTf)2L27 was isolated as a weighable blue solid (stable over weeks in a dry box). 
 
 
2.4.2. Retro-Dieckmann fragmentation 
Once we had tuned conditions for the Michael addition of 4a on enone 114, we 
had to optimise the retro-Dieckmann fragmentation of intermediate 115a to the 
alkenyl nitrile 116a. In the original work by Baraldi, a treatment with NaOH in an 
Et2O/THF mixture was used, but early experiments showed that this protocol led to the 
formation of byproducts, including the reformation of the starting acylimidazole. In 
addition, control experiments showed a slight erosion of the ee between the Michael 
adduct and the isolated retro-Dieckmann product (4-5% reduction). Hence, we 
screened alternative hydroxide sources and solvents (Table 15). Potassium carbonate 
failed to trigger the fragmentation in useful yields and provoked instead degradation 
to unidentified byproducts (Table 15, entries 1-3). Sodium methoxide was more 
effective, with an NMR yield of 61%, but it took 2 d to reach full conversion (Table 15, 
Table 14. Further screening of conditions using L27a
CH2Cl2 -
5
6
aAll reactions were run on a 0.27 mmol scale at a concentration of 0.1 M.bNMR yield using CH2Br2.
ND = not determined. cDetermined by chiral HPLC analysis.
3
4
Entry eec (%)Yieldb (%)
Solvent, Additive
0 °C
Cu(OTf)2 (10 mol%)
L27 (11 mol%)
4a
+
-
-
-
-
Other variation from conditions
2
1
-
-
112 (1.1 equiv.)
59
66
33
54
75
38
90
21
37
52
75
93
O
MeN
N
Me
SO
CNO Me
113a
N
N
Me
S
O
CN
CH2Cl2
Toluene
-
-
Solvent
CH2Cl2
CH2Cl2
CHCl3
THF
Additive
-
-
7 Preformed Cu(OTf)2•L27complex was used 60 92
EtOH (1 equiv.)
NEt3 (1 equiv.)
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entry 4). We then found that tetra-n-butylammonium hydroxide (TBAH) in CH2Cl2 
triggers the reaction in 76% yield (Table 15, entry 5). Lowering the reaction 
temperature and switching the solvent to methanol or THF resulted in reduced yields 
(Table 15, entries 6-8). Henceforth, upon completion of the Michael addition, the 
reaction was treated with TBAH (2 equiv. relative to the THT), avoiding the isolation of 
the intermediate adduct. 
 
The optimised one-pot experimental protocol, with the preparation of the 
Cu/L27 complex in advance, is relatively straightforward. The use of the BOX ligands in 
organic solvents under anhydrous conditions furnished the Michael adduct in decent 
yield and high selectivity. Moreover, among the many other metals known to promote 
conjugate additions, copper is one of the most appealing. In particular, it is much more 
abundant and generally less toxic than alternative metals. Yet, we were intrigued by 
the large body of work on the applications of lanthanide/BOX complexes in 
asymmetric conjugate additions. Therefore, we decided to run additional experiments 
with scandium triflate instead of copper. 
 
  
Table 15. Improvement of the retro-Dieckmann stepa
aAll reactions were run on a 0.14 mmol scale at a concentration of 0.1 M. bNMR yield using CH2Br2.
ND = not determined. c0.25 M in MeOH. dTBAH = tetra-n-butylammonium hydroxide, 1 M in MeOH.
eReaction run at -78 °C.
Entry Hydroxide source Yieldb (%)
Solvent
Hydroxide source
Reaction timeSolvent
5
6e
2
3
4
8
7
12 h
12 h
2 d
5 min
45 min
5 min
5 min
MeOH/H2O (5:1)
CH2Cl2/H2O (3:2)
CH2Cl2
CH2Cl2
CH2Cl2
THF
MeOH
1 12 hMeOH/H2O (5:1) 0
<5
<5
61
76
59
13
27
SO
CNO Me
113a
N
N
Me
CN
O Me
114a
N
N
Me
K2CO3
K2CO3
K2CO3
MeONac
TBAHd
TBAHd
TBAHd
TBAHd
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2.4.3. Scandium mediated Michael addition 
Based on previous reports in the field, we initially screened a number of ligands 
in CHCl3, using conditions similar to those established for the copper system: 1.1 equiv. 
of 114, a 10 mol% catalyst loading and a reaction temperature of 0 °C (Table 16). With 
oxazoline L21, the Michael adduct was formed in 67% yield but 0% ee (Table 16, 
entry 1). As could be expected, BOX L27 and BipyBOX L33 also performed poorly: with 
L27, the product was obtained in 69% yield, while with L33 the reaction had not 
reached completion after 24 h; in both cases, no selectivity was observed (Table 16, 
entries 2 and 6). PyBOX ligands were more efficient, inducing moderate to high ees 
(Table 16, entries 3-5). In particular, we were happy to find that the scandium/L32 
combination afforded the product in 83% yield and 93% ee. This compared favourably 
to the copper/L27 catalyst which gave a similar selectivity but a lower yield of 59%. A 
brief comparison of CHCl3 with CH2Cl2 and toluene confirmed the former as the solvent 
of choice, as the product was otherwise formed in a lower ee (Table 16, entries 7-8). 
Given the outcome of this short survey of scandium-based conditions, we settled on 
this protocol, henceforth referred to as Sc/L32 conditions. 
 
Having explored a range of parameters to improve the model reaction 
outcome, an examination of the molar price of the catalysts shows that, based on the 
Sigma Aldrich catalogue, the respective chiral ligands are 10–40 times more expensive 
Table 16. Screening of ligands and solvents with Sc(OTf)3a
aAll reactions were run on a 0.27 mmol scale at a concentration of 0.1 M.bNMR yield using CH2Br2.
ND = not determined. cDetermined by chiral HPLC analysis.
Entry Ligand eec (%)Yieldb (%)
Solvent
0 °C
Sc(OTf)3 (10 mol%)
Ligand (11 mol%)
4a
+
Reaction timeSolvent
L27
5 L32
6 L33
2
3 L30
4 L31
8 L32
7 L32
30 min
3 h
30 min
30 min
24 h
2 h
15 min
CHCl3
CHCl3
CHCl3
CHCl3
CHCl3
Toluene
CH2Cl2
112 (1.1 equiv.)
L211 2 hCHCl3 67
69
ND
69
83
ND
ND
54
0
93
0
0
56
44
88
80
O
MeN
N
Me
SO
CNO Me
113a
N
N
Me
S
O
CN
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than the metal source. This renders the ten-fold cost difference between copper and 
scandium virtually moot, and the two-fold cost of L32 compared to L27 makes the use 
of the copper/L27 complex more effective. In addition, the scandium protocol requires 
to use CHCl3 as the solvent, which is less desirable than CH2Cl2 from an environmental 
and a toxicity standpoint. Yet, given the increased yield and comparable selectivity of 
the Sc/L32 catalyst, it is difficult to favour one method at this stage. 
 
  
  
 
84 
2.4.4. Mechanistic considerations 
The extensive body of work in BOX-controlled Michael additions offers a strong 
rationale for the selectivity of the copper catalyst (Figure 10). Crystal structures have 
shown that Cu/BOX complexes involve a square-planar, or distorted square-planar, 
coordination geometry.[200] Upon chelation, the bidentate Michael acceptor 4a would 
therefore occupy the same plane as the oxazolines, and nucleophilic attack from the 
less hindered a-Re face would yield (S)-115a. 
 
Despite their chelation to a tridentate ligand, Sc/PyBOX complexes can 
accommodate a higher coordination number and adopt both octahedral and 
pentagonal bipyramidal geometries (Figure 11.A). The combination of a bulky 
substrate with a hindered ligand can limit the catalytic intermediate to the octahedral 
configuration, while smaller molecules such as acylimidazoles 4 can form seven-
coordinate complexes incorporating two equivalents of substrate3 (Figure 11.B).[211] 
The planar imidazoles occupy equatorial sites, leaving the carbonyls at the apical 
positions. In this situation, the a-Re face is less shielded by the PyBOX, leading to the 
addition product (S)-115a, the same as that obtained with the Cu/L27 catalyst. 
 
3 A similar complex would be obtained if one molecule of substrate 4a were replaced by a 
molecule of the conjugate addition product, 115a. 
Figure 10. Proposed origin of enantioselectivity with the Cu/L27 catalyst
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While the absolute configuration of the new stereogenic centre has not been 
confirmed at this stage, HPLC analysis shows that both catalytic systems yield the same 
enantiomer of alkenyl nitrile 116a, despite the opposite absolute configuration of L27 
and L32. This observation lends credence the binding modes presented above 
(Figure 12). 
 
  
Figure 11. Origin of enantioselectivity with the Sc/L32 catalyst
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2.5. Scope of the Michael addition/retro-Dieckmann sequence 
With optimised conditions in hand for the Michael addition of THT 114 on 
enone 4a, it was time to investigate the tolerance of the reaction to structural 
modifications. Michael acceptors 4 can potentially bear various b-substituents R' to 
access diversely decorated stereocenters, whereas alternatives to the 
N-methylimidazole chelating moiety may impact the stereoselectivity and yield of the 
reaction, as well as provide different post-functionalisation possibilities. In addition, 
we were eager to explore other THT reagents to prepare more complex acrylates. 
 
2.5.1. Variation of the scope of enone substituents 
We started to explore the scope by changing the enone b-substituent, which 
can have a drastic influence on the steric and electronic properties. The substrates 
were prepared by one of three methods depending on the chemical group, following 
reported procedures. When possible, an aldol condensation was used, which was 
mostly applicable for aromatic derivatives. Conversely, alkyl substituents were usually 
assembled either via a Horner-Wadsworth-Emmons or a 1,2-addition of 
N-methylimidazole on the corresponding a,b-unsaturated aldehyde. 
The aldol route started with the addition of N-methylimidazole 121 on 
4-acetylmorpholine 122 [n-BuLi, THF, -78 °C] to provide intermediate ketone 123 in 
70% yield (Scheme 44). The latter was then engaged in an aldol condensation with 
aldehydes 124 to deliver the desired substrates 4. In most cases, experimentally 
straightforward conditions delivered the a,b-unsaturated carbonyl in high yields 
[Method A: KOH, EtOH].[50] Hence, various aromatic substrates were obtained in 
70-98% yield, including phenyl, 4-chlorophenyl, 4-methoxyphenyl and 
2,6-dimethylphenyl functionalised enones 4e,h,i,j. The heteroaromatic 2-furyl 
derivative 4k was prepared as well in 77% yield. tert-Butylaldehyde also furnished the 
desired enone 4d (85%). However, this procedure failed to afford the cyclohexyl 
derivative 4g, which was eventually prepared under cryogenic conditions in 44% yield 
[Method B: LDA, THF, -78 °C].[217] 
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Several other substrates were synthesised from aldehyde precursors 124, 
which were engaged in a HWE olefination with phosphonate 125 [NaH, THF, -78 °C]. 
The resulting Weinreb amides 126 readily underwent 1,2-addition upon treatment 
with lithiated N-methylimidazole 121 [n-BuLi, THF, -78 °C] (Scheme 45).[63] This 
approach furnished the i-propyl, cyclopropyl and i-butyl derivatives 4c,l,m in 37-46% 
yield over two steps.  
 
A different option was followed when a,b-unsaturated aldehyde precursors 127 
were commercially available. In this case, the aldehyde was treated with 
N-methylimidazole [n-BuLi, THF, -78 °C] to furnish alcohol 128, which was then 
oxidised to the desired ketone using MnO2 [THF, 0 °C] (Scheme 46).[63] This approach 
allowed the preparation of the ethyl and heptyl derivatives 4n and 4o in 53% and 54% 
yield, respectively. 
Scheme 44. Preparation of enones by an aldol reaction
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Additionally, a,b,g,d-unsaturated acyl imidazole 4p was generated in one step 
from sorbic acid 129, through the 1,2-addition of lithiated N-methylimidazole 121 
[n-BuLi, THF, –78 °C, 61%] (Scheme 47). 
 
With a set of a,b-unsaturated acyl imidazoles in hand, we attempted the one-
pot Michael addition/retro-Dieckmann cascade with cyano-THT 114. First and 
foremost, the racemic products were prepared using achiral catalyst Cu(OTf)2/L11 in 
CH2Cl2. While most substrates readily underwent the sequence, the tert-butyl and 
2,6-dimethylphenyl derivatives 4d and 4h failed to react with 114, even upon trying 
harsher conditions [Cu(OTf)2/L11, DMF, 80 °C] (Scheme 48). This lack of reactivity is 
likely due to the larger steric bulk of the substrate precluding the approach of the 
nucleophile, which points to a limit of the reaction.  
 
Scheme 46. Preparation of enones via a 1,2-addition/oxidation sequence
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Scheme 47. Preparation of α,β,γ,δ-unsaturated acyl imidazole 4p
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Scheme 48. Limits of the Michael addition/retro-Dieckmann
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When employing the chiral catalysts Cu/L27, we were pleased to find that most 
alkyl-substituted enones furnished the desired alkenyl nitriles in high selectivities 
(Scheme 49). The best ees were obtained when R' was a secondary carbon (96% for 
ethyl 116n, 95% for n-heptyl 116o and 92% for i-butyl 116m). Tertiary alkyl 
substituents also furnished the products with decent ees (68% for cyclopropyl 116l and 
i-propyl 116c, 70% for cyclohexyl 116g). Moderate to good yields were observed for 
those substrates (33–61%), with the linear alkyls giving the best results. 
In contrast, the Michael addition was much more sluggish for aromatic 
derivatives. Therefore, the reaction was left for longer reaction times (up to two days), 
but while acceptable yields were obtained (59–73%), the selectivity was modest 
(18-48%). In the case of a,b,g,d-unsaturated substrate 4p, the 1,4-addition 
acrylate 116p was isolated in 55% yield, consistent with the b-carbon having the 
largest coefficient of the LUMO, albeit as a racemate. Subsequently, upon HPLC 
monitoring of the reaction before quenching with TBAH, we determined that the 
Michael adduct was initially formed in a modest 28% ee, but that the intermediate 
suffered an erosion in ee before the final retro-Dieckmann fragmentation. Considering 
the slower reaction rate for those substrates, it is possible that the chiral catalyst's 
activity decreases over the course of the reaction, leading to a larger amount of 
product formed in a non-selective background process. In addition, the 
enantioenriched intermediate enolate is susceptible to undergo a retro-Michael 
addition, regenerating enone 4. Under the conditions, higher ees for aromatic 
substrates can only be obtained at the cost of a lower yield by stopping the reaction 
before completion. 
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Upon switching the catalyst to Sc/L32, a markedly consistent enantioselectivity 
was observed (Scheme 50). Once again, the alkyl substituents were well tolerated, as 
the desired alkenyl nitriles were formed in generally better ees than with the copper 
catalytic system. In particular, secondary alkyls were obtained in 88–94% ee and the 
tertiary ones in 76–84% ee. The yields were also improved, staying in a 43–72% range. 
Again, aromatic substrates were less accommodating, requiring longer reaction times 
(1-2 days) and delivering the corresponding alkenyl nitriles in moderate yields and 
selectivity (56–70% ee). 
Scheme 49. Scope of the Michael addition/retro-Dieckmann using the Cu/L27 catalyst
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From a practical point of view, we have demonstrated that our two catalytic 
protocols can deliver the Michael adducts in high selectivity, and that somewhat better 
results are usually obtained with Sc/L32 rather than with Cu/L27. The results 
presented herein show that the Michael addition/retro-Dieckmann sequence is most 
effective for b-alkyl substrates. The significantly different behaviour of b-aryl enones 
suggests that a new optimisation of the conditions or possibly a markedly different 
catalytic system may be required to obtain these substrates with higher selectivities. 
With that in mind, we considered other structural modifications.  
Scheme 50. Scope of the Michael addition/retro-Dieckmann using the Sc/L32 catalyst
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2.5.2. Variation of the acyl chelating moiety 
Further to the enone b-substituent, we wanted to investigate the role of the 
N-methyl acylimidazole bidentate complexing group. To that end, we examined similar 
heterocycles as well as more distinct functional groups, such as an amide and a 
thioester. 
In order to shed some light on the influence of the chelating moiety's steric 
bulk, we prepared the N-isopropyl imidazole analogue in two steps from crotonyl 
chloride 130. The latter was first treated with N,O-dimethylhydroxylamine 
hydrochloride to generate Weinreb amide 131 [pyridine, CH2Cl2, 87%], which was 
subsequently converted to the corresponding N-isopropyl acylimidazole 132 
[N-isopropylimidazole, n-BuLi, THF, -78 °C, 42%] (Scheme 51.A).[62] Conversely, a 
thiazole analogue was synthesised to investigate a comparatively less hindered 
substrate, given the replacement of the methyl-substituted nitrogen with a sulfur 
atom. Indeed, this class of substrates can display high selectivities in conjugate 
additions. The direct addition of TMS-thiazole 133 onto crotonyl chloride 130 [CH2Cl2, 
27%] furnished a,b-unsaturated acylthiazole 134 (Scheme 51.B).[211]  
 
In addition to the carbonyl derivatives described above, we were curious about 
other a,b-unsaturated acyl derivatives. Hence, an amide coupling between 7-azaindole 
amine 135 and crotonic acid 136 produced amide 137 [EDCIHCl, DMAP, CH2Cl2, 16%], 
which has been used in various Lewis acid catalysed reactions (Scheme 52.A).[218,219] 
The activation of this substrate would proceed via a 6-membered metallacycle, unlike 
the 5-membered complex formed with the imidazole and thiazole derivatives. Finally, 
due to their fruitful use in the asymmetric conjugate addition of Grignards,[220] a 
Scheme 51. Preparation of Michael acceptors with different chelating moeities
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thioester Michael acceptor was prepared in three steps. After conversion of 
bromoacetic acid 138 to the thioester [ethanethiol, DCC, DMAP, CH2Cl2], nucleophilic 
substitution with PPh3 and subsequent deprotonation furnished the phosphorus 
ylide 139 in 73% yield.[221] Wittig olefination with benzaldehyde then yielded the 
a,b-unsaturated thioester 140 with an excellent (E)-selectivity [CHCl3, 95%] 
(Scheme 52.B). 
 
When we treated the Michael acceptors with THT 114 in the presence of 
copper catalyst [CH2Cl2], several failed to engage in the conjugate addition: the 
Weinreb amide 141, the 7-azaindole amide 142 and the thioester 143 were not formed 
(in fact, no conversion of the substrate was observed whatsoever), even upon heating 
the reaction mixture to reflux (Scheme 53). A tentative effort to convert commercially 
available trans-b-nitrostyrene to 144 also failed to proceed under these conditions. 
However, we were pleased to see the formation of N-isopropylimidazole 145 and 
thiazole 146. Upon using the chiral catalytic system Cu/L27, we found that 145 was 
generated in 25% yield and 70% ee, which was significantly less satisfactory than the 
model substrate 116a (63% yield, 93% ee). Similarly, using the Sc/L32 catalyst, 145 was 
obtained in 44% yield and 92% ee; a better yield (83%) and similar enantioselectivity 
was observed for the model substrate 116a. This points to a detrimental influence of 
larger chelating groups. Conversely, thiazole 146 was obtained in high yield (68%) and 
98% ee, the best selectivity so far with our scandium catalyst.  
HO
O
Br
1) EtSH, DCC
    DMAP, CH2Cl2
EtS
O
PPh3
Ph
O
H
136
2) PPh3, PhH
    then aq. Na2CO3
    73% (2 steps)
137
EtS
O
138
PhCHCl3
reflux
95%
Scheme 52. Preparation of additional Michael acceptors
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This survey of common alternatives to the N-methylimidazole moiety shows 
that having a bidentate coordination motif is not enough to ensure the Michael 
addition can proceed. Only a,b-unsaturated carbonyls with a b-nitrogen available for 
the formation of a metallacyclopentane delivered the desired adducts. In addition, a 
detrimental effect of the steric bulk of the chelating group was observed as lower 
yields and selectivities were obtained with an N-isopropylimidazole; conversely, the 
enantiodiscrimination was best with smaller thiazole 146. Those considerations 
suggest that bulkier chelating groups may hinder the approach of the nucleophile from 
the ligand-favored face, possibly by distortion of the complex.  
Despite the strong credentials of the N-methylimidazole when it comes to post-
synthetic transformations,[60–63] the excellent selectivity obtained with a thiazole 
moiety suggests that further attempts to expand the scope of the Michael 
addition/retro-Dieckmann sequence could be based on this heterocycle. 
 
2.5.3. Variation of the scope of THT acrylate synthons 
Several acrylate synthons were reported in the seminal work by Baraldi and 
co-workers: 4-methoxycarbonyl THT 147, 4-methoxycarbonyl-5-methyl THT 148 and 
bicyclic diketones 149 and 150 (Figure 13).[171,173] Of those, only 147 is commercially 
available. Thus, methods to convert an acrylic derivative to the a-anion surrogate are 
needed to expand the scope of the strategy beyond the formation of alkenyl nitriles. 
Scheme 53. Influence of the chelating group R'' on the conjugate addition
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The THT surrogates 104 are usually prepared in moderate yields from methyl 
thioglycolate 151 and a parent acrylate 152 through a cascade Michael addition of the 
thiolate followed by Dieckmann cyclisation of the resulting diester (Scheme 54).[222] For 
instance, 147 was obtained in 67% yield under optimised conditions.[223] However, this 
approach suffers from selectivity issues as during the cyclisation, non-symmetric 
diesters can give two different isomers, which are generally obtained as a mixture. The 
ratio of products is highly dependent on the experimental conditions and the 
separation of isomers can be challenging. 
 
Efforts to develop more selective Dieckmann condensations were pioneered 
with the development of a dithiol ester variant, which proceeds in high yields under 
milder conditions.[224] Inspired by this work, Yamada et al. reported a selective 
synthesis of b-ketoesters using half-thiol diesters. In particular, 153 was converted to 
THT 154 in 70% yield (Scheme 55).[225] However, the preparation of the precursor half-
thiol diester requires several steps. A similar tactic leveraging the difference of 
reactivity between Weinreb amides and esters was successful in ensuring the 
chemoselective formation of cyclic b-ketoesters and b-ketoamides, albeit no example 
of THT were reported.[226] As a result, further investigations will be necessary to ensure 
a more convenient transformation of a-acrylates to the corresponding THT surrogates. 
 
Figure 13. Reported α-acrylate anion surrogates
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Scheme 54. Preparation of α-acrylate anion surrogates from acrylate and thioglycolate
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During our investigations, we converted cyclohexenone 155 to its THT 
surrogate 149 [methyl thioglycolate 151, MeONa, MeOH, 0 °C to reflux, 43%] 
(Scheme 56.A). The asymmetric Michael addition/retro-Dieckmann sequence was then 
attempted with both 149 and commercially available 147. The reaction of 147 with 
a,b-unsaturated ketone 4a in the presence of Cu/L27 was slow; full conversion was 
only reached after one day. The desired acrylate 156 was eventually isolated in a low 
yield (36%) and a modest ee (60%) (Scheme 56.B). Unfortunately, conducting the 
reaction with Sc/L32 was even worse as no product was generated under otherwise 
identical conditions. Turning to cyclohexanone derivative 149, we were unable to 
obtain the product, either in the presence of a copper/L11 catalyst in CH2Cl2 under 
reflux, or using K2CO3 in refluxing acetone. 
 
Finally, we considered derivatising the THT with an ancillary amine, which gives 
a nucleophilic enamine. This strategy has been extensively applied to asymmetric 
Michael additions based on a chiral auxiliary.[227,228] Therefore, cyano-THT 114 was 
treated with benzylamine to afford enamine 157 in 73% [Na2SO4, benzene, 80 °C] 
(Scheme 57). The latter was then engaged in the Michael addition with 4a in the 
presence of the copper/L27 catalyst, but only limited conversion was observed by TLC, 
showing the reaction to be much slower, and HPLC analysis of the crude mixture 
revealed that the product was formed with virtually no selectivity (ee = 12%). The utter 
failure of the enamine nucleophile to improve on previous results with this substrate 
discouraged us to try to derivatise other THT such as 147. 
Scheme 56. Study of the scope of THT derivatives
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As we have shown, generalising the Michael addition/retro-Dieckmann 
sequence to other THT nucleophiles is not obvious, as conditions optimised for 
THT 114 transferred with limited success to 147 and 149. With such a limited subset of 
a-acrylate anion surrogates, it is difficult to draw firm conclusions. Yet, the prominent 
influence of steric parameters on the reaction's outcome is consistent with the better 
results obtained with a small, linear nitrile substituent on the THT nucleophile 
compared to other reagents. Hence, the approach of the nucleophile may simply be 
hindered by sheer steric bulk, resulting in slower reactivity and lower selectivity for 
larger THT derivatives. To sum up, while the approach is efficient to build alkenyl 
nitriles, more work is still needed to fairly assess the tolerance of the method to more 
diverse acrylic derivatives. 
  
Scheme 57. Preparation of α-acrylate anion surrogates from half-thiol diester
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2.6. Synthesis of chromanes using a-acrylate anion surrogates 
 
The benzodihydropyran heterocycle, generally referred to as chromane 
(Figure 14), forms the basis of a number of bioactive compounds. While the parent 
dehydrogenated benzopyran (chromene) template is more commonly encountered in 
natural products and synthetic libraries, the unsaturated chromane analogues can 
exhibit unique activity.[229] The most prominent benzodihydropyrans are probably 
a-tocopherol and the other components of vitamin E, which display important anti-
oxidant and radical scavenging properties (Figure 15).[230] The chromane subunit has 
also been incorporated in several active pharmaceutical ingredients, such as the 
antidiabetic troglitazone,[231] and the selective estrogen receptor modulator 
ormeloxifene.[232] Given these desirable biological properties, there has been a rising 
interest in developing new synthetic methods to build diversely decorated chromanes, 
including asymmetric reactions.[233,234] Among the plethora of approaches, some of the 
most fruitful strategies in recent years have relied on Michael addition/cyclisation 
cascades starting from phenols, or cycloadditions of o-quinone methides.[235–237] 
 
Based on our a-acrylate surrogate approach, we devised a new retrosynthesis 
of a generic chromane 158. The ether ring would arise from the annulation of 
acrylate 159 through an intramolecular conjugate addition of the phenol on the 
Figure 14. Chromane and parent chromene structures and numbering
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electron-poor alkene. The latter compound could be formed by the hydrolytic retro-
Dieckmann fragmentation of 160, obtained via the key Michael addition of THT 104 on 
o-quinone methide 161, which in turn would derive from benzylic alcohol 162. The 
latter would ultimately stem from the 1,2-addition of an organometallic nucleophile 
onto ketone 163 (Scheme 58). This route would potentially furnish diverse substituents 
on the aromatic ring as well as on the pyrane. However, we anticipated that steric 
hindrance may preclude the swift formation of neopentylic intermediate 160; hence, 
we elected to first focus on aldehyde substrates (R2 = H). 
 
To explore the viability of our synthetic plan, we started our project with 
salicylaldehyde 164, which was converted to benzylic alcohol 165 [PhLi, THF, -78 °C, 
59%]. We initially tried to generate the o-methide quinone using a catalytic amount of 
Lewis acid, Sc(OTf)3, in the presence of cyano-THT 114 [toluene]. Though the reaction 
was messy, after purification, the main product was identified as tricyclic adduct 166 
(Scheme 59). The isolation of this product in 24% yield, as a mixture of diastereomers 
in a 3:1 ratio, confirmed that nucleophile 114 does react with the transient o-methide 
quinone, but the resulting phenol then readily attacks the THT ketone. Attempts to use 
nitromethane or HFIP as the solvent resulted in the decomposition of the starting 
material to intractable products. In dichloroethane, 1H NMR showed a small amount of 
166 was present in the crude mixture.  
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Scheme 58. Retrosynthesis of chromanes from THT derivatives
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At this juncture, we decided to protect the phenolic hydroxyl group. Given the 
profusion of electrophilic and nucleophilic sites in the reaction mixture, we reasoned 
that masking the phenol would reduce the potential for by-product formation. Even 
after protection, the doubly benzilic alcohol would still be highly activated and should 
lead to the formation of a carbocationic species, which would undergo a nucleophilic 
attack by THT 114.[238] To this end, salicylaldehyde 164 was acetylated [Ac2O, DMAP, 
pyridine, 98%]. The resulting aldehyde 167 was treated with phenyl lithium 
[THF, -78 °C], but 1H NMR analysis of the crude showed a mixture of aromatic 
products and benzylic alcohol 168 could not be isolated (Scheme 60). 
 
Next, we attempted to use a TBS protecting group. To this end, phenol 165 was 
converted to the bissilyl enol ether 169 [TBSCl, imidazole, DMAP, DMF, 91%], which 
was subsequently treated with PPTS in ethanol, with the aim of deprotecting the 
benzylic alcohol while leaving the phenol ether untouched.[239] The desired product 
was not observed, and instead we isolated ethyl ether 170 in 91% yield (Scheme 61). 
The deprotected alcohol is likely generated transiently, before reacting with the 
solvent under the acid conditions. This observation underscores the high reactivity of 
bisbenzylic alcohols. 
Scheme 59. Initial attempts with a free phenol
162
Ph
O
OH
Ph
OH
O
H
OH
112
Sc(OTf)3 (10 mol%)
Toluene
60 °C, 3 h
24%
CN
S
O
163
THF
59%
PhLi
164
(dr = 3:1)
S
OH
CN
Scheme 60. Tentative synthesis of an acetylated precursor
162
OH
Ph
OAc
O
H
OH
166
PhLi
THF
-78 °C
165
O
H
OAcPyridine
98%
Ac2O
DMAP (10 mol%)
  
 
101 
 
In the end, phenol 165 was selectively methylated to deliver benzylic 
alcohol 171 [MeI, K2CO3, acetone, 89%]. Upon exposure of the latter to cyano-THT 114 
under Lewis acid catalysis [Sc(OTf)3 (10 mol%), toluene, 60 °C, 10 min], the desired 
adduct 172 was obtained in 76% yield, as an inseparable mixture of diastereomers in a 
2.5:1 ratio. Then, retro-Dieckmann cleavage of the THT ring under basic conditions 
furnished alkenyl nitrile 173 in 68% yield [NaOH, H2O/toluene]. After deprotection of 
the phenol [BBr3, CH2Cl2], exposure to K2CO3 [MeCN/H2O, 80 °C] triggered the required 
oxo-Michael annulation to afford chromane 174 in 96% yield over two steps, as a 
separable mixture of diastereomers in a 3:1 ratio (Scheme 62). Hence, we had 
demonstrated the viability of this synthetic route. 
 
The heightened reactivity of bisbenzylic alcohol 171 was also highlighted by the 
formation of a small amount of pseudodimeric ether 175, which stems from the 
nucleophilic attack of one equivalent of the alcohol onto the carbocation generated by 
a second equivalent (Scheme 63). Control experiments showed that, in the presence of 
114 and scandium triflate, ether 175 can undergo fragmentation and conversion to the 
alkylated THT 172. 
Scheme 61. Tentative synthesis of a silyl precursor
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Scheme 62. Completion of the chromane synthetic route
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Moreover, the addition of 114 on 171 was attempted using chiral Brønsted acid 
176 instead of Sc(OTf)3. While the reaction took one day to reach completion instead 
of 10 min, the Michael adduct was obtained in a similar yield of 73%, and a 
comparable dr. The product was slightly enantioenriched, with ee = 15% for the major 
diastereomer and ee = 7% for the minor one (Scheme 64). Although the selectivity is 
limited, this result is encouraging and further investigations using Lewis acid/chiral 
ligand complexes are underway in the group. Furthermore, the diastereoselectivity of 
the final annulation may be improved by a careful control of the reaction conditions or 
the use of a bulkier catalyst. 
 
In a nutshell, a new approach towards the synthesis of 2-nitrile chromanes has 
been devised and validated with the preparation of 174 in 26% yield over six steps. 
Following this proof-of-concept, further work is now needed to assess the generality of 
the reaction and the possibility to generate the products enantioselectively using a 
chiral catalyst. More broadly, the alkylation of a-acrylate anion surrogate 114 with an 
activated alcohol showcases the potential of THT derivatives as versatile synthons to 
access a-functionalised acrylates.  
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Scheme 63. Formation of a pseudodimeric byproduct upon Lewis acid activation
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2.7. Perspectives 
Despite the challenges posed by the intermediate formation of a highly 
hindered quaternary centre, the applicability of THT nucleophiles to act as a-acrylate 
anion surrogates in asymmetric conjugate additions has been convincingly 
demonstrated (Scheme 65). Using a Lewis acid catalyst and a bis(oxazoline) ligand to 
induce the reaction, a variety of a-substituted alkenyl nitriles was prepared in high 
selectivity and decent yields. Limits of the protocol, namely aryl-substituted Michael 
acceptors and bulky substrates, have been identified, calling for further investigations 
to expand the scope of the method. In addition, the newly obtained a-substituted 
alkenyl nitriles exhibit several reactive sites prone to post-functionalisation, which 
make them valuable precursors towards various heterocycles. 
 
In initial efforts to broaden the applications of THT derivatives as a-acrylate 
anion surrogates, we also realised the synthesis of a chromane heterocycle starting 
from salicylaldehyde (Scheme 66). We expect this approach to be useful in the 
construction of a range of chiral derivatives. 
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Scheme 65. Michael addition/retro-Dieckmann of α-acrylate anion surrogates
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3. Development of an expedient entry toward phosphonated 
oxaheterocycles  
3.1. Phosphonic acids and derivatives as relevant tools in 
medicinal chemistry 
3.1.1. General properties of phosphonates 
Phosphonic acids have a rich history in biochemistry, thanks to the unique 
properties of the C-P bond.[240] Indeed, they provide a more stable analogue to the P-O 
bonds found in phosphates. Despite their lower dissociation energy, several factors 
render phosphonates significantly less vulnerable to nucleophilic attack. First, 
carbanions are a poor leaving group compared to alkoxides; furthermore, oxygen 
atoms linked to the phosphorus centre can be activated under acidic conditions, unlike 
their carbon counterparts; finally, upon nucleophilic attack, carbon substituents are 
less electronegative and therefore tend to occupy an equatorial position in the 
pentacoordinate intermediate or transition state, rather than the apical position 
required for a leaving group.[241] This superior metabolic stability has made 
phosphonates useful in medicinal chemistry as mimics of polar groups such as 
phosphates but also carboxylates. Moreover, they have also been used as analogues of 
the unstable tetrahedral intermediates formed in acyl transfer reactions (Figure 16). 
 
As a result of their particular characteristics, many organisms have evolved a 
range of phosphonate metabolites that exhibit various bioactivities, such as the 
bacteria-produced antibiotic fosfomycin (Figure 17).[242] In medicinal chemistry, 
phosphonates have featured in several commercialised pharmaceuticals, including 
anti-osteoporosis alendronate[243] and antiviral cidofovir.[244] They also figure 
prominently in the agrochemical industry, such as in the natural herbicide 
bialaphos.[245] 
 
Figure 16. Phosphonates and analogues thereof
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In particular, five- and six-membered oxacycles bearing a phosphonate at the 
2 position have garnered significant interest as analogues of b-phosphate 
carbohydrates (Figure 18). Notably, several derivatives have displayed antiviral[246] and 
anti-tumoral activities,[247] for instance cyclic cidofovir analogue 177,[248] or 178, a 
phosphonated analogue of zanamivir, active against influenza.[249] Phosphonates such 
as diphosphate analogue 179 have found use in galactosyltransferase inhibition, which 
is involved in transplant rejection.[250,251] Other applications include mimicking the 
carboxylic moiety of sialic acids, a family of sugars involved in various biochemical 
pathways and displaying antiviral properties.[252] 
 
Owing to their continued relevance in biological systems, synthetic approaches 
towards phosphonate derivatives remain an active research topic in phosphorus 
chemistry. 
 
3.1.2. Known routes towards 2-phosphonated oxacycles 
Generally, phosphonic acids are prepared from the corresponding phosphonate 
esters via acid hydrolysis or, for more sensitive substrates, by treatment with 
bromotrimethylsilane.[253] For cyclic derivatives, one of the most common synthetic 
method relies on the Lewis-acid catalysed substitution of a carbohydrate with a 
Figure 17. Bioactive compounds incorporating a phosphonate unit
O(HO)2OP
N
N
N
NH
O
NH2
Cidofovir
Antiviral
HO
(HO)2OP
O
Fosfomycin
Natural product,
antibiotic
(HO)2OP PO(OH)2
OH
H2N
Alendronate
Anti-osteoporosis
Figure 18. Bioactive compounds incorporating a phosphonate unit
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phosphite, which requires appropriate protecting groups to ensure site selectivity 
(Scheme 67.A).[254–257] In a related design, treating 2-nitroglycals with a phosphite 
provided the 2-phosphonate pyranose after 1,4-addition (Scheme 67.B).[258,259] The 
limited a/b selectivity is another drawback of these tactics and alternative approaches 
have been developed based on the cyclisation of a wide array of precursors. 
 
Tetrahydrofurans were prepared from a-hydroxyphosphonates by 
intramolecular nucleophilic substitution of a mesylate group, giving a mixture of 
epimers (Scheme 68.A),[260] and iodoetherification, which after some optimisation 
afforded the product in high selectivity (Scheme 68.B).[248] Phosphonated 
isobenzofurans have been synthesised from m-functionalised benzaldehydes via 
addition of a phosphite on the carbonyl and cyclisation through acetalisation,[261] 
lactonisation[262] or alkyne hydroalkoxylation (Scheme 68.C).[263] The latter was highly 
substrate dependant, and in all cases a limited subset of isobenzofurans was obtained. 
Acetalisation strategies have also been applied to convert g-hydroxyketophosphonates 
into pyranose derivatives, but this method required the multistep synthesis of 
precursors (Scheme 68.D).[264,265] More exotic annulations have been described based 
on substitution by a carbanion,[266] NHC-mediated addition of homoenolates to acyl 
phosphonates[267,268] and the rhodium-catalysed O-H insertion of diazoketone 
carbenes.[269] 
Scheme 67. Synthesis of phosphonated oxacycles from carbohydrates
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Finally, one of the most remarkable tactics yet was based on the hetero Diels-
Alder cycloaddition of acyl phosphonates with alkenes, which provided 
phosphonopyrans in high yields with excellent control over the relative and absolute 
stereochemistry (Scheme 69). Several variants have been reported with catalysts 
including copper, DABCO, cinchona alkaloids and chiral squaramides, some of them 
affording products with orthogonal substitution patterns.[216,270–272] 
 
In view of those existing routes and their limitations, we envisioned an 
opportunity to provide a complementary approach based on the longstanding interest 
in palladium-catalysed allylic alkylations held in the group.[2,273–276]  
Scheme 68. Synthesis of phosphonated oxacycles via cyclisations
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3.2. Objectives and mechanistic considerations 
With the aim of providing a more straightforward approach towards 
phosphonated heterocycles, we considered that unsaturated oxacycles 180 could arise 
from the ring-closing metathesis (RCM) of dienes 181, which would be obtained via the 
O-allylation of a-hydroxyphosphonates 182. The latter would stem from the addition 
of phosphites 183 to alkenylaldehydes 184. This design would allow a particularly 
atom-economic assemblage of the building-blocks (Scheme 70). 
 
We envisioned that the introduction of phosphite 183 via a Pudovik reaction 
would be pedestrian, given the extensive literature on catalytic addition of phosphites 
to aldehydes.[244] Among the strategies available, a number of chiral complexes and 
organocatalysts have been used to generate a-hydroxyphosphonates with high levels 
of enantioselectivity.[277–284] Therefore, we anticipated that our phosphonated 
oxacyclic targets could eventually be prepared in an asymmetric fashion as well.  
In contrast, the allylation of a-hydroxyphosphonate 182 represented an 
unsolved challenge (Scheme 71). Indeed, under the strongly basic conditions required 
by traditional O-allylation methods, deprotonated intermediate 185 could undergo an 
elimination which would regenerate the starting aldehyde (path a).[285,286] We 
expected that in the presence of a π-allyl complex, this mechanistic pathway would be 
strongly disfavoured relative to the formation of the O-allylation product (path b). 
However, a phospha-Brook rearrangement of 185 could also be envisioned, resulting 
in a-phosphate carbanion 186, which would afford phosphate 187 upon reprotonation 
(path c).[287–290] Alternatively, carbanion 186 may yield the C-allylation product 188 
(path d). At the outset of the project, we were also interested in this possibility, which 
would result in the formation of a chiral centre and therefore offer a stereocontrol 
opportunity. With these various reactivities available upon deprotonation of 
a-hydroxyphosphonate 182, we anticipated that the allylation would be the key step in 
our synthetic route. 
Scheme 70. Retrosynthesis approach towards phosphono-oxaheterocycles
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Assuming the successful synthesis of a-oxoallyl phosphonate 181, we planned 
to use standard ruthenium alkylidene catalysts to trigger the RCM of substrates 
incorporating a pendant alkene moiety, which are easily handled and have proven 
their versatility since their emergence two decades ago.[291,292] 
  
Scheme 71. Challenges in the allylation of α-hydroxyphosphonates
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3.3. Development of a Pudovik/O-allylation sequence for the 
preparation of a-allyloxyphosphonates 
3.3.1. Optimisation of conditions 
At the start of our study, commercial 4-chlorobenzaldehyde 184a and diethyl 
phosphite were smoothly converted to the corresponding 
a-hydroxyphosphonate 182a using 1.01 equiv. of aldehyde, following a procedure 
reported in the patent literature [Et3N (50 mol%), neat, 50 °C, 99%].[293] The latter was 
then turned to carbonate 189 [allyl chloroformate, DMAP, pyridine, CH2Cl2, 0 °C, 99%], 
in order to attempt a decarboxylative palladium-catalysed allylation (Scheme 72).4 
 
Upon treating the carbonate with Pd(PPh3)4 [5 mol%] in toluene at 50 °C and a 
0.25 M concentration in a-hydroxyphosphonate, we were pleased to observe the 
formation of the corresponding O-allyl product 181a in 76% yield. A survey of the 
conditions (Table 17) showed that adding a sub-stochiometric amount of Cs2CO3 
[25 mol%] enhanced the yield to 82% (Table 17, entry 2). A similar result was obtained 
when replacing Cs2CO3 with K2CO3. Using other solvents did not improve the outcome 
(Table 17, entries 3-4). Conversely, switching the catalyst to a more easily handled 
Pd2dba3/PPh3 combination further increased the yield to 89% (Table 17, entry 5). 
Finally, conducting the reaction at a higher concentration of 0.5 M enabled the 
formation of 181a in an optimal yield of 90% with a reduced catalyst loading (Table 17, 
entry 6).  
 
4 The optimisation study was mostly conducted by our collaborators in Dr Laurent El Kaim's 
group at ENSTA ParisTech, France. 
Scheme 72. Formation of α-hydroxyphosphonate and prefunctionalisation
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To streamline the formation of 181a, we next investigated the direct 
intermolecular allylation of a-hydroxyphosphonate 182a. The success of this 
endeavour was less straightforward, as upon generation of the π-allyl complex, the 
methoxide side-product can compete with the a-hydroxyphosphonate 
(Scheme 73).[294] Therefore, the oxyallylation of standard aliphatic alcohols is generally 
less evident than that of phenols. 
 
In our case, we suspected that the phosphonate group would increase the 
acidity of 182a and thus facilitate the Tsuji-Trost allylation.[295] Indeed, in the presence 
of allyl methyl carbonate, 182a was converted to the desired a-allyloxyphosphonate 
181a under the conditions previously adopted (Table 18). Again, the yield was slightly 
improved from 85% to 91% when using Cs2CO3 (Table 18, entries 1-2). This effect is 
possibly linked to a facilitated regeneration of the Pudovik adduct if some 
fragmentation of the latter to the starting aldehyde occurred during the allylation. 
Alternatively, the carbonate could replace the methoxide as a counter-ion of the 
Table 17. Screening of conditions for the intramolecular allylationa
aReactions run by collaborators in Dr El Kaim's group. bReaction run at 40 °C.
Entry Catalyst Yield
Conditions
AdditiveSolvent
5
6
2
3
4
Cs2CO3 (25 mol%)
Cs2CO3 (25 mol%)
Cs2CO3 (25 mol%)
Cs2CO3 (25 mol%)
Cs2CO3 (25 mol%)
Toluene
MeCN
CH2Cl2b
Toluene
Toluene
1 -Toluene 76%
82%
42%
71%
89%
90%
Pd(PPh3)4 (5 mol%)
Pd(PPh3)4 (5 mol%)
Pd(PPh3)4 (5 mol%)
Pd(PPh3)4 (5 mol%)
Pd2dba3 + PPh3 (5 mol%)
Pd2dba3 + PPh3 (2.5 mol%)
O
PO(OEt)2
O
187
O
Cl
Concentration
0.25 M
0.25 M
0.25 M
0.25 M
0.5 M
0.25 M
O
PO(OEt)2
179a
Cl50 °C, 30 min
Scheme 73. Possible allylation by-product using intermolecular conditions
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π-allyl, reducing the formation of the undesired methyl allyl ether. Either way, a high 
yield of 90% was obtained with a reduced catalyst loading (2.5 mol% of Pd2dba3) at a 
0.5 M concentration of 182a (Table 18, entry 4). Furthermore, a control experiment 
using the same conditions but without the palladium led to the formation of the 
phospha-Brook product 187a in quantitative yield (Table 18, entry 5), stressing the 
importance of using palladium-based conditions to ensure that the O-allylation 
proceeds efficiently. 
 
Under no circumstance did we observe the C-allylated product 188. This result 
precluded the development of alternative conditions favouring the formation of this 
chiral phosphate, but was consistent with the inability of hard nucleophiles (generally, 
pKa > 25) to engage in Tsuji-Trost allylations without preformation of an alkyl metal 
precursor. Therefore, the implementation of this particular transformation would likely 
require the introduction of a second metal to trigger the phospha-Brook 
rearrangement and stabilise the resulting carbanion. We attempted to adapt 
conditions developed by Kazmaier et al. for the allylation of glycolates [LiHMDS, ZnCl2 
then allyl methyl carbonate, Pd2(dba)3, PPh3], but to no avail due to the intermediate 
hydroxide undergoing phospha-Brook rearrangement/reprotonation or elimination of 
the phosphonate (Scheme 74).[296] A related strategy was more recently employed in 
the sequential silylation/Brook rearrangement/C-allylation of aldehydes using a dual 
copper/palladium catalytic system and offers possible avenues for further 
investigation.[297] 
Table 18. Screening of conditions for the intermolecular allylation
Entry Catalyst Product (Yield)
(1 equiv.)
conditions
Additive
5
2a
3a
4a
Cs2CO3 (25 mol%)
Cs2CO3 (25 mol%)
Cs2CO3 (25 mol%)
Cs2CO3 (25 mol%)
1a - 179a (85%)
179a (91%)
179a (62%)
179a (90%)
185a (99%)
Pd2dba3 + PPh3 (5 mol%)
Pd2dba3 + PPh3 (5 mol%)
Pd2dba3 + PPh3 (2.5 mol%)
Pd2dba3 + PPh3 (2.5 mol%)
-
OH
PO(OEt)2
180a
Cl
Concentration
0.25 M
0.25 M
0.5 M
0.25 M
0.25 M
O
PO(OEt)2
179a
ClToluene, 50 °C, 30 min
O
O
MeO OPO(OEt)2
185a
Cl
or
aReactions run by collaborators in Dr El Kaim's group.
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At this juncture, we focused on our optimised conditions for the 
Pudovik/O-allylation sequence and turned to an evaluation of the scope. 
 
3.3.2. Preparation of substrates 
Given the novelty of our protocol to prepare a-allyloxyphosphonates, we 
assessed a representative set of commercial aldehydes. In addition, to later complete 
the synthesis of phosphonated oxacycles, we prepared a number of non-commercial 
alkenyl aldehydes precursors. 
First, 2-bromobenzaldehyde 190 was engaged in a Suzuki coupling with 
potassium vinyltrifluoroborate [PdCl2(dppf), Et3N, reflux] to afford 1,4-alkenyl 
aldehyde 191 in 71% yield. We anticipated that this compound would eventually yield 
a dihydrobenzoxepine (Scheme 75). 
 
Next, we prepared precursors to macrocycles using both ether and ester bonds 
(Scheme 76). Hence, a Williamson etherification between salicylaldehyde and 
8-bromo-1-octene [K2CO3, DMF, 80 °C] delivered 1,11-alkenyl aldehyde 192 in 
quantitative yield. Similarly, 3-hydroxybenzaldehyde furnished 1,12-alkenyl 
aldehyde 193 in 73% yield. Finally, the same aldehyde was also coupled with 
8-nonenoic acid [DCC, DMAP, toluene] to provide 194 in 96% yield. 
Scheme 74. Attempted C-allylation of an α-hydroxyphosphonate
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O
O
MeO
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Scheme 75. Preparation of a 1,4 alkenyl aldehyde via Suzuki coupling
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With a number of commercial and freshly prepared aldehydes in hand, we 
evaluated the generality of our Pudovik/allylation sequence. 
 
3.3.3. Scope of the Pudovik/O-allylation 
The solvent-free Pudovik reaction was broadly applicable to various substrates 
(Scheme 77). This step generally yielded the pure a-hydroxyphosphonate 182 in 
quantitative yield after a simple filtration over a pad of silica gel. The reaction was 
compatible with different phosphites, affording 182a-c, as well as a range of 
aldehydes, providing 182d-q, including electron-poor and electron-rich arenes 
(182d-h), furfural (182j), and a styrene derivative (182k). Some phosphonates were 
obtained in slightly lower yield, namely the 3-pyridyl 182i (71%), the vinyl 182l (72%) 
and the aliphatic derivatives 182m (81%) and 182n (87%). The alkenyl aldehydes 
previously prepared were converted to the corresponding a-hydroxyphosphonates in 
high yields (182o-r). Methyl pyruvate furnished quaternary alcohol 182s in 66% yield. 
Unfortunately, under these conditions, alkynyl aldehyde 184t only yielded trace 
amounts of the desired product.5 
 
5 a-Hydroxyphosphonates 182b-e and 182g,j,m were prepared by our collaborators in Dr 
Laurent El Kaim's group at ENSTA ParisTech, France. 
Scheme 76. Preparation of precursors to macrocyclic oxacycles
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Going forward, the conditions settled for the allylation of 182a efficiently 
provided a set of structurally diverse a-allyloxyphosphonates (Scheme 78). The 
influence of the phosphite was minimal, though the smaller dimethyl phosphite 181b 
was obtained in slightly higher yield (94%) than the diethyl and diisopropyl analogues 
181a and 181c. Both electron-rich and electron-poor aryls substituents were well-
tolerated (74-94% yield for 181d-g), as well as heteroaryls (78-96% yield for 181i-j), 
although the formation of 3-pyridyl 181i required a longer reaction time. Phenolic 
a-allyloxyphosphonates 182h was converted to the bisallylated product in 71% yield 
when using 2.0 equiv. of methyl carbonate, whereas with lower amounts the allylation 
primarily targeted the phenol. Styrene 182k readily underwent allylation in 77% yield. 
In contrast, the formation of vinylic and aliphatic a-hydroxyphosphonates 181l-n 
(58-82%) required higher temperatures (80-100 °C). As expected, aromatic substrates 
Scheme 77. Scope of the Pudovik reaction
aReaction complete after 5 min of manual mixing.
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prefunctionalised with a pendant olefin were also converted to the desired dienes in 
74-97% yield (181o-q). The presence of Cs2CO3 led to the hydrolysis of the ester linker 
of 182r, but removing the additive allowed the allylation to proceed in 82% yield. 
Conversely, 182s only furnished the phosphate resulting from a phospha-Brook 
rearrangement under the conditions. Finally, the influence of the allyl was evaluated: 
the addition of a linear phenyl substituent resulted in a slightly decreased yield (60-
64% for 181g' and 181j' instead of 85-96% for 181g and 181j), while a branched methyl 
did not impact the outcome (88% for 181k'). The tolerance of allyl substituents is 
particularly interesting as it provides further means of structural diversification.6 
 
 
6 a-Allyloxyphosphonates 181b-e and 182g,g',j,j',m were prepared by our collaborators in Dr 
Laurent El Kaim's group at ENSTA ParisTech, France. 
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Having prepared a number of a-allyloxyphosphonates, we also attempted to 
engage them in a second C-allylation using more drastic conditions. With the more 
reactive hydroxyl nucleophilic site already alkylated, we reasoned that the 
combination of the phosphonate and a sufficiently electron-withdrawing group might 
stabilise the benzylic carbon enough for a Tsuji-Trost allylation to proceed. Therefore, 
we treated 4-nitrophenyl 182u, which has a particularly acidic benzylic proton,[298] with 
an excess of methyl allyl carbonate at 100 °C and obtained bis-allylated product 181u 
Scheme 78. Scope of the allylation
aReaction conducted with 2.0 equiv. of carbonate. bReaction conducted without Cs2CO3.
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in 40% yield (Scheme 79). Unfortunately, this protocol was not applicable to other 
substrates. In fact, the peculiar reactivity of 182u underscores the reactivity gap 
between soft and hard nucleophiles in the context of Tsuji-Trost allylations. 
 
In order to probe further applications of our strategy, we investigated 
a-aminophosphonates. Those analogues can be formed from aldehydes, amines and 
phosphites in the three-component Kabachnik-Fields reaction, which avoids the 
isolation of an intermediate imine before the addition of the phosphite 
(Scheme 80).[299,300] First, we treated our model aldehyde 184a with benzylamine and 
diethyl phosphite [80 °C, under microwave irradiation]. Those conditions resulted in 
the formation of aniline 195, which was converted quantitatively to allylaniline 196 
when subjected to Tsuji-Trost conditions. Thus, we switched the substrate to 
4-methoxybenzaldehyde 184g, which gave the desired a-aminophosphonate 197 in 
80% yield. Unfortunately, the palladium-catalysed allylation was particularly sluggish, 
and a-allylaminophosphonate 198 was isolated in a low 20% yield. The recovery of 
72% of starting material suggests that the reaction may not have reached completion 
due to deactivation of the catalyst, and the allylation of amines derivatives was not 
pursued further. 
Scheme 79. Bis-allylation
Toluene
50 °C, 30 min
then 100 °C, 12 h
40 %
Pd2dba3 (2.5 mol%)
PPh3 (10 mol%)
Cs2CO3 (25 mol%)
PO(OEt)2
O2N
O
O
MeO
+
180u
OH
PO(OEt)2
O2N
179u
O
(3.0 equiv.)
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3.3.4. Extension of the method to ketones 
While the Pudovik/Tsuji-Trost sequence is efficient for the preparation of 
tertiary a-allyloxyphosphonates from aldehydes, it would be desirable to extend the 
approach to the synthesis of quaternary a-allyloxyphosphonates (Scheme 81). An early 
attempt using 182s, prepared from methyl pyruvate, failed due to the high propensity 
of this a-hydroxyphosphonates to undergo phospha-Brook rearrangement. Instead, we 
used acetophenone 199, which was converted to 200 using a catalytic amount of 
n-BuLi [HPO(OEt)2, neat, 98%].[301] 
 
The allylation protocol optimised previously proved less efficient in the case of 
200, which led us to screen the conditions on this substrate (Table 19). Indeed, 
a-oxyallylphosphonate 201 was obtained in only 14% yield (Table 19, entry 1), which 
Scheme 80. Attempts to extend the approach to α-aminophosphonates
Toluene
50 °C, 5 h
99%
Pd2dba3 (2.5 mol%)
PPh3 (10 mol%) 
Cs2CO3 (25 mol%)
Cl
O
O
MeO
182a
H
80 °C, µW
55%
H2NBn
HPO(OEt)2 PO(OEt)2
BnHN
193
OHO
PO(OEt)2
N
Bn 194
OH
Toluene
50 °C, 12 h
20% (75% brsm)
Pd2dba3 (2.5 mol%)
PPh3 (10 mol%) 
Cs2CO3 (25 mol%)
MeO
O
O
MeO
182g
H
80 °C, µW
80%
H2NBn
HPO(OEt)2 PO(OEt)2
MeO
195
NHO
PO(OEt)2
MeO
196
NBnBn
Scheme 81. Preparation of quaternary α-allyloxyphosphonates
R1 R2R1
O
R2
HPO(OR)2
R1 R2
Pd
PO(OR)2HO PO(OR)2O
197
Me
O
Me
HPO(OEt)2 (1.2 equiv.)
198
PO(OEt)2HO
n-BuLi (0.1 mol%)
98%
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was improved to 21% by increasing the reaction time to 1 h (Table 19, entry 2). The 
elimination of the phosphonate remained the dominant pathway, as the starting 
acetophenone was the major product. Replacing Cs2CO3 with t-BuOK resulted only in 
decomposition (Table 19, entry 3), and increasing the temperature was detrimental to 
the formation of the desired product 201 (Table 19, entry 4). A screening of solvents 
showed that no allylation occurred in polar solvents such as alcohols or DMSO, while 
hydrocarbons and ethers fared slightly better (Table 19, entries 5-11). The best yield, 
27%, was eventually obtained by running the reaction in diethyl ether for 2 h 
(Table 19, entry 12). Longer reaction times produced proportionally more side-
products, while reducing the concentration to 0.1 M also reduced the yields.  
 
Given the low yields obtained under a range of conditions, we turned back to 
the a-allyloxyphosphonates prepared previously and set out to investigate their 
potential for further scaffold complexification, starting with the preparation of 
phosphonated oxacycles. 
  
Table 19. Screening of conditions for the allylation of a quaternary α-hydroxyphosphonatea
27%
24%
Entry
13%
75:25
2
3
1
67:33
83:17
13%
< 5%
Pd2(dba)3 (2.5 mol%)
PPh3 (10 mol%)
Base (25 mol%)
0%
93:7
5
6
4
20:80
N/A
0%
0%
Me
198
PO(OEt)2HO
Me
199
PO(OEt)2O
O
O
MeO+
(1 equiv.)
Me
197
O
+
Solvent, conditions
Base
Cs2CO3
Cs2CO3
t-BuOK
Cs2CO3
Cs2CO3
Cs2CO3
aReaction run on 0.15 mmol at a concentration of 0.5 M. bDetermined by 1H NMR using CH2Br2 as an internal standard.
Solvent
Toluene
Toluene
Toluene
Toluene
TFE
BnOH
Temperature
50 °C
50 °C
50 °C
80 °C
50 °C
50 °C
Time
30 min
1 h
30 min
30 min
1 h
1 h
9%
N/A
8
9
7
N/A
14:86
0%
21%
14%
N/A
11
12
10
38:62
-
199/197b Yieldb
Cs2CO3
Cs2CO3
Cs2CO3
Cs2CO3
Cs2CO3
Cs2CO3
DMSO
CH2Cl2
m-Xylene
MTBE
Et2O
Et2O
50 °C
50 °C
50 °C
50 °C
50 °C
50 °C
1 h
1 h
1 h
1 h
1 h
2 h
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3.4. Synthesis of phosphonated oxaheterocycles via RCM of 
allyloxyphosphonates 
Commercial ruthenium alkylidene complexes such as Grubbs or Hoveyda-
Grubbs catalysts have been successfully applied to the preparation of small sized 
oxacycles and macrocycles.[302–304] Indeed, when subjected to Grubbs' second-
generation catalyst under standard conditions [CH2Cl2, reflux, 0.1 M], medium rings 
180k,m,n,u were readily formed in high yields (81-92%, Scheme 82.A). Control 
experiments showed that the Hoveyda-Grubbs second-generation catalyst gave similar 
results (±4%). Hence, furan 180k and oxepin 180m were obtained in respectively 53% 
and 41% yield in three steps. 2-Vinylbenzaldehyde was converted to benzooxepin 180n 
in a higher overall yield of 83%, mostly thanks to a more efficient phosphonylation and 
allylation, while pyran 180u was produced in 26% from 4-nitrobenzaldehyde, due to 
the lower yield of the bis-allylation. These examples validate the approach for the 
formation of small oxacycles. 
Macrocycles 180o-q were also obtained efficiently (69-99%), although they 
required more dilute conditions [1 mM] to prevent oligomerisation (Scheme 82.B). 
When using higher concentrations, an enol ether byproduct was observed; the 
isomerisation of allyl ethers in the presence of ruthenium complexes is usually 
prevented by additives such as benzoquinone.[305–308] However, upon lowering the 
concentration, the desired product was obtained cleanly even without additive. Hence, 
the RCM allowed the formation of 14-membered oxacycle 180o in 52% overall yield, as 
well as [12]- and [13]metacyclophanes 180p and 180q in 48% and 80% yield over three 
steps. The macrocycles were obtained as mixture of E/Z isomers in a consistent ratio of 
4:1, as assessed by 1H NMR, with the double bond configuration assigned by 
13C NMR.[309,310] This selectivity is in agreement with previous results observed with the 
widely available Grubbs' second-generation catalyst,[311] but the development of 
Z-selective catalysts in recent years provides a platform to favour the formation of the 
other geometrical isomer.[310] 
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In addition, we attempted the formation of 10-membered ring 180h from 
diene 181h using several experimental protocols (Table 20). Under the 
macrocyclization conditions used previously, no conversion of 181h was observed 
(Table 20, entry 1). Encouragingly, switching to Hoveyda-Grubbs second-generation 
catalyst resulted in the formation of oligomers (Table 20, entry 2). To make sure that 
no double-bond isomerisation to an enol ether occurred, the reaction was also run 
with a catalytic amount of acetic acid, but this again resulted in oligomerisation 
(Table 20, entry 3). As expected, increasing the concentration failed to improve the 
outcome (Table 20, entry 4). Given the high enthalpic cost required for the formation 
of medium-sized rings such as 180h, we did not pursue those attempts further. 
Scheme 82. Scope of the metathesis
CH2Cl2, 45 °C
4 h
Grubbs II (4-6 mol %)
NN
Ru
Cl
Cl
PPh3
Ph
Grubbs 2nd generation
catalyst
PO(OR)2
O O
PO(OR)2
178179
O
NO2
O
PO(OEt)2
O
PO(OEt)2
178k
89%
178u
82%
178n
92%
178m
81%
PO(OEt)2 O
PO(OEt)2
O
PO(OEt)2
O
O PO(OEt)2
OO
16
14
178o
92% (E/Z = 4:1)
178p
69% (E/Z = 4:1)
178q
99% (E/Z = 4:1)
O
O
PO(OEt)2
15
A. Small cycles: C = 0.1 M, 4 mol% Grubbs II
B. Macrocycles: C = 0.001 M, 6 mol% Grubbs II
  
 
124 
 
In a nutshell, our Pudovik/Tsuji-Trost O-allylation/RCM sequence grants access 
to phosphonated heterocycles of small and large size in an expedient manner, 
providing a platform to investigate their biological properties. We also envisioned to 
exploit the a-allyloxyphosphonate scaffold in further transformations. 
  
Table 20. RCM attempts to form a 10-phosphonooxacycle
Entry Catalyst ResultAdditive
2
3
4
-
Acetic acid (10 mol%)
-
1 - No conversion
Mixture of oligomers
Mixture of oligomers
Mixture of oligomers
Grubbs II
Hoveyda-Grubbs II
Hoveyda-Grubbs II
Hoveyda-Grubbs II
Concentration
0.001 M
0.001 M
0.05 M
0.001 M
CH2Cl2, 45 °C
Catalyst (4 mol%) 10
178h
O
O
PO(OEt)2
O
O
PO(OEt)2
179h
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3.5. Late-stage functionalisation of a-oxyphosphonates  
3.5.1. [2,3]-Wittig rearrangement 
Allyl ethers have been used as precursors to homoallylic alcohols via the 
[2,3]-Wittig rearrangement, a sigmatropic isomerisation that can generally proceed 
with a variety of heteroatoms or carbanions (Scheme 83.A). The rearrangement of 
a-allyloxy derivatives is usually triggered by the formation of the carbanion using a 
strong Brønsted base. A number of asymmetric versions have been described, enabling 
the stereocontrolled formation of new carbon-carbon bonds.[312,313] In the case of 
a-allyloxyphosphonates, the Wittig rearrangement yields a-hydroxy-
a-allylphosphonates which can be isolated directly or undergo a further in situ 
phospha-Brook rearrangement (Scheme 83.B).[314,315] 
 
 Inspired by those reports, we treated our model a-allyloxyphosphonate 181a 
with a variety of Brønsted bases (Table 21). However, under previously reported 
conditions using t-BuOK, LDA or LiHMDS, no conversion was observed. Upon switching 
to n-BuLi, we obtained traces of the [2,3]-Wittig rearrangement/phosphonate 
elimination product 202. While the formation of this acyclic allylic ketone is of limited 
synthetic interest, we foresaw that the application of this reactivity to oxacycles 180 
could be useful in the construction of strained ketones. 
Scheme 83. [2,3]-Wittig rearrangement
A. General [2,3]-Wittig rearrangement and typical transition state
B. Rearrangement of α-allyloxyphosphonates
X
Y
1
2
2 3
1
X
Y
1
2
2 3
1
O
R
(EtO)2OP
[2,3]B O
R
(EtO)2OP
O
R
(EtO)2OP
OH
R
(EtO)2OP
H
OPO(OEt)2
Rphospha-Brook
X Y
H
H
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The formation of cyclobutanones 203 intrigued us particularly, and to this end 
we treated seven-membered oxacycles 180m-n with n-BuLi and LDA [THF, –78 °C] 
(Table 22). In this case, however, the allyloxyphosphonates were unreactive. Using the 
more reactive t-BuLi did not change the outcome. Despite the unquestioned formation 
of the intermediate carbanion, 180 appeared unable to undergo further 
transformations. 
 
We surmised that the limited reactivity of our substrates is probably linked to 
the steric constrains on the carbanion. In previously reported [2,3]-Wittig 
rearrangements of a-allyoxyphosphonates, the carbanion is prepared from freely 
rotating, less substituted substrates (Scheme 84). Conversely, cyclic substrates 180m-n 
Table 21. Screening of [2,3]-Wittig rearrangement conditions
Entry Base (equiv.) ResultSolvent
2
3
5
THF
THF
THF
1 DMF No conversion
No conversion
No conversion
Formation of 200
t-BuOK (0.1)
LDA (0.1)
LiHMDS (0.1)
n-BuLi (0.1)
Temperature
-78 °C
-78 °C
-78 °C
90 °C
Conditions
186a
OPO(OEt)2O
PO(OEt)2
179a
Cl Cl
+
Cl
200
O
6 THF Formation of 200n-BuLi (1.1) -78 °C
4 THF No conversionLiHMDS (1.1) -78 °C
Table 22. Screening of [2,3]-Wittig rearrangement conditions
Entry Base ResultSubstrate
2
3
178m
178m
1 178m No reaction
No reaction
No reaction
n-BuLi
LDA
t-BuLi
Base (1.1 equiv.)
O
PO(OEt)2
178m-n
O PO(OEt)2 O
201m-n
O
PO(OEt)2 THF
-78 °C to rt
5
6
178n
178n
4 178n No reaction
No reaction
No reaction
n-BuLi
LDA
t-BuLi
O PO(OEt)2
O PO(OEt)2
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may not be able to adopt the necessary envelope-shaped five-membered transition 
state, making them unable to rearrange to strained cyclobutanes. 
 
At this point, we considered a potential alternative thermal isomerisation, the 
Claisen rearrangement. 
 
3.5.2. Claisen rearrangement 
The Claisen rearrangement is another common [3,3] sigmatropic isomerisation, 
transforming allyl vinyl ethers into 1,4-alkenyl carbonyl derivatives (Scheme 85).[316] 
The reaction is driven by the formation of the carbon-oxygen double bond and 
generally proceeds via a chair-like transition state, affording substituted products with 
excellent stereocontrol, though side products obtained through a boat-like transition 
state are sometimes observed. 
 
The reaction is applicable to both aromatic ethers and aliphatic substrates. In 
the latter case, the vinyl ethers precursors can be generated as enolates in various 
ways or prepared by the 1,2-H migration of allyl ethers. This transformation can be 
mediated by several metals such ruthenium, rhodium, iron, iridium and palladium.[317] 
Indeed, one-pot 1,2-H isomerisation/Claisen rearrangement sequences have been 
repeatedly implemented to build structurally complex products from simpler, more 
accessible diallyl ethers (Scheme 86).[318–320] However, this strategy is not without 
Scheme 84. Previously reported α-allyloxyphosphonates [2,3]-Wittig rearrangements
O
(RO)2OP
OH
(RO)2OP
R' R'
O
(RO)2OP
R'
CO2R
OPO(OR)2
RO2C
R'
[2,3]-Wittig
[2,3]-Wittig
phospha-Brook
Scheme 85. The Claisen rearrangement
X
1
2
2
3
1 3 X
1
2
2
3
1 3 X = O, N, S
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challenges as both double bonds are susceptible to isomerisation, resulting in possible 
mixtures. 
  
Having prepared a few a,a-diallyloxyphosphonates in the course of this project, 
we evaluated the possibility to reorganise their structure using an available ruthenium 
catalyst (Table 23). Treating 181l with RuClH(CO)(PPh3)3 [DMF, 140 °C] led to the 
formation of a complex mixture, with trace amounts of aldehyde as indicated by 
1H NMR (Table 23, entry 1).[321] Changing the solvent to THF [130 °C] gave cleaner 
results, but no Claisen rearrangement was observed; instead, we isolated dienol 204, 
resulting from the double isomerisation of the substrate (Table 23, entry 2).[322] A 
similar outcome was observed with toluene (Table 23, entry 3). Better results were 
obtained with styrene 181k, as the desired 1,4-alkenyl aldehyde 205k was obtained, 
albeit as a 2:1 mixture of diastereomers (Table 23, entries 4-5). Finally, methallyl 
analogue 181k' gave only trace amounts of the desired product along with other 
unidentified isomerisation products (Table 23, entries 6-7). 
Scheme 86. Conversion of diallyl ethers to homoallylic carbonyls
O
O
R
1,2-H
O
R
[3,3]
R
OO
R
[3,3]
R
1,2-H
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Our results confirm the potential of a,a-diallyloxyphosphonate to yield 
reorganised 1,4-alkenyl aldehyde bearing two adjacent stereocenters, while 
highlighting regio- and stereo-selectivity issues during the 1,2-H migration. The 
substitution pattern plays a major role in the reactivity of the substrates, as evidenced 
by the divergence between aliphatic derivative 181k and styrene 181k, in accord with 
observations reported in the literature. 
 
  
Table 23. Screening of 1,2-H isomerisation/Claisen rearrangement conditionsa
RuClH(CO)(PPh3)3
(5 mol%)
Conditions
O
PO(OEt)2
MeO
O
PO(OEt)2
179l
179k (R = H)
179k' (R = Me)
Entry Time ResultSubstrate
2
5
179l
179k
1 179l Degradation
44% 202, Z/E 4:1
41% 203k, dr 2:1
120 min
120 min
30 min
7 179k'
6 179k' Degradation with traces of aldehydeb
Degradation with traces of aldehydeb
3 h
8 h
Solvent
DMF
THF
Toluene
DMF
Toluene
Temperature
140 °C
130 °C
115 °C
140 °C
115 °C
O
PO(OEt)2
4 179k 66% 203k, dr 2:130 minDMF 140 °C
aAll reactions run in sealed tube under microwave irradiation. bLess than 5% aldehyde as indicated by 1H NMR.
202
MeO
O
PO(OEt)2
H
R
MeR
203k (R = H)
203k' (R = Me)
RuClH(CO)(PPh3)3
(5 mol%)
Conditions
3 179l Degradation with traces of Z-20230 minToluene 115 °C
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3.6. Conclusion 
In summary, a straightforward preparation of a-allyloxyphosphonates from 
aldehydes was implemented through a two-step Pudovik phosphonylation/Tsuji-Trost 
type O-allylation. The selective O-allylation of a-hydroxyphosphonates under 
palladium catalysis is particularly noteworthy as it circumvents the phospha-Brook 
rearrangement which typical occurs under standard alkylation conditions. The 
generality of the reaction with regards to various aromatic, heteroaromatic and 
aliphatic substrates showcases the proficiency of transition metal catalysis 
(Scheme 87). 
  
The application of the Pudovik/O-allylation sequence to alkenyl aldehydes 
afforded dienes which were readily subjected to RCM, completing the synthesis of 
valuable phosphonated oxacycles of various sizes (Scheme 88). This strategy opens a 
route towards functionalised phosphonates with a low environmental footprint, as it 
relies on catalytic systems and displays high atom economy, with the only by-products 
being CO2, methanol and ethylene. 
   
Scheme 87. Two-step access to α-oxyphosphonates
R1
O Pd2(dba)3, PPh3, Cs2CO3
Toluene, 50 °C, 30 min50 °C, 12-24 hH
HPO(OR)2
Et3N
R1
OH
PO(OR)2
R1
O
PO(OR)2
R2
R3
MeO2CO
R2
R3
R1 =
O2N
21 examples
Y = 58–97%
MeO NBr
Ph
Y = 71–99%
Scheme 88. Synthesis of phosphono-oxaheterocycles
O
PO(OR)2
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H
O 1. Pudovik reaction
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O
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69-99%
O
PO(OEt)2
O
PO(OEt)2
O
O
PO(OEt)2
15
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16
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4. Experimental 
4.1. General considerations 
Reactions were conducted in oven-dried or flame-dried glassware under a positive 
pressure of dry nitrogen, and at ambient room temperature, unless specified 
otherwise. Anhydrous solvents were either obtained from commercial sources or dried 
with a MBRAUN Solvent Purification System SPS-800.[323] Petroleum ether refers to the 
40-60 °C boiling fraction. Commercially available chemicals were purchased from 
Sigma Aldrich, Alfa Aesar, Fluorochem or Acros Organics, and where specified, purified 
by standard techniques. Evaporations were carried out on Büchi rotavapors under 
reduced pressure with a bath temperature of 35-40 °C, unless specified otherwise, 
using a dry ice condenser. Further drying of pure compounds was ensured by exposure 
to high-vacuum (ca. 5 mbar) for a few hours. 
Analytical TLC was performed with Merck silica gel plates, pre-coated with silica gel 60 
F254 (0.2 mm), to monitor reactions. Visualisation was effected by quenching of UV 
fluorescence (lmax = 254 nm or 360 nm) and by staining with p-anisaldehyde, 
potassium permanganate or vanillin TLC stain solutions, followed by heating.[324]  
Flash chromatography employed VWR (230–400 mesh) silica gel. Preparative TLC was 
performed with Analtech silica gel plates, pre-coated with silica gel 60 F254 (0.5 or 
1.0 mm). 
NMR spectra were recorded at 298 K using a Bruker AVANCE 400 spectrometer. 
1H NMR spectra were recorded at 400 MHz and residual solvent peaks were used as an 
internal reference (CHCl3 d 7.26, Acetone-d6 d 2.05). Data are reported as follows: 
chemical shift in ppm, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet or overlap of nonequivalent resonances), coupling constants, 
integration. 13C NMR spectra were recorded at 101 MHz and solvent peaks were used 
as an internal reference (CDCl3 d 77.2 ppm, Acetone-d6 d 29.8 ppm). Data are reported 
as follows: chemical shift in ppm, apparent multiplicity, coupling constants and 
integration where relevant. The assignment of 1H and 13C signals was assisted by DEPT, 
COSY, HSQC and HMBC experiments where necessary. 31P NMR spectra were recorded 
at 162 MHz.  
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IR spectra were recorded on a Perkin Elmer Spectrum 65 FT-IR spectrometer and are 
reported in frequency of absorption at the peak maximum (cm–1). 
Melting points were determined in open glass capillaries and are uncorrected. 
Low resolution mass spectra were recorded on an Agilent 1100 series LC-MS (with a 
6310 ion trap) under electrospray ionization (ESI). For compounds containing bromine, 
the mass of 79Br was used; for chlorinated compounds, the mass of 35Cl was used. 
High-resolution mass spectra were recorded on a Waters SYNAPT G2-Si High 
Definition Mass Spectrometry system equipped with an Acquity UPLC BEH C18 column 
(2.1 x 50 mm; 130Å) using a solvent gradient (0->100% Acetonitrile in Water + 0.1% 
Formic acid) in positive electrospray ionization (ESI+) mode. The instrument was tuned 
using a Leucin Enkephalin mix to optimum resolution and signal intensity and was 
calibrated using a Waters Major Mix IMS/ToF in a range of m/z 50-1200.  
High-pressure liquid chromatography analysis was carried out on an Agilent 1100 
system, using a mixture of hexane and isopropyl alcohol at a flow rate of 1 mL/min 
using Chiralpak columns (250 x 4.6 mm; 5 μm).  
 
4.2. DNA-based catalysis 
4.2.1. General considerations 
Preparation of stock solutions of DNA. st-DNA solutions were prepared by dissolving 
commercial st-DNA from Sigma Aldrich (reported to be about 2,000 base-pairs 
long)[325] in MilliQ water to a concentration of 4.5 mg/mL (6.9 mM concentration 
relative to base pairs) at most two weeks before use. Synthetic oligonucleotides 
solutions were prepared by dissolving 1.0 equiv. of the bipyridine-modified 
oligonucleotide strand and 1.2 equiv. of the corresponding counter-strand in MilliQ 
water to a concentration of 3.3 mM. The resulting solution was stirred at 90 °C for 
5 minutes and allowed to cool to room temperature. 
Representative procedure for the preparation of stock solutions of buffer. 200 mM 
stock solutions of MOPS buffer were prepared by dissolving 
3-(N-morpholino)propanesulfonic acid (1.05 g, MW = 209.26 g/mol) in MilliQ water 
(10 mL) to obtain a 0.5 M solution. The pH was adjusted as desired using a 0.1 M 
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solution of KOH (MW = 56.11 g/mol). To the resulting solution was added a given 
volume of MilliQ water to obtain a 200 mM concentration.  
 
Preparation of stock solutions of [Cu(ligand)]. 9 mM stock solutions of copper/ligand 
were prepared by dissolving 0.09 mmol of the desired copper source and 0.11 mmol of 
the desired ligand in MilliQ water (10 mL). 
General experimental procedure for DNA reactions. Reactions run with DNA were 
conducted in 500 μL or 1.5 mL eppendorfs. The stock solutions of DNA, buffer and 
copper/ligand were added in this order, followed by a given volume of MilliQ water to 
reach the desired concentrations. For a final concentration x of copper co-factor, a 
DNA concentration of 7x was used (relative to base-pairs), with a final concentration in 
buffer of 20 mM. If used, a co-solvent was added at this stage. The resulting solution 
was mixed for 30 min at room temperature to ensure the formation of the catalytic 
complex. Mixing was ensured either by shaking at 1200 rpm or by continuous inversion 
at approximately 20 rpm. The substrate or substrates were then added, and the 
reaction was mixed for one to three days. Work-ups were conducted in the following 
manner: the solution was diluted with an appropriate organic solvent (200-500 μL), 
vortexed and frozen to –78 °C. The supernatant organic phase was collected, and the 
aqueous phase was allowed to warm up to room temperature using sonication. The 
procedure was repeated 5 times. The combined organic phases were allowed to 
evaporate, leaving a crude residue that was dissolved in isopropyl alcohol and 
subjected to HPLC analysis.  
Buffers used in this work with pH range and MW
N
N
OH
O
O
HEPES
6.8 - 8.2
MW = 238.30
S
HO
O
N
OH
O
O
S
MES
5.5 - 6.7
MW = 195.23
NH2
OH
OH
HO
TRIS
7.0 - 9.0
MW = 121.14
N
N
OH
O
O
PIPES
6.1 - 7.9
MW = 302.37
S
HO
O
O
S
O
N S OH
O O
MOPS
6.5 - 7.9
MW = 209.26
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4.2.2. [3+2] cycloaddition 
N-Hydroxybenzimidoyl chloride (23) 
 
Molecular formula: C7H6ClNO MW = 155.58 g.mol-1 
(E)-benzaldehyde oxime (666 mg, 5.50 mmol, 1.0 equiv.) was dissolved in chloroform 
(22 mL) and pyridine (44 µL, 0.55 mmol, 0.10 equiv.) was added. The reaction mixture 
was stirred at 50 °C, then N-chlorosuccinimide (881 mg, 6.60 mmol, 1.2 equiv.) was 
added in portions. The reaction mixture was stirred at this temperature for 3 h. Upon 
completion, the reaction was diluted with H2O (20 mL) and the aqueous layer was 
extracted with Et2O (3 x 30 mL). The pooled organic layers were dried over anhydrous 
Na2SO4 and concentrated to afford the title compound as a white solid (463 mg, 
2.98 mmol, 54%). Spectral data matched those reported in the literature.[326]  
1H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 7.89-7.80 (m, 2H), 7.49-7.38 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 140.3, 132.6, 130.9, 128.7 (2C), 127.4 (2C). 
 
(E)-1-(1-Methyl-1H-imidazol-2-yl)but-2-en-1-one (4a) 
 
Molecular formula: C8H10N2O MW = 150.18 g.mol-1 
A 500 mL RBF equipped with an addition funnel was charged with N-methylimidazole 
(7.9 mL, 100 mmol, 2.2 equiv.) and THF (150 mL). The solution was cooled to –78 °C 
and n-BuLi (2.16 M solution in hexanes, 46.1 mL, 100 mmol, 2.2 equiv.) was dropwise 
added. The reaction mixture was then stirred at room temperature for 60 min. The 
solution was cooled to –78 °C and a solution of crotonic acid (3.9 g, 45.1 mmol, 
1.0 equiv.) in THF (10 mL) was dropwise added. The reaction mixture was then slowly 
allowed to warm to room temperature and stirred for 16 h. The reaction was 
N
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quenched by addition of a saturated aqueous solution of NaHCO3 (150 mL) and 
extracted with EtOAc (4 x 150 mL). The pooled organic layers were washed with a 
saturated aqueous solution of NaCl (50 mL), dried over anhydrous Na2SO4 and 
concentrated. The crude was purified by flash chromatography over silica gel 
(PE/EtOAc 2:1 to 1:1) to afford a colourless oil (1.97 g, 13.1 mmol, 29%). Spectral data 
matched those reported in the literature.[50] 
1H NMR (400 MHz, CDCl3) δ 7.40 (dq, J = 15.5, 1.6 Hz, 1H), 7.17-7.05 (m, 2H), 7.03 (s, 
1H), 4.03 (s, 3H), 1.98 (dd, J = 6.9, 1.6 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 180.8, 144.0, 143.8, 129.3, 127.9, 127.2, 36.4, 18.6. 
  
(1-Methyl-1H-imidazol-2-yl)(4-methyl-3-phenyl-4,5-dihydroisoxazol-5-yl)methanone 
(25) 
 
Molecular formula: C15H15N3O2 MW = 269.30 g.mol-1 
To a solution of oxime chloride 23 (187 mg, 1.20 mmol, 1.2 equiv.) in a mixture of 
acetone (0.50 mL) and pH 6 phosphate buffer (0.1 M, 10 mL) was added enone 4a 
(150 mg, 1.0 mmol, 1.0 equiv.). The reaction mixture was stirred at room temperature 
for 16 h. The aqueous layer was then extracted with EtOAc (3 x 15 mL). The pooled 
organic layers were dried over anhydrous Na2SO4 and concentrated. Purification by 
flash chromatography over silica gel (Hexane/EtOAc 3:1 to 1:3) afforded the desired 
compound as a colourless oil (79 mg, 0.29 mmol, 24%). 
Rf = 0.50 (PE/EtOAc 1:1). 
1H NMR (400 MHz, CDCl3) δ 7.73-7.64 (m, 2H), 7.41-7.35 (m, 3H), 7.21 (d, J = 0.9 Hz, 
1H), 7.11 (s, 1H), 5.89 (d, J = 4.2 Hz, 1H), 4.06-3.93 (m, 4H), 1.56 (d, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 186.3, 160.1, 141.2, 130.2, 130.2, 128.8 (2C), 128.3, 127.8, 
127.4 (2C), 87.8, 46.7, 36.0, 18.0. 
MS-ESI: m/z 270 ([M+H]+). 
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HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (88:12) 
at 35 °C on an IA column, with UV detection (l = 280 nm). Retention times of the 
enantiomers of 25: 27.8 min and 29.7 min. Retention time of enone 4a: 6.2 min. 
Retention time of oxime chloride 23: 4.8 min. Retention time of hydration product 5a: 
14.5 min. After calibration in the relevant range, the absorbance ratio of product 25 
relative to enone 4a was assessed to be virtually equal to the ratio of their 
concentrations. 
 
Screening of DNA conditions for the formation of 25 and representative HPLC results. 
Reactions with DNA were conducted on a 0.6 µmol scale at a concentration of 1.0 mM 
relative to oxime chloride 23, following the general protocol. Extractions were 
conducted with Et2O. 
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 DAD1 E, Sig=280,16 Ref=360,100 (SA-MC\ARCHIVES\CYCLOA~1\METHOD~1\MC326E.D)
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=====================================================================
Injection Date  : 4/21/2017 1:54:10 PM           Seq. Line :   1
Sample Name     : MC326-10                        Location : Vial 31
Acq. Operator   : LG                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 2 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MARTIN1.M
Last changed    : 4/21/2017 1:49:42 PM by LG
Analysis Method : C:\HPCHEM\1\METHODS\ARSENI~1\FR629.M
Last changed    : 12/18/2018 4:56:09 PM by Nicolas
                  (modified after loading)
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=====================================================================
                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Sample Amount         :      1.00000  [ng/ul]   (not used in calc.)
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 E, Sig=280,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  27.819 BB    0.6011 5474.13330  133.85095  49.8617
   2  29.726 BB    0.6522 5504.50098  123.92216  50.1383
Totals :                  1.09786e4   257.77311
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\CYCLOA~1\METHOD~1\MC326E.D    Sample Name: MC326-10
Instrument 1 12/18/2018 4:57:55 PM Nicolas Page 1 of 1
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HPLC of the crude in MOPS buffer pH 6.5, with 30 mol% copper (Table 1, entry 4):  
 
 
HPLC of the crude in MOPS buffer pH 6.5, with 30 mol% copper (Table 1, entry 4):  
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=====================================================================
Injection Date  : 5/3/2017 8:05:05 PM            Seq. Line :   3
Sample Name     : MC340                           Location : Vial 40
Acq. Operator   : LG                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MARTIN1.M
Last changed    : 4/26/2017 6:53:28 PM by LG
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-CYC1.M
Last changed    : 12/18/2018 5:24:16 PM by Nicolas
                  (modified after loading)
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=====================================================================
                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 E, Sig=280,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   5.919 BB    0.1395   54.26212    5.99916   6.1694
   2  15.729 BV    0.6331  519.10236   11.44561  59.0202
   3  28.470 MF    0.9134  159.74858    2.91495  18.1629
   4  30.245 FM    0.9300  146.42101    2.62413  16.6476
Totals :                   879.53406   22.98385
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\CYCLOA~1\SCREEN~1\MC340A.D       Sample Name: MC340
Instrument 1 12/18/2018 5:40:32 PM Nicolas Page 1 of 1
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=====================================================================
Injection Date  : 5/4/2017 1:14:29 AM            Seq. Line :   9
Sample Name     : MC346                           Location : Vial 46
Acq. Operator   : LG                                   Inj :   1
Acq. Instrument : Instrument 1               Inj Volume : 20 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MARTIN1.M
Last changed    : 4/26/2017 6:53:28 PM by LG
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-CYC1.M
Last changed    : 12/18/2018 5:24:16 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 E, Sig=280,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   5.911 BP    0.1325   16.56221    1.96084   1.2792
   2  15.710 BB    0.5402 1133.55273   31.17756  87.5481
   3  28.610 MF    0.8777   73.70013    1.39946   5.6921
   4  30.384 FM    0.9168   70.96187    1.29001   5.4806
Totals :                  1294.77694   35.82787
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\CYCLOA~1\SCREEN~1\MC346A.D       Sample Name: MC346
Instrument 1 12/18/2018 5:36:42 PM Nicolas Page 1 of 1
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HPLC of the crude in MOPS buffer pH 7.5, with 100 mol% copper (Table 1, entry 15):  
 
 
 
HPLC of the crude in TRIS buffer pH 8.5, with 100 mol% copper and DMF (10% v/v) 
(Table 1, entry 18):  
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=====================================================================
Injection Date  : 5/23/2017 11:35:32 AM          Seq. Line :   2
Sample Name     : MC368                           Location : Vial 68
Acq. Operator   : MC                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MC-CYC1.M
Last changed    : 5/23/2017 10:39:42 AM by MC
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-CYC1.M
Last changed    : 12/18/2018 5:24:16 PM by Nicolas
                  (modified after loading)
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=====================================================================
                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 E, Sig=280,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   5.959 BP    0.1350   14.45313    1.66974   1.8211
   2  16.126 MM    0.5152  735.09375   23.78153  92.6214
   3  29.721 MF    0.8735   24.58491 4.69081e-1   3.0977
   4  31.671 FM    0.9435   19.52240 3.44875e-1   2.4598
Totals :                   793.65418   26.26523
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\CYCLOA~1\SCREEN~1\MC368.D        Sample Name: MC368
Instrument 1 12/18/2018 5:28:37 PM Nicolas Page 1 of 1
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=====================================================================
Injection Date  : 5/23/2017 8:04:08 PM           Seq. Line :   5
Sample Name     : MC375                           Location : Vial 75
Acq. Operator   : MC                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MC-CYC1.M
Last changed    : 5/23/2017 10:39:42 AM by MC
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-CYC1.M
Last changed : 12/18/2018 5:19:14 PM by Nicolas
                  (modified after loading)
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=====================================================================
                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 E, Sig=280,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   5.963 BP    0.1390   13.62348    1.48576   1.4914
   2  16.136 MM    0.5951  879.61310   24.63629  96.2919
   3  29.757 MM    0.8476   12.79312 2.51545e-1   1.4005
   4  31.701 MM    0.8076    7.45645 1.53875e-1   0.8163
Totals :                   913.48615   26.52747
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\CYCLOA~1\SCREEN~1\MC375.D        Sample Name: MC375
Instrument 1 12/18/2018 5:21:05 PM Nicolas Page 1 of 1
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HPLC of the crude in TRIS buffer pH 8.5, with 100 mol% copper and acetone 
(10% v/v) (Table 1, entry 21):  
 
 
(3a,8b)-3-phenyl-3a,8b-dihydro-4H-indeno[2,1-d]isoxazole (27) 
 
Molecular formula: C16H13NO MW = 235.29 g.mol-1 
To a solution of oxime chloride 23 (373 mg, 1.20 mmol, 1.2 equiv.) in a mixture of 
DMSO (0.50 mL) and pH 6 phosphate buffer (0.1 M, 10 mL) was added indene 26 
(150 mg, 1.0 mmol, 1.0 equiv.). The reaction mixture was stirred at room temperature 
for 16 h. The aqueous layer was then extracted with EtOAc (3 x 15 mL). The pooled 
organic layers were dried over anhydrous Na2SO4 and concentrated. Purification by 
flash chromatography over silica gel (Hexane/EtOAc 3:1 to 1:3) afforded the desired 
compound as a white solid (187 mg, 0.79 mmol, 33%) as a 95:5 mixture with the 
secondary diastereomer, as indicated by NMR and HPLC. Spectral data matched those 
reported in the literature.[58] 
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=====================================================================
Injection Date  : 5/23/2017 5:29:18 PM           Seq. Line :   2
Sample Name     : MC372                           Location : Vial 72
Acq. Operator   : MC                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MC-CYC1.M
Last changed    : 5/23/2017 10:39:42 AM by MC
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-CYC1.M
Last changed    : 12/18/2018 5:24:16 PM by Nicolas
                  (modified after loading)
min0 5 10 15 20 25 30
mAU
0
5
10
15
20
25
30
35
 DAD1 E, Sig=280,16 Ref=360,100 (SA-MC\ARCHIVES\CYCLOA~1\SCREEN~1\MC372.D)
 5
.9
64
  Ar
ea:
 12
78.
24
 1
6.
10
1
  Ar
ea:
 18
.01
53
 2
9.
77
2
  Ar
ea:
 10
.03
03
 3
1.
58
9
=====================================================================
                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 E, Sig=280,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   5.964 BV    0.1403   15.93849    1.74985   1.2054
   2  16.101 MM    0.5621 1278.24463   37.90401  96.6735
   3  29.772 MM    0.8494   18.01535 3.53496e-1   1.3625
   4  31.589 MM    0.7929   10.03031 2.10840e-1   0.7586
Totals :                  1322.22878   40.21820
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\CYCLOA~1\SCREEN~1\MC372.D        Sample Name: MC372
Instrument 1 12/18/2018 5:24:37 PM Nicolas Page 1 of 1
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1H NMR (400 MHz, CDCl3) δ 7.74-7.66 (m, 2H), 7.57 (dd, J = 5.3, 3.5 Hz, 1H), 7.45-7.39 
(m, 3H), 7.28-7.34 (m, 2H), 7.23-7.18 (m, 1H), 6.23 (d, J = 9.4 Hz, 1H), 4.55 (ddd, J = 9.4, 
9.0, 2.7 Hz, 1H), 3.49 (dd, J = 16.8, 9.0 Hz, 1H), 3.25 (dd, J = 16.8, 2.7 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 158.7, 140.9, 140.8, 130.0, 129.7, 129.2, 128.9 (2C), 127.8, 
127.3 (2C), 126.0, 124.9, 89.7, 50.6, 36.7. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (88:12 
isocratic) at 35 °C on an IA column, with UV detection (l = 254 nm). Retention times of 
the enantiomers of 27: 9.8 min and 14.4 min. Retention time of indene 26: 3.4 min. 
Retention time of oxime chloride 23: 4.8 min. 
 
Screening of DNA conditions for the formation of 27 and representative HPLC results. 
Reactions with DNA were conducted on a 0.6 µmol scale at a concentration of 1.0 mM 
relative to oxime chloride 23, following the general protocol. Extractions were 
conducted with Et2O. 
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=====================================================================
Injection Date  : 5/15/2017 11:05:43 AM          Seq. Line :   1
Sample Name     : MC363                           Location : Vial 1
Acq. Operator   : MC                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MARTIN1.M
Last changed    : 5/15/2017 11:04:04 AM by MC
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-CYC1.M
Last changed    : 12/19/2018 3:26:56 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 D, Sig=254,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.024 MM    0.2090   27.17752    2.16758   2.4446
   2   9.800 MM    0.2220  528.88361   39.71120  47.5722
   3  13.078 MM    0.3025   27.51562    1.51614   2.4750
   4  14.401 MM    0.3136  528.17303   28.07406  47.5083
Totals :                  1111.74978   71.46898
 Results obtained with enhanced integrator!
=====================================================================
                       *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\CYCLOA~1\METHOD~2\MC363B.D       Sample Name: MC363
Instrument 1 12/19/2018 3:27:13 PM Nicolas Page 1 of 1
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HPLC of the crude with st-DNA, pH 6.5, without copper (control experiment):  
 
 
 
HPLC of the crude with st-DNA, Cu(NO3)2, L12, pH 6.5:  
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Injection Date  : 5/23/2017 3:24:56 PM           Seq. Line :   8
Sample Name     : MC378                           Location : Vial 78
Acq. Operator   : MC                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MC-CYC2.M
Last changed    : 5/23/2017 10:41:03 AM by MC
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-CYC2.M
Last changed    : 12/19/2018 4:07:56 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 D, Sig=254,16 Ref=360,1 0
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   4.347 MM    0.1757   30.79357    2.92168   9.8558
   2   9.978 MM    0.2154  121.39941    9.39139  38.8550
   3  14.853 MM    0.3178  160.24886    8.40394  51.2892
Totals :                   312.44183   20.71702
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\CYCLOA~1\SCREEN~2\MC378.D        Sample Name: MC378
Instrument 1 12/19/2018 4:08:09 PM Nicolas Page 1 of 1
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Injection Date  : 5/23/2017 4:06:32 PM           Seq. Line :   9
Sample Name     : MC379                           Location : Vial 79
Acq. Operator   : MC                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Acq. Method     : :\HPCHEM\1\METHODS\ARSENI~1\MC-CYC2.M
Last changed    : 5/23/2017 10:41:03 AM by MC
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-CYC2.M
Last changed    : 12/19/2018 4:07:56 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier           :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 D, Sig=254,16 Ref=360,1 0
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   4.343 MM    0.2020   16.21212    1.33761  10.4847
   2   9.977 MM    0.2193   65.57584    4.98438  42.4092
   3  14.836 MM    0.3133   72.83842    3.87524  47.1061
Totals :                   154.62638   10.19724
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\CYCLOA~1\SCREEN~2\MC379.D        Sample Name: MC379
Instrument 1 12/19/2018 4:09:26 PM Nicolas Page 1 of 1
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HPLC of the crude with st-DNA, Cu(NO3)2, L12, pH 6.5, acetone (10% v/v):  
 
 
 
 
4.2.3. Nazarov cyclisation 
Preparation of the divinyl ketones substrates. We thank David Leboeuf, from Paris-
Sud University, for providing substrates 30, 31, 32 and 33, which were prepared 
according to reported procedures.[79,327–329] 
General procedure for the preparation of racemic Nazarov adducts. The divinyl 
ketone was charged in an over-dried reaction vial and Sc(OTf)3 (0.20 equiv.) was 
added. The vial was evacuated and backfilled with N2, then 1,2-dichloroethane 
(2 mL/mmol) was added. The vial was sealed, and the reaction mixture was stirred at 
90 °C for 2-4 h. The reaction mixture was concentrated and purified by flash 
chromatography over silica gel (PE/Et2O). 
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Injection Date  : 5/23/2017 8:55:50 PM           Seq. Line :   6
Sample Name     : MC380                           Location : Vial 80
Acq. Operator   : MC                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MC-CYC2.M
Last changed    : 5/23/2017 10:41:03 AM by MC
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-CYC2.M
Last changed    : 12/19/2018 3:59:00 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 D, Sig=254,16 Ref=360,1 0
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   4.342 MM    0.1786   27.93106    2.60645   9.6981
   2   9.991 MM    0.2229  114.70233    8.57728  39.8266
   3  14.903 MM    0.3298  145.37083    7.34632  50.4752
Totals :                   288.00423   18.53005
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\CYCLOA~1\SCREEN~2\MC380.D        Sample Name: MC380
Instrument 1 12/19/2018 4:06:51 PM Nicolas Page 1 of 1
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Methyl 3-oxo-1-phenyl-1,2,3,4-tetrahydrocyclopenta[b]indole-2-carboxylate (32) 
 
Molecular formula: C19H15NO3 MW = 305.33 g.mol-1 
This compound was obtained as an amorphous solid (29 mg, 98%) yield after 
purification by flash chromatography (PE/Et2O 1:1). Spectral data matched those 
reported in the literature.[327] 
1H NMR (400 MHz, CDCl3) δ 9.62 (s, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.40 (ddd, J = 8.4, 7.0, 
1.2 Hz, 1H), 7.37-7.24 (m, 6H), 7.09 (t, J = 7.5 Hz, 1H), 5.08 (d, J = 2.9 Hz, 1H), 3.94 (d, 
J = 2.9 Hz, 1H), 3.86 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 187.0, 169.6, 148.1, 144.7, 140.8, 137.2, 129.1 (2C), 128.3, 
127.6, 127.5 (2C), 123.0, 122.4, 121.4, 113.9, 67.9, 53.0, 44.2. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (90:10 
for 19 min then increase over 1 min then 65:35 for 10 min) at 30 °C on an IC column, 
with UV detection (l = 230 nm). Retention times of the enantiomers of 33: 15.6 min 
and 18.2 min. Retention time of the starting material: 30.4 min. 
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Injection Date  : 7/6/2017 1:22:26 PM            Seq. Line :   1
Sample Name     : SAS18                           Location : Vial 61
Acq. Operator   : MC                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 10 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MARTIN1.M
Last changed    : 7/6/2017 1:20:48 PM by MC
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-NAZ1.M
Last changed    : 12/19/2018 6:14:46 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 B, Sig=230,8 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  15.556 PB    0.4326 9074.94336  326.16391  49.6558
   2  18.155 PB    0.5100 9200.75000  279.54306  50.3442
Totals :                  1.82757e4   605.70697
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\NAZAROV\SAS018\SAS18A.D          Sample Name: SAS18
Instrument 1 12/19/2018 6:14:49 PM Nicolas Page 1 of 1
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1-Phenyl-1,4-dihydrocyclopenta[b]indol-3(2H)-one (33) 
 
Molecular formula: C17H13NO MW = 247.30 g.mol-1 
This compound was obtained as an amorphous solid (17 mg, 67% yield) after 
purification by flash chromatography (PE/Et2O 3:1). Spectral data matched those 
reported in the literature.[327] 
1H NMR (400 MHz, CDCl3) δ 9.18 (s, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.42-7.35 (m, 2H), 
7.34-7.28 (m, 2H), 7.24 (dt, J = 7.9, 1.4 Hz, 3H), 7.11-7.06 (m, 1H), 4.71 (dd, J = 6.6, 
2.3 Hz, 1H), 3.56 (dd, J = 18.5, 6.6 Hz, 1H), 2.93 (dd, J = 18.5, 2.3 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 193.7, 148.8, 144.0, 142.7, 139.0, 129.0 (2C), 127.6, 
127.3 (2C), 127.1, 123.3, 122.2, 121.1, 113.7, 51.8, 39.7. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (96:4 
for 18 min then increase over 1 min then 85:15 for 6 min) at 30 °C on an IC column, 
with UV detection (l = 230 nm). Retention times of the enantiomers of 34: 14.6 min 
and 16.3 min. Retention time of the starting material: 24.7 min. 
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Injection Date  : 7/12/2017 12:17:09 PM          Seq. Line :   2
Sample Name     : SAS25                           Location : Vial 71
Acq. Operator   : MC                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 10 µl
Acq. Method     : C:\HPCHEM\1\METHODS\SA-MC\MC-MTH04.M
Last changed    : 7/12/2017 11:52:26 AM by MC
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-NAZ1.M
Last changed    : 12/19/2018 6:14:46 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 B, Sig=230,8 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  14.642 BB    0.3788 8554.91895  352.92529  50.0399
   2  16.306 BB    0.4252 8541.28516  314.12357  49.9601
Totals :                  1.70962e4   667.04886
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\NAZAROV\SAS025\SAS25C.D          Sample Name: SAS25
Instrument 1 12/19/2018 6:21:00 PM Nicolas Page 1 of 1
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3a-Methyl-3-phenyl-2,3,3a,4,5,6-hexahydro-1H-inden-1-one (34) 
 
Molecular formula: C16H18O MW = 226.32 g.mol-1 
This compound was obtained as an amorphous solid (19 mg, 67% yield) after 
purification by flash chromatography (PE/Et2O 6:1). The relative configuration was 
assigned by analogy with a close analog whose X-ray structure has been reported in 
the literature.[79] 
1H NMR (400 MHz, CDCl3) δ 7.38-7.31 (m, 2H), 7.30-7.22 (m, 3H), 6.71 (t, J = 3.7 Hz, 
1H), 3.08 (dd, J = 13.3, 7.2 Hz, 1H), 2.90 (dd, J = 17.9, 13.3 Hz, 1H), 2.48 (dd, J = 17.9, 
7.2 Hz, 1H), 2.39-2.19 (m, 2H), 1.87 (dt, J = 12.3, 3.3 Hz, 1H), 1.83-1.74 (m, 1H), 
1.74-1.61 (m, 1H), 1.46 (td, J = 13.0, 3.8 Hz, 1H), 0.77 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 205.2, 146.4, 138.3, 132.6, 128.4 (2C), 128.3 (2C), 127.0, 
52.3, 42.4, 39.9, 35.1, 25.4, 19.9, 18.2. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol 
(isochratic 93:7) at 30 °C on an IC column, with UV detection (l = 280 nm). Retention 
times of the enantiomers of 35: 19.4 min and 25.0 min. Retention time of the starting 
material: 12.7 min. 
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Methyl-7-oxo-5-phenyl-2,3,4,5,6,7-hexahydrocyclopenta[b]pyran-6-carboxylate (35) 
 
Molecular formula: C16H16O4 MW = 272.30 g.mol-1 
This compound was obtained as an amorphous solid (12 mg, 43% yield) after 
purification by flash chromatography (PE/Et2O 2:1 to 1:1). Spectral data matched those 
reported in the literature.[79] 
1H NMR (400 MHz, CDCl3) δ 7.37-7.32 (m, 2H), 7.31-7.27 (m, 1H), 7.16-7.11 (m, 2H), 
4.26-4.22 (m, 1H), 4.20-4.11 (m, 2H), 3.77 (s, 3H), 3.33 (d, J = 2.4 Hz, 1H), 2.28-2.16 (m, 
1H), 2.15-2.05 (m, 1H), 1.99-1.89 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 193.0, 168.8, 149.8, 147.5, 139.8, 129.2 (2C), 127.7, 
127.4 (2C), 67.1, 59.2, 52.9, 47.7, 22.3, 21.3. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol 
(isochratic 70:30) at 30 °C on an IC column, with UV detection (l = 254 nm). Retention 
times of the enantiomers of 35: 29.8 min and 31.4 min. Retention time of the starting 
material: 36.4 min. 
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Injection Date  : 7/20/2017 10:25:52 PM          Seq. Line :   5
Sample Name     : SAS041                          Location : Vial 91
Acq. Operator   : Will                                 Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 10 µl
Acq. Method     : C:\HPCHEM\1\METHODS\SA-MC\MC-MTH07.M
Last changed    : 7/12/2017 10:30:01 AM by MC
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-NAZ1.M
Last changed    : 12/19/2018 6:14:46 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 E, Sig=280,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  19.372 BB    0.3696 3607.36499  151.60634  49.9116
   2  24.992 BB    0.4737 3620.14111  119.39960  50.0884
Totals :                  7227.50610  271.00594
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\NAZAROV\SAS041\SAS41M07.D       Sample Name: SAS041
Instrument 1 12/19/2018 6:39:28 PM Nicolas Page 1 of 1
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Injection Date  : 7/21/2017 8:22:40 PM           Seq. Line :   4
Sample Name     : SAS042                          Location : Vial 92
Acq. Operator   : MC                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 10 µl
Acq. Method     : C:\HPCHEM\1\METHODS\SA-MC\MC-MTH30.M
Last changed    : 7/21/2017 7:07:39 PM by MC
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-NAZ1.M
Last changed    : 12/19/2018 6:45:21 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 D, Sig=2 4,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  29.758 BV    0.6205 1008.01373   25.42980  49.5995
   2  31.427 VB    0.6582 1024.29407   23.98470  50.4005
Totals :                  2032.30780   49.41450
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\NAZAROV\SAS042\SAS42M30.D       Sample Name: SAS042
Instrument 1 12/19/2018 6:45:22 PM Nicolas Page 1 of 1
  
 
148 
4.2.4. Silylation of enones 
3-(Dimethyl(phenyl)silyl)cyclopentan-1-one (41) 
  
Molecular formula: C13H18OSi MW = 218.37 g.mol-1 
Cu(acac)2 (8.8 mg, 0.035 mmol, 5 mol%) and 2,2ʹ-bipyridyl (6.1 mg, 0.039 mmol, 
6 mol%) were dissolved in water (2 mL). Cyclopentenone (69 µL, 0.7 mmol, 1.0 equiv.) 
and dimethylphenylsilyl-pinacolatoboron 38 (229 µL, 0.84 mmol, 1.2 equiv.). The 
reaction mixture was stirred at room temperature for 24 h. The reaction was diluted 
with water (5 mL) and the aqueous layer was extracted with EtOAc (3 x 10 mL). The 
pooled organic layers were dried over anhydrous Na2SO4 and concentrated. 
Purification by flash chromatography over silica gel (Hexane/Et2O 6:1) afforded the 
desired compound as a colourless oil (124 mg, 0.57 mmol, 82%). Spectral data 
matched those reported in the literature.[330] 
1H NMR (400 MHz, CDCl3) δ 7.53-7.48 (m, 2H), 7.41-7.33 (m, 3H), 2.34-2.17 (m, 2H), 
2.16-2.04 (m, 2H), 1.90 (dd, J = 18.2, 13.0 Hz, 1H), 1.76-1.62 (m, 1H), 1.61-1.48 (m, 1H), 
0.33 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 221.0, 137.1, 133.9 (2C), 129.4, 128.0 (2C), 40.3, 39.4, 
25.1, 24.1, -4.8, -4.8. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol 
(isochratic 94:6) at 30 °C on an IC column, with UV detection (l = 254 nm). Retention 
times of the enantiomers of 41: 11.2 min and 12.7 min. Retention time of the 
cyclopentenone starting material: 7.7 min. Retention time of the silyl donor 38: 
4.6 min. 
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Screening of DNA conditions for the formation of 41 and representative HPLC results. 
Reactions with DNA were conducted on a 2.5 µmol scale at a concentration of 8.3 mM 
relative to cyclopentenone, following the general protocol. Extractions were 
conducted alternatively with Et2O and hexane. 
HPLC of the crude with Cu(NO3)2, L12, pH 6.5, 5.0 equiv. of 38 (Table 5, entry 3):  
 
 
 
  
min0 2 4 6 8 10 12 14
mAU
0
2
4
6
8
 DAD1 C, Sig=254,16 Ref=360,100 (SA-MC\ARCHIVES\SILYLA~1\METHOD~1\ND680B.D)
 1
1.
18
0
 1
2.
66
3
=====================================================================
Injection Date  : 6/7/2017 1:31:36 PM            Seq. Line :   1
Sample Name     : NF680                           Location : Vial 41
Acq. Operator   : ND                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 10 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MARTIN1.M
Last changed    : 6/7/2017 1:29:51 PM by ND
Analysis Method : C:\HPCHEM\1\METHODS\ESH10-1.M
Last changed    : 3/4/2019 1:26:06 PM by Elias
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 C, Sig=254,16 Ref=360,1 0
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  11.180 BB    0.2041  119.45919    9.04402  49.9539
   2  12.663 BB    0.2346  119.67986    7.90752  50.0461
Totals :                   239.13905   16.95154
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\SILYLA~1\METHOD~1\ND680B.D       Sample Name: NF680
Instrument 1 3/4/2019 1:26:51 PM Elias Page 1 of 1
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Injection Date  : 6/13/2017 4:52:55 AM           Seq. Line :  21
Sample Name     : MC-399                          Location : Vial 87
Acq. Operator   : ND                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 15 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MC-ND-1.M
Last changed    : 6/12/2017 3:15:44 PM by ND
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\MC463.M
Last changed    : 12/21/2018 6:51:12 PM by Nicolas
                  (modified after loading)
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=====================================================================
                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 D, Sig=254,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  10.972 VB    0.2224  344.19702   23.84526  50.2346
   2  12.471 BB    0.1816  340.98218   28.50159  49.7654
Totals :                   685.17920   52.34685
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\MC-ND-~1\SCREEN\MC-399.D        Sample Name: MC-399
Instrument 1 12/21/2018 7:04:53 PM Nicolas Page 1 of 1
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HPLC of the crude with Cu(NO3)2, L12, pH 7.5, 1.2 equiv. of 38 (Table 5, entry 4): 
 
 
HPLC of the crude with ON9c/ON6c, pH 6.5, 5.0 equiv. of 38 (Table 6, entry 6): 
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=====================================================================
Injection Date  : 6/13/2017 3:40:02 AM           Seq. Line :  19
Sample Name     : MC-398                          Location : Vial 85
Acq. Operator   : ND                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 15 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MC-ND-1.M
Last changed    : 6/12/2017 3:15:44 PM by ND
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\MC463.M
Last changed    : 12/21/2018 6:51:12 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 D, Sig=254,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.786 BP    0.1771   66.81167    5.85677  40.1978
   2  10.533 MM    0.2998   67.45878    3.75042  40.5871
   3  10.990 MM    0.2541   16.83460    1.10432  10.1287
   4  12.482 BB    0.1762   15.10222    1.31308   9.0864
Totals :                   166.20727   12.02458
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\MC-ND-~1\SCREEN\MC-398.D        Sample Name: MC-398
Instrument 1 12/21/2018 7:03:27 PM Nicolas Page 1 of 1
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Injection Date  : 6/13/2017 7:55:20 AM           Seq. Line :  26
Sample Name     : ND-691                          Location : Vial 92
Acq. Operator   : ND                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 15 µl
Acq. Method     : C:\HPCHEM\1\METHODS\ARSENI~1\MC-ND-1.M
Last changed    : 6/12/2017 3:15:44 PM by ND
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\MC463.M
Last changed    : 12/21/2018 6:51:12 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 D, Sig=254,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  10.948 MM    0.2322  201.80682   14.48468  41.4738
   2  12.415 MM    0.2356  284.78244   20.14605  58.5262
Totals :                   486.58926   34.63073
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\MC-ND-~1\SCREEN\ND-691.D        Sample Name: ND-691
Instrument 1 12/21/2018 7:11:45 PM Nicolas Page 1 of 1
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4.2.5. Propargylation of phenols 
1-Phenylprop-2-yn-1-yl acetate (42) 
 
Molecular formula: C11H10O2 MW = 174.20 g.mol-1 
To a solution of 1-phenyl-2-propyn-1-ol in (150 µL, 1.23 mmol, 1.0 equiv.) in CH2Cl2 
(6 mL) at 0 °C were added acetic anhydride (175 µL, 1.85 mmol, 1.5 equiv.), 
triethylamine (258 µL, 1.85 mmol, 1.5 equiv.) and then DMAP (15.1 mg, 0.12 mmol, 
10 mol%). The reaction mixture was stirred for 2 h. Upon completion, the reaction was 
quenched with water (10 mL). The aqueous phase was extracted with CH2Cl2 
(3 x 10 mL) The pooled organic layers were washed with a saturated aqueous solution 
of NaCl and dried over anhydrous MgSO4. The crude was purified by flash column 
chromatography over silica gel (PE/EtOAc 10:1) to furnish the title compound as a 
colourless oil (215 mg, 1.08 mmol, 88%). Spectral data matched those reported in the 
literature.[331] 
1H NMR (400 MHz, CDCl3) δ 7.58-7.49 (m, 2H), 7.45-7.34 (m, 3H), 6.45 (d, J = 2.2 Hz, 
1H), 2.66 (d, J = 2.2 Hz, 1H), 2.12 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.9, 136.6, 129.2 (2C), 128.9 (2C), 127.8, 80.4, 75.5, 
65.4, 21.2. 
 
3,4,5-Trimethoxy-4-(1-phenylprop-2-yn-1-yl)cyclohexa-2,5-dien-1-one (44) 
 
Molecular formula: C18H18O4 MW = 298.34 g.mol-1 
OAc
Ph
Ph
O
MeO
OMeMeO
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Initial attempts to prepare 44 as a racemate using a Cu(OTf)2/2,2'-bipyridyl catalyst 
failed, therefore an analytically pure sample was prepared using chiral ligand 
2,6-bis[(4S)-4-phenyl-2-oxazolinyl]pyridine following reported results.[101] 
Copper triflate (2.6 mg, 0.007 mmol, 5 mol%) and 2,6-bis[(4S)-4-phenyl-2-
oxazolinyl]pyridine (2.9 mg, 0.008 mmol, 6 mol%) were stirred at room temperature 
for 1 h in methanol (1.5 mL). Acetate 42 (25 mg, 0.14 mmol, 1.0 equiv.), 
3,4,5-dimethoxyphenol 43 (31.7 mg, 0.17 mmol, 1.2 equiv.) and triethylamine (24 µL, 
0.17 mmol, 1.2 equiv.) were then added. The resulting mixture was stirred overnight. 
The solvent was removed under reduced pressure and the crude was purified by 
preparative TLC (Hexane/EtOAc 1:1) to furnish the title compound as a yellow oil 
(17 mg, 0.06 mmol, 40%). Spectral data matched those reported in the literature.[101] 
HPLC analysis showed the compound to have an ee of 30%. 
1H NMR (400 MHz, CDCl3) δ 7.23 (s, 5H), 5.52 (d, J = 1.6 Hz, 1H), 5.50 (d, J = 1.6 Hz, 1H), 
4.54 (d, J = 2.7 Hz, 1H), 3.84 (s, 3H), 3.64 (s, 3H), 3.17 (s, 3H), 2.34 (d, J = 2.7 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 186.8, 168.2, 167.4, 134.9, 129.3 (2C), 128.1, 127.9 (2C), 
107.6, 105.4, 81.5, 81.3, 73.4, 56.3, 55.8, 53.8, 45.8. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (85:15 
for 19 min then increase over 1 min then 60:40 for 12 min) at 30 °C on an IC column, 
with UV detection (l = 254 nm). Retention times of the enantiomers of 44: 16.8 min 
and 18.5 min. Retention time of phenol 43: 30.9 min. 
  
  
 
153 
 
 
Screening of DNA conditions for the formation of 44 and representative HPLC results. 
Reactions with DNA were conducted on a 0.5 µmol scale at a concentration of 0.8 mM 
relative to acetate 42, following the general protocol. Extractions were conducted with 
a 1:1 mixture of Et2O and EtOAc. The ratio of product 44 relative to acetate 42 was 
assessed using the Beer-Lambert law after calibration of their absorbance ratio in the 
relevant range. 
HPLC of the crude with Cu(NO3)2, L8, MOPS pH 7.5 (Table 8, entry 6): 
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=====================================================================
Injection Date  : 10/2/2017 5:05:52 PM           Seq. Line :   5
Sample Name     : MC463-3                         Location : Vial 81
Acq. Operator   : LH                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 10 µl
Acq. Method     : C:\HPCHEM\1\METHODS\SA-MC\MC-MTH15.M
Last changed    : 10/2/2017 4:32:37 PM by LH
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\MC463.M
Last changed    : 12/20/2018 9:57:01 PM by Nicolas
                  (modified after loading)
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=====================================================================
                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 D, Sig=254,16 Ref=36 ,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  16.840 BB    0.4184 3212.50684  119.21140  35.3065
   2  18.467 BB    0.4752 5886.40723  192.23938  64.6935
Totals :                  9098.91406  311.45078
 Results obtained with enhanced integrator!
=====================================================================
                     *** End of Repor  ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\PHENOL~1\MC463\MTHDEV~1\ICCOLU~1\MC463M15.D MC463-3
Instrument 1 12/20/2018 9:57:05 PM Nicolas Page 1 of 1
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Injection Date  : 10/18/2017 7:23:36 PM          Seq. Line :   6
Sample Name     : MC540                           Location : Vial 73
Acq. Operator   : MC                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Acq. Method     : C:\HPCHEM\1\METHODS\SA-MC\MC463.M
Last changed    : 10/2/2017 6:47:46 PM by LH
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\MC463.M
Last changed    : 12/20/2018 10:48:57 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 D, Sig=254,16 Ref=36 ,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  15.137 MF    0.4205  127.16177    5.03978  29.0681
   2  16.511 FM    0.5412  228.80803    7.04621  52.3037
   3  29.622 MM    0.3311   81.49109    4.10173  18.6282
Totals :                   437.46088   16.18772
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\PHENOL~1\MC463\SCREEN\2NDSCR~1\MC540.D        MC540
Instrument 1 12/20/2018 10:51:33 PM Nicolas Page 1 of 1
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HPLC of the crude with Cu(NO3)2, L8, HEPES pH 8.2 (Table 8, entry 15): 
 
 
 
3,5-Dimethoxy-4-(1-phenylprop-2-yn-1-yl)phenol (50) 
 
Molecular formula: C17H16O3 MW = 268.31 g.mol-1 
Initial attempts to prepare 50 as a racemate using a Cu(OTf)2/2,2'-bipyridyl catalyst 
failed, therefore an analytically pure sample was prepared using chiral ligand 
2,6-bis[(4S)-4-phenyl-2-oxazolinyl]pyridine following reported results.[101] 
Copper triflate (5.2 mg, 0.014 mmol, 5 mol%) and 2,6-bis[(4S)-4-phenyl-2-
oxazolinyl]pyridine (5.8 mg, 0.016 mmol, 6 mol%) were stirred at room temperature 
for 1 h in methanol (3 mL). Acetate 42 (50 mg, 0.29 mmol, 1.0 equiv.), 
3,5-dimethoxyphenol49 (53.1 mg, 0.34 mmol, 1.2 equiv.) and triethylamine (48 µL, 
0.34 mmol, 1.2 equiv.) were then added. The resulting mixture was stirred overnight. 
The solvent was removed under reduced pressure and the crude was purified by 
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Injection Date  : 11/7/2017 5:51:32 AM           Seq. Line :  13
Sample Name     : MC569                           Location : Vial 73
Acq. Operator   : MC                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Acq. Method     : C:\HPCHEM\1\METHODS\SA-MC\MC463.M
Last changed    : 10/19/2017 5:04:08 PM by MC
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\MC463.M
Last changed    : 12/20/2018 10:48:57 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 D, Sig=254,16 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  16.699 MF    0.4719  229.80931    8.11728  32.1055
   2  18.182 FM    0.5300  421.57169   13.25689  58.8956
   3  30.466 MM    0.3915   64.41350    2.74198   8.9989
Totals :                   715.79449   24.11615
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\PHENOL~1\MC463\SCREEN\5THSCR~1\MC569.D        MC569
Instrument 1 12/20/2018 10:54:46 PM Nicolas Page 1 of 1
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preparative TLC (Hexane/EtOAc 3:1) to furnish the title compound as a yellow oil 
(68 mg, 0.25 mmol, 88%). Spectral data matched those reported in the literature.[101] 
HPLC analysis showed the compound to have an ee of 14%. 
1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 7.4 Hz, 2H), 7.26 (t, J = 7.5 Hz, 2H), 7.20-7.14 
(m, 1H), 6.04 (s, 2H), 5.70 (d, J = 2.6 Hz, 1H), 5.37-5.21 (m, 1H), 3.67 (s, 6H), 2.28 (d, 
J = 2.7 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 158.7 (2C), 156.4, 141.0, 127.9 (2C), 127.3 (2C), 126.0, 
110.7, 93.1 (2C), 85.0, 69.2, 56.0 (2C), 30.7. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol 
(isochratic 88:12) at 30 °C on an IA column, with UV detection (l = 230 nm). Retention 
times of the enantiomers of 50: 10.9 min and 13.2 min. Retention time of phenol49: 
9.1 min.  
  
 
 
Screening of DNA conditions for the formation of 50. Reactions with DNA were 
conducted on a 0.5 µmol scale at a concentration of 0.8 mM relative to acetate 42, 
following the general protocol. Extractions were conducted with a 1:1 mixture of Et2O 
and EtOAc. No Friedel-Crafts product 50 was observed under the attempted 
conditions. 
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Injection Date  : 10/6/2017 3:01:28 PM           Seq. Line :   3
Sample Name     : MC495                           Location : Vial 41
Acq. Operator   : LH                                   Inj :   1
Acq. Instrument : Instrument 1                  Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 5 µl
Acq. Method     : C:\HPCHEM\1\METHODS\SA-MC\MC-MTH12.M
Last changed    : 10/6/2017 2:58:40 PM by LH
Analysis Method : C:\HPCHEM\1\METHODS\SA-MC\ARCHIVE\DNA\MC-NAZ1.M
Last changed    : 12/19/2018 7:43:04 PM by Nicolas
                  (modified after loading)
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                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 B, Sig=230,8 Ref=360,100
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  10.896 BB    0.2487 5258.62695  321.65179  43.4775
   2  13.209 BB    0.2907 6836.42676  358.17374  56.5225
Totals :                  1.20951e4   679.82553
 Results obtained with enhanced integrator!
=====================================================================
                          *** End of Report ***
Data File D:\HPCHEM\1\DATA\SA-MC\ARCHIVES\PHENOL~1\MC495\MTHDEV~1\IACOLU~1\MC495M12.D   MC495
Instrument 1 12/19/2018 7:44:01 PM Nicolas Page 1 of 1
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4.2.6. Endiandric acids 
Ethyl (2E,4E)-5-phenylpenta-2,4-dienoate (precursor to 65) 
 
Molecular formula: C13H14O2 MW = 202.25 g.mol-1 
To a solution of cinnamaldehyde 64 (5.7 mL, 45 mmol, 1.0 equiv.) in CH2Cl2 (100 mL) 
was added (carbethoxylethylene)triphenylphosphorane (17.4 g, 50.0 mmol, 
1.1 equiv.). The reaction mixture was stirred at room temperature for 16 h. Upon 
completion, the mixture was concentrated under reduced pressure and the crude was 
purified by flash chromatography over silica gel (PE/EtOAc 9:1) to afford the desired 
ester as a colourless oil (7.21 g, 35.6 mmol, 79%). Spectral data matched those 
reported in the literature.[332] 
1H NMR (400 MHz, CDCl3) δ 7.51-7.27 (m, 6H), 6.95-6.81 (m, 2H), 5.99 (d, J = 15.3 Hz, 
1H), 4.24 (q, J = 7.1 Hz, 2H), 1.32 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 167.2, 144.6, 140.5, 136.2, 129.1, 128.9 (2C), 127.3 (2C), 
126.4, 121.5, 60.5, 14.5. 
 
(2E,4E)-5-Phenylpenta-2,4-dien-1-ol (65) 
 
Molecular formula: C11H12O MW = 160.22 g.mol-1 
To a solution of the ester (1.0 g, 4.9 mmol, 1.0 equiv.) in CH2Cl2 (15 mL) was dropwise 
added DIBAL-H (1.0 M solution in CH2Cl2, 10.5 mL, 10.5 mmol, 2.2 equiv.) at 0 °C. The 
reaction was stirred at this temperature for 45 min. Upon completion, the reaction 
was quenched by slow addition of saturated aqueous sodium potassium tartrate 
solution (20 mL). The biphasic mixture was stirred at room temperature for 2 h, then 
diluted with Et2O (20 mL). The aqueous phase was extracted with Et2O (2 x 20 mL). The 
combined organic layers were washed with a saturated aqueous solution of NaCl 
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(20 mL), dried over anhydrous MgSO4 and concentrated. Flash chromatography over 
silica gel (PE/EtOAc 4:1) afforded alcohol 65 as a white powder (660 mg, 4.12 mmol, 
84%). Spectral data matched those reported in the literature.[333] 
1H NMR (400 MHz, CDCl3) δ 7.44-7.37 (m, 2H), 7.36-7.28 (m, 2H), 7.28-7.20 (m, 1H), 
6.80 (dd, J = 15.6, 10.5 Hz, 1H), 6.56 (d, J = 15.6 Hz, 1H), 6.43 (dd, J = 15.2, 10.5 Hz, 1H), 
5.97 (dt, J = 15.2, 5.8 Hz, 1H), 4.25 (d, J = 5.8 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 137.3, 133.0, 132.6, 131.8, 128.8 (2C), 128.3, 127.8, 126.5 
(2C), 63.6.  
 
((1E,3E)-5-bromopenta-1,3-dien-1-yl)benzene (68) 
 
Molecular formula: C11H11Br MW = 223.11 g.mol-1 
To a solution of alcohol 65 (0.200 g, 1.25 mmol, 1.0 equiv.) in dry Et2O (5 mL) was 
dropwise added PBr3 (0.13 mL, 1.31 mmol, 1.05 equiv.) at 0 °C. After stirring at this 
temperature for 30 min., the reaction was quenched with ice-water and diluted with 
Et2O (10 mL). The aqueous phase was separated and back extracted with Et2O (20 mL). 
The combined organic layers were washed with a saturated aqueous solution of 
NaHCO3 (10 mL) and a saturated aqueous solution of NaCl (10 mL) and eventually dried 
over anhydrous MgSO4. Concentration under reduced pressure furnished the title 
compound as a white solid (243 mg, 1.09 mmol, 87%). The title compound was found 
to be unstable on SiO2 gel and crude material was used in subsequent reactions. 
Spectral data matched those reported in the literature.[334] 
1H NMR (400 MHz, CDCl3) δ 7.45-7.39 (m, 2H), 7.38-7.31 (m, 2H), 7.29-7.23 (m, 1H), 
6.78 (dd, J = 15.6, 10.5 Hz, 1H), 6.62 (d, J = 15.6 Hz, 1H), 6.47 (dd, J = 14.9, 10.5 Hz, 1H), 
6.01 (dt, J = 14.9, 8.0 Hz, 1H), 4.12 (d, J = 8.0 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 136.9, 135.3, 134.7, 129.1, 128.8 (2C), 128.2, 127.5, 126.7 
(2C), 33.5. 
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5-((tert-Butyldimethylsilyl)oxy)pent-2-ynal (68) 
 
Molecular formula: C11H20O2Si MW = 212.36 g.mol-1 
A 3-necked RBF equipped with a thermometer was charged with (but-3-yn-1-
yloxy)(tert-butyl)dimethylsilane 67 (1.47 mL, 7.11 mmol, 1.0 equiv.) and THF (50 mL). 
The solution was cooled to −78 °C and n-BuLi (2.5 M solution in hexanes, 3.4 mL, 
8.5 mmol, 1.2 equiv.) was added dropwise. After stirring for 30 min. at the same 
temperature, 4-formylmorpholine (1.0 mL, 10 mmol, 1.4 equiv.) was added dropwise. 
The reaction mixture was then allowed to warm to room temperature and stirred for 
an additional 2 h. Upon completion, a saturated aqueous solution of NH4Cl (60 mL) was 
added and the reaction mixture was diluted with Et2O (60 mL). The layers were 
separated, and the aqueous layer was extracted with Et2O (2 x 50 mL). The combined 
organic layers were washed with a saturated aqueous solution of NaCl (30 mL), dried 
over anhydrous MgSO4 and concentrated under reduced pressure (bath at 0 °C, 
pressure no less than 20 mbar, as the product is volatile). Flash column 
chromatography over silica gel (PE/Et2O 95:5) afforded the title compound as a yellow 
oil (1.14 g, 5.36 mmol, 76%). Spectral data matched those reported in the 
literature.[335] 
1H NMR (400 MHz, CDCl3) δ 7.26 (t, J = 0.9 Hz, 1H), 1.88 (t, J = 6.7 Hz, 2H), 0.71 (td, 
J = 6.7, 0.9 Hz, 2H), -1.02 (s, 9H), -1.83 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 177.1, 96.3, 82.4, 60.8, 26.0 (3C), 23.7, 18.4, -5.2 (2C). 
 
((6-Bromohexa-3,5-diyn-1-yl)oxy)(tert-butyl)dimethylsilane (63) 
 
Molecular formula: C12H19BrOSi  MW = 287.27 g.mol-1 
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Note: extra care was taken when handling trimethylsilyldiazomethane as vapour 
inhalation has resulted in the death of two researchers over the last few years. 
TMS diazomethane (2.0 M in hexanes, 390 μL, 0.78 mmol, 1.1 equiv.) and THF (6 mL) 
were charged in a round-bottomed flask and cooled to −78 °C, then n-BuLi (2.5 M in 
hexanes, 310 μL, 0.78 mmol, 1.1 equiv.) was added. The resulting orange solution was 
stirred for a further 15 min., then aldehyde 68 (150 mg, 0.71 mmol, 1.0 equiv.) 
dissolved in THF (1 mL) was added slowly over 5 min. The reaction mixture was then 
warmed to room temperature and stirred for 1 h, until effervescence had ceased 
(release of N2) and TLC monitoring indicated the completion of the reaction. The 
resulting solution, which contained the intermediate terminal diyne, was then re-
cooled to −78 °C. A second portion of n-BuLi (2.5 M in hexanes, 370 μL, 0.92 mmol, 
1.3 equiv.) was added, and the mixture was stirred for 15 min. N-Bromosuccinimide 
(190 mg, 1.07 mmol, 1.5 equiv.) was then added and the reaction mixture was stirred 
at room temperature in the dark for 1 h. The reaction was quenched with saturated 
aqueous NH4Cl solution (10 mL) and diluted with Et2O (10 mL). The aqueous phase was 
separated and back extracted with Et2O (10 mL). The combined organic layers were 
washed with a saturated aqueous solution of NaCl (10 mL), dried over anhydrous 
MgSO4 and concentrated under reduced pressure. Purification by flash column 
chromatography over silica gel (PE/CH2Cl2 9:1) afforded the title compound as a yellow 
oil (120 mg, 0.42 mmol, 59%). Spectral data matched those reported in the 
literature.[123] 
1H NMR (400 MHz, CDCl3) δ 3.73 (t, J = 6.9 Hz, 2H), 2.46 (t, J = 6.9 Hz, 2H), 0.90 (s, 9H), 
0.08 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 74.4, 66.5, 65.6, 61.2, 37.3, 25.8 (3C), 23.5, 18.3, –5.3 
(2C).  
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tert-Butyldimethyl((10-(trimethylsilyl)deca-3,5,7,9-tetrayn-1-yl)oxy)silane (70) 
 
Molecular formula: C19H28OSi2 MW = 328.60 g.mol-1 
tert-Butyl(deca-3,5,7,9-tetrayn-1-yloxy)dimethylsilane (70') 
 
Molecular formula: C16H20OSi MW = 256.42 g.mol-1 
To a solution of 1,4-bis(trimethylsilyl)butadiyne 64 (575 mg, 2.96 mmol, 1.3 equiv.) in 
THF (5 mL) was added a solution of MeLiLiBr complex (1.5 M in Et2O, 2.0 mL, 
3.0 mmol, 1.3 equiv.). The reaction mixture was stirred for 30 min at room 
temperature, then cooled to 0 °C. Zinc bromide (768 mg, 3.41 mmol, 1.3 equiv.) was 
charged in a RBF and dried by heating with a Bunsen burner under high-vacuum 
(7 mbar) until the salt melted. The vessel was allowed to cool under a flow of N2, and 
THF (8 mL) was added. The zinc bromide solution was then transferred to the lithium 
butadiynyl solution and the resulting mixture was stirred at room temperature for an 
additional 30 min. Diynyl bromide 65 (654 mg, 2.28 mmol, 1.0 equiv.), toluene (15 mL), 
and PdCl2(dppf) (83 mg, 0.11 mmol, 5.0 mol %) were then added sequentially and the 
reaction mixture was stirred in the dark for 20 h. The reaction was quenched with 
saturated aqueous NH4Cl solution (50 mL) and diluted with Et2O (50 mL). The aqueous 
phase was separated and back extracted with Et2O (50 mL). The pooled organic layers 
were washed with a saturated aqueous solution of NaCl (50 mL), dried over anhydrous 
MgSO4 and concentrated. Purification by flash column chromatography over silica gel 
(PE/CH2Cl2 100:0 to 85:15) afforded a mixture of TMS-capped tetrayne 70 and free 
tetrayne 70' in a 65:35 ratio as a yellow oil (503 mg, 1.66 mmol, 56% total). Pure 
terminal tetrayne 70' has been reported to decompose violently and exothermically, so 
the mixture was engaged in the next step without further purification. Spectral data 
matched those reported in the literature.[123] 
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1H NMR (400 MHz, CDCl3) δ 3.75 (t, J = 6.8 Hz, 2H), 2.55-2.50 (m, 2H), 0.90 (s, 9H), 0.20 
(s, 9H), 0.07 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 88.2, 87.3, 78.6, 66.7, 62.9, 62.8, 61.2, 61.1, 60.6, 26.0 
(3C), 24.1, 18.4, –0.4 (3C), –5.2 (2C). 
 
tert-Butyldimethyl(((12E,14E)-15-phenylpentadeca-12,14-dien-3,5,7,9-tetrayn-1-
yl)oxy)silane (57) 
 
Molecular formula: C27H30OSi MW = 398.62 g.mol-1 
To a solution of TMS tetrayne 70 (706 mg, 2.15 mmol, 2.1 equiv.) in MeOH (12 mL) was 
added potassium carbonate (311 mg, 2.25 mmol, 2.2 equiv.) at 0 °C. The reaction 
mixture was stirred for 10 min. under N2 and then diluted with Et2O (20 mL) and H2O 
(20 mL). One crystal of BHT was added at this time. The aqueous layer was extracted 
with Et2O (10 mL). The combined organic layers were washed with H2O (10 mL), a 
saturated aqueous solution of NaCl (10 mL), and dried over anhydrous MgSO4. At this 
stage the solution containing the terminal tetrayne was carefully concentrated at 0 °C 
to a total volume of ~2.0 mL (As the terminal tetrayne was reported to decompose 
violently and exothermically to intractable products when left neat for periods longer 
than 1 minute, the utmost care and attention was taken). The flask was then 
evacuated under high vacuum (7 mbar) and back-filled with N2 (3 × 10 s cycles). Dry 
THF (10 mL) was then immediately added. The resulting solution was transferred to a 
solution of t-BuMgCl (1.0 M in THF, 2.1 mL, 2.5 equiv.). The reaction vessel was heated 
at 40 °C for 30 min and subsequently cooled to room temperature.  
A second reaction vessel was charged with allylic bromide 68 (228 mg, 1.02 mmol, 1.0 
equiv.), copper(I) iodide (59 mg, 0.31 mmol, 30 mol%) and dry THF (5 mL), and the 
reaction mixture was warmed to 50 °C. The tetrayne Grignard reagent solution was 
then added over 20 min and the reaction was stirred for a further 30 min once the 
addition was complete. The reaction was then quenched with saturated aqueous NH4Cl 
Ph
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solution (20 mL) and diluted with Et2O (20 mL). The aqueous phase was extracted with 
Et2O (20 mL). The pooled organic layers were washed with a saturated aqueous 
solution of NaCl (20 mL) and dried over anhydrous MgSO4. Concentration under 
reduced pressure and purification by flash chromatography over phosphate buffered 
(pH 7) silica gel (Hexane/CH2Cl2 100:0 to 85:15) furnished the title compound as an 
orange oil (0.243 mmol by 1H NMR analysis using BHT as an internal standard, 28% 
from bromide 68). Spectral data matched those reported in the literature.[123] 
1H NMR (400 MHz, CDCl3) δ 7.45-7.37 (m, 2H), 7.34 (t, J = 7.6 Hz, 2H), 7.28-7.23 (m, 
1H), 6.78 (dd, J = 15.7, 10.4 Hz, 1H), 6.58 (d, J = 15.7 Hz, 1H), 6.46 (dd, J = 15.1, 10.4 Hz, 
1H), 5.71 (dt, J = 15.1, 5.8 Hz, 1H), 3.78 (t, J = 6.8 Hz, 3H), 3.21 (d, J = 5.8 Hz, 2H), 2.55 
(t, J = 6.8 Hz, 2H), 0.93 (s, 9H), 0.11 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 137.2, 133.2, 132.7, 128.7 (2C), 127.9, 127.7, 126.5 (2C), 
125.6, 78.0, 76.7, 67.8, 66.8, 62.0, 61.8, 61.4, 61.2, 60.8, 26.0 (3C), 24.1, 22.9, 
18.4, -5.2 (2C). 
 
4-Bromobut-3-yn-1-ol (74) 
 
Molecular formula: C4H5BrO MW = 148.99 g.mol-1 
To a solution of alkyne 73 (2.00 mL, 26.3 mmol, 1.0 equiv.) in acetone (70 mL) were 
added freshly recrystallized N-bromosuccinimide (5.64 g, 31.6 mmol, 1.2 equiv.) and 
silver nitrate (672 mg, 3.95 mmol, 15 mol%). The reaction mixture was stirred in the 
dark for 3 h. Upon completion, the reaction mixture was diluted with Et2O (70 mL) and 
H2O (70 mL). The aqueous layer was extracted with Et2O (2 x 60 mL). The pooled 
organic extracts were washed with a saturated aqueous solution of NaCl (40 mL), dried 
over anhydrous MgSO4 and concentrated under reduced pressure. Flash 
chromatography over silica gel (PE/EtOAc 4:1) afforded the title compound as a 
colourless oil (3.37 g, 22.6 mmol, 86%). Spectral data matched those reported in the 
literature.[128] 
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1H NMR (400 MHz, CDCl3) δ 3.72 (t, J = 6.3 Hz, 2H), 2.47 (t, J = 6.3 Hz, 2H), 2.02 (s, 1H). 
13C NMR (101 MHz, CDCl3) δ 77.2, 60.9, 40.2, 24.1. 
 
6-(Trimethylsilyl)hexa-3,5-diyn-1-ol (76) 
 
Molecular formula: C9H14OSi MW = 166.30 g.mol-1 
Piperidine (5 mL) was distilled over CaH2 prior to use and degassed by sonication under 
a flow of N2. Ethynyltrimethylsilane (1.14 mL, 8.05 mmol, 2.0 equiv.) and 
bromoalkyne 74 (600 mg, 4.03 mmol, 1.0 equiv.) were added and the mixture was 
cooled to 0 °C. Copper(I) chloride (76.8 mg, 0.403 mmol, 10 mol%) was then added, 
and the reaction mixture was stirred at this temperature for 30 min. Upon completion, 
the reaction was quenched with saturated aqueous NH4Cl solution (10 mL) and diluted 
with CH2Cl2 (15 mL). The aqueous layer was separated and back extracted with 
additional CH2Cl2 (2 × 15 mL). The combined organic extracts were washed with 
saturated aqueous NH4Cl solution (10 mL), then a saturated aqueous solution of NaCl 
(10 mL), and dried over anhydrous MgSO4. Concentration under reduced pressure 
furnished the title compound as a red oil (502 mg, 3.02 mmol, 75%) which was used 
without further purification. Spectral data matched those reported in the 
literature.[128] 
1H NMR (400 MHz, CDCl3) δ 3.71 (t, J = 6.4 Hz, 2H), 2.51 (t, J = 6.4 Hz, 2H), 2.41 (s, 1H), 
0.15 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 88.2, 84.0, 76.6, 67.2, 60.7, 23.7, –0.3 (3C). 
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7-Methylocta-3,5-diyne-1,7-diol (78) 
 
Molecular formula: C9H12O2 MW = 152.19 g.mol-1 
2,7-Dimethylocta-3,5-diyne-2,7-diol (78') 
 
Molecular formula: C9H12O2 MW = 152.19 g.mol-1 
To a suspension of copper powder (12.6 mg, 0.20 mmol, 5 mol%) and TMEDA (119 µL, 
0.79 mmol, 20 mol%) in a mixture of CHCl3 (8 mL) and 1,4-dioxane (3 mL) were added 
2-methylbut-3-yn-2-ol 77 (0.50 mL, 5.25 mmol, 1.3 equiv.) and 3-butyn-1-ol 73 
(0.30 mL, 3.96 mmol, 1.0 equiv.). The reaction mixture was stirred under air at 50 °C 
for 24 h. The mixture was diluted with CHCl3 (40 mL) and a saturated aqueous NH4Cl 
solution (20 mL). The organic layer was washed with said solution and dried over 
anhydrous MgSO4. Purification of the crude by flash chromatography over silica gel 
(PE/EtOAc 4:1 to 2:1) afforded first homocoupling product 78' (white solid, 227 mg, 
1.37 mmol, 34%), followed by heterocoupling product 78 (yellow oil, 399 mg, 
2.62 mmol, 66%). The spectral data for 78' matched those reported in the 
literature.[336] 
Spectral data for 78: 
1H NMR (400 MHz, CDCl3) δ 3.75 (t, J = 6.3 Hz, 2H), 2.55 (t, J = 6.3 Hz, 2H), 2.02 (br. s, 
2H), 1.52 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 80.7, 78.3, 67.2, 66.3, 65.7, 60.8, 31.3 (2C), 23.8. 
Spectral data for 78': 
1H NMR (400 MHz, CDCl3) δ 1.81 (br. s, 2H), 1.53 (s, 12H). 
13C NMR (101 MHz, CDCl3) δ 84.2 (2C), 66.5 (2C), 65.7 (2C), 31.2 (4C).   
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Dodeca-3,5,7,9-tetrayne-1,12-diol (83) 
 
Molecular formula: C12H10O2 MW = 186.21 g.mol-1 
To an open flask containing a solution of capped diyne 77 (450 mg, 2.71 mmol, 
1.0 equiv.) in DMF (3 mL) was added copper(I) chloride (287 mg, 2.87 mmol, 
1.06 equiv.). The reaction mixture was stirred at 60 °C under air for 2 h, then the 
reaction mixture was filtered through a short plug of silica gel (EtOAc) and 
concentrated under reduced pressure. Purification by flash chromatography over silica 
gel (CH2Cl2/EtOAc 3:1 to 1:1) afforded the title compound as an orange solid (210 mg, 
1.13 mmol, 83%). This compound was found to be unstable and slowly decomposed to 
intractable products in a matter of minutes when left neat. Spectral data matched 
those reported in the literature.[128] 
1H NMR (400 MHz, Acetone-d6) δ 4.12 (t, J = 5.8 Hz, 2H), 3.66 (td, J = 6.3, 5.8 Hz, 4H), 
2.53 (t, J = 6.3 Hz, 4H). 
13C NMR (101 MHz, Acetone-d6) δ 80.6 (2C), 66.3 (2C), 62.3 (2C), 60.6 (2C), 60.5 (2C), 
24.3 (2C). 
 
((4-Bromobut-3-yn-1-yl)oxy)(tert-butyl)dimethylsilane (precursor to 84) 
 
Molecular formula: C10H19BrOSi MW = 263.25 g.mol-1 
To a solution of alkyne 67 (560 μL, 2.71 mmol, 1.0 equiv.) in acetone (10 mL) were 
added freshly recrystallized N-bromosuccinimide (579 mg, 3.25 mmol, 1.2 equiv.) and 
silver nitrate (69 mg, 0.41 mmol, 15 mol%). The reaction mixture was stirred in the 
dark overnight. Upon completion, the reaction mixture was diluted with Et2O (20 mL) 
and H2O (20 mL). The aqueous layer was extracted with Et2O (2 x 20 mL). The pooled 
organic extracts were washed with a saturated aqueous solution of NaCl (10 mL), dried 
HOOH
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over anhydrous MgSO4 and concentrated under reduced pressure. Flash 
chromatography over silica gel (PE/CH2Cl2, 95:5 to 90:10) afforded the desired alkynyl 
bromide as a colourless oil (469 mg, 2.54 mmol, 94%). Spectral data matched those 
reported in the literature.[337] 
1H NMR (400 MHz, CDCl3) δ 3.73 (t, J = 7.0 Hz, 2H), 2.41 (t, J = 7.0 Hz, 2H), 0.90 (s, 9H), 
0.07 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 77.7, 61.7, 39.2, 26.0 (3C), 24.2, 18.5, –5.1 (2C). 
 
tert-Butyldimethyl((6-(trimethylsilyl)hexa-3,5-diyn-1-yl)oxy)silane (84) 
 
Molecular formula: C15H28BrOSi2 MW = 280.56 g.mol-1 
Piperidine (5 mL) was distilled over CaH2 prior to use and degassed by sonication under 
a flow of N2. Ethynyltrimethylsilane (375 μL, 2.66 mmol, 2.0 equiv.) and the alkynyl 
bromide (350 mg, 1.33 mmol, 1.0 equiv.) were added and the mixture was cooled to 
0 °C. Copper(I) iodide (25 mg, 0.13 mmol, 10 mol%) was then added, and the reaction 
mixture was stirred at this temperature for 30 min. Upon completion, the reaction was 
quenched with saturated aqueous NH4Cl solution (10 mL) and diluted with CH2Cl2 
(15 mL). The aqueous layer was separated and back extracted with additional CH2Cl2 
(2 × 15 mL). The combined organic extracts were washed with saturated aqueous 
NH4Cl solution (10 mL), then a saturated aqueous solution of NaCl (10 mL), and dried 
over anhydrous MgSO4. Concentration under reduced pressure furnished the title 
compound as a brown oil (335 mg, 3.02 mmol, 75%) which was used without further 
purification. Spectral data matched those reported in the literature.[128] 
1H NMR (400 MHz, CDCl3) δ 3.72 (t, J = 7.1 Hz, 2H), 2.47 (t, J = 7.1 Hz, 2H), 0.89 (s, 9H), 
0.17 (s, 9H), 0.06 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 88.4, 83.5, 77.0, 66.8, 61.5, 26.0 (3C), 23.8, 18.4, –0.2 
(3C), –5.2 (2C). 
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2,2,3,3,18,18,19,19-Octamethyl-4,17-dioxa-3,18-disilaicosa-7,9,11,13-tetrayne (87) 
 
Molecular formula: C24H38O2Si2 MW = 414.74 g.mol-1 
To a solution of protected diyne 84 (241 mg, 1.45 mmol, 1.0 equiv.) in MeOH (5 mL) 
was added potassium carbonate (201 mg, 1.45 mmol, 1.0 equiv.). The reaction mixture 
was stirred at room temperature for 10 min. Upon completion, the reaction mixture 
was diluted with Et2O (20 mL) and H2O (10 mL). The aqueous layer was extracted with 
Et2O (2 x 10 mL). The pooled organic extracts were washed with a saturated aqueous 
solution of NaCl (10 mL), dried over anhydrous MgSO4 and concentrated.  
The crude was directly solved in CH2Cl2 (5 mL), then copper(I) chloride (14 mg, 
0.15 mmol, 10 mol%) and TMEDA (260 μL, 1.74 mmol, 1.2 equiv.) were added. The 
reaction mixture was stirred at room temperature under air for 1 h then the reaction 
was quenched by the addition of saturated aqueous NH4Cl solution (10 mL) and diluted 
with CH2Cl2 (5 mL). The aqueous layer was extracted with CH2Cl2 (10 mL). The combined 
organic layers were washed with a saturated aqueous solution of NaCl (10 mL), dried 
over anhydrous MgSO4 and concentrated to afford the title compound as a colourless 
oil (274 mg, 0.66 mmol, 91%). Spectral data matched those reported in the 
literature.[128] 
 1H NMR (400 MHz, CDCl3) δ 3.74 (t, J = 6.8 Hz, 4H), 2.51 (t, J = 6.8 Hz, 4H), 0.89 (s, 
18H), 0.07 (s, 12H). 
13C NMR (101 MHz, CDCl3) δ 77.8 (2C), 66.9 (2C), 61.6 (2C), 61.2 (2C), 61.0 (2C), 26.0 
(6C), 24.1 (2C), 18.4 (2C), –5.2 (4C). 
  
TBSOOTBS
  
 
168 
Representative procedure for the attempted preparation of tetraenes by Rieke zinc 
reduction 
(3Z,5Z,7Z,9Z)-Dodeca-3,5,7,9-tetraene-1,12-diol (79a) 
 
Molecular formula: C12H18O2 MW = 194.27 g.mol-1 
(7Z,9Z,11Z,13Z)-2,2,3,3,18,18,19,19-Octamethyl-4,17-dioxa-3,18-disilaicosa-
7,9,11,13-tetraene (79a) 
 
Molecular formula: C24H46O2Si2 MW = 422.80 g.mol-1 
Zinc bromide (20.7 g, 91.8 mmol, 170 equiv.) was charged in a RBF and dried by 
heating with a Bunsen burner under high-vacuum (7 mbar) until the salt melted. The 
vessel was allowed to cool under a flow of Ar, and THF (40 mL) was added. A separate 
3-neck 250 mL RBF, equipped with a large magnetic stir bar and a crushed glass pipette 
tip, was flame-dried under high vacuum, and then cooled under Ar. The reaction vessel 
was charged with naphthalene (520 mg, 4.05 mmol, 7.6 equiv.) and THF (20 mL). Finely 
sliced Li metal (1.3 g, 183.6 mmol, 340 equiv.) was added and the mixture was stirred 
until the deep green lithium naphthalenide complex was observed. The mixture was 
stirred for an additional 15 min, then cooled to 0 °C, and the solution of ZnBr2 
prepared previously was added over 10 min. A fine black zinc suspension developed 
over the course of addition. The Rieke zinc solution was stirred for a further 1 h at 
ambient room temperature. 
A solution of the tetrayne (0.54 mmol, 1.0 equiv.) in THF (10.0 mL) was then added at 
0 °C, immediately followed by dry EtOH (10.0 mL). The resulting mixture was slowly 
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allowed to warm to room temperature and stirred for 15 h in the dark. The reaction 
was then cautiously quenched with saturated aqueous NH4Cl solution (100 mL) at 0 °C 
under Ar, and stirred for 1 h at room temperature. Exposure to light was minimised 
during the work up. The resulting mixture was filtered over a cotton plug to remove 
metallic residues and diluted with EtOAc for tetraene 79a (50 mL) (Et2O was used for 
extractions of tetraene 79b). The aqueous layer was separated and back extracted 
with additional solvent (50 mL). The organic layers were combined, washed with a 
saturated aqueous solution of NaCl (50 mL) and dried over anhydrous MgSO4. The 
crude was purified by flash chromatography over phosphate buffered (pH 7) silica gel 
(CH2Cl2/EtOAc 3:1 to 1:1 for 79a, Hexane/CH2Cl2 4:1 for 79b). Complex mixtures were 
obtained regardless of subsequent runs with varying equivalents of Rieke zinc and 
repeated purification attempts, including using silver nitrate loaded silica gel.[129] 
Spectral data for 79a:  
1H NMR (400 MHz, CDCl3) δ 6.58-6.45 (m, 2H), 6.38-6.15 (m, 4H), 5.53-5.41 (m, 2H), 
3.74-3.66 (m, 4H), 2.53-2.46 (m, 4H). 
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Best sample isolated after reduction of tetrayne 83: 
 
 
 
  
OHHO
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Expected NMR of model tetraene 79a (reproduced from Sherburn et al.)[128] 
 
 
General procedure for the attempted electrocyclisation of tetraenes 
2,2'-(Bicyclo[4.2.0]octa-2,4-diene-7,8-diyl)bis(ethan-1-ol) (86a) 
 
Molecular formula: C12H18O2 MW = 194.27 g.mol-1 
7,8-Bis(2-((tert-butyldimethylsilyl)oxy)ethyl)bicyclo[4.2.0]octa-2,4-diene (86b) 
 
Molecular formula: C24H46O2Si2 MW = 422.80 g.mol-1 
The impure tetraene 79 (ca. 0.1 mmol) was dissolved in toluene (2 mL), the resulting 
solution was degassed by sparging and the reaction vessel was sealed. The reaction 
mixture was stirred in the dark at 120 °C for 3 days. The solvent was removed under 
reduced pressure and the crude was purified by flash chromatography over silica gel 
(Toluene/EtOAc 1:1). 1H NMR analysis showed the presence of peaks corresponding to 
the desired bicyclic adduct. 
S20 
vigorously under Ar until the deep green lithium naphthalenide complex was observed. The mixture 
was stirred for an additional 15 min, then cooled to 0 oC, and anhydrous ZnBr2 (2.0 M in dry THF, 2.50 
mol, 8 mol. equiv.) was added slowly over 30 min. A fine black zinc suspension developed over the 
course of addition. The Rieke zinc solution was stirred for a further 45 min at ambient temperature 
prior to use.  
 
To the reaction vessel containing Rieke zinc (approx. 8 mol. equiv.) was added dodeca-3,5,7,9-
tetrayne-1,12-diol (0.058 g, 0.31 mmol, 1.0 mol. equiv.) dissolved in dry THF (1.2 mL), and dry 
MeOH (2.0 mL). The resulting mixture was heated at 66 oC for 15 h, then cooled to ambient room 
temperature, and quenched under Ar with sat. aq. NH4Cl solution (5 mL). The aqueous layer was 
extracted with EtOAc (3 × 15 mL), and the organic layers were combined, washed with brine (20 mL), 
and dried over MgSO4. Concentration under reduced pressure, and purification by flash column 
chromatography (SiO2, 1:1 petroleum ether 40-60/EtOAc) furnished (3Z,5Z,7Z,9Z)-dodeca-3,5,7,9-
tetraene-1,12-diol (0.014 g, 0.072 mmol, 23%) as a colourless solid. 
 
1H NMR (300 MHz, CDCl3) δ 6.51 (ddd, J = 11.4 Hz, 10.8 Hz, 3.6 Hz, 2H), 6.31 (dd, J = 11.4 Hz, 3.0 
Hz, 2H), 6.21 (t, J = 11.0 Hz, 2H), 5.47 (dt, J = 10.4 Hz, 7.8 Hz, 2H), 3.70 (dt, J = 6.0 Hz, 5.4 Hz, 4H), 
2.49 (dt, J = 6.6 Hz, 6.3 Hz, 4H) ppm;  
13C NMR (100 MHz, CDCl3) δ 133.9, 131.8, 128.3, 128.1, 62.4, 31.6 ppm;  
HRMS (EI): calculated for C12H18O2 [M]+•: 194.1307; found 194.1305 
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Peaks characteristic of the putative adduct 86a 
 
 
  
HO OHH H
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4.3. Asymmetric transformations of a-acrylate anions surrogates 
4.3.1. Preparation of substrates 
General procedure A for aldolisation with KOH 
To a solution of methylketone 121 (1.0 equiv.) in ethanol (2 mL/mmol) were added the 
desired aldehyde (1.0 equiv.) followed by potassium hydroxide (20 mol%). The reaction 
mixture was stirred until TLC indicated completion (from 1 h to several days). The 
product was isolated either by direct filtration of the precipitate, which was washed 
with ethanol and hexane, or by addition of water (5 mL/mmol) and extraction with 
EtOAc (3 x 10 mL/mmol), drying of the combined organic layers over anhydrous 
MgSO4, concentration under reduced pressure and purification by flash 
chromatography over silica gel (PE/EtOAc). 
General procedure B for aldolisation with LDA 
To a solution of diisopropylamine (1.3 equiv.) in THF (3 mL/mmol) was added n-BuLi 
(2.5 M in hexane, 1.2 equiv.) dropwise at –78 °C. After stirring for 30 min at room 
temperature, the reaction mixture was cooled to –78 °C again and a solution of 
methylketone 121 (1.0 equiv.) in THF (3 mL/mmol) was dropwise added. The solution 
was stirred at room temperature for 60 min. After cooling to –78 °C, a solution of the 
desired aldehyde (1.5 equiv.) in THF (3 mL/mmol) was added dropwise. The reaction 
was allowed to warm to room temperature and stirred overnight. Upon completion, 
the reaction was quenched by addition of a saturated aqueous solution of NaHCO3 
(10 mL/mmol). The aqueous layer was extracted with EtOAc (2 x 10 mL/mmol). The 
pooled organic layers were dried over anhydrous MgSO4 and concentrated under 
reduced pressure. The crude was purified by flash chromatography over silica gel 
(PE/EtOAc). 
General procedure C for Horner-Wadsworth-Emmons 
Sodium hydride (60% dispersion in mineral oil, 1.2 equiv.) was suspended in THF 
(3 mL/mmol). A solution of phosphonate 123 (1.2 equiv.) in THF (1 mL/mmol) was 
added dropwise at 0 °C (exothermic reaction) until gas evolution had ceased. The 
mixture was allowed to warm to room temperature and stirred for 1 h before the 
addition of the desired aldehyde (1.0 equiv.). The reaction mixture was stirred 
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overnight under vigorous stirring. A saturated aqueous solution of NaHCO3 was added 
(5 mL/mmol), the reaction mixture was diluted with Et2O (5 mL/mmol), the layers were 
separated and the aqueous layer was extracted with Et2O (2 x 5 mL). The pooled 
organic layers were washed with a saturated aqueous solution of NaCl, dried over 
anhydrous MgSO4 and concentrated under reduced pressure. The crude was purified 
by flash chromatography over silica gel (PE/Et2O). 
General procedure D for the addition of N-methylimidazole 121 to Weinreb amides 
To a solution of N-methylimidazole (2.0 equiv.) in THF (5 mL/mmol) was added n-BuLi 
(2.5 M solution in hexanes, 2.0 equiv.) dropwise at 0 °C. The reaction was stirred for 
20 min, then cooled to –78 °C. The desired Weinreb amide (1.1 equiv.) was added 
dropwise and the mixture was stirred for 1 h at this temperature. Upon completion, 
the reaction was quenched by addition of a saturated aqueous solution of NH4Cl. The 
aqueous phase was extracted with EtOAc (3 x 5 mL/mmol). The pooled organic layers 
were washed with a saturated aqueous solution of NaCl, dried over anhydrous MgSO4 
and concentrated under reduced pressure. The crude was purified by flash 
chromatography over silica gel (PE/EtOAc). 
General procedure E for the addition of N-methylimidazole 121 to aldehydes 
To a solution of N-methylimidazole (1.0 equiv.) in THF (5 mL/mmol) was added n-BuLi 
(2.5 M solution in hexanes, 1.1 equiv.) dropwise at 0 °C. The reaction was stirred for 
20 min, then cooled to –78 °C. The desired aldehyde (1.1 equiv.) was added dropwise 
and the mixture was stirred for 1 h at this temperature. Upon completion, the reaction 
was quenched by addition of a saturated aqueous solution of NH4Cl. The aqueous 
phase was extracted with EtOAc (3 x 5 mL/mmol). The pooled organic layers were 
washed with a saturated aqueous solution of NaCl, dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The crude was purified by flash 
chromatography over silica gel (PE/EtOAc). 
General procedure F for MnO2 oxidation 
The desired alcohol was dissolved in THF (10 mL/mmol) and manganese(IV) oxide 
(10 equiv.) was added. The reaction mixture was stirred for 8 h. Upon completion, the 
reaction mixture was filtered over a pad of Celite (EtOAc) and concentrated under 
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reduced pressure. The crude was purified by flash chromatography over silica gel 
(PE/EtOAc). 
 
1-(1-methyl-1H-imidazol-2-yl)ethan-1-one (121) 
 
Molecular formula: C6H8N2O MW = 124.14 g.mol-1 
To a solution of N-methylimidazole (9.3 mL, 80 mmol, 1.0 equiv.) in THF (50 mL) was 
added n-BuLi (2.5 M solution in hexanes, 35.2 mL, 88 mmol, 1.1 equiv.) dropwise at 
0 °C. The reaction mixture was stirred for 20 min, then transferred via cannula to a 
solution of 4-acetylmorpholine in THF (50 mL) at –78 °C. The resulting mixture was 
allowed to warm to room temperature and stirred for a further 16 h. The reaction was 
then quenched by addition of a 3 M aqueous solution of HCl (3.3 mL), diluted with 
additional water and the aqueous phase was extracted with EtOAc (3 x 100 mL). The 
pooled organic layers were washed with a saturated aqueous solution of NaCl, dried 
over anhydrous MgSO4 and concentrated under reduced pressure. Purification by flash 
chromatography over silica gel (PE/EtOAc 1:1) afforded the desired product as a 
colourless oil (7.4 g, 59 mmol, 74%). Spectral data matched those reported in the 
literature.[50] 
1H NMR (400 MHz, CDCl3) δ 7.11 (s, 1H), 7.00 (s, 1H), 3.98 (s, 3H), 2.64 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 190.5, 143.1, 128.9, 126.8, 36.1, 27.1. 
 
(E)-4,4-Dimethyl-1-(1-methyl-1H-imidazol-2-yl)pent-2-en-1-one (4d) 
 
Molecular formula: C11H16N2O MW = 192.26 g.mol-1 
Me
O
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This compound was isolated as a yellow oil (610 mg, 85% yield) following general 
procedure A. Spectral data matched those reported in the literature.[63] 
1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 15.9 Hz, 1H), 7.18 (s, 1H), 7.12 (d, J = 15.9 Hz, 
1H), 7.04 (s, 1H), 4.04 (s, 3H), 1.15 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 181.4, 158.6, 144.0, 129.3, 127.2, 121.4, 36.5, 34.2, 28.9 
(3C). 
 
(E)-1-(1-Methyl-1H-imidazol-2-yl)-3-phenylprop-2-en-1-one (4e) 
 
Molecular formula: C13H12N2O MW = 212.25 g.mol-1 
This compound was isolated as a yellow solid (856 mg, 75% yield) following general 
procedure A. Spectral data matched those reported in the literature.[50] 
1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 16.0 Hz, 1H), 7.83 (d, J = 16.0 Hz, 1H), 7.73-7.67 
(m, 2H), 7.44-7.36 (m, 3H), 7.22 (d, J = 0.9 Hz, 1H), 7.08 (d, J = 0.9 Hz, 1H), 4.10 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 180.7, 144.2, 143.5, 135.1, 130.6, 129.5, 129.0 (2C), 128.9 
(2C), 127.4, 123.0, 36.5. 
 
(E)-3-Cyclohexyl-1-(1-methyl-1H-imidazol-2-yl)prop-2-en-1-one (4g) 
 
Molecular formula: C13H18N2O MW = 218.30 g.mol-1 
This compound was isolated as a yellow oil (308 mg, 44% yield) following general 
procedure B. Spectral data matched those reported in the literature.[63] 
N
N
OMe
O
N
N
Me
  
 
177 
1H NMR (400 MHz, CDCl3) δ 7.35 (dd, J = 15.8, 1.4 Hz, 1H), 7.16 (s, 1H), 7.06 (dd, 
J = 15.8, 6.8 Hz, 1H), 7.02 (s, 1H), 4.03 (s, 3H), 2.31-2.18 (m, 1H), 1.88-1.79 (m, 2H), 
1.79-1.72 (m, 2H), 1.72-1.63 (m, 1H), 1.38-1.13 (m, 5H). 
13C NMR (101 MHz, CDCl3) δ 181.3, 153.8, 144.0, 129.2, 127.1, 123.9, 41.0, 36.4, 31.9 
(2C), 26.1, 25.9 (2C). 
  
(E)-3-(2,6-Dimethylphenyl)-1-(1-methyl-1H-imidazol-2-yl)prop-2-en-1-one (4h) 
 
Molecular formula: C15H16N2O MW = 240.31 g.mol-1 
This compound was isolated as a yellow oil (983 mg, 99% yield) following general 
procedure A. 
1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 16.4 Hz, 1H), 7.73 (d, J = 16.4 Hz, 1H), 7.20 (s, 
1H), 7.17-7.06 (m, 4H), 4.11 (s, 3H), 2.43 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 180.7, 144.1, 142.0, 137.4 (2C), 134.6, 129.5, 128.5, 128.5, 
128.4 (2C), 127.4, 36.5, 21.4 (2C). 
HRMS: calc for [C15H17N2O]+: 241.1341; found: 241.1334. 
IR: 2929, 2661, 1689, 1597, 1466, 1431, 1301, 1136, 921, 762 cm-1. 
 
(E)-3-(4-Chlorophenyl)-1-(1-methyl-1H-imidazol-2-yl)prop-2-en-1-one (4i) 
 
Molecular formula: C13H11N2O MW = 246.69 g.mol-1 
This compound was isolated as a yellow solid (466 mg, 70% yield) following general 
procedure A. Spectral data matched those reported in the literature.[50] 
N
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1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 16.0 Hz, 1H), 7.77 (d, J = 16.0 Hz, 1H), 7.67-7.60 
(m, 2H), 7.41-7.35 (m, 2H), 7.24 (s, 1H), 7.10 (s, 1H), 4.10 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 179.8, 143.5, 142.1, 136.3, 133.3, 129.8 (2C), 129.0 (2C), 
128.8, 127.2, 123.1, 36.3.  
  
(E)-3-(4-Methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)prop-2-en-1-one (4i) 
 
Molecular formula: C14H14N2O2 MW = 242.28 g.mol-1 
This compound was isolated as a yellow solid (459 mg 81% yield) following general 
procedure A. Spectral data matched those reported in the literature.[50] 
1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 15.9 Hz, 1H), 7.75 (d, J = 15.9 Hz, 1H), 7.65-7.56 
(m, 2H), 7.17 (d, J = 0.9 Hz, 1H), 7.01 (d, J = 0.9 Hz, 1H), 6.89-6.83 (m, 2H), 4.04 (s, 3H), 
3.78 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 180.8, 161.8, 144.3, 143.4, 130.7 (2C), 129.3, 127.9, 127.2, 
120.7, 114.5 (2C), 55.5, 36.5. 
 
(E)-3-(Furan-2-yl)-1-(1-methyl-1H-imidazol-2-yl)prop-2-en-1-one (4k) 
 
Molecular formula: C11H10N2O2 MW = 202.21 g.mol-1 
This compound was isolated as a brown solid (1.27 g, 77% yield) following general 
procedure A. Spectral data matched those reported in the literature.[50] 
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1H NMR (400 MHz, CDCl3) δ 7.91 (dd, J = 15.8, 0.6 Hz, 1H), 7.58 (d, J = 15.8 Hz, 1H), 
7.51 (dd, J = 1.8, 0.6 Hz, 1H), 7.20 (d, J = 0.9 Hz, 1H), 7.05 (d, J = 0.9 Hz, 1H), 6.73 (d, 
J = 3.4 Hz, 1H), 6.48 (dd, J = 3.4, 1.8 Hz, 1H), 4.07 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 180.5, 152.1, 145.1, 144.2, 129.6, 129.5, 127.2, 121.0, 
115.7, 112.6, 36.4. 
 
Diethyl (2-(methoxy(methyl)amino)-2-oxoethyl)phosphonate (123) 
 
Molecular formula: C8H18NO5P MW = 139.21 g.mol-1 
Triethyl phosphonoacetate (29.7 mL, 150 mmol, 1.0 equiv.) in stirred in an aqueous 
solution of NaOH (1 M, 150 mL) for 5 h at 80 °C. After cooling to room temperature, 
the resulting mixture layer was acidified by slow addition of an a 12 M aqueous 
solution of HCl until pH = 1 (ca. 12 mL) then extracted with ethyl acetate (5 x 150 mL) 
and concentrated under vacuum (no brine or drying agent was used as complexation 
of the intermediate occurs). The resulting yellow oil was dissolved in CH2Cl2 (300 mL) 
and N,N'-carbonyldiimidazole (22.3 g, 138 mmol, 1.1 equiv.) was added portionwise 
(resulting in quick and strong CO2 formation). The mixture was stirred until gas 
evolution ceased, then N,O-dimethyl hydroxylamine hydrochloride (13.4 g, 138 mmol, 
1.1 equiv.) was added. The resulting mixture was stirred at room temperature for 16 h. 
Water (150 mL) was added and the aqueous layer was extracted with CH2Cl2 (300 mL). 
The pooled organic layers were washed with water (2 x 150 mL) and concentrated 
under vacuum. Purification by flash chromatography over silica gel (EtOAc/EtOH 8:2) 
afforded the title compound as a pale oil (32.3 g, 135 mmol, 90%). Spectral data 
matched those reported in the literature.[63] 
1H NMR (400 MHz, CDCl3) δ 4.18 (dqd, J = 9.6, 7.1, 1.6 Hz, 4H), 3.77 (s, 3H), 3.21 (s, 3H), 
3.16 (d, J = 22.0 Hz, 4H), 1.34 (t, J = 7.1 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 166.3, 62.7, 62.6, 61.6, 32.3, 30.9, 16.5, 16.5. 
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31P NMR (162 MHz, CDCl3) δ 21.3. 
 
(E)-N-methoxy-N,4-dimethylpent-2-enamide (precursor to 4c) 
 
Molecular formula: C8H15NO2 MW = 157.21 g.mol-1 
This product was obtained as a pale oil (702 mg, 60% yield) following general 
procedure C. Spectral data matched those reported in the literature.[63] 
1H NMR (400 MHz, CDCl3) δ 6.94 (dd, J = 15.4, 6.9 Hz, 1H), 6.33 (d, J = 15.4 Hz, 1H), 
3.69 (s, 3H), 3.23 (s, 3H), 2.55-2.43 (m, 1H), 1.07 (d, J = 6.8 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 167.5, 154.2, 116.0, 61.7, 32.5, 31.3, 21.7 (2C). 
 
(E)-4-Methyl-1-(1-methyl-1H-imidazol-2-yl)pent-2-en-1-one (4c) 
 
Molecular formula: C10H14N2O MW = 178.24 g.mol-1 
This compound was isolated as a pale oil (138 mg, 61% yield) following general 
procedure D. Spectral data matched those reported in the literature.[63] 
1H NMR (400 MHz, CDCl3) δ 7.35 (dd, J = 15.7, 1.4 Hz, 1H), 7.16 (s, 1H), 7.09 (dd, 
J = 15.7, 6.7 Hz, 1H), 7.03 (s, 1H), 4.03 (s, 3H), 2.63-2.51 (m, 1H), 1.12 (d, J = 6.8 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 181.2, 155.0, 144.0, 129.3, 127.2, 123.5, 36.4, 31.5, 21.5 
(2C). 
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(E)-3-Cyclopropyl-N-methoxy-N-methylacrylamide (precursor to 4l) 
 
Molecular formula: C8H13NO2 MW = 155.20 g.mol-1 
This compound was isolated as a pale oil (859 mg, 74% yield) following general 
procedure C. Spectral data matched those reported in the literature.[338] 
1H NMR (400 MHz, CDCl3) δ 6.49 (d, J = 15.2 Hz, 1H), 6.41 (dd, J = 15.2, 9.5 Hz, 1H), 
3.70 (s, 3H), 3.22 (s, 3H), 1.66-1.56 (m, 1H), 0.95-0.89 (m, 2H), 0.66-0.61 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 167.2, 152.7, 115.8, 61.8, 32.5, 14.9, 8.6 (2C). 
 
(E)-3-Cyclopropyl-1-(1-methyl-1H-imidazol-2-yl)prop-2-en-1-one (4l) 
 
Molecular formula: C10H12N2O MW = 176.22 g.mol-1 
This compound was isolated as a yellow oil (159 mg, 56% yield) following general 
procedure D.  
1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 15.4 Hz, 1H), 7.16 (d, J = 0.9 Hz, 1H), 7.02 (d, 
J = 0.9 Hz, 1H), 6.60 (dd, J = 15.4, 10.1 Hz, 1H), 4.03 (s, 3H), 1.79-1.65 (m, 1H), 1.05-0.96 
(m, 2H), 0.78-0.68 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 180.3, 154.2, 143.9, 129.2, 127.1, 123.6, 36.4, 15.4, 9.5 
(2C). 
HRMS: calc for [C10H13N2O]+: 177.1028; found: 177.1004. 
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(E)-N-Methoxy-N,5-dimethylhex-2-enamide (precursor to 4m) 
 
Molecular formula: C9H17NO2 MW = 171.24 g.mol-1 
This product was obtained as a pale oil (790 mg, 62% yield) following general 
procedure C. Spectral data matched those reported in the literature.[63] 
1H NMR (400 MHz, CDCl3) δ 6.96 (dt, J = 15.3, 7.5 Hz, 1H), 6.38 (dt, J = 15.3, 1.5 Hz, 1H), 
3.70 (s, 3H), 3.24 (s, 3H), 2.17-2.07 (m, 2H), 1.82-1.71 (m, 1H), 0.93 (d, J = 6.7 Hz, 6H). 
 
(E)-5-Methyl-1-(1-methyl-1H-imidazol-2-yl)hex-2-en-1-one (4m) 
 
Molecular formula: C11H16N2O MW = 192.26 g.mol-1 
This compound was isolated as a colourless oil (125 mg, 74% yield) following general 
procedure D. Spectral data matched those reported in the literature.[63] 
1H NMR (400 MHz, CDCl3) δ 7.40 (dt, J = 15.5, 1.4 Hz, 1H), 7.17 (s, 1H), 7.11 (dt, 
J = 15.5, 7.5 Hz, 1H), 7.04 (s, 1H), 4.05 (s, 3H), 2.24-2.18 (m, 2H), 1.89-1.78 (m, 1H), 
0.95 (d, J = 6.8 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 180.8, 147.9, 143.9, 129.3, 127.3, 127.2, 42.0, 36.4, 28.2, 
22.6 (2C) 
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(E)-1-(1-Methyl-1H-imidazol-2-yl)pent-2-en-1-ol (precursor to 4n) 
 
Molecular formula: C9H14N2O MW = 166.22 g.mol-1 
This compound was isolated as a yellow oil (1.7 g, 94% yield) following general 
procedure E. Spectral data matched those reported in the literature.[63] 
1H NMR (400 MHz, CDCl3) δ 6.91 (s, 1H), 6.80 (s, 1H), 5.84-5.68 (m, 2H), 5.22 (dt, 
J = 6.3, 0.9 Hz, 1H), 3.63 (s, 3H), 2.19-2.00 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H). 
 
(E)-1-(1-Methyl-1H-imidazol-2-yl)pent-2-en-1-one (4n) 
 
Molecular formula: C9H12N2O MW = 164.21 g.mol-1 
This compound was isolated as a yellow oil (949 mg, 56% yield) following general 
procedure F. Spectral data matched those reported in the literature.[63] 
1H NMR (400 MHz, CDCl3) δ 7.39 (dt, J = 15.7, 1.6 Hz, 1H), 7.23-7.12 (m, 2H), 7.03 (s, 
1H), 4.04 (s, 3H), 2.39-2.29 (m, 2H), 1.13 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 180.9, 150.2, 143.8, 129.2, 127.1, 125.4, 36.4, 25.9, 12.4. 
 
(E)-1-(1-Methyl-1H-imidazol-2-yl)dec-2-en-1-ol (precursor to 4o) 
 
Molecular formula: C14H24N2O MW = 236.36 g.mol-1 
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This compound was isolated as a yellow oil (2.2 g, 84% yield) following general 
procedure E. Spectral data matched those reported in the literature.[63] 
1H NMR (400 MHz, CDCl3) δ 6.93 (d, J = 1.3 Hz, 1H), 6.81 (d, J = 1.3 Hz, 1H), 5.81-5.67 
(m, 2H), 5.22-5.19 (m, 1H), 3.63 (s, 3H), 2.11-2.03 (m, 2H), 1.38 (m, 2H), 1.33-1.20 (m, 
8H), 0.86 (t, J = 6.9 Hz, 3H). 
  
(E)-1-(1-Methyl-1H-imidazol-2-yl)dec-2-en-1-one (4o) 
 
Molecular formula: C14H22N2O MW = 234.34 g.mol-1 
This compound was isolated as a yellow oil (1.4 g, 65% yield) following general 
procedure F. Spectral data matched those reported in the literature.[63] 
1H NMR (400 MHz, CDCl3) δ 7.39 (dt, J = 15.6, 1.5 Hz, 1H), 7.18-7.08 (m, 2H), 7.03 (s, 
1H), 4.04 (s, 3H), 2.35-2.26 (m, 2H), 1.57-1.46 (m, 2H), 1.38-1.21 (m, 8H), 0.87 (t, 
J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 180.9, 149.2, 143.9, 129.3, 127.2, 126.3, 36.4, 32.9, 31.9, 
29.4, 29.2, 28.4, 22.8, 14.2. 
 
(2E,4E)-1-(1-Methyl-1H-imidazol-2-yl)hexa-2,4-dien-1-one (4p) 
 
Molecular formula: C10H12N2O MW = 176.22 g.mol-1 
A RBF equipped with an addition funnel was charged with N-methylimidazole (3.5 mL, 
44 mmol, 2.2 equiv.) and THF (80 mL). The solution was cooled to –78 °C and n-BuLi 
(2.5 M solution in hexanes, 17.6 mL, 44 mmol, 2.2 equiv.) was dropwise added. The 
reaction mixture was then stirred at room temperature for 30 min. The solution was 
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cooled to –78 °C and a solution of sorbic acid (2.2 g, 20 mmol, 1.0 equiv.) in THF 
(10 mL) was dropwise added. The reaction mixture was then stirred for 2 h at room 
temperature. The reaction was quenched by addition of a saturated aqueous solution 
of NaHCO3 (100 mL) and extracted with EtOAc (2 x 100 mL). The pooled organic layers 
were washed with a saturated aqueous solution of NaCl (50 mL), dried over anhydrous 
MgSO4 and concentrated. The crude was purified by flash chromatography over silica 
gel (PE/Et2O 1:1) to afford a white solid (2.13 g, 12.1 mmol, 61%). Spectral data 
matched those reported in the literature.[339] 
1H NMR (400 MHz, CDCl3) δ 7.49-7.34 (m, 2H), 7.17 (d, J = 0.9 Hz, 1H), 7.03 (d, J = 0.9 
Hz, 1H), 6.40-6.20 (m, 2H), 4.05 (s, 3H), 1.89 (d, J = 5.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 181.2, 144.2, 144.1, 141.2, 130.9, 129.1, 127.1, 124.3, 
36.5, 19.1. 
 
(E)-N-Methoxy-N-methylbut-2-enamide (129) 
 
Molecular formula: C6H11NO2 MW = 129.16 g.mol-1 
N,O-Dimethylhydroxylamine hydrochloride (500 mg, 5.13 mmol, 1.0 equiv.) and 
crotonyl chloride 128 (565 µL, 5.90 mmol, 1.15 equiv.) were dissolved in CH2Cl2 (13 
mL). While stirring at 0 °C, pyridine (912 µL, 11.3 mmol, 2.2 equiv.) was dropwise 
added. The reaction mixture was stirred at this temperature for 20 min then at room 
temperature for 3 h. The reaction was then diluted with EtOAc (80 mL). The organic 
layer was washed with a 1 M aqueous solution of HCl (60 mL), a saturated aqueous 
solution of NaHCO3 (60 mL) and a saturated aqueous solution of NaCl (60 mL), dried 
over anhydrous Na2SO4 and concentrated under reduced pressure. The crude was 
purified by flash chromatography over silica gel (PE/Et2O 75:25 to 60:40) to afford the 
title compound as a yellow oil (575 mg, 4.45 mmol, 87%). Spectral data matched those 
reported in the literature.[62] 
O
MeNMeO
Me
  
 
186 
1H NMR (400 MHz, CDCl3) δ 6.98 (dq, J = 15.3, 6.9 Hz, 1H), 6.41 (dq, J = 15.3, 1.7 Hz, 
1H), 3.69 (s, 3H), 3.23 (s, 3H), 1.90 (dd, J = 6.9, 1.7 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 167.2, 143.0, 120.4, 61.8, 32.5, 18.4. 
 
(E)-1-(1-Isopropyl-1H-imidazol-2-yl)but-2-en-1-one (130) 
 
Molecular formula: C10H14N2O MW = 178.24 g.mol-1 
To a solution of Weinreb amide 129 (300 mg, 2.32 mmol, 1.0 equiv.) in THF (10 mL) 
was added n-BuLi (2.5 M solution in hexanes, 1.7 mL, 4.2 mmol, 1.8 equiv.) dropwise at 
–78 °C. The reaction mixture was stirred at this temperature for 15 min, then a 
solution of N-isopropyl-1H-imidazole (475 µL, 4.18 mmol, 1.8 equiv.) in THF (5 mL) was 
dropwise added. The reaction mixture was stirred for 4 h at room temperature. Upon 
completion, the reaction was quenched by addition of a saturated aqueous solution of 
NaHCO3 (15 mL) and extracted with EtOAc (3 x 15 mL). The pooled organic layers were 
washed with a saturated aqueous solution of NaCl (15 mL), dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. Purification by flash column 
chromatography (PE/EtOAc 4:1 to 3:1) afforded the title compound (175 mg, 
0.98 mmol, 42%). Spectral data matched those reported in the literature.[62] 
1H NMR (400 MHz, CDCl3) δ 7.47 (dq, J = 15.5, 1.7 Hz, 1H), 7.29 (d, J = 1.1 Hz, 1H), 7.22 
(d, J = 1.1 Hz, 1H), 7.12 (dq, J = 15.5, 6.9 Hz, 1H), 5.67 (hept, J = 6.7 Hz, 1H), 2.01 (dd, 
J = 6.9, 1.7 Hz, 3H), 1.48 (d, J = 6.7 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 180.9, 143.7, 143.1, 129.8, 128.7, 121.3, 49.4, 23.8 (2C), 
18.6. 
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(E)-1-(Thiazol-2-yl)but-2-en-1-one (132) 
 
Molecular formula: C7H7NOS MW = 153.20 g.mol-1 
While crotonyl chloride 128 is commercially available, this compound was prepared 
freshly to avoid contamination with inseparable side-products. 
A solution of crotonic acid (500 mg, 5.8 mmol, 1.0 equiv.) and DMF (2 drops) in CH2Cl2 
(12 mL) was cooled to 0 °C and connected to a bubbler containing an aqueous solution 
of NaOH. Oxalyl chloride (541 µL, 6.4 mmol, 1.1 equiv.) was added dropwise, then the 
reaction mixture was allowed to stir at room temperature until gas evolution ceased 
(about 4 h). An aliquot was taken to confirm the clean formation of crotonyl 
chloride 128 by 1H NMR. 2-(Trimethylsilyl)thiazole 131 (1.39 mL, 8.7 mmol, 1.5 equiv.) 
was then added to the reaction mixture and the reaction was stirred for 1 h. Upon 
completion, the mixture was diluted with EtOAc (80 mL), washed with a saturated 
aqueous solution of NaHCO3 (20 mL) and a saturated aqueous solution of NaCl (20 mL), 
then dried over anhydrous Na2SO4 and concentrated under reduced pressure. 
Purification by flash column chromatography over silica gel (PE/Et2O 7:1) delivered the 
title compound as a pale oil (239 mg, 1.56 mmol, 27%). Spectral data matched those 
reported in the literature.[211] 
1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 3.0 Hz, 1H), 7.64 (d, J = 3.0 Hz, 1H), 7.39-7.22 
(m, 2H), 2.01 (dd, J = 6.5, 1.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 181.7, 168.5, 147.1, 144.8, 126.3, 126.2, 19.0. 
 
(E)-1-(2,3-Dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl)but-2-en-1-one (135) 
 
Molecular formula: C11H12N2O MW = 188.23 g.mol-1 
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To a solution of crotonic acid (119 mg, 1.39 mmol, 1.0 equiv.), 2,3-dihydro-7-azaindole 
(200 mg, 1.66 mmol, 1.2 equiv.) and DMAP (85 mg, 0.69 mmol, 50 mol%) in CH2Cl2 
(14 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(319 mg, 1.66 mmol, 1.2 equiv.) at room temperature. The reaction mixture was 
stirred at this temperature for 24 h, then diluted with H2O (15 mL) and extracted with 
CH2Cl2 (2 x 20 mL). The pooled organic layers were dried over anhydrous MgSO4 and 
concentrated under reduced pressure. Purification by flash chromatography over silica 
gel (Hexane/EtOAc 3:1 to 1:1) afforded the desired product as a yellow oil (80 mg, 
0.43 mmol, 26%). Spectral data matched those reported in the literature. 
1H NMR (400 MHz, CDCl3) δ 8.10 (ddt, J = 5.2, 1.4, 1.0 Hz, 1H), 7.78 (dq, J = 15.2, 1.7 Hz, 
1H), 7.43 (dq, J = 7.2, 1.4 Hz, 1H), 7.11 (dq, J = 15.2, 6.9 Hz, 1H), 6.84 (dd, J = 7.2, 
5.2 Hz, 1H), 4.12 (t, J = 8.5 Hz, 2H), 3.02 (t, J = 8.5 Hz, 2H), 1.96 (dd, J = 6.9, 1.7 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 165.4, 156.2, 146.2, 142.7, 133.5, 126.4, 124.6, 118.0, 
46.0, 24.3, 18.5. 
 
S-Ethyl 2-(triphenyl-λ5-phosphaneylidene)ethanethioate (137) 
 
Molecular formula: C22H21OPS MW = 364.44 g.mol-1 
To a solution of bromoacetic acid 136 (3.5 g, 25 mmol, 1 equiv.), ethanethiol (2.4 mL, 
33 mmol, 1.3 equiv.) and DMAP (308 mg, 2.5 mmol, 10 mol%) in CH2Cl2 (125 mL) at 
0 °C was added dicyclohexylcarbodiimide (5.5 g, 25 mmol, 1.05 equiv.) portionwise. 
The reaction mixture was allowed to warm to room temperature overnight and the 
solution was filtered through a pad of Celite (CH2Cl2). The filtrate was washed with a 
saturated aqueous solution of NaHCO3 (50 mL), water (50 mL) and a saturated 
aqueous solution of NaCl (50 mL), then dried over anhydrous Na2SO4 and concentrated 
under reduced pressure. The crude was dissolved in benzene, filtered over a pad of 
Celite (benzene) to remove traces of byproducts, and concentrated to afford a yellow 
oil. 
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The resulting thioester was dissolved in benzene (36 mL) and triphenylphosphine 
(6.6 g, 25 mmol, 1 equiv.) was added. The solution was allowed to stand for 3 d. 
Subsequently, the resulting white crystals were filtered and washed with toluene to 
afford the intermediate phosphonium bromide (8.98 g, 20.2 mmol, 80%). The latter 
was dissolved in CH2Cl2 (35 mL) and a solution of sodium carbonate (10.7 g, 101 mmol, 
5 equiv.) in water was added. The resulting mixture was stirred vigorously for 30 min. 
The layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 
60 mL). The pooled organic layers were concentrated under reduced pressure to a 
volume of ca. 5 mL. The mixture was diluted with pentane to precipitate the title 
compound as white crystals (5.16 g, 14.2 mmol, 70%). After filtration, a second crop 
was similarly isolated from the mother liquor (1.54 g, 4.23 mmol, 21%). 
Spectral data matched those reported in the literature.[221] 
1H NMR (400 MHz, CDCl3) δ 7.67-7.59 (m, 6H), 7.56 (ddq, J = 6.8, 4.7, 1.6 Hz, 3H), 
7.51-7.42 (m, 6H), 3.66 (d, J = 22.6 Hz, 1H), 2.84 (q, J = 7.4 Hz, 2H), 1.25 (t, J = 7.3 Hz, 
3H). 
13C NMR (101 MHz, CDCl3) δ 180.6 (d, J = 5.1 Hz, 3C), 133.2 (d, J = 10.4 Hz, 6C), 132.3 
(d, J = 2.8 Hz, 3C), 129.0 (d, J = 12.4 Hz, 6C), 127.0 (d, J = 91.1 Hz), 47.1 (d, J = 109.5 Hz), 
23.2, 16.5. 
31P NMR (162 MHz, CDCl3) δ 13.5. 
 
S-Ethyl (E)-3-phenylprop-2-enethioate (138) 
 
Molecular formula: C11H12OS MW = 192.28 g.mol-1 
A solution of benzaldehyde (125 µL, 1.23 mmol, 1.0 equiv.) and phosphaneylidene 137 
(583 mg, 1.60 mmol, 1.3 equiv.) in CHCl3 (6 mL) was stirred under reflux for 18 h. The 
solution was then concentrated in vacuo and purification by flash chromatography 
over silica gel (PE/Et2O 90:10) afforded the desired product as a colourless oil, as 
EtS
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mixture of E/Z isomers in a >95:5 ratio (1H NMR). Spectral data matched those 
reported in the literature.[340] 
1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 15.9 Hz, 1H), 7.57-7.50 (m, 2H), 7.43-7.36 (m, 
3H), 6.71 (d, J = 15.9 Hz, 1H), 3.02 (q, J = 7.4 Hz, 2H), 1.32 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 190.1, 140.3, 134.3, 130.6, 129.1 (2C), 128.5 (2C), 125.3, 
23.5, 15.0. 
 
Tetrahydrobenzo[b]thiophene-3,4(2H,3aH)-dione (147) 
 
Molecular formula: C8H10N2S MW = 170.23 g.mol-1 
To a solution of sodium methoxide (2.3 g, 42 mmol, 1.05 equiv.) in methanol (40 mL) 
was added a solution of methyl thioglycolate (3.6 mL, 40 mmol, 1.0 equiv.) in methanol 
(10 mL) dropwise at 0 °C. Next, a solution of 2-cyclohexen-1-one (3.9 mL, 40 mmol, 
1.0 equiv.) in methanol (10 mL) was added dropwise at this temperature. The reaction 
mixture was then allowed to warm to room temperature and was stirred under reflux 
overnight. After removal of the solvent, the brown residue was dissolved in Et2O and 
extracted with a 2 N aqueous solution of sodium hydroxide. Acidification of the 
alkaline extracts with HCl, extraction with Et2O, and evaporation of the solvent gave a 
brown crude residue. The crude was dissolved in CH2Cl2 (5 mL), diluted with PE (15 mL) 
and kept overnight at –20 °C to afford the title compound as pale crystals (2.9 g, 
17 mmol, 43%). Spectral data matched those reported in the literature.[341] 
1H NMR (400 MHz, CDCl3) δ 3.60 (s, 1H), 3.55-3.48 (m, 1H), 2.71-2.62 (m, 1H), 
2.16-1.99 (m, 1H), 1.93-1.73 (m, 3H), 1.72-1.53 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 177.8, 81.1, 50.4, 46.3, 43.6, 39.0, 31.7, 19.6. 
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4-(Benzylamino)-2,5-dihydrothiophene-3-carbonitrile (155) 
 
Molecular formula: C12H12N2S MW = 216.30 g.mol-1 
This procedure was adapted from Garg.[342] To a solution of THT 114 (150 mg, 
1.18 mmol, 1.0 equiv.) in benzene (15 mL) were added benzylamine (193 µL, 
1.77 mmol, 1.5 equiv.) and anhydrous sodium sulfate (750 mg, 5:1 w/w). The reaction 
mixture was stirred under reflux for 4 h, then filtered through a plug of anhydrous 
Na2SO4. Evaporation under reduced pressure yielded a crude solid residue, which was 
purified via flash chromatography over basic alumina (Hexane/EtOAc 4:1 to 1:1) to 
afford the desired enamine as a white solid (186 mg, 0.86 mmol, 73 %). 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.26 (m, 5H), 4.95 (br. s, 1H), 4.47 (d, J = 5.9 Hz, 2H), 
3.79 (s, 4H). 
13C NMR (101 MHz, CDCl3) δ 159.9, 137.7, 129.1 (2C), 128.2, 127.3 (2C), 118.2, 72.7, 
49.1, 36.5, 35.0. 
MS-ESI: m/z 217 ([M+H]+), 184 ([M-S+H]+), 92 ([Bn+H]+). 
 
4.3.2. Optimisation of the Michael addition and retro-Dieckmann  
3-(4-(1-Methyl-1H-imidazol-2-yl)-4-oxobutan-2-yl)-4-oxotetrahydrothiophene-3-
carbonitrile (113a) 
 
Molecular formula: C13H15N3O2S MW = 277.34 g.mol-1 
To a solution of enone 4a (40 mg, 0.27 mmol, 1.0 equiv.) in DMF (2 mL) were added 
copper nitrate trihydrate (13 mg, 0.054 mmol, 20 mol%), L12 (11 mg, 0.059 mmol, 
22 mol%) and THT 114 (172 mg, 1.35 mmol, 5 equiv.). The solution was stirred for 3 d, 
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then diluted with H2O (5 mL). The aqueous layer was extracted with EtOAc (3 x 5 mL). 
The pooled organic layers were washed with a 10% aqueous solution of NaCl 
(5 x 5 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. 
Purification by flash chromatography over silica gel (Hexane/Et2O/HCO2H 1:2:0.01 to 
1:4:0.01) provided first leftover THT 114, then the title compound as a brown solid 
(44 mg, 0.16 mmol, 60%). 
1H NMR (400 MHz, CDCl3) δ 7.12 (s, 1H), 7.03 (s, 1H), 3.96 (s, 3H), 3.61-3.50 (m, 2H), 
3.47-3.34 (m, 2H), 3.27-3.18 (m, 2H), 3.18-3.08 (m, 1H), 1.15 (d, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 203.3, 190.1, 142.7, 129.5, 127.4, 117.0, 55.1, 41.8, 36.7, 
36.2, 33.8, 32.0, 16.6. 
3-Methyl-5-(1-methyl-1H-imidazol-2-yl)-2-methylene-5-oxopentanenitrile (116a) 
 
Molecular formula: C11H13N3O MW = 203.25 g.mol-1 
To a solution of enone 4a (40 mg, 0.27 mmol, 1.0 equiv.) in DMF (2 mL) were added 
potassium carbonate (187 mg, 1.35 mmol, 5 equiv.) and THT 114 (172 mg, 1.35 mmol, 
5 equiv.). The solution was stirred for 3 d, then diluted with H2O (5 mL). The aqueous 
layer was extracted with EtOAc (3 x 5 mL). The pooled organic layers were washed 
with a 10% aqueous solution of NaCl (5 x 5 mL), dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. Purification by flash chromatography over silica 
gel (Hexane/Et2O 1:2 to 1:4) provided the title compound as a dark oil (26 mg, 
0.13 mmol, 48%). 
1H NMR (400 MHz, CDCl3) δ 7.13 (s, 1H), 7.03 (s, 1H), 5.83 (s, 1H), 5.81 (s, 1H), 3.98 (s, 
3H), 3.37 (dd, J = 16.9, 7.4 Hz, 1H), 3.26 (dd, J = 16.9, 6.7 Hz, 1H), 3.13 (dqd, J = 7.4, 6.8, 
6.7 Hz, 1H), 1.24 (d, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 190.1, 142.9, 129.5, 129.4, 127.9, 127.4, 117.8, 43.9, 36.3, 
34.7, 19.5. 
HRMS: calc for [C11H14N3O]+: 204.1137; found: 204.1049. 
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HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (90:10 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
21.5 and 24.1 min. 
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Representative procedure for the screening of conditions for the Michael addition 
An oven-dried reaction vial was charged with Cu(OTf)2 (9.8 mg, 0.027 mmol, 10 mol%) 
and the desired ligand (0.029 mmol, 11 mol%), then dried for 15 min under high-
vacuum. The desired anhydrous solvent (2 mL) was added, and catalyst formation was 
ensured by stirring the resulting solution for 1 h at room temperature. Enone 4a 
(40 mg, 0.27 mmol, 1.0 equiv.) was also dried under high-vacuum for 15 min prior to 
dissolution in the chosen anhydrous solvent (1 mL) and transfer to the reaction vial via 
syringe. The resulting solution was cooled to 0 °C, and cyano-THT 114 (37 mg, 
0.29 mmol, 1.1 equiv.) was added. Upon completion of the reaction as indicated by 
TLC (toluene/acetone 9:1, UV and vanillin), the reaction mixture was diluted with a 
saturated aqueous solution of NaCl (5 mL) and the aqueous phase was extracted with 
EtOAc (3 x 10 mL). The combined organic layers were dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude residue was dissolved in CDCl3 
(500 µL) and an aliquot (ca. 10 µL) was taken for HPLC analysis. CH2Br2 (14 µL, 
0.20 mmol) was added to the crude solution in CDCl3, and the yield was determined by 
1H NMR analysis. To ensure reliable yield determination, a second 1H NMR analysis was 
carried out after concentrating the sample. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (90:10 
for 35 min then gradient to 55:45 over 35 min) at 25 °C on an IC column, with UV 
detection (l = 280 nm). This allowed the separation of the starting material, the 
enantiomers of the Michael addition product and the enantiomers of the final retro-
Dieckmann product. Retention time of cyano-THT 114: 21.5 min. Retention times of 
the enantiomers of 116a: 27.9 and 31.3 min. Retention time of 4a: 39.1 min. Retention 
times of the enantiomers of 113a: 57.1 and 64.7 min. 
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Representative procedure for the screening of conditions for the retro-Dieckmann 
A reaction vial was charged with 113a (40 mg, 0.14 mmol, 1.0 equiv.) and the desired 
solvent (1.5 mL) was added. The desired hydroxide source was added, and the reaction 
mixture was stirred for the indicated time. Upon completion of the reaction as 
indicated by TLC (toluene/acetone 9:1, UV and vanillin), the reaction mixture was 
diluted with a saturated aqueous solution of NaCl (5 mL) and the aqueous phase was 
extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. The crude residue was 
dissolved in CDCl3 (500 µL) and an aliquot (ca. 10 µL) was taken for HPLC analysis. 
CH2Br2 (14 µL, 0.20 mmol) was added to the crude solution in CDCl3, and the yield was 
determined by 1H NMR analysis. 
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4.3.3. Michael addition/retro-Dieckmann products 
Preparation of Cu(OTf)2L27 
 
Molecular formula: C23H22CuF6N2O8S2 MW = 696.09 g.mol-1 
Adapting a procedure from Evans,[216] copper(II) triflate (99 mg, 0.27 mmol, 1.0 equiv) 
and L27 (100 mg, 0.30 mmol, 1.1 equiv.) were charged in a vial equipped with a 
magnetic stirrer, and dried under high-vacuum for 15 min. After back-filling with 
nitrogen, CH2Cl2 (3 mL) was added and the resulting solution was stirred for 1 h. The 
solvent was removed with a steady stream of N2 to afford a blue solid that was kept in 
a dry cabinet. 
 
General procedure for the preparation of racemic Michael addition/retro-Dieckmann 
products 
The desired enone 4 (1.0 equiv.) was dissolved in CH2Cl2 (10 mL/mmol). Cu(OTf)2 
(10 mol%) and L11 (11 mol%) were added to the reaction mixture, followed by cyano-
THT 114 (1.1 equiv). After completion of the reaction as indicated by TLC 
(toluene/acetone 9:1, UV and vanillin), or if the reaction was not complete, after 2 d, 
TBAH (2.2 equiv.) was added and the reaction mixture was stirred for 5 min. The 
reaction mixture was then diluted with a saturated aqueous solution of NaCl (5 mL) 
and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic 
layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. 
The crude residue was purified by flash chromatography over silica gel (Hexane/Et2O 
1:2 to 1:4). 
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General procedure for the asymmetric Michael addition/retro-Dieckmann using the 
copper catalyst 
An oven-dried reaction vial was charged with, if solid, enone 4 (1.0 equiv.) and the 
Cu(OTf)2L27 complex (10 mol%). The solids were dried for 15 min under high-vacuum. 
Anhydrous CH2Cl2 (10 mL/mmol) was added, and if an oil, enone 4 (0.20-0.25 mmol, 
1.0 equiv.) was added as a solution in CH2Cl2. The resulting solution was cooled to 0 °C, 
and cyano-THT 114 (1.1 equiv.) was added. Upon completion of the reaction as 
indicated by TLC (toluene/acetone 9:1, UV and vanillin), or if the reaction was not 
complete, after 2 d, TBAH (2.2 equiv.) was added and the reaction mixture was stirred 
for 5 min. The reaction mixture was then diluted with a saturated aqueous solution of 
NaCl (5 mL) and the aqueous phase was extracted with EtOAc (3 x 10 mL). The 
combined organic layers were dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The crude residue was purified by flash chromatography over silica 
gel (Hexane/Et2O 1:2 to 1:4). 
 
General procedure for the asymmetric Michael addition/retro-Dieckmann using the 
scandium catalyst 
An oven-dried reaction vial was charged with Sc(OTf)3 (10 mol%) and L32 (11 mol%), 
then dried for 15 min under high-vacuum. CHCl3 (2 mL) was added, and catalyst 
formation was ensured by stirring the resulting solution for 1 h at room temperature. 
Enone 4 (0.20-0.25 mmol, 1.0 equiv.) was also dried under high-vacuum for 15 min 
prior to addition, either directly if a solid or as a solution in CHCl3 if an oil. The resulting 
solution was cooled to 0 °C, and cyano-THT 114 (1.1 equiv.) was added. Upon 
completion of the reaction as indicated by TLC (toluene/acetone 9:1, UV and vanillin), 
or if the reaction was not complete, after 2 d, TBAH (2.2 equiv.) was added and the 
reaction mixture was stirred for 5 min. The reaction mixture was then diluted with a 
saturated aqueous solution of NaCl (5 mL) and the aqueous phase was extracted with 
EtOAc (3 x 10 mL). The combined organic layers were dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude residue was purified by flash 
chromatography over silica gel (Hexane/Et2O 1:2 to 1:4). 
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3-Ethyl-5-(1-methyl-1H-imidazol-2-yl)-2-methylene-5-oxopentanenitrile (114n) 
 
Molecular formula: C12H15N3O MW = 217.27 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (33 mg, 61% yield, er = 98:2 using the Cu/L27 catalyst, and 38 mg, 
72% yield, er = 94:6 using the Sc/L32 catalyst). 
1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 0.9 Hz, 1H), 7.03 (d, J = 0.9 Hz, 1H), 5.88 (s, 1H), 
5.79 (s, 1H), 3.98 (s, 3H), 3.38 (dd, J = 17.1, 8.4 Hz, 1H), 3.29 (dd, J = 17.1, 5.7 Hz, 1H), 
2.95-2.85 (m, 1H), 1.67-1.56 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 190.3, 142.9, 131.2, 129.4, 127.3, 126.3, 117.6, 42.5, 42.0, 
36.3, 26.5, 11.5. 
HRMS: calc for [C12H16N3O]+: 218.1293; found: 218.1125. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (80:20 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
11.5 and 13.5 min. 
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3-(2-(1-Methyl-1H-imidazol-2-yl)-2-oxoethyl)-2-methylenedecanenitrile (114o) 
 
Molecular formula: C17H25N3O MW = 287.41 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (38 mg, 52% yield, er = 97.5:2.5 using the Cu/L27 catalyst, and 44 mg, 
69% yield, er = 98:2 using the Sc/L32 catalyst). 
1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 0.9 Hz, 1H), 7.03 (d, J = 0.9 Hz, 1H), 5.86 (s, 1H), 
5.79 (s, 1H), 3.98 (s, 3H), 3.37 (dd, J = 17.1, 8.4 Hz, 1H), 3.29 (dd, J = 17.1, 5.7 Hz, 1H), 
2.98 (tt, J = 8.4, 5.7 Hz, 1H), 1.61-1.52 (m, 2H), 1.33-1.21 (m, 10H), 0.91-0.84 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 190.3, 143.0, 131.0, 129.4, 127.3, 126.6, 117.7, 42.9, 40.4, 
36.3, 33.5, 31.9, 29.4, 29.3, 27.0, 22.8, 14.2. 
HRMS: calc for [C17H26N3O]+: 288.2076; found: 288.1952. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (85:15 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
10.5 and 13.8 min.  
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5-Methyl-3-(2-(1-methyl-1H-imidazol-2-yl)-2-oxoethyl)-2-methylenehexanenitrile 
(114m) 
 
Molecular formula: C14H19N3O MW = 245.33 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (16 mg, 33% yield, er = 96:4 using the Cu/L27 catalyst, and 22 mg, 
43% yield, er = 97:3 using the Sc/L32 catalyst.) 
1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 0.9 Hz, 1H), 7.03 (d, J = 0.9 Hz, 1H), 5.86 (s, 1H), 
5.81 (s, 1H), 3.98 (s, 3H), 3.37 (dd, J = 17.2, 8.6 Hz, 1H), 3.26 (dd, J = 17.2, 5.4 Hz, 1H), 
3.15-3.16 (m, 1H), 1.65-1.54 (m, 2H), 1.38-1.30 (m, 1H), 0.93 (d, J = 6.4 Hz, 3H), 0.91 (d, 
J = 6.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 190.3, 142.9, 131.0, 129.4, 127.3, 126.7, 117.6, 43.2, 42.6, 
38.3, 36.3, 25.4, 23.3, 21.7. 
HRMS: calc for [C14H20N3O]+: 246.1606; found: 246.1502. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (70:20 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
7.0 and 8.7 min. 
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3-Cyclopropyl-5-(1-methyl-1H-imidazol-2-yl)-2-methylene-5-oxopentanenitrile (114l) 
 
Molecular formula: C13H15N3O MW = 229.28 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (19 mg, 41% yield, er = 84:16 using the Cu/L27 catalyst, and 31 mg, 
58% yield, er = 91:9 using the Sc/L32 catalyst). 
1H NMR (400 MHz, CDCl3) δ 7.13 (s, 1H), 7.03 (s, 1H), 5.85 (s, 1H), 5.81 (s, 1H), 3.97 (s, 
3H), 3.55 (dd, J = 16.7, 8.6 Hz, 1H), 3.43 (dd, J = 16.7, 5.5 Hz, 1H), 2.26-1.17 (m, 1H), 
1.02-0.92 (m, 1H), 0.63-0.50 (m, 2H), 0.30-0.18 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 190.2, 143.0, 130.1, 129.4, 127.3, 126.5, 118.2, 45.3, 42.8, 
36.3, 15.4, 5.2, 4.8. 
HRMS: calc for [C13H16N3O]+: 230.1208; found: 230.1293. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (70:30 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
8.6 and 10.0 min. 
  
N
N
OMe
CN
  
 
204 
 
 
 
 
  
min0 2 4 6 8 10 12
mAU
0
50
100
150
200
 DAD1 C, Sig=280,16 Ref=360,100 (SA-MC\MARDI\MC748R~1\MC748M30.D)
 8
.5
86
 9
.9
80
min0 2 4 6 8 10 12
mAU
0
1
2
3
4
5
6
7
8
 DAD1 C, Sig=280,16 Ref=360,100 (SA-MC\MC751-1B.D)
  A
rea
: 1
2.8
07
3
 8
.6
83
  A
rea
: 1
32
.56
2
 1
0.
12
1
N
N
OMe
CN
  
 
205 
3-Isopropyl-5-(1-methyl-1H-imidazol-2-yl)-2-methylene-5-oxopentanenitrile (114c) 
 
Molecular formula: C13H17N3O MW = 231.30 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (21 mg, 44% yield, er = 84:16 using the Cu/L27 catalyst, and 27 mg, 
54% yield, er = 92:8 using the Sc/L32 catalyst). 
1H NMR (400 MHz, CDCl3) δ 7.14 (d, J = 0.9 Hz, 1H), 7.03 (d, J = 0.9 Hz, 1H), 5.89 (s, 1H), 
5.76 (s, 1H), 3.97 (s, 3H), 3.47 (dd, J = 17.3, 10.0 Hz, 1H), 3.32 (dd, J = 17.3, 4.1 Hz, 1H), 
2.84-2.76 (m, 1H), 1.96-1.84 (m, 1H), 1.00 (d, J = 6.8 Hz, 3H), 0.99 (d, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 190.6, 143.0, 131.7, 129.4, 127.3, 125.6, 118.3, 46.4, 39.8, 
36.3, 31.1, 20.3, 19.9. 
HRMS: calc for [C13H18N3O]+: 232.1450; found: 232.1390. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (85:15 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
10.5 and 11.9 min. 
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3-Cyclohexyl-5-(1-methyl-1H-imidazol-2-yl)-2-methylene-5-oxopentanenitrile (114g) 
 
Molecular formula: C16H21N3O MW = 271.36 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (22 mg, 40% yield, er = 85:15 using the Cu/L27 catalyst, and 25 mg, 
61% yield, er = 88:12 using the Sc/L32 catalyst). 
1H NMR (400 MHz, CDCl3) δ 7.14 (d, J = 1.0 Hz, 1H), 7.02 (d, J = 1.0 Hz, 1H), 5.88 (s, 1H), 
5.74 (s, 1H), 3.97 (s, 3H), 3.41 (d, J = 8.6 Hz, 1H), 3.39 (d, J = 5.6 Hz, 1H), 2.82 (ddd, 
J = 8.6, 7.5, 5.6 Hz, 1H), 1.82-1.72 (m, 4H), 1.70-1.64 (m, 1H), 1.57-1.49 (m, 2H), 
1.22-1.10 (m, 2H), 1.06-0.96 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 190.7, 143.0, 131.6, 129.4, 127.3, 125.7, 118.4, 45.7, 40.6, 
39.8, 36.3, 30.8, 30.4, 26.4 (2C), 26.4. 
HRMS: calc for [C16H22N3O]+: 272.1669; found: 272.1763. 
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HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (80:20 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
10.9 and 18.0 min. 
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5-(1-Methyl-1H-imidazol-2-yl)-2-methylene-5-oxo-3-phenylpentanenitrile (114e) 
 
Molecular formula: C16H15N3O MW = 265.32 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (39 mg, 73% yield, er = 74:26 using the Cu/L27 catalyst, and 19 mg, 
36% yield, er = 78:22 using the Sc/L32 catalyst). 
1H NMR (400 MHz, CDCl3) δ 7.36-7.30 (m, 4H), 7.29-7.22 (m, 1H), 7.14 (d, J = 1.0 Hz, 
1H), 7.02 (d, J = 1.0 Hz, 1H), 5.91 (s, 1H), 5.85 (s, 1H), 4.32 (t, J = 7.5 Hz, 1H), 3.94 (s, 
3H), 3.82 (dd, J = 17.3, 7.5 Hz, 1H), 3.75 (dd, J = 17.3, 7.5 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 189.1, 142.8, 139.4, 130.3, 129.5, 129.1 (2C), 128.0 (2C), 
127.8, 127.5, 126.6, 118.1, 45.0, 42.3, 36.2. 
HRMS: calc for [C16H16N3O]+: 266.1293; found: 266.1276. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (70:30 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
9.3 and 11.4 min. 
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3-(4-Chlorophenyl)-5-(1-methyl-1H-imidazol-2-yl)-2-methylene-5-oxopentanenitrile 
(114i) 
 
Molecular formula: C16H14ClN3O MW = 299.76 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (35 mg, 59% yield, er = 71:29 using the Cu/L27 catalyst, and 33 mg, 
54% yield, er = 85:15 using the Sc/L32 catalyst). 
1H NMR (400 MHz, CDCl3) δ 7.32-7.24 (m, 4H), 7.15 (d, J = 0.9 Hz, 1H), 7.03 (d, 
J = 0.9 Hz, 1H), 5.93 (d, J = 1.1 Hz, 1H), 5.86 (d, J = 1.1 Hz, 1H), 4.30 (dd, J = 7.6, 7.3 Hz, 
1H), 3.94 (s, 3H), 3.76 (d, J = 7.3 Hz, 1H), 3.75 (d, J = 7.6 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 188.7, 142.7, 137.8, 133.7, 130.5, 129.6, 129.4 (2C), 129.2 
(2C), 127.6, 126.2, 117.8, 44.4, 42.1, 36.2. 
HRMS: calc for [C16H15ClN3O]+: 300.0904; found: 300.0726. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (80:20 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
9.6 and 12.1 min. 
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3-(4-Methoxyphenyl)-5-(1-methyl-1H-imidazol-2-yl)-2-methylene-5-
oxopentanenitrile (114j) 
 
Molecular formula: C17H17N3O2 MW = 295.34 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (46 mg, 63% yield, er = 59:41 using the Cu/L27 catalyst, and 48 mg, 
66% yield, er = 81:19 using the Sc/L32 catalyst). 
1H NMR (400 MHz, CDCl3) δ 7.26-7.20 (m, 2H), 7.14 (s, 1H), 7.02 (s, 1H), 6.88-6.82 (m, 
2H), 5.88 (s, 1H), 5.82 (s, 1H), 4.27 (t, J = 7.1 Hz, 1H), 3.93 (s, 3H), 3.78 (s, 3H), 3.85-3.67 
(m, 2H). 
13C NMR (101 MHz, CDCl3) δ 189.3, 159.1, 142.9, 131.3, 129.8, 129.5, 129.1 (2C), 127.4, 
126.9, 118.2, 114.4 (2C), 55.4, 44.3, 42.3, 36.2. 
HRMS: calc for [C17H18N3O2]+: 296.1399; found: 296.1369. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (70:30 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
12.7 and 14.9 min. 
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(E)-3-(2-(1-Methyl-1H-imidazol-2-yl)-2-oxoethyl)-2-methylenehex-4-enenitrile (114p) 
 
Molecular formula: C13H15N3O MW = 229.28 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (31 mg, 55% yield, er = 50:50 using the Cu/L27 catalyst). 
1H NMR (400 MHz, CDCl3) δ 7.14 (s, 1H), 7.03 (s, 1H), 5.87 (s, 1H), 5.81 (s, 1H), 
5.70-5.58 (m, 1H), 5.42 (ddd, J = 15.4, 7.5, 1.9 Hz, 1H), 3.98 (s, 3H), 3.65 (q, J = 7.5 Hz, 
1H), 3.51-3.36 (m, 2H), 1.68 (d, J = 6.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 189.7, 142.9, 130.0, 129.4, 129.0, 129.0, 127.4, 126.1, 
118.1, 42.6, 42.1, 36.3, 18.1. 
HRMS: calc for [C13H16N3O]+: 230.1293; found: 230.1208. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (80:20 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
12.4 and 15.0 min. 
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5-(1-Isopropyl-1H-imidazol-2-yl)-3-methyl-2-methylene-5-oxopentanenitrile (143) 
 
Molecular formula: C13H17N3O MW = 231.30 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (14 mg, 25% yield, er = 85:15 using the Cu/L27 catalyst, and 23 mg, 
44% yield, er = 96:4 using the Sc/L32 catalyst). 
1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 1.0 Hz, 1H), 7.16 (d, J = 1.0 Hz, 1H), 5.83 (s, 1H), 
5.80 (s, 1H), 5.50 (hept, J = 6.7 Hz, 1H), 3.39 (dd, J = 16.9, 7.5 Hz, 1H), 3.28 (dd, J = 16.9, 
6.7 Hz, 1H), 3.13 (dqd, J = 7.5, 6.9, 6.7 Hz, 1H), 1.43 (d, J = 6.7 Hz, 6H), 1.24 (d, 
J = 6.9 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 190.2, 142.2, 129.9, 129.5, 128.7, 121.6, 117.9, 49.4, 44.5, 
34.8, 23.8, 23.7, 19.5. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (85:15 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
11.4 and 12.4 min. 
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3-Methyl-2-methylene-5-oxo-5-(thiazol-2-yl)pentanenitrile (144) 
 
Molecular formula: C10H10N2OS MW = 206.26 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (46 mg, 68% yield, er = 99:1 using the Sc/L32 catalyst). 
1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 3.0 Hz, 1H), 7.70 (d, J = 3.0 Hz, 1H), 5.86 (s, 1H), 
5.84 (s, 1H), 3.46 (dd, J = 17.2, 7.2 Hz, 1H), 3.28 (dd, J = 17.2, 6.9 Hz, 1H), 3.19 (ddq, 
J = 7.2, 6.9, 6.8 Hz, 1H), 1.27 (d, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 191.3, 166.6, 145.0, 130.1, 127.5, 126.8, 117.6, 43.4, 34.7, 
19.4. 
HRMS: calc for [C10H11N2OS]+: 207.0592; found: 207.0591. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (98:2 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
32.0 and 34.0 min. 
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Methyl 3-methyl-5-(1-methyl-1H-imidazol-2-yl)-2-methylene-5-oxopentanoate (154) 
 
Molecular formula: C12H16N2O3 MW = 236.27 g.mol-1 
This compound was prepared following the general procedures, and isolated as an 
amorphous solid (22 mg, 36% yield, er = 80:20 using the Cu/L27 catalyst). 
1H NMR (400 MHz, CDCl3) δ 7.12 (s, 1H), 7.01 (s, 1H), 6.18 (s, 1H), 5.62 (s, 1H), 3.98 (s, 
3H), 3.75 (s, 3H), 3.45-3.31 (m, 2H), 3.31-3.21 (m, 1H), 1.18 (d, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 191.5, 167.6, 145.1, 143.4, 129.1, 127.0, 123.7, 52.0, 44.9, 
36.3, 31.1, 20.4. 
HRMS: calc for [C12H17N2O3]+: 237.1239; found: 237.1223. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (70:30 
isocratic) at 25 °C on an IC column, with UV detection (l = 280 nm). Retention times: 
10.6 and 14.8 min. 
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4.3.4. Chromanes 
2-(Hydroxy(phenyl)methyl)phenol (165) 
 
Molecular formula: C13H12O2 MW = 200.24 g.mol-1 
Salicylaldehyde (2.0 mL, 18.8 mmol, 1.0 equiv.) was dissolved in THF (60 mL). The 
solution was cooled to –78 °C and phenyl lithium (1.9 M solution in dibutyl ether, 
20.7 mL, 39.4 mmol, 2.1 equiv.) was dropwise added. The reaction was allowed to 
warm to room temperature overnight and quenched with a saturated aqueous 
solution of NH4Cl (50 mL) at 0 °C. The mixture was diluted with EtOAc (50 mL) and the 
layers were separated. The aqueous layer was extracted with EtOAc (2 x 50 mL), the 
pooled organic layers were dried over anhydrous MgSO4 and concentrated. 
Purification by flash chromatography over silica gel (PE/EtOAc 95:5 to 9:1) afforded the 
title compound as a yellow solid (2.20 g, 11.0 mmol, 59%). Spectral data matched 
those reported in the literature.[343] 
1H NMR (400 MHz, CDCl3) δ 7.92 (s, 1H), 7.42-7.30 (m, 5H), 7.20 (ddd, J = 8.6, 7.1, 
2.0 Hz, 1H), 6.92-6.79 (m, 3H), 5.98 (s, 1H), 3.11 (s, 1H). 
13C NMR (101 MHz, CDCl3) δ 155.5, 141.9, 129.4, 128.8 (2C), 128.4, 128.3, 126.9 (2C), 
126.8, 120.1, 117.4, 77.1. 
 
3a-Hydroxy-9-phenyl-3,3a-dihydro-1H-thieno[3,4-b]chromene-9a(9H)-carbonitrile 
(166) 
 
Molecular formula: C18H15NO2S MW = 309.38 g.mol-1 
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Benzylic alcohol 165 (30 mg, 0.15 mmol, 1.0 equiv.) and THT 114 (29 mg, 0.23 mmol, 
1.5 equiv.) were dissolved in toluene (500 µL). Scandium triflate (3.7 mg, 0.008 mmol, 
5 mol%) were added and the reaction mixture was stirred at 60 °C for 3 h. Upon 
completion, the reaction was diluted with saturated aqueous NaHCO3 solution (5 mL) 
and EtOAc (5 mL). The layers were separated and the aqueous layer was extracted 
with EtOAc (5 mL). The pooled organic layers were dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. Purification by flash chromatography over silica 
gel (Toluene/EtOAc 6:1) afforded the title compound as a yellow solid, as a mixture of 
diastereomers in a 3:1 ratio (11 mg, 0.036 mol, 24%). 
1H NMR major diastereomer (400 MHz, CDCl3) δ 7.47-7.34 (m, 5H), 7.29-7.21 (m, 1H), 
7.06-6.87 (m, 3H), 4.56 (s, 1H), 3.78 (d, J = 11.4 Hz, 1H), 3.32 (br. s, 1H), 3.29-3.18 (m, 
2H), 2.89 (d, J = 10.6 Hz, 1H). 
1H NMR minor diastereomer (400 MHz, CDCl3) δ 7.47-7.34 (m, 5H), 7.29-7.21 (m, 1H), 
7.06-6.87 (m, 2H), 6.82 (dt, J = 7.8, 1.4 Hz, 1H), 4.62 (s, 1H), 3.62 (br. s, 1H), 3.38 (d, 
J = 11.0 Hz, 1H), 3.29-3.18 (m, 2H), 2.99 (d, J = 11.0 Hz, 1H). 
13C NMR major diastereomer (101 MHz, CDCl3) δ 152.1, 137.1, 130.8, 129.2, 129.2, 
129.0, 128.7, 122.6, 121.7, 118.1, 117.5, 102.8, 53.3, 47.4, 39.6, 36.1. 
13C NMR minor diastereomer (101 MHz, CDCl3) δ 151.4, 137.0, 130.0, 129.4, 129.0, 
122.6, 120.8, 118.7, 117.6, 105.9, 51.1, 45.4, 36.4, 34.5. 
 
2-Formylphenyl acetate (165) 
 
Molecular formula: C9H8O3 MW = 164.16 g.mol-1 
Salicylaldehyde (1.80 mL, 16.9 mmol, 1.0 equiv.) was dissolved in pyridine (12 mL). The 
reaction was cooled to 0 °C, then acetic anhydride (2.33 mL, 24.7 mmol, 1.5 equiv.) 
and DMAP (195 mg, 1.60 mmol, 10 mol%) were added. The reaction mixture was 
stirred at room temperature for 3 h. Upon completion, the mixture was diluted with 
EtOAc (40 mL), washed with an aqueous 1 M solution of HCl (3 x 20 mL), and with a 
O
OAc
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saturated aqueous solution of NaCl (20 mL). The organic layer was dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. Purification by flash 
chromatography over silica gel (PE/EtOAc 90:10) afforded the title compound as a 
white solid (2.74 g, 16.7 mmol, 99%). Spectral data matched those reported in the 
literature.[344] 
1H NMR (400 MHz, CDCl3) δ 10.11 (s, 1H), 7.88 (dd, J = 7.7, 1.8 Hz, 1H), 7.64 (ddd, 
J = 8.2, 7.4, 1.8 Hz, 1H), 7.45-7.36 (m, 1H), 7.18 (dd, J = 8.2, 1.1 Hz, 1H), 2.40 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 188.9, 169.4, 151.6, 135.4, 131.4, 128.2, 126.6, 123.6, 
21.0. 
 
tert-Butyl(2-(((tert-butyldimethylsilyl)oxy)(phenyl)methyl)phenoxy)dimethylsilane 
(167) 
 
Molecular formula: C25H40O2Si2 MW = 428.76 g.mol-1 
To a solution of benzylic alcohol 165 (500 mg, 2.5 mmol, 1.0 equiv.) in DMF (12.5 mL) 
at 0 °C were added TBSCl (1.5 g, 10 mmol, 4.0 equiv.), imidazole (680 mg, 10 mmol, 
4.0 equiv.) and DMAP (61 mg, 0.50 mmol, 20 mol%). The reaction mixture was stirred 
at 50 °C for 16 h. Upon completion, H2O (20 mL) was added and the aqueous phase 
was extracted with EtOAc (2 x 25 mL). The combined organic extracts were washed 
with a 10% aqueous solution of NaCl (5 x 10 mL) and dried over anhydrous MgSO4. 
Purification by flash chromatography over silica gel (PE/Et2O 100:0 to 95:5) afforded 
the desired product as a colourless oil (975 mg, 2.27 mmol, 91%). 
1H NMR (400 MHz, CDCl3) δ 7.53 (dd, J = 7.7, 1.9 Hz, 1H), 7.42-7.36 (m, 2H), 7.28-7.23 
(m, 2H), 7.21-7.14 (m, 1H), 7.10 (ddd, J = 8.1, 7.4, 1.9 Hz, 1H), 6.94 (td, J = 7.4, 1.2 Hz, 
1H), 6.78 (dd, J = 8.1, 1.2 Hz, 1H), 6.26 (s, 1H), 1.02 (s, 9H), 0.93 (s, 9H), 0.31 (s, 3H), 
0.28 (s, 3H), 0.03 (s, 3H), –0.05 (s, 3H). 
OTBS
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13C NMR (101 MHz, CDCl3) δ 151.8, 145.5, 135.8, 128.3, 128.0 (2C), 127.7, 126.6, 126.2 
(2C), 121.3, 117.8, 69.7, 26.0 (6C), 18.5, 18.5, –3.7, –3.8, –4.6, –4.8. 
 
tert-Butyl(2-(ethoxy(phenyl)methyl)phenoxy)dimethylsilane (168) 
 
Molecular formula: C21H30O2Si MW = 342.55 g.mol-1 
To a solution of silyl enol ether 167 (400 mg, 0.93 mmol, 1.0 equiv.) in ethanol (5 mL) 
was added PPTS (234 mg, 0.93 mmol, 1.0 equiv.). The mixture was stirred for 16 h 
under reflux. The reaction was diluted with H2O (5 mL) and the aqueous layer was 
extracted with CH2Cl2 (2 x 15 mL). The pooled organic layers were dried over 
anhydrous MgSO4 and concentrated under reduced pressure. Purification by flash 
chromatography over silica gel (PE/EtOAc 95:5 to 90:10) afforded the title compound 
as a colourless oil (266 mg, 0.85 mmol, 91%). 
1H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 7.7, 1.8 Hz, 1H), 7.39-7.33 (m, 2H), 7.32-7.26 
(m, 2H), 7.24-7.17 (m, 1H), 7.16-7.10 (m, 1H), 6.96 (td, J = 7.5, 1.2 Hz, 1H), 6.81 (dd, 
J = 8.2, 1.2 Hz, 1H), 5.85 (s, 1H), 3.54 (q, J = 7.0 Hz, 2H), 1.27 (t, J = 7.0 Hz, 3H), 0.99 (s, 
9H), 0.28 (s, 3H), 0.22 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 153.2, 142.7, 132.8, 128.3 (2C), 128.2, 128.1, 127.1, 127.1 
(2C), 121.5, 118.4, 76.9, 64.7, 26.0 (3C), 18.5, 15.6, –3.8 (2C). 
 
(2-Methoxyphenyl)(phenyl)methanol (169) 
 
Molecular formula: C14H14O MW = 214.26 g.mol-1 
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To a suspension of benzylic alcohol 165 (800 mg, 4.0 mmol, 1.0 equiv.) and methyl 
iodide (373 µL, 6.0 mmol, 1.5 equiv.) in acetone (13.3 mL) was added potassium 
carbonate (1.1 g, 8.0 mmol, 2.0 equiv.). The reaction mixture was stirred under reflux 
overnight. After cooling to room temperature, the reaction was diluted with a 
saturated aqueous solution of NaHCO3 (15 mL) and with EtOAc (30 mL). The layers 
were separated, and the aqueous layer was extracted with EtOAc (30 mL). The pooled 
organic layers were dried over anhydrous MgSO4 and concentrated under reduced 
pressure. Purification by flash chromatography over silica gel (PE/EtOAc 5:1) afforded 
the title compound as a yellow oil (759 mg, 3.54 mmol, 89%). Spectral data matched 
those reported in the literature.[345] 
1H NMR (400 MHz, CDCl3) δ 7.44-7.38 (m, 2H), 7.36-7.31 (m, 2H), 7.31-7.22 (m, 3H), 
6.96 (td, J = 7.5, 1.1 Hz, 1H), 6.90 (dd, J = 8.2, 1.1 Hz, 1H), 6.07 (d, J = 4.1 Hz, 1H), 3.82 
(s, 3H), 3.08 (d, J = 4.8 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 156.9, 143.4, 132.1, 128.8, 128.3 (2C), 128.0, 127.3, 126.7 
(2C), 120.9, 110.9, 72.4, 55.5. 
 
3-((2-Methoxyphenyl)(phenyl)methyl)-4-oxotetrahydrothiophene-3-carbonitrile 
(170) 
 
Molecular formula: C19H17NO2S MW = 323.41 g.mol-1 
Benzylic alcohol 169 (20 mg, 0.093 mmol, 1.0 equiv.) and THT 114 (14 mg, 0.11 mmol, 
1.2 equiv.) were dissolved in toluene (500 µL). Scandium triflate (4.6 mg, 0.009 mmol, 
10 mol%) were added and the reaction mixture was stirred at 60 °C for 15 min. Upon 
completion, the reaction was diluted with saturated aqueous NaHCO3 solution (5 mL) 
and EtOAc (5 mL). The layers were separated and the aqueous layer was extracted 
with EtOAc (5 mL). The pooled organic layers were dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. Purification by flash chromatography over silica 
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gel (Hexane/EtOAc 9:1 to 1:1) afforded the title compound as a yellow solid, as a 
mixture of diastereomers in a 2.5:1 ratio (23 mg, 0.070 mol, 76%). 
1H NMR major diastereomer (400 MHz, CDCl3) δ 7.64-7.57 (m, 3H), 7.42-7.36 (m, 2H), 
7.35-7.22 (m, 2H), 6.98 (td, J = 7.7, 1.2 Hz 1H), 6.85 (dd, J = 8.3, 1.2 Hz, 1H), 5.52 (s, 
1H), 3.78 (s, 3H), 3.62 (d, J = 17.6 Hz, 1H), 3.46-3.38 (m, 2H), 3.10 (d, J = 12.3 Hz, 1H).  
1H NMR minor diastereomer (400 MHz, CDCl3) δ 7.76 (dd, J = 7.7, 1.6 Hz, 1H), 7.47-7.43 
(m, 2H), 7.35-7.22 (m, 4H), 7.01 (td, J = 7.7, 1.2 Hz, 1H), 6.90 (dd, J = 8.3, 1.2 Hz, 1H), 
5.31 (s, 1H), 3.83 (s, 3H), 3.52 (d, J = 17.7 Hz, 1H), 3.46-3.38 (m, 1H), 3.35 (d, 
J = 12.2 Hz, 1H), 3.16 (d, J = 12.2 Hz, 1H). 
13C NMR minor diastereomer (101 MHz, CDCl3) δ 201.3, 156.4, 137.7, 130.3, 129.6 
(2C), 129.2 (2C), 128.6, 128.1, 125.5, 121.3, 118.4, 110.7, 55.5, 55.4, 42.6, 34.9, 34.9. 
13C NMR minor diastereomer (101 MHz, CDCl3) δ 201.2, 157.2, 137.7, 130.3, 129.5 
(2C), 129.3, 129.2 (2C), 127.9, 126.7, 121.3, 118.5, 111.4, 55.7, 55.1, 44.2, 35.4, 35.0. 
HPLC analysis was carried out using a mixture of hexane and isopropyl alcohol (80:20 
isocratic) at 25 °C on an IC column, with UV detection (l = 230 nm). Retention times: 
11.0 and 13.2 min (minor diastereomer), 14.3, 20.7 min (major diastereomer). 
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HPLC of product when using chiral catalyst (R)-174 instead of Sc(OTf)3 
 
 
 
2,2'-(Oxybis(phenylmethylene))bis(methoxybenzene) (173) 
 
Molecular formula: C28H26O3 MW = 410.51 g.mol-1 
This product was isolated as a minor, less polar byproduct of the formation of 169 
when using (R)-174 as a catalyst (5 mg, 0.012 mmol, 13%). 
1H NMR (400 MHz, CDCl3) δ 7.65 (dt, J = 7.6, 1.6 Hz, 2H), 7.41-7.32 (m, 4H), 7.29-7.17 
(m, 8H), 6.97 (qd, J = 7.6, 1.1 Hz, 2H), 6.81 (dt, J = 8.2, 1.1 Hz, 2H), 5.83 (s, 1H), 5.80 (s, 
1H), 3.65 (s, 3H), 3.65 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 156.9, 156.7, 142.8, 142.7, 131.3, 128.3, 128.2, 128.0 (4C), 
127.6, 127.6 (2C), 127.5, 127.5 (2C), 127.0, 127.0, 120.9, 120.8, 110.6, 110.6, 100.1, 
74.2, 74.1, 55.4 (2C). 
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2-((2-Methoxyphenyl)(phenyl)methyl)acrylonitrile (171) 
 
Molecular formula: C17H15NO MW = 249.31 g.mol-1 
THT adduct 172 (40 mg, 0.12 mmol, 1.0 equiv.) was dissolved in toluene (1.2 mL) and 
sodium hydroxide (2.77 M solution in H2O, 47 µL, 0.13 mmol, 3.0 equiv.) was added. 
The solution was stirred for 16 h. The reaction was quenched by addition of saturated 
aqueous NaHCO3 and diluted with a 10% aqueous solution of Na2SO4 to salt-out the 
product. The aqueous layer was extracted with EtOAc (2 x 10 mL). Purification by flash 
chromatography over silica gel (Hexane/EtOAc 5:1) afforded the title compound as a 
white solid (20 mg, 0.080 mmol, 68%). 
1H NMR (400 MHz, CDCl3) δ 7.38-7.31 (m, 2H), 7.31-7.25 (m, 2H), 7.23-7.17 (m, 2H), 
7.01 (dd, J = 7.6, 1.8 Hz, 1H), 6.97-6.87 (m, 2H), 6.08 (d, J = 1.3 Hz, 1H), 5.49 (d, 
J = 1.3 Hz, 1H), 5.41 (s, 1H), 3.80 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 156.9, 139.0, 132.1, 129.6, 129.2 (2C), 128.9, 128.8 (2C), 
127.8, 127.4, 125.8, 120.7, 119.1, 110.9, 55.6, 48.3. 
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4-Phenylchromane-3-carbonitrile (172) 
 
Molecular formula: C16H13NO MW = 235.29 g.mol-1 
Alkenyl nitrile 171 (18.0 mg, 0.053 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (500 µL) 
and boron tribromide (1 M solution in CH2Cl2, 160 µL, 0.16 mmol, 3.0 equiv.) was 
dropwise added at 0 °C. The solution was stirred for 2 h at this temperature. Upon 
completion, the reaction was quenched by slow addition of water. Potassium 
carbonate was then added until basification of the reaction medium. The organic 
solvent was removed under reduced pressure. The resulting solution in water (ca. 
5 mL) was diluted with acetonitrile (3 mL). The reaction mixture was then stirred at 
80 °C for 2 d. The aqueous layer was extracted with EtOAc (2 x 10 mL). The pooled 
organic layers were dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. 1H and 13C NMR of the crude showed formation of the desired product as a 
mixture of diastereomers in a 3:1 ratio (a/b). Purification by flash chromatography 
over silica gel (Hexane/Et2O 4:1) afforded pure 172a (8.0 mg, 0.034 mmol, 64%), pure 
172b (2.0 mg, 0.009 mmol, 16%) and an additional impure fraction (2.0 mg, 
0.009 mmol, 16%). 
Spectral data for 172a: 
 1H NMR (400 MHz, CDCl3) δ 7.42-7.28 (m, 3H), 7.25-7.13 (m, 3H), 6.99-6.92 (m, 1H), 
6.92-6.87 (m, 1H), 6.87-6.81 (m, 1H), 4.42 (d, J = 7.7 Hz, 1H), 4.38 (dd, J = 11.1, 3.1 Hz, 
1H), 4.27 (dd, J = 11.1, 7.7 Hz, 1H), 3.21 (td, J = 7.7, 3.1 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 154.0, 141.6, 130.7, 129.2 (2C), 129.0, 128.9 (2C), 128.1, 
121.9, 121.4, 118.6, 117.3, 63.9, 45.2, 34.4. 
Spectral data for 172b: 
1H NMR (400 MHz, CDCl3) δ 7.41-7.30 (m, 3H), 7.25-7.16 (m, 3H), 7.01-6.86 (m, 3H), 
4.47 (d, J = 5.6 Hz, 1H), 4.38-4.28 (m, 2H), 3.46 (ddd, J = 7.6, 5.6, 3.8 Hz, 1H). 
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13C NMR (101 MHz, CDCl3) δ 153.9, 139.7, 130.5, 123.0 (2C), 129.1, 128.7 (2C), 128.2, 
121.8, 121.1, 117.5, 117.3, 63.0, 43.0, 32.7. 
The relative configuration of 172a and 172b was assigned based on the coupling 
constants of the ring protons. 
 
 
  
O
NH
H
H
H
5.6 (axial-equatorial)
3.8 (axial-
equatorial)
7.6 (axial-axial)
O
H
N
H
H
H
7.7 (axial-axial)
172a 172b
3.1
  (axial-
      equatorial)
J values in Hz
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4.4. Phosphonates 
4.4.1. Preparation of substrates 
All the starting aldehydes were commercially available except for aldehydes 189-192, 
which were prepared following reported procedures. 
2-Vinylbenzaldehyde (189) 
 
Molecular formula: C9H8O MW = 132.16 g.mol-1 
A round-bottomed flask was charged with 2-bromobenzaldehyde (600 mg, 3.24 mmol, 
1.00 equiv.) and triethylamine (985 mg, 9.73 mmol, 3.00 equiv.) in isopropanol 
(33 mL). The solution was degassed by sonication under N2 bubbling for 15 min, then 
PdCl2(dppf) (132 mg, 0.162 mmol, 0.05 equiv.) and potassium vinyltrifluoroborate 
(608 mg, 4.54 mmol, 1.40 equiv.) were added and the solution was stirred for 18 h at 
85 °C. The reaction mixture was then filtered over a pad of Celite and concentrated 
under reduced pressure. The crude was purified by flash chromatography over silica 
gel (PE/Et2O, 95:5 to 85:15) to afford the title compound as a yellow oil (302 mg, 
2.29 mmol, 71%). Spectral data matched those reported in the literature.[346] 
1H NMR (400 MHz, CDCl3) δ 10.29 (s, 1H), 7.83 (d, J = 7.5 Hz, 1H), 7.59-7.50 (m, 3H), 
7.47-7.40 (m, 1H), 5.70 (dd, J = 17.4, 1.2 Hz, 1H), 5.51 (dd, J = 11.0, 1.2 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ. 193.0, 141.1, 134.4, 133.9, 133.5, 131.8, 128.5, 128.0, 
120.0. 
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2-(Oct-7-en-1-yloxy)benzaldehyde (190) 
 
Molecular formula: C15H20O2 MW = 232.32 g.mol-1 
To a solution of 2-hydroxybenzaldehyde (250 μL, 3.28 mmol, 1.00 equiv.) in DMF 
(8.0 mL) were added potassium carbonate (590 mg, 4.27 mmol, 1.30 equiv.) and 
8-bromo-1-octene (606 mg, 3.61 mmol, 1.10 equiv.). The resulting solution was stirred 
for 3 h at 80 °C. Upon completion, the reaction mixture was diluted with water 
(10 mL). The aqueous layer was then extracted with Et2O (3 x 10 mL). The pooled 
organic layers were then washed with a saturated aqueous solution of NaCl (3 x 
10 mL), dried over anhydrous MgSO4 and concentrated under reduced pressure. The 
crude was then purified by flash chromatography over silica gel (PE/Et2O, 100:0 to 
95:5) to afford the title compound as a colorless oil (752 mg, 3.24 mmol, 99%). 
1H NMR (400 MHz, CDCl3) δ 10.51 (d, J = 0.8 Hz, 1H), 7.83 (dd, J = 7.7, 1.8 Hz, 1H), 7.52 
(ddd, J = 8.4, 7.3, 1.9 Hz, 1H), 7.03-6.94 (m, 2H), 5.81 (ddt, J = 17.0, 10.2, 6.9 Hz, 1H), 
5.00 (dq, J = 17.0, 1.7 Hz, 1H), 4.94 (ddt, J = 10.2, 1.7, 1.2 Hz, 1H), 4.07 (t, J = 6.4 Hz, 
2H), 2.06 (dtdd, J = 6.9, 6.7, 1.7, 1.2 Hz, 2H), 1.90-1.79 (m, 2H), 1.55-1.46 (m, 2H), 1.46-
1.34 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 190.0, 161.7, 139.0, 136.0, 128.3, 125.0, 120.6, 114.5, 
112.6, 68.6, 33.8, 29.2, 28.9 (2C), 26.1. 
HRMS: calc for [C15H21O2]+: 233.1542; found: 233.1546. 
IR: 3681 (w), 3076 (s), 2929 (s), 2857 (s), 2758 (s), 1686 (s), 1640 (s), 1598 (s), 1457 (m), 
1386 (s), 1285 (m), 1250 (s), 1160 (s), 1033 (m), 909 (s), 840 (s), 755 (m) cm-1. 
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3-(Oct-7-en-1-yloxy)benzaldehyde (191) 
 
Molecular formula: C15H20O2 MW = 232.32 g.mol-1 
To a solution of 3-hydroxybenzaldehyde (176 mg, 1.44 mmol, 1.00 equiv.) in DMF 
(2.0 mL) were added potassium carbonate (259 mg, 1.87 mmol, 1.30 equiv.) and 
8-bromo-1-octene (303 mg, 1.59 mmol, 1.10 equiv.). The resulting solution was stirred 
for 3 h at 80 °C. Upon completion, the reaction mixture was diluted with water 
(10 mL). The aqueous layer was then extracted with EtOAc (3 x 10 mL). The pooled 
organic layers were then washed with a saturated aqueous solution of NaCl 
(3 x 10 mL), dried over anhydrous MgSO4 and concentrated under reduced pressure. 
The crude was then purified by flash chromatography over silica gel (PE/Et2O, 90:10 to 
80:20) to afford the title compound as a colorless oil (243 mg, 1.05 mmol, 73%). 
Spectral data matched those reported in the literature.[347] 
1H NMR (400 MHz, CDCl3) δ 9.97 (s, 1H), 7.48-7.40 (m, 2H), 7.39-7.37 (m, 1H), 
7.20-7.14 (m, 1H), 5.82 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.00 (dq, J = 17.0, 1.7 Hz, 1H), 
4.94 (ddt, J = 10.2, 2.3, 1.2 Hz, 1H), 4.01 (t, J = 6.5 Hz, 2H), 2.11-2.02 (m, 2H), 1.86-1.74 
(m, 2H), 1.55-1.33 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 192.4, 159.9, 139.1, 137.9, 130.1, 123.5, 122.1, 114.5, 
112.9, 68.4, 33.8, 29.2, 29.0 (2C), 26.0. 
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3-Formylphenyl non-8-enoate (192) 
 
Molecular formula: C16H20O3 MW = 260.33 g.mol-1 
To a solution of 3-hydroxybenzaldehyde (200 mg, 1.64 mmol, 1.00 equiv.) in toluene 
(5.0 mL) were added at 0 °C DMAP (20.0 mg, 0.16 mmol, 0.10 equiv.), DCC (372 mg, 
1.80 mmol, 1.10 equiv.) and 8-nonenoic acid (310 μL, 1.80 mmol, 1.10 equiv.). The 
resulting solution was stirred at this temperature for 30 min. Upon completion, the 
reaction mixture was directly purified by flash column chromatography over silica gel 
(Hexane/Et2O, 95:5 to 85:15) to afford the title compound as a colorless oil (410 mg, 
1.57 mmol, 96%). 
1H NMR (400 MHz, CDCl3) δ 10.00 (s, 1H), 7.75 (ddd, J = 7.6, 1.4, 1.2 Hz, 1H), 7.61 (dd, 
J = 2.4, 1.4 Hz, 1H), 7.55 (dd, J = 8.1, 7.6 Hz, 1H), 7.35 (ddd, J = 8.1, 2.4, 1.2 Hz, 1H), 
5.81 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.00 (dq, J = 17.0, 1.7 Hz, 1H), 4.94 (ddt, J = 10.2, 
1.7, 1.3 Hz, 1H), 2.59 (t, J = 7.5 Hz, 2H), 2.11-2.03 (m, 2H), 1.82-1.71 (m, 2H), 1.48-1.32 
(m, 6H). 
13C NMR (101 MHz, CDCl3) δ. 191.3, 172.1, 151.5, 139.0, 137.9, 130.2, 127.9, 127.4, 
122.4, 114.5, 34.4, 33.8, 29.1, 28.8, 28.8, 24.9. 
HRMS: calc for [C16H20NaO3]+: 283.1310; found: 283.1305. 
IR: 3075 (s), 2928 (s), 2856 (s), 2730 (s), 1760 (s), 1700 (s), 1640 (s), 1589 (m), 
1452 (m), 1386 (s), 1228 (m), 1136 (s), 1108 (s), 1000 (s), 909 (s), 799 (m), 679 (s), 
643 (s) cm-1. 
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4.4.2. Synthesis of the a-hydroxyphosphonates 
General procedure G: Pudovik reaction 
A mixture of aldehyde (1.01 equiv.), diethyl phosphite (1.00 equiv.) and triethylamine 
(0.50 equiv.) was stirred at room temperature or 50 °C for the indicated time. The 
reaction mixture was then diluted with chloroform and concentrated under reduced 
pressure to remove the triethylamine. 
Diethyl ((4-chlorophenyl)(hydroxy)methyl)phosphonate (180a) 
 
Molecular formula: C11H16ClO4P MW = 278.69 g.mol-1 
Following the general procedure G, the synthesis was carried out with 
4-cholorobenzaldehyde (710 mg, 5.05 mmol). The solution was stirred at room 
temperature and left overnight. The title compound was obtained as a white solid 
(1.39 g, 4.99 mmol, quantitative). Spectral data matched those reported in the 
literature.[348] 
1H NMR (400 MHz, CDCl3) δ 7.38 (dd, J = 8.4, 2.2 Hz, 2H), 7.27 (d, J = 8.4 Hz, 2H), 5.47 (dd, 
J = 8.6, 5.7 Hz, 1H), 4.96 (dd, J = 11.4, 5.7 Hz, 1H), 4.05-3.94 (m, 4H), 1.22 (t, J = 6.0 Hz, 3H), 
1.18 (t, J = 6.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 135.7 (d, J = 1.5 Hz), 133.7 (d, J = 3.8 Hz), 128.5 (d, 
J = 5.6 Hz, 2C), 128.3 (d, J = 2.7 Hz, 2C), 70.0 (d, J = 161.0 Hz), 63.6 (d, J = 7.1 Hz), 63.1 
(d, J = 7.4 Hz), 16.4 (d, J = 5.6 Hz). 
31P NMR (162 MHz, CDCl3) δ 19.0. 
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Dimethyl ((4-chlorophenyl)(hydroxy)methyl)phosphonate (180b) 
 
Molecular formula: C9H12ClO4P MW = 250.61 g.mol-1 
Following a modified version of general procedure G, the synthesis was carried out 
with 4-chlorobenzaldehyde (710 mg, 5.05 mmol), dimethylphosphite (0.46 mL, 
5.0 mmol) and triethylamine (0.35 mL, 2.5 mmol). The solution was stirred at room 
temperature and left overnight. The crude was then purified by flash column 
chromatography over silica gel (CH2Cl2/EtOAc, 100:0 to 0:100) to afford the title 
compound as a white solid (689 mg, 2.75 mmol, 55%). Spectral data matched those 
reported in the literature.[278] 
1H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 8.4, 2.2 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 5.04 (d, 
J = 10.8 Hz, 1H), 4.18 (br. s, 1H), 3.73 (d, J = 5.4 Hz, 3H), 3.70 (d, J = 5.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 134.9, 134.3 (d, J = 3.9 Hz), 128.8 (d, J = 2.6 Hz, 2C), 128.5 (d, 
J = 5.8 Hz, 2C), 70.1 (d, J = 159.8 Hz), 54.2 (d, J = 7.0 Hz), 53.9 (d, J = 7.4 Hz). 
m.p. = 99-100 °C. 
HRMS: calc for [C9H12ClO4P]: 250.0162; found: 250.0164. 
IR: 3360, 3035, 3006, 2958, 1493, 1251, 1040 cm-1. 
 
Diisopropyl ((4-chlorophenyl)(hydroxy)methyl)phosphonate (180c) 
 
Molecular formula: C13H20ClO4P MW = 306.72 g.mol-1 
Following a modified version of general procedure G, the synthesis was carried out 
with 4-cholorobenzaldehyde (710 mg, 5.05 mmol), diisopropylphosphite (0.83 ml, 
5.0 mmol) and triethylamine (0.35 ml, 2.5 mmol). The solution was stirred at room 
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temperature and left overnight. The title compound was obtained as a white solid 
(1.50 g, quantitative). 
1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J = 8.3, 2.1 Hz, 2H), 7.32 (d, J = 8.3 Hz, 2H), 4.94 
(d, J = 10.8 Hz, 1H), 4.70-4.56 (m, 2H), 3.99 (br. s, 1H), 1.27 (d, J = 6.1 Hz, 3H), 1.26 (d, 
J = 6.2 Hz, 6H), 1.18 (d, J = 6.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 135.5, 133.6 (d, J = 3.8 Hz), 128.7 (d, J = 5.7 Hz, 2C), 128.3 
(d, J = 2.3 Hz, 2C), 72.3 (d, J = 7.4 Hz), 71.9 (d, J = 7.8 Hz), 70.4 (d, J = 161.2 Hz), 24.2 (d, 
J = 3.2 Hz), 24.1 (d, J = 3.8 Hz), 24.0 (d, J = 5.1 Hz), 23.7 (d, J = 5.3 Hz). 
m.p. = 122-123 °C. 
HRMS: calc for [C13H20ClO4P]: 306.0788; found: 306.0785. 
IR: 3367, 2984, 2937, 1493, 1200, 996 cm-1. 
 
Dimethyl (hydroxy(4-nitrophenyl)methyl)phosphonate (180d) 
 
Molecular formula: C9H12NO6P MW = 261.17 g.mol-1 
Following a modified version of general procedure G, the synthesis was carried out 
with 4-nitrobenzaldehyde (831 mg, 5.5 mmol, 1.1 equiv.), dimethylphosphite (0.46 mL, 
5.0 mmol, 1.0 equiv.) and triethylamine (0.35 mL, 2.5 mmol, 0.5 equiv.). The title 
compound was obtained as an orange solid (1.2 g, 4.6 mmol, 91%) after a very fast 
reaction completed in five minutes under mechanical mixing with spatula and 
immediately purified by flash column chromatography over silica gel (CH2Cl2/EtOAc, 
100:0 to 0:100). Spectral data matched those reported in the literature.[278] 
1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 8.7 Hz, 2H), 7.67 (dd, J = 8.7, 2.2 Hz, 2H), 5.22 
(d, J = 12.3 Hz, 1H), 4.79 (br. s, 1H), 3.78 (d, J = 8.9 Hz, 3H), 3.75 (d, J = 9.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 147.8 (d, J = 3.7 Hz), 143.9, 127.7 (d, J = 5.3 Hz, 2C), 123.6 
(d, J = 2.6 Hz, 2C), 70.1 (d, J = 158.6 Hz), 54.6 (d, J = 7.1 Hz), 53.9 (d, J = 7.6 Hz). 
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HRMS: calc for [C9H12O6P]: 261.0402; found: 261.0396. 
IR : 3246, 2958, 2854, 1518, 1347, 1236, 1027, 864 cm-1. 
 
Diethyl (hydroxy(2-nitrophenyl)methyl)phosphonate (180r) 
 
Molecular formula: C11H16NO6P MW = 289.22 g.mol-1 
Following the general procedure G, the synthesis was carried out with 
2-nitrobenzaldehyde (764 mg, 5.05 mmol). The solution was stirred at room 
temperature and left overnight. The title compound was obtained as a white solid 
(1.44 g, 4.99 mmol, quantitative). Spectral data matched those reported in the 
literature.[278] 
1H NMR (400 MHz, CDCl3) δ 8.02-7.97 (m, 2H), 7.67 (t, J = 7.5 Hz, 1H), 7.44 (t, 
J = 7.7 Hz, 1H), 6.29 (d, J = 13.8 Hz, 1H), 5.79 (br. s, 1H), 4.15-4.07 (m, 4H), 1.26-1.19 
(m, 6H). 
13C NMR (101 MHz, CDCl3) δ 147.6 (d, J = 5.7 Hz), 133.4 (d, J = 2.7 Hz), 133.1, 129.0 (d, 
J = 4.3 Hz), 128.4 (d, J = 2.8 Hz), 124.8 (d, J = 1.5 Hz), 65.6 (d, J = 160.4 Hz), 64.3 (d, 
J = 7.1 Hz), 63.4 (d, J = 7.4 Hz), 16.4 (d, J = 5.3 Hz), 16.2 (d, J = 5.5 Hz). 
 
Diethyl ((2-bromophenyl)(hydroxy)methyl)phosphonate (180f) 
 
Molecular formula: C11H16BrO4P MW = 323.12 g.mol-1 
Following the general procedure G, the synthesis was carried out with 
2-bromobenzaldehyde (63 μL, 0.54 mmol). The solution was stirred at 50 °C for 2 h. 
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The mixture was concentrated to afford the title compound as a colorless oil (170 mg, 
0.53 mmol, 98%). Spectral data matched those reported in the literature.[349] 
1H NMR (400 MHz, CDCl3) δ 7.75 (ddd, J = 7.8, 2.1, 1.8 Hz, 1H), 7.54 (ddd, J = 8.0, 1.5, 
1.3 Hz, 1H), 7.36 (dd, J = 7.8, 7.3 Hz, 1H), 7.16 (dddd, J = 8.0, 7.3, 1.8, 1.5 Hz, 1H), 5.53 
(d, J = 11.6 Hz, 1H), 4.68 (br. s, 1H), 4.25-3.89 (m, 4H), 1.31 (t, J = 7.1 Hz, 3H), 1.20 (t, 
J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 136.8, 132.7 (d, J = 2.1 Hz), 129.7 (d, J = 1.6 Hz), 129.7, 
127.7 (d, J = 3.0 Hz), 123.4 (d, J = 8.6 Hz), 69.7 (d, J = 160.7 Hz), 63.8 (d, J = 7.1 Hz), 63.3 
(d, J = 7.1 Hz), 16.5 (d, J = 5.8 Hz), 16.5 (d, J = 5.6 Hz). 
 
Diethyl (hydroxy(4-methoxyphenyl)methyl)phosphonate (180g) 
 
Molecular formula: C12H19O5P MW = 274.25 g.mol-1 
Following the general procedure G, the synthesis was carried out with anisaldehyde 
(607 µl, 5.05 mmol). The solution was stirred at room temperature and left overnight. 
The title compound was obtained as a white solid (1.37 g, 5.00 mmol, quantitative). 
Spectral data matched those reported in the literature.[278] 
1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 8.0 Hz, 2H), 6.86 (d, J = 8.0 Hz, 2H), 4.93 (d, 
J = 9.8 Hz, 1H), 4.39 (br. s, 1H), 4.07-3.81 (m, 4H), 3.78 (s, 3H), 1.25 (t, J = 7.0 Hz, 3H), 
1.19 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.5, 128.8, 128.6 (d, J = 5.5 Hz, 2C), 113.8 (2C), 70.4 (d, 
J = 161.1 Hz), 63.4 (d, J = 6.5 Hz), 63.1 (d, J = 6.8 Hz), 55.3, 16.5 (d, J = 4.2Hz), 16.4 (d, 
J = 3.6 Hz). 
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Diethyl (hydroxy(3-hydroxyphenyl)methyl)phosphonate (180h) 
 
Molecular formula: C11H17O5P MW = 260.23 g.mol-1 
Following the general procedure G, the synthesis was carried out with 
3-hydroxybenzaldehyde (1.0 g, 8.2 mmol). The solution was stirred at 50 °C for 12 h. 
The crude was then purified by flash chromatography over silica gel (CH2Cl2/EtOAc, 
60:40) to afford the title compound as a white solid (2.1 g, 7.0 mmol, 85%). Spectral 
data matched those reported in the literature.[350] 
1H NMR (400 MHz, CDCl3) δ 8.06 (br. s, 1H), 7.29-7.26 (m, 1H), 7.17 (t, J = 7.8 Hz, 1H), 
6.87 (d, J = 7.8 Hz, 1H), 6.80 (d, J = 8.1 Hz, 1H), 4.93 (d, J = 11.9 Hz, 1H), 4.16-3.66 (m, 
5H), 1.26 (t, J = 7.1 Hz, 3H), 1.16 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.2, 137.5, 129.6, 119.0 (d, J = 7.2 Hz), 116.1, 114.4 (d, 
J = 4.9 Hz), 71.0 (d, J = 161.5 Hz), 63.7 (d, J = 7.2 Hz, 2C), 16.5 (d, J = 5.8 Hz), 16.4 (d, 
J = 5.7 Hz). 
31P NMR (162 MHz, CDCl3) δ 20.8. 
m.p. = 106-107 °C. 
 
Diethyl (hydroxy(pyridin-3-yl)methyl)phosphonate (180i) 
 
Molecular formula: C10H16NO4P MW = 245.21 g.mol-1 
Following the general procedure G, the synthesis was carried out with nicotinaldehyde 
(500 μL, 5.33 mmol). The solution was stirred at 50 °C for 12 h. The crude was then 
purified by flash chromatography over silica gel (CH2Cl2/MeOH, 95:5) to afford the title 
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compound as a colorless oil (113 mg, 0.305 mmol, 71%). Spectral data matched those 
reported in the literature.[351] 
1H NMR (400 MHz, CDCl3) δ 8.63 (s, 1H), 8.51-8.47 (m, 1H), 7.87 (dq, J = 8.0, 2.1 Hz, 
1H), 7.28 (dd, J = 8.0, 4.9 Hz, 1H), 5.59 (br. s, 1H), 5.05 (d, J = 11.5 Hz, 1H), 4.14-4.01 
(m, 4H), 1.25 (t, J = 7.1 Hz, 3H), 1.23 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 149.0 (d, J = 3.3 Hz), 148.5 (d, J = 6.6 Hz), 135.1 (d, 
J = 4.9 Hz), 133.3, 123.4 (d, J = 2.5 Hz), 68.6 (d, J = 162.2 Hz), 63.7 (d, J = 7.1 Hz), 63.3 
(d, J = 7.4 Hz), 16.5, 16.5. 
31P NMR (162 MHz, CDCl3) δ 20.0. 
 
Diethyl (furan-2-yl(hydroxy)methyl)phosphonate (180j) 
 
Molecular formula: C9H15O5P MW = 234.19 g.mol-1 
Following the general procedure G, the synthesis was carried out with furfuraldehyde 
(0.41 mL, 5,0 mmol). The solution was stirred at room temperature for 12 h. The crude 
was then purified by flash column chromatography over silica gel (CH2Cl2/EtOAc, 100:0 
to 0:100) to afford the title compound as a yellow oil (1.15 g, 4.9 mmol, quantitative). 
Spectral data matched those reported in the literature.[348] 
1H NMR (400 MHz, CDCl3) δ 7.41 (m, 1H), 6.51 (m, 1H), 6.37 (m, 1H), 5.00 (dd, J = 13.3, 
7.1 Hz, 1H), 4.62 (br. s, 1H), 4.19-3.99 (m, 4H), 1.35-1.22 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 150.1, 142.9, 110.8, 109.4 (d, J = 5.8 Hz), 64.8 (d, 
J = 166.7 Hz), 63.6 (d, J = 6.8 Hz), 63.4 (d, J = 6.8 Hz), 16.7 (d, J = 5.9 Hz), 16.4 (d, 
J = 5.8 Hz). 
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Diethyl (E)-(1-hydroxy-3-(4-methoxyphenyl)allyl)phosphonate (180k) 
 
Molecular formula: C14H21O5P MW = 300.29 g.mol-1 
Following the general procedure G, the synthesis was carried out with 
4-methoxycinnamaldehyde (819 mg, 5.05 mmol). The solution was stirred at room 
temperature and left overnight. The title compound was obtained as a white solid 
(1.50 g, 5.00 mmol, quantitative). Spectral data matched those reported in the 
literature.[352] 
1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 6.71 (ddd, 
J = 15.9, 4.7, 1.5 Hz, 1H), 6.17 (ddd, J = 15.9, 6.6, 5.5 Hz, 1H), 4.62 (ddd, J = 12.2, 6.6, 
1.5 Hz, 1H), 4.19 (dqd, J = 8.3, 7.1, 1.3 Hz, 4H), 3.81 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H), 1.32 
(t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.6, 132.4 (d, J = 13.2 Hz), 129.3, 128.0 (d, J = 1.6 Hz, 
2C), 121.5, 114.1 (2C), 69.8 (d, J = 161.3 Hz), 63.3 (d, J = 7.0 Hz), 63.2 (d, J = 7.1 Hz), 
55.4, 16.7 (d, J = 5.6 Hz, 2C). 
 
Diethyl (1-hydroxyallyl)phosphonate (180l) 
 
Molecular formula: C7H15O4P MW = 194.17 g.mol-1 
Following the general procedure G, the synthesis was carried out with acrolein 
(755 mg, 13.5 mmol). The reaction mixture was stirred for 12 h. The crude was purified 
by flash chromatography over silica gel (CH2Cl2/EtOAc/MeOH, 66:33:0 to 50:50:1) to 
afford the title compound as a yellow oil (1.86 g, 9.63 mmol, 72%). Spectral data 
matched those reported in the literature.[350] 
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1H NMR (400 MHz, CDCl3) δ 5.99 (dddd, J = 17.2, 10.4, 5.5, 4.4 Hz, 1H), 5.48 (ddt, 
J = 17.2, 5.1, 1.6 Hz, 1H), 5.31 (ddt, J = 10.4, 3.4, 1.6 Hz, 1H), 4.49 (ddt, J = 13.4, 5.5, 
1.6 Hz, 1H), 4.23-4.11 (m, 4H), 1.32 (t, J = 7.1 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 132.8 (d, J = 4.0 Hz), 117.3 (d, J = 12.2 Hz), 69.7 (d, 
J = 159.7 Hz), 63.3 (d, J = 7.1 Hz), 63.2 (d, J = 7.2 Hz), 16.6, 16.6. 
31P NMR (162 MHz, CDCl3) δ 21.0. 
 
Diethyl (1-hydroxy-3-phenylpropyl)phosphonate (180m) 
 
Molecular formula: C13H21O4P MW = 272.28 g.mol-1 
Following the general procedure G, the synthesis was carried out with 
hydrocinnamaldehyde (678 mg, 5.05 mmol). The solution was stirred at room 
temperature and left overnight. The crude was then purified by flash column 
chromatography over silica gel (CH2Cl2/EtOAc, 100:0 to 0:100) to afford the title 
compound as a white oil (1.11 g, 4.07 mmol, 81%). Spectral data matched those 
reported in the literature.[353] 
1H NMR (400 MHz, CDCl3) δ 7.30-7.17 (m, 5H), 4.20-4.11 (m, 4H), 3.86 (m, 1H), 3.16 
(br. s, 1H), 2.96 (m, 1H), 2.74 (m, 1H), 2.05 (m, 2H), 1.32 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 141.4, 128.7 (2C), 128.5 (2C), 126.1, 67.0 (d, J = 161.1 Hz), 
62.8 (d, J = 7.0 Hz), 62.6 (d, J = 7.2 Hz), 33.1, 31.8 (d, J = 14.0 Hz), 16.7 (d, J = 3.6 Hz), 
16.6 (d, 3.7 Hz).  
HRMS: calc for [C13H21O4P]: 272.1177; found: 272.1183. 
IR: 3284, 3026, 2980, 2928, 1496, 1294, 1017, 960, 852 cm-1. 
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Diethyl (1-hydroxypent-4-en-1-yl)phosphonate (180n) 
 
Molecular formula: C9H19O4P MW = 222.22 g.mol-1 
Following the general procedure G, the synthesis was carried out with pentenal 
(250 mg, 1.90 mmol). The reaction mixture was stirred at 50 °C for 3 h. The crude was 
purified by flash chromatography over silica gel (CH2Cl2/EtOAc, 70:30 to 60:40) to 
afford the title compound as a pale yellow oil (645 mg, 2.90 mmol, 87%). 
1H NMR (400 MHz, CDCl3) δ 5.79 (ddt, J = 17.1, 10.2, 6.6 Hz, 1H), 5.06 (dq, J = 17.1, 
1.7 Hz, 1H), 5.02-4.97 (m, 1H), 4.22-4.10 (m, 4H), 3.91-3.83 (m, 1H), 3.30 (br. s, 1H), 
2.42-2.30 (m, 1H), 2.19 (dq, J = 14.4, 7.1 Hz, 1H), 1.91-1.70 (m, 2H), 1.33 (td, J = 7.1, 
1.9 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 137.7, 115.6, 67.2 (d, J = 161.1 Hz), 62.8 (d, J = 7.0 Hz), 
62.7 (d, J = 7.1 Hz), 30.6 (d, J = 1.6 Hz), 29.8 (d, J = 13.8 Hz), 16.7, 16.6. 
31P NMR (162 MHz, CDCl3) δ 25.2. 
HRMS: calc for [C9H19NaO4P]+: 245.0919; found: 245.0914. 
IR: 3314 (w), 2981 (m), 2864 (m), 1641 (s), 1445 (m), 1394 (s), 1231 (s), 1054 (s), 
1033 (s), 968 (s), 790 (s) cm-1. 
 
Diethyl (hydroxy(2-vinylphenyl)methyl)phosphonate (180o) 
 
Molecular formula: C13H19O4P MW = 270.26 g.mol-1 
Following the general procedure G, the synthesis was carried out with 
2-vinylbenzaldehyde (250 mg, 1.90 mmol). The solution was stirred at 50 °C for 3 h. 
The title compound was obtained as a pale yellow solid (508 mg, quantitative). 
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1H NMR (400 MHz, CDCl3) δ 7.70-7.63 (dt, J = 7.5, 2.1 Hz, 1H), 7.46 (d, J = 7.5 Hz, 1H), 
7.36-7.27 (m, 2H), 7.07 (dd, J = 17.3, 10.9 Hz, 1H), 5.63 (dd, J = 17.3, 1.4 Hz, 1H), 5.36 
(dd, J = 10.9, 1.4 Hz, 1H), 5.35 (dd, J = 11.2, 5.3 Hz, 1H), 4.19-3.86 (m, 4H), 3.24 (dd, 
J = 10.7, 5.3 Hz, 1H), 1.30 (t, J = 7.1 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 137.0 (d, J = 7.3 Hz), 134.6, 134.2 (d, J = 1.5 Hz), 128.4 (d, 
J = 3.1 Hz), 128.0 (d, J = 3.0 Hz), 127.7 (d, J = 4.5 Hz), 126.4 (d, J = 2.2 Hz), 117.2, 67.3 
(d, J = 160.3 Hz), 63.6 (d, J = 7.0 Hz), 63.1 (d, J = 7.4 Hz), 16.5 (t, J = 5.7 Hz, 2C). 
31P NMR (162 MHz, CDCl3) δ 21.1. 
m.p. = 95-96 °C. 
HRMS: calc for [C13H19NaO4P]+: 293.0919; found: 293.0916. 
IR: 3276 (w), 2981 (m), 2864 (m), 1480 (s), 1391 (s), 1233 (s), 1033 (m), 974 (m) 
773 (s) cm-1. 
 
Diethyl (hydroxy(2-(oct-7-en-1-yloxy)phenyl)methyl)phosphonate (180p) 
 
Molecular formula: C19H31O5P MW = 370.43 g.mol-1 
Following the general procedure G, the synthesis was carried out with 
3-(oct-7-en-1-yloxy)benzaldehyde (75 μL, 0.58 mmol). The solution was stirred at 50 °C 
for 12 h. The crude was then purified by flash chromatography over silica gel 
(CH2Cl2/EtOAc, 80:20 to 50:50) to afford the title compound as a white solid (166 mg, 
0.448 mmol, 77%). 
1H NMR (400 MHz, CDCl3) δ 7.49 (dt, J = 7.6, 2.1 Hz, 1H), 7.29-7.23 (m, 1H), 6.97 (t, 
J = 7.6 Hz, 1H), 6.87 (d, J = 8.4 Hz, 1H), 5.81 (ddt, J = 17.1, 10.2, 6.7 Hz, 1H), 5.39 (d, 
J = 12.4 Hz, 1H), 5.00 (dq, J = 17.1, 1.7 Hz, 1H), 4.94 (ddt, J = 10.2, 1.7, 1.2 Hz, 1H), 4.13 
(p, J = 7.2 Hz, 2H), 4.07-3.95 (m, 3H), 3.92-3.81 (m, 1H), 2.12-2.01 (m, 2H), 1.87-1.76 
(m, 2H), 1.53-1.35 (m, 6H), 1.31 (t, J = 7.0 Hz, 3H), 1.16 (t, J = 7.1 Hz, 3H). 
P(O)(OEt)2
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13C NMR (101 MHz, CDCl3) δ 156.5 (d, J = 6.3 Hz), 139.1, 129.4 (d, J = 3.0 Hz), 128.8 (d, 
J = 5.1 Hz), 125.1, 120.8 (d, J = 2.6 Hz), 114.5, 111.6 (d, J = 2.1 Hz), 68.5, 66.2 (d, 
J = 160.3 Hz), 63.1 (d, J = 7.0 Hz), 62.9 (d, J = 6.8 Hz), 33.8, 29.4, 29.0, 28.9, 26.1, 16.6 
(d, J = 5.8 Hz), 16.4 (d, J = 5.5 Hz). 
31P NMR (162 MHz, CDCl3) δ 21.8. 
m.p. = 64-66 °C. 
HRMS: calc for [C19H32O5P]+: 371.1988; found: 371.1987. 
IR: 3290 (w), 2981 (s), 2928 (s), 2859 (s), 1640 (s), 1601 (m), 1492 (s), 1455 (m), 
1391 (s), 1240 (m), 1162 (s), 1033 (m), 963 (s), 909 (s), 798 (s), 751 (m), 632 (s) cm-1. 
 
Diethyl (hydroxy(3-(oct-7-en-1-yloxy)phenyl)methyl)phosphonate (180q) 
 
Molecular formula: C19H31O5P MW = 370.43 g.mol-1 
Following the general procedure G, the synthesis was carried out with 3-(oct-7-en-1-
yloxy)benzaldehyde (100 mg, 0.430 mmol). The solution was stirred at 50 °C for 3 h. 
The crude was then purified by flash chromatography over silica gel (CH2Cl2/EtOAc, 
80:20 to 50:50) to afford the title compound as a colorless oil (113 mg, 0.305 mmol, 
71%). 
1H NMR (400 MHz, CDCl3) δ 7.21 (t, J = 7.9 Hz, 1H), 7.07-7.04 (m, 1H), 7.01 (dd, J = 7.4, 
2.1 Hz, 1H), 6.86-6.80 (m, 1H), 5.79 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 5.03-4.88 (m, 3H), 
4.13-3.88 (m, 6H), 3.83 (br. s, 1H), 2.04 (q, J = 7.2 Hz, 2H), 1.75 (p, J = 6.8 Hz, 2H), 
1.48-1.29 (m, 6H), 1.25 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.2 (d, J = 2.6 Hz), 139.0, 138.3 (d, J = 1.8 Hz), 129.2 (d, 
J = 2.5 Hz), 119.4 (d, J = 5.9 Hz), 114.5 (d, J = 3.2 Hz), 114.4, 113.0 (d, J = 5.7 Hz), 70.8 
(d, J = 159.1 Hz), 67.9, 63.4 (d, J = 7.0 Hz), 63.1 (d, J = 7.3 Hz), 33.8, 29.3, 28.9, 28.9, 
26.0, 16.5 (d, J = 3.3 Hz), 16.4 (d, J = 3.3 Hz). 
O P(O)(OEt)2
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31P NMR (162 MHz, CDCl3) δ 20.7. 
HRMS: calc for [C19H31NaO5P]+: 393.1807; found: 393.1802. 
IR: 3284 (w), 2937 (m), 2870 (s), 1606 (s), 1262 (s), 1233 (s), 1168 (s), 1033 (m), 
904 (s) cm-1. 
 
3-((Diethoxyphosphoryl)(hydroxy)methyl)phenyl non-8-enoate (180r) 
 
Molecular formula: C20H31O6P MW = 398.44 g.mol-1 
Following the general procedure G, the synthesis was carried out with 3-formylphenyl 
non-8-enoate (150 mg, 0.58 mmol). The solution was stirred at 50 °C for 2 h. The 
mixture was concentrated to afford the title compound as a colorless oil (227 mg, 
0.57 mmol, 99%). 
1H NMR (400 MHz, CDCl3) δ 7.39-7.32 (m, 2H), 7.24-7.20 (m, 1H), 7.05-6.99 (m, 1H), 
5.81 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.02 (d, J = 11.1 Hz, 1H), 5.00 (dq, J = 17.0, 1.7 Hz, 
1H), 4.94 (ddt, J = 10.2, 1.7, 1.3 Hz, 1H), 4.14-3.94 (m, 4H), 2.54 (t, J = 7.5 Hz, 2H), 
2.09-2.01 (m, 2H), 1.74 (p, J = 7.6 Hz, 2H), 1.48-1.32 (m, 6H), 1.26 (t, J = 7.0 Hz, 3H), 
1.23 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.3, 150.9 (d, J = 3.0 Hz), 139.1, 138.3, 129.3 (d, 
J = 2.6 Hz), 124.4 (d, J = 5.7 Hz), 121.4 (d, J = 3.3 Hz), 120.4 (d, J = 5.7 Hz), 114.5, 70.5 
(d, J = 158.6 Hz), 63.6 (d, J = 7.0 Hz), 63.5 (d, J = 7.2 Hz), 34.5, 33.8, 29.1, 28.8, 28.8, 
25.0, 16.5 (d, J = 2.3 Hz), 16.5 (d, J = 2.0 Hz). 
31P NMR (162 MHz, CDCl3) δ 20.2. 
HRMS: calc for [C20H32O6P]+: 399.1937; found: 399.1945. 
IR: 3269 (w), 2981 (s), 2930, 2858, 1759 (s), 1610 (m), 1485 (s), 1443 (m), 1392 (s), 
1370 (s), 1224 (m), 1143 (s), 1032 (m), 964 (s), 910 (s), 793 (s), 729 (s), 692 (s) cm-1. 
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Methyl 2-(diethoxyphosphoryl)-2-hydroxypropanoate (180s) 
 
Molecular formula: C8H17O6P MW = 240.19 g.mol-1 
Following the general procedure G, the synthesis was carried out with ethyl pyruvate 
(500 μL, 5.53 mmol). The solution was stirred at 50 °C for 12 h. The mixture was 
concentrated to afford the title compound as a colorless oil (870 mg, 3.63 mmol, 66%). 
Spectral data matched those reported in the literature.[354] 
1H NMR (400 MHz, CDCl3) δ 4.27-4.12 (m, 4H), 3.86 (s, 3H), 3.64-3.59 (m, 1H), 1.64 (d, 
J = 15.9 Hz, 3H), 1.38-1.28 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 173.2, 74.6 (d, J = 160.1 Hz), 64.1 (d, J = 7.4 Hz), 63.9 (d, 
J = 7.4 Hz), 53.8, 21.3, 16.6 (d, J = 2.3 Hz), 16.6 (d, J = 2.4 Hz). 
31P NMR (162 MHz, CDCl3) δ 17.5. 
 
4.4.3. Synthesis of the a-allyloxyphosphonates 
General procedure H: O-allylation 
To a solution of 𝛼-hydroxyphosphonate (1.0 equiv.) in toluene (0.5 M solution) were 
added Pd2(dba)3 (0.025 equiv.), triphenylphosphine (0.10 equiv.), cesium carbonate 
(0.25 equiv.) and allyl methyl carbonate (1.0 equiv.) and the resulting mixture was 
stirred at the indicated temperature for the indicated time. The reaction mixture was 
then filtered over a pad of Celite and concentrated under reduced pressure. 
Diethyl ((allyloxy)(4-chlorophenyl)methyl)phosphonate (179a) 
 
Molecular formula: C14H20ClO4P MW = 318.73 g.mol-1 
MeO2C
OH
PO(OEt)2Me
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Following the general procedure H, the synthesis was carried out with 
hydroxyphosphonate 180a (279 mg, 1.00 mmol). The mixture was then stirred for 
30 minutes at 50 °C. The crude product was purified by flash column chromatography 
over silica gel (CH2Cl2/EtOAc, 100:0 to 80:20) to afford the title compound as a yellow 
oil (287 mg, 0.90 mmol, 90%). 
1H NMR (400 MHz, CDCl3) δ 7.38 (dd, J = 8.6, 2.1 Hz, 2H), 7.34 (d, J = 8.6 Hz, 2H), 5.86 
(m, 1H), 5.28-5.18 (m, 2H), 4.67 (d, J = 16.0 Hz, 1H), 4.14-3.97 (m, 5H), 3.90 (dd, 
J = 12.8, 6.3 Hz, 1H), 1.25 (t, J = 6.8 Hz, 3H), 1.24 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 134.4 (d, J = 3.7 Hz), 133.7, 133.5 (d, J = 2.0 Hz), 129.5 (d, 
J = 5.8 Hz, 2C), 128.7 (d, J = 2.5 Hz, 2C), 118.6, 76.6 (d, J = 169.4 Hz), 71.4 (d, 
J = 13.5 Hz), 63.4 (d, J = 7.1 Hz), 63.1 (d, J = 6.8 Hz), 16.6 (d, J = 5.4 Hz), 16.5 (d, 
J = 5.6 Hz). 
31P NMR (101 MHz, CDCl3) δ 18.8. 
HRMS: calc for [C14H20O4P]: 318.0788; found: 318.0800. 
IR: 3045, 2988, 2957, 1754, 1514, 1419, 1285, 1177 cm-1. 
 
Dimethyl ((allyloxy)(4-chlorophenyl)methyl)phosphonate (179b) 
 
Molecular formula: C12H16ClO4P MW = 290.68 g.mol-1 
Following the general procedure H, the synthesis was carried out with 
hydroxyphosphonate 180b (251 mg, 1.00 mmol). The mixture was then stirred for 
30 minutes at 50 °C. The crude product was purified by flash column chromatography 
over silica gel (CH2Cl2/EtOAc, 100:0 to 80:20) to afford the title compound as a yellow 
oil (273 mg, 94%). 
P(O)(OMe)2
O
Cl
  
 
249 
1H NMR (400 MHz, CDCl3) δ 7.46-7.28 (m, 4H), 5.86 (dddd, J = 17.0, 10.4, 6.3, 5.1 Hz, 
1H), 5.35-5.14 (m, 2H), 4.71 (d, J = 16.0 Hz, 1H), 4.12 (dd, J = 12.7, 5.1 Hz, 1H), 3.90 (dd, 
J = 12.7, 6.3 Hz, 1H), 3.72 (d, J = 10.5 Hz, 3H), 3.69 (d, J = 10.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 134.6 (d, J = 3.7 Hz), 133.5, 133.2 (d, J = 1.6 Hz), 129.5 (d, 
J = 5.8 Hz, 2C), 128.9 (d, J = 2.4 Hz, 2C), 118.8, 76.4 (d, J = 169.6 Hz), 71.4 (d, 
J = 13.8 Hz), 54.1 (d, J = 6.8 Hz), 53.8 (d, J = 6.8 Hz). 
31P NMR (162 MHz, CDCl3), δ 21.0. 
HRMS: calc for [C12H16ClO4P]: 290.0475; found: 290.0469. 
IR: 3033, 3014, 2958, 1490, 1239, 1055, 1039, 935 cm-1. 
 
Diisopropyl ((allyloxy)(4-chlorophenyl)methyl)phosphonate (179c) 
 
Molecular formula: C16H24ClO4P MW = 346.79 g.mol-1 
Following the general procedure B, the synthesis was carried out with 
hydroxyphosphonate 180c (307 mg, 1.00 mmol). The mixture was then stirred for 
30 minutes at 50 °C. The crude product was purified by flash column chromatography 
over silica gel (CH2Cl2/EtOAc, 100:0 to 80:20) to afford the title compound as a yellow 
oil (312 mg, 0.90 mmol, 90%). 
1H NMR (400 MHz, CDCl3) δ 7.38 (dd, J = 8.5, 2.0 Hz, 2H), 7.32 (d, J = 8.5 Hz, 2H), 5.86 
(dddd, J = 16.9, 10.7, 6.3, 5.2 Hz, 1H), 5.36-5.02 (m, 2H), 4.65 (m, 2H), 4.60 (d, 
J = 16.2 Hz, 1H), 4.11 (dd, J = 12.7, 5.2 Hz, 1H), 3.90 (dd, J = 12.7, 6.3 Hz, 1H), 1.29 (d, 
J = 6.2 Hz, 3H), 1.27 (d, J = 6.2 Hz, 3H), 1.24 (d, J = 6.2 Hz, 3H), 1.14 (d, J = 6.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 134.2 (d, J = 3.7 Hz), 133.9 (d, J = 1.5 Hz), 133.8, 129.7 (d, 
J = 5.8 Hz, 2C), 128.5 (d, J = 2.5 Hz, 2C), 118.5, 76.9 (d, J = 171.8 Hz), 71.9 (d, J = 7.2 Hz), 
71.7 (d, J = 7.2 Hz), 71.4 (d, J = 13.8 Hz), 24.4 (d, J = 3.4 Hz), 24.3 (d, J = 3.2 Hz), 24.0 (d, 
J = 5.6 Hz), 23.8 (d, J = 5.3 Hz). 
P(O)(Oi-Pr)2
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31P NMR (162 MHz, CDCl3), δ 17.3. 
HRMS: calc for [C16H24ClO4P]: 346.1101; found: 346.1114. 
IR: 3407, 3035, 2995, 1490, 1248, 1089, 999, 934 cm-1. 
 
Dimethyl ((allyloxy)(4-nitrophenyl)methyl)phosphonate (179d) 
 
Molecular formula: C12H16NO6P MW = 301.23 g.mol-1 
Following the general procedure H, the synthesis was carried out with 
hydroxyphosphonate 180d (261 mg, 1.00 mmol). The mixture was then stirred for 
30 minutes at 50 °C. The crude product was purified by flash column chromatography 
over silica gel (CH2Cl2/EtOAc, 100:0 to 80:20) to afford the title compound as a yellow 
oil (222 mg, 0.74 mmol, 74%). 
1H NMR (400 MHz, CDCl3) δ 8.24 (d, J = 8.7 Hz, 2H), 7.63 (dd, J = 8.7, 1.9 Hz, 2H), 5.88 
(m, 1H), 5.30-5.25 (m, 2H), 4.85 (d, J = 17.1 Hz, 1H), 4.16 (dd, J = 12.7, 5.1 Hz, 1H), 3.98 
(dd, J = 12.7, 6.4 Hz, 1H), 3.77-3.73 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 148.1 (d, J = 3.4 Hz), 142.5 (d, J = 1.4 Hz), 133.2, 128.7 (d, 
J = 5.3 Hz, 2C), 123.8 (d, J = 2.6 Hz, 2C), 119.2, 76.5 (d, J = 167.5 Hz), 72.1 (d, 
J = 12.7 Hz), 54.3 (d, J = 6.9 Hz), 53.9 (d, J = 6.8 Hz). 
HRMS: calc for [C12H15NO6P]-: 300.0642; found: 300.0638.  
IR: 3473, 2956, 2854, 2360, 1645, 1518, 1345, 1252, 1023, 862 cm-1. 
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Diethyl ((allyloxy)(2-nitrophenyl)methyl)phosphonate (179e) 
 
Molecular formula: C14H20NO6P MW = 329.29 g.mol-1 
Following the general procedure B, the synthesis was carried out with 
hydroxyphosphonate 180e (290 mg, 1.00 mmol). The mixture was then stirred for 
30 minutes at 50 °C. The crude product was purified by flash column chromatography 
over silica gel (CH2Cl2/EtOAc, 100:0 to 80:20) to afford the title compound as a yellow 
oil (308 mg, 94%). 
1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 8.2 Hz, 1H), 7.91 (dd, J = 7.9, 1.7 Hz, 1H), 7.66 
(t, J = 7.9 Hz, 1H), 7.46 (m, 1H), 5.90 (d, J = 17.5 Hz, 1H), 5.89 (m, 1H), 5.34-5.29 (m, 
2C), 4.20-3.97 (m, 6H), 1.25 (t, J = 7.1 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 148.8 (d, J = 6.0 Hz), 133.4, 133.3, 131.1 (d, J = 1.0 Hz), 
129.6 (d, J = 4.3 Hz), 128.9 (d, J = 3.1 Hz), 124.9 (d, J = 2.0 Hz), 119.0, 72.6 (d, 
J = 12.6 Hz), 71.8 (d, J = 169.2 Hz), 63.5 (d, J = 6.9 Hz), 63.2 (d, J = 6.9 Hz), 16.4 (d, 
J = 5.7 Hz), 16.3 (d, J = 5.8 Hz). 
HRMS: calc for [C14H20NO6P-PO3Et2]: 192.0661; found: 192.0665. 
IR: 3478, 2981, 2909, 2867, 1571, 1349, 1015, 863 cm-1. 
 
Diethyl ((allyloxy)(2-bromophenyl)methyl)phosphonate (179f) 
 
Molecular formula: C14H20BrO4P MW = 363.19 g.mol-1 
Following the general procedure H, the synthesis was carried out with 
hydroxyphosphonate 180f (100 mg, 0.31 mmol). The mixture was then stirred for 1 h 
P(O)(OEt)2
O
NO2
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O
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at 50 °C. The crude product was purified by flash chromatography over silica gel 
(CH2Cl2/EtOAc, 90:10 to 80:20) to afford the title compound as a yellow oil (89 mg, 
0.25 mmol, 79%). 
1H NMR (400 MHz, CDCl3) δ 7.71 (ddd, J = 7.8, 2.1, 1.9 Hz, 1H), 7.54 (ddd, J = 8.0, 1.5, 
1.2 Hz, 1H), 7.36 (dd, J = 7.8, 7.3 Hz, 1H), 7.17 (dddd, J = 8.0, 7.3, 1.9, 1.5 Hz, 1H), 5.85 
(dddd, J = 17.1, 10.3, 6.6, 5.2 Hz, 1H), 5.26 (dq, J = 17.1, 1.4 Hz, 1H), 5.25 (d, J = 16.1 Hz, 
1H), 5.21 (dq, J = 10.3, 1.4 Hz, 1H), 4.24-3.82 (m, 6H), 1.30 (t, J = 7.1 Hz, 3H), 1.19 (t, 
J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 134.9, 133.6, 132.7 (d, J = 2.1 Hz), 130.5 (d, J = 4.0 Hz), 
129.9 (d, J = 3.0 Hz), 127.8 (d, J = 2.9 Hz), 124.6 (d, J = 8.5 Hz), 118.8, 75.6 (d, 
J = 171.6 Hz), 71.5, 63.3 (d, J = 6.7 Hz), 63.2 (d, J = 6.7 Hz), 16.6 (d, J = 5.9 Hz), 16.4 (d, 
J = 5.8 Hz). 
31P NMR (162 MHz, CDCl3) δ 18.2. 
HRMS: calc for [C14H21BrO4P]+: 363.0361; found: 363.0349. 
IR: 3064 (s), 2982 (s), 2909 (m), 2865 (s), 1647 (s), 1568 (s), 1469 (s), 1436 (s), 
1391 (m), 1254 (s), 1216 (s), 1162 (m), 1047 (s), 1020 (s), 962 (s), 730 (m), 697 (s) cm-1. 
 
Diethyl ((allyloxy)(4-methoxyphenyl)methyl)phosphonate (179g) 
 
Molecular formula: C15H23O5P MW = 314.32 g.mol-1 
Following the general procedure H, the synthesis was carried out with 
hydroxyphosphonate 180g (274 mg, 1.00 mmol). The mixture was then stirred for 
30 minutes at 50 °C. The crude product was purified by flash column chromatography 
over silica gel (CH2Cl2/EtOAc, 100:0 to 80:20) to afford the title compound as a yellow 
oil (247 mg, 0.79 mmol, 79%). 
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1H NMR (400 MHz, CDCl3) δ 7.36 (dd, J = 8.4, 2.1 Hz, 2H), 6.90 (d, J = 8.4 Hz, 2H), 5.86 
(dddd, J = 17.0, 10.4, 6.5, 5.0 Hz, 1H), 5.30-5.17 (m, 2H), 4.65 (d, J = 15.3 Hz, 1H), 
4.07-3.95 (m, 4H), 3.91-3.80 (m, 2H), 3.81 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H), 1.21 (t, 
J = 7.1 Hz, 3H). 
13C NMR (CDCl3, 100.6 MHz) δ 159.8 (d, J = 2.8 Hz), 134.0, 129.6 (d, J = 6.2 Hz, 2C), 
126.6 (d, J = 1.5 Hz, 2C), 118.3, 114.0 (d, J = 2.1 Hz), 76.6 (d, J = 156.1 Hz), 70.8 (d, 
J = 2.8 Hz), 63.2 (d, J = 7 Hz), 63.0 (d, J = 6.8 Hz), 55.4, 16.6 (d, J = 5.7 Hz), 16.5 (d, 
J = 5.8 Hz). 
HRMS: calc for [C15H23O5P]: 314.1283; found: 314.1276. 
IR: 3373, 2960, 2908, 2369, 2341, 1713, 1606, 1510, 1245, 1017, 962 cm-1.  
 
Diethyl ((allyloxy)(3-(allyloxy)phenyl)methyl)phosphonate (179h) 
 
Molecular formula: C17H25O5P MW = 340.36 g.mol-1 
Following a modified general procedure H, the synthesis was carried out with 
hydroxyphosphonate 180h (200 mg, 0.77 mmol) and 2.0 equiv of allyl methyl 
carbonate (175 µL, 1.54 mmol). The mixture was then stirred for 4 h at 50 °C. The 
crude product was purified by flash chromatography over silica gel (CH2Cl2/EtOAc, 98:2 
to 90:10) to afford the title compound as a yellow oil (186 mg, 0.54 mmol, 71%). 
1H NMR (400 MHz, CDCl3) δ 7.25 (t, J = 7.9 Hz, 1H), 7.05-7.02 (m, 1H), 7.02-6.98 (m, 
1H), 6.89-6.84 (m, 1H), 6.04 (ddt, J = 17.3, 10.5, 5.4 Hz, 1H), 5.87 (dddd, J = 17.1, 10.4, 
6.5, 5.0 Hz, 1H), 5.40 (dq, J = 17.3, 1.5 Hz, 1H), 5.29-5.22 (m, 2H), 5.20 (dq, J = 10.5, 1.5 
Hz, 1H), 4.67 (d, J = 16.0 Hz, 1H), 4.54 (dt, J = 5.4, 1.5 Hz, 2H), 4.17-3.86 (m, 6H), 1.24 
(dt, J = 11.9, 7.1 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 158.6 (d, J = 2.6 Hz), 136.2 (d, J = 1.8 Hz), 133.7, 133.1, 
129.3 (d, J = 2.4 Hz), 120.7 (d, J = 6.0 Hz), 118.2, 117.6, 115.0 (d, J = 3.1 Hz), 114.0 (d, 
P(O)(OEt)2
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J = 5.6 Hz), 77.0 (d, J = 169.0 Hz), 71.1 (d, J = 14.1 Hz), 68.7, 63.2 (d, J = 7.0 Hz), 62.9 (d, 
J = 6.8 Hz), 16.4 (d, J = 5.9 Hz), 16.3 (d, J = 5.9 Hz). 
Diethyl ((allyloxy)(pyridin-3-yl)methyl)phosphonate (179i) 
 
Molecular formula: C13H20NO4P MW = 285.28 g.mol-1 
Following the general procedure H, the synthesis was carried out with 
hydroxyphosphonate 180i (150 mg, 0.62 mmol). The mixture was then stirred for 12 h 
at 50 °C. The crude product was purified by flash chromatography over silica gel 
(CH2Cl2/MeOH, 98:2 to 95:5) to afford the title compound as a yellow oil (159 mg, 
0.48 mmol, 78%). 
1H NMR (400 MHz, CDCl3) δ 8.60 (m, 2H), 7.84 (dq, J = 7.9, 2.0 Hz, 1H), 7.33 (dd, J = 7.9, 
4.8 Hz, 1H), 5.86 (dddd, J = 17.0, 10.3, 6.3, 5.2 Hz, 1H), 5.30-5.20 (m, 2H), 4.72 (d, 
J = 16.0 Hz, 1H), 4.18-3.93 (m, 6H), 1.27 (t, J = 7.1 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 149.7, 149.5 (d, J = 6.6 Hz), 135.8 (d, J = 4.6 Hz), 133.5, 
131.2, 123.6, 118.8, 75.1 (d, J = 170.4 Hz), 71.7 (d, J = 12.3 Hz), 63.5 (d, J = 6.9 Hz), 63.3 
(d, J = 6.8 Hz), 16.5 (t, J = 5.4 Hz, 2C). 
31P NMR (162 MHz, CDCl3) δ 17.6. 
HRMS: calc for [C13H21NO4P]+: 286.1208; found: 286.1204. 
IR: 2982 (s), 2930 (m), 2862 (s), 1731 (s), 1647 (m), 1590 (s), 1424 (s), 1392 (m), 
1256 (s), 1163 (s), 1047 (s), 1021 (s), 967 (s), 793 (m), 748 (s), 714 (s) cm-1. 
 
Diethyl ((allyloxy)(furan-2-yl)methyl)phosphonate (179j) 
 
N
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O
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Molecular formula: C12H19O5P MW = 274.25 g.mol-1 
Following the general procedure H, the synthesis was carried out with 
hydroxyphosphonate 180j (272 mg, 1.00 mmol). The mixture was then stirred for 
30 minutes at 50 °C. The crude product was purified by flash column chromatography 
over silica gel (CH2Cl2/EtOAc, 100:0 to 80:20) to afford the title compound as a yellow 
oil (263 mg, 0.96 mmol, 96%). 
1H NMR (400 MHz, CDCl3) δ 7.44 (m, 1H), 6.52 (m, 1H), 6.38 (m, 1H), 5.84 (m, 1H), 
5.30-5.15 (m, 2H), 4.76 (dd, J = 17.0, 5.0 Hz, 1H), 4.18-4.02 (m, 5H), 3.94-3.87 (m, 1H) 
1.34-1.23 (m, 6H). 
13C NMR (CDCl3, 100.6 MHz) δ 148.4, 143.4 (d, J = 2.1 Hz), 133.6, 118.7, 111.2 (d, 
J = 6.4Hz), 110.9 (d, J = 0.9 Hz), 71.1 (d, J = 13.3 Hz), 69.5, 63.4 (d, J = 6.8 Hz), 63.3 (d, 
J = 6.7 Hz), 16.6 (d, J = 5.8 Hz), 16.5 (d, J = 5.9 Hz). 
HRMS: calc for [C12H19O5P]: 274.0970; found: 274.0959. 
IR: 3390, 2960, 1725, 1638, 1230, 1017, 966, 845 cm-1. 
 
Diethyl (E)-(1-(allyloxy)-3-(4-methoxyphenyl)allyl)phosphonate (179k) 
 
Molecular formula: C17H25O4 MW = 340.36 g.mol-1 
Following the general procedure H, the synthesis was carried out with 
hydroxyphosphonate 180k (300 mg, 1.0 mmol). The mixture was then stirred for 
30 min at 50 °C. The crude product was purified by flash chromatography over silica gel 
(CH2Cl2/EtOAc, 100:0 to 80:20) to afford the title compound as a yellow oil (262 mg, 
0.48 mmol, 77%). 
1H NMR (400 MHz, CDCl3) δ 7.35 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 6.64 (ddd, 
J = 15.8, 4.2, 1.2 Hz, 1H), 6.07 (ddd, J = 15.8, 7.7, 5.3 Hz, 1H), 5.89 (dddd, J = 17.3, 10.4, 
6.3, 5.2 Hz, 1H), 5.31 (dq, J = 17.3, 1.5 Hz, 1H), 5.22 (dq, J = 10.4, 1.5 Hz, 1H), 4.33 (ddd, 
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J = 15.7, 7.7, 1.2 Hz, 1H), 4.25-4.13 (m, 4H), 4.11 (d, J = 12.8 Hz, 1H), 3.97 (d, 
J = 12.8 Hz, 1H), 3.81 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H), 1.31 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.8, 134.4 (d, J = 13.5 Hz), 134.1, 129.0 (d, J = 2.5 Hz), 
128.1 (d, J = 1.6 Hz, 2C), 120.2 (d, J = 4.3 Hz), 118.2, 114.1 (2C), 76.2 (d, J = 170.6 Hz), 
71.0 (d, J = 12.2 Hz), 63.2 (d, J = 6.9 Hz), 63.0 (d, J = 7.0 Hz), 55.4, 16.7 (d, J = 3.9 Hz), 
16.6 (d, J = 4.0 Hz). 
HRMS: calc for [C17H25O5P]: 340.1440; found: 340.1449. 
IR: 3373, 2960, 2908, 2369, 2341, 1713, 1606, 1510, 1245, 1017, 962 cm-1. 
 
Diethyl (1-(allyloxy)allyl)phosphonate (179l) 
 
Molecular formula: C10H19O4P MW = 234.23 g.mol-1 
Following the general procedure H, the synthesis was carried out with diethyl 
(1-hydroxyallyl)phosphonate 180l (600 mg, 3.09 mmol). The mixture was stirred for 5 h 
at 100 °C. The crude product was purified by flash chromatography over silica gel 
(CH2Cl2/EtOAc, 90:10 to 70:30) to afford the title compound as a yellow oil (630 mg, 
2.54 mmol, 82%). 
1H NMR (400 MHz, CDCl3) δ 5.94-5.82 (m, 2H), 5.44 (ddt, J = 17.2, 4.8, 1.5 Hz, 1H), 5.37 
(ddt, J = 10.5, 3.0, 1.5 Hz, 1H), 5.29 (dq, J = 17.3, 1.4 Hz, 1H), 5.21 (dq, J = 10.4, 1.4 Hz, 
1H), 4.24-4.11 (m, 6H), 4.04 (ddt, J = 12.9, 6.2, 1.4 Hz, 1H), 1.32 (td, J = 7.0, 1.7 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 134.0, 131.6 (d, J = 3.7 Hz), 119.5 (d, J = 12.5 Hz), 118.1, 
76.2 (d, J = 168.1 Hz), 71.4 (d, J = 11.6 Hz), 63.2 (d, J = 7.0 Hz), 63.0 (d, J = 6.8 Hz), 16.6 
(d, J = 3.5 Hz), 16.6 (d, J = 3.7 Hz). 
31P NMR (162 MHz, CDCl3) δ 19.5. 
HRMS: calc for [C10H19NaO4P]+: 257.0919; found: 257.0913. 
IR: 2982 (s), 2910 (m), 2868 (s), 1641 (s), 1444 (m), 1392 (m), 1252 (s), 1163 (s), 
1019 (m), 958 (s), 786 (s), 749 (s), 624 (s) cm-1. 
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Diethyl (1-(allyloxy)-3-phenylpropyl)phosphonate (179m) 
 
Molecular formula: C16H25O4P MW = 312.35 g.mol-1 
Following the general procedure H, the synthesis was carried out with 
hydroxyphosphonate 180m (272 mg, 1.00 mmol). The mixture was then stirred for 
1 hour 30 minutes at 100 °C. The crude product was purified by flash column 
chromatography over silica gel (CH2Cl2/EtOAc, 100:0 to 80:20) to afford the title 
compound as a yellow oil (211 mg, 0.68 mmol, 68%). 
1H NMR (400 MHz, CDCl3) δ 7.30-7.17 (m, 5H), 5.93 (m, 1H), 5.32-5.18 (m, 2H), 4.34 
(dd, J = 12.4, 5.4 Hz, 1H) 4.20-4.10 (m, 4H), 4.04 (ddd, J = 12.4, 6.2, 1.2 Hz, 1H) 3.59 (dt, 
J = 9.1, 4.4 Hz, 1H), 2.91 (m, 1H), 2.67 (ddd, J = 13.8, 9.1, 7.4 Hz, 1H), 2.10-2.00 (m, 2H), 
1.33 (t, J = 7.1 Hz, 3H), 1.31 (t, J = 7.1 Hz, 3H). 
13C NMR (CDCl3, 100.6 MHz) δ 141.4, 134.4, 128.6 (2C), 128.5 (2C), 126.1, 117.9, 74.3 
(d, J = 164.0 Hz), 73.1 (d, J = 2.3 Hz), 62.5 (d, J = 7.0 Hz), 62.3 (d, J = 7.2 Hz), 32.2 (d, 
J = 2.7 Hz), 32.0 (d, J = 13.1 Hz), 16.7 (d, J = 2.5 Hz), 16.6 (d, J = 2.2 Hz). 
HRMS: calc for [C16H25O4P]: 312.1490; found: 312.1498. 
IR: 3475, 3027, 2980, 1391, 1269, 1077, 956 cm-1. 
 
Diethyl (1-(allyloxy)pent-4-en-1-yl)phosphonate (179n) 
 
Molecular formula: C12H23O4P MW = 262.29 g.mol-1 
Following the general procedure H, he synthesis was carried out with diethyl 
(1-hydroxypent-4-en-1-yl)phosphonate 180n (100 mg, 0.450 mmol). The mixture was 
stirred overnight at 80 °C. The crude product was purified by flash chromatography 
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O
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over silica gel (CH2Cl2/EtOAc, 60:40 to 50:50) to afford the title compound as a yellow 
oil (160 mg, 0.262 mmol, 58%). 
1H NMR (400 MHz, CDCl3) δ 5.90 (ddt, J = 17.2, 10.4, 6.2, 5.4 Hz, 1H), 5.88-5.72 (m, 1H), 
5.28 (dq, J = 17.2, 1.4 Hz, 1H), 5.18 (dq, J = 10.4, 1.4 Hz, 1H), 5.04 (dq, J = 17.1, 1.6 Hz, 
1H), 4.99 (dq, J = 10.1, 1.6 Hz, 1H), 4.33 (dd, J = 12.4, 6.2 Hz, 1H), 4.23-4.10 (m, 4H), 
4.05 (dd, J = 12.4, 6.2 Hz, 1H), 3.60 (dt, J = 9.0, 4.7 Hz, 1H), 2.39-2.08 (m, 2H), 1.91-1.76 
(m, 2H), 1.33 (td, J = 7.1, 3.7 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 137.8, 134.5, 117.9, 115.7, 74.4 (d, J = 164.2 Hz), 73.2, 
62.6 (d, J = 6.9 Hz), 62.4 (d, J = 7.2 Hz), 30.0 (d, J = 13.3 Hz), 29.9 (d, J = 2.9 Hz), 16.7 (d, 
J = 5.5 Hz, 2C). 
31P NMR (162 MHz, CDCl3) δ 23.0. 
HRMS: calc for [C12H23NaO4P]+: 285.1232; found: 285.1226. 
IR: 3079 (s), 2980 (s), 2930 (s), 2869 (s), 1734 (s), 1641 (s), 1444 (s), 1392 (s), 1243 (s), 
1163 (s), 1096 (s), 1021 (m), 959 (m), 786 (s) cm-1. 
 
Diethyl ((allyloxy)(2-vinylphenyl)methyl)phosphonate (179o) 
 
Molecular formula: C16H23O4P MW = 310.33 g.mol-1 
Following the general procedure H, the synthesis was carried out with diethyl 
(hydroxyl[2-vinylphenyl]methyl)phosphonate 180o (200 mg, 0.740 mmol). The mixture 
was stirred 2 h at 50 °C. The crude product was purified by flash chromatography over 
silica gel (CH2Cl2/EtOAc, 90:10 to 80:20) to afford the title compound as a yellow oil 
(209.8 mg, 0.676 mmol, 91%). 
1H NMR (400 MHz, CDCl3) δ 7.60-7.55 (m, 1H), 7.44-7.38 (m, 1H), 7.33-7.19 (m, 2H), 
7.04 (dd, J = 17.3, 10.9 Hz, 1H), 5.81 (dddd, J = 17.1, 10.4, 6.6, 5.0 Hz, 1H), 5.56 (dd, 
J = 17.3, 1.4 Hz, 1H), 5.29 (dd, J = 10.9, 1.4 Hz, 1H), 5.22-5.10 (m, 2H), 5.01 (d, 
P(O)(OEt)2
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J = 16.1 Hz, 1H), 4.17-3.92 (m, 4H), 3.93-3.68 (m, 2H), 1.22 (t, J = 7.1 Hz, 3H), 1.14 (t, 
J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 138.1 (d, J = 6.8 Hz), 134.6, 133.9, 132.1 (d, J = 1.8 Hz), 
128.5 (d, J = 4.5 Hz), 128.5 (d, J = 3.1 Hz), 128.0 (d, J = 3.0 Hz), 126.4 (d, J = 2.3 Hz), 
118.5, 117.1, 73.4 (d, J = 170.5 Hz), 71.0 (d, J = 14.4 Hz), 63.1 (dd, J = 12.9, 6.9 Hz, 2C), 
16.5 (dd, J = 12.2, 5.8 Hz, 2C). 
31P NMR (162 MHz, CDCl3) δ 21.1. 
HRMS: calc for [C16H23NaO4P]+: 333.1232; found: 333.1226. 
IR: 2981 (s), 2924 (s), 2857 (s), 1627 (m), 1445 (m), 1391 (m), 1254 (s), 1162 (m), 
1020 (m), 962 (s), 751 (s) cm-1. 
 
Diethyl ((allyloxy)(2-(oct-7-en-1-yloxy)phenyl)methyl)phosphonate (179p) 
 
Molecular formula: C22H35O5P MW = 410.49 g.mol-1 
Following the general procedure H, the synthesis was carried out with diethyl 
([allyloxy][2-(oct-7-en-1-yloxy)phenyl]methyl)phosphonate 180p (100 mg, 0.27 mmol). 
The mixture was then stirred for 4 h at 50 °C. The crude product was purified by flash 
chromatography over silica gel (CH2Cl2/EtOAc, 90:10 to 80:20) to afford the title 
compound as a yellow oil (82 mg, 0.20 mmol, 74%). 
1H NMR (400 MHz, CDCl3) δ 7.61 (dt, J = 7.7, 2.1 Hz, 1H), 7.29-7.22 (m, 1H), 6.98 (t, 
J = 7.5 Hz, 1H), 6.84 (d, J = 8.3 Hz, 1H), 5.95-5.75 (m, 2H), 5.34 (d, J = 15.3 Hz, 1H), 5.23 
(dq, J = 17.2, 1.7 Hz, 1H), 5.18-5.13 (m, 1H), 5.00 (dq, J = 17.2, 1.7 Hz, 1H), 4.97-4.91 
(m, 1H), 4.20-3.85 (m, 8H), 2.07 (q, J = 7.0 Hz, 2H), 1.83-1.74 (m, 2H), 1.53-1.32 (m, 
6H), 1.27 (t, J = 7.0 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 157.1 (d, J = 6.9 zHz), 139.1, 134.3, 129.4 (d, J = 2.9 Hz), 
129.4 (d, J = 4.3 Hz), 123.6, 120.8 (d, J = 2.9 Hz), 117.9, 114.5, 111.3 (d, J = 2.0 Hz), 71.2 
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(d, J = 14.0 Hz), 69.8 (d, J = 172.4 Hz), 68.4, 63.0 (d, J = 3.0 Hz), 62.9 (d, J = 3.0 Hz), 33.8, 
29.4, 29.0 (2C), 26.1, 16.6 (d, J = 5.9 Hz), 16.5 (d, J = 5.9 Hz). 
31P NMR (162 MHz, CDCl3) δ 19.6. 
HRMS: calc for [C22H35NaO5P]+: 433.2120; found: 433.2114. 
IR: 2981 (s), 2937 (s), 2865 (s), 1600 (s), 1491 (s), 1454 (m), 1244 (s), 1054 (s), 1033 (s), 
1016 (s), 752 (s), 722 (s) cm-1. 
 
Diethyl ((allyloxy)(3-(oct-7-en-1-yloxy)phenyl)methyl)phosphonate (179q) 
 
Molecular formula: C22H35O5P MW = 410.49 g.mol-1 
Following the general procedure H, the synthesis was carried out with diethyl ([allyl-
oxy][3-(oct-7-en-1-yloxy)phenyl]methyl)-phosphonate 180q (250.0 mg, 0.675 mmol). 
The mixture was then stirred for 4 h at 50 °C. The crude product was purified by flash 
chromatography over silica gel (Toluene/EtOAc, 70:30) to afford the title compound as 
a yellow oil (270 mg, 0.658 mmol, 97%). 
1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 7.9 Hz, 1H), 7.02-6.96 (m, 2H), 6.84 (ddt, 
J = 8.3, 1.4, 1.0 Hz, 1H), 5.94-5.75 (m, 2H), 5.26 (dq, J = 17.2, 1.6 Hz, 1H), 5.21 (dq, 
J = 10.4, 1.3 Hz, 1H), 5.00 (dq, J = 17.2, 1.7 Hz, 1H), 4.93 (ddt, J = 10.2, 2.3, 1.3 Hz, 1H), 
4.67 (d, J = 16.0 Hz, 1H), 4.18-3.86 (m, 8H), 2.11-2.01 (m, 2H), 1.82-1.71 (m, 2H), 
1.52-1.34 (m, 6H), 1.26 (t, J = 7.1 Hz, 3H), 1.23 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.1 (d, J = 2.6 Hz), 138.9, 136.0 (d, J = 1.8 Hz), 133.7, 
129.2 (d, J = 2.4 Hz), 120.3 (d, J = 6.0 Hz), 118.1, 114.8 (d, J = 3.1 Hz), 114.2, 113.7 (d, 
J = 5.5 Hz), 77.0 (d, J = 168.9 Hz), 71.0 (d, J = 14.0 Hz), 67.8, 63.1 (d, J = 7.0 Hz), 62.9 (d, 
J = 7.0 Hz), 33.6, 29.1, 28.8, 28.7, 25.8 16.4 (d, J = 5.9 Hz), 16.3 (d, J = 5.8 Hz). 
31P NMR (162 MHz, CDCl3) δ 19.3. 
HRMS: calc for [C22H35NaO5P]+: 433.2120; found: 433.2114. 
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IR: 2984 (m), 1732 (m), 1463 (m), 1394 (s), 1371 (s), 1236 (s), 1164 (s), 1138 (s), 
1017 (s), 977 (s), 796 (s), 763 (s) cm-1. 
3-((Allyloxy)(diethoxyphosphoryl)methyl)phenyl non-8-enoate (179r) 
 
Molecular formula: C23H35O6P MW = 438.50 g.mol-1 
Following the general procedure H, the synthesis was carried out without cesium 
carbonate with 3-([allyloxy][diethoxyphosphoryl]methyl)phenyl non-8-enoate (50 mg, 
0.13 mmol). The mixture was then stirred for 4 h at 50 °C. The crude product was 
purified by flash chromatography over silica gel (CH2Cl2/EtOAc, 90:10 to 80:20) to 
afford the title compound as a yellow oil (45 mg, 0.10 mmol, 82%). 
1H NMR (400 MHz, CDCl3) δ 7.35 (t, J = 7.8 Hz, 1H), 7.29 (dq, J = 7.9, 1.7 Hz, 1H), 7.17 
(q, J = 2.1 Hz, 1H), 7.03 (dq, J = 8.0, 1.9 Hz, 1H), 5.93-5.71 (m, 2H), 5.25 (dq, J = 17.3, 
1.6 Hz, 1H), 5.20 (dq, J = 10.4, 1.4 Hz, 1H), 4.99 (dq, J = 17.2, 1.6 Hz, 1H), 4.93 (ddt, 
J = 10.2, 2.4, 1.4 Hz, 1H), 4.70 (d, J = 16.1 Hz, 1H), 4.20-3.87 (m, 6H), 2.53 (t, J = 7.5 Hz, 
2H), 2.05 (q, J = 7.1 Hz, 2H), 1.73 (p, J = 7.5 Hz, 2H), 1.46-1.31 (m, 6H), 1.23 (td, J = 7.1, 
3.8 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 172.1, 150.9 (d, J = 2.7 Hz), 139.0, 136.6 (d, J = 1.8 Hz), 
133.7, 129.4 (d, J = 2.5 Hz), 125.4 (d, J = 5.7 Hz), 121.7 (d, J = 3.1 Hz), 121.3 (d, 
J = 5.6 Hz), 118.5, 114.4, 76.8 (d, J = 168.9 Hz), 71.4 (d, J = 13.6 Hz), 63.4 (d, J = 7.0 Hz), 
63.2 (d, J = 6.7 Hz), 34.5, 33.8, 29.0, 28.8, 28.8, 24.9, 16.5 (t, J = 5.5 Hz, 2C). 
31P NMR (162 MHz, CDCl3) δ 18.1. 
HRMS: calc for [C23H36O6P]+: 439.2250; found: 439.2260. 
IR: 3077 (s), 2980 (s), 2929 (s), 2858 (s), 1760 (s), 1642 (s), 1609 (s), 1590 (s), 1485 (s), 
1444 (m), 1368 (m), 1256 (m), 1143 (s), 1050 (s), 1023 (s), 964 (s), 913 (s), 791 (m), 
694 (s) cm-1. 
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Diethyl ((cinnamyloxy)(4-methoxyphenyl)methyl)phosphonate (179g') 
 
Molecular formula: C21H27O5P MW = 390.42 g.mol-1 
Following a modified version of general procedure H, the synthesis was carried out 
with hydroxyphosphonate 180g (274 mg, 1.00 mmol) with phenylallyl methyl 
carbonate (192 mg, 1.00 mmol) instead of allyl methyl carbonate. The mixture was 
then stirred for 30 minutes at 50 °C. The crude product was purified by flash column 
chromatography over silica gel (CH2Cl2/EtOAc, 100:0 to 80:20) to afford the title 
compound as a yellow oil (249 mg, 0.64 mmol, 64%). 
1H NMR (400 MHz, CDCl3) δ 7.41-7.23 (m, 7H), 6.92 (d, J = 8.5 Hz, 2H), 6.54 (d, 
J = 16.0 Hz, 1H), 6.24 (ddd, J = 16.0, 6.9, 5.4 Hz, 1H), 4.71 (d, J = 15.3 Hz, 1H) 4.28 (ddd, 
J = 12.7, 5.4, 1.1 Hz, 1H), 4.13-3.91 (m, 5H), 3.82 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.22 (t, 
J = 7.1 Hz, 3H).  
13C NMR (CDCl3, 100.6 MHz) δ 159.9 (d, J = 2.9 Hz), 136.6, 133.6, 129.7 (d, J = 6.0 Hz, 
2C), 128.7 (2C), 128.0 (2C), 126.7, 126.6, 125.2, 114.0 (d, J = 2.1 Hz, 2C), 76.6 (d, 
J = 162.4 Hz), 70.5 (d, J = 14.2 Hz), 63.2 (d, J = 6.9 Hz), 63.0 (d, J = 6.8 Hz), 55.4, 16.6 (d, 
J = 5.7 Hz), 16.5 (d, J = 5.8 Hz). 
HRMS: calc for [C21H28O5P-PhCHCHCH2O]: 258.1021; found: 258.1021. 
IR: 3581, 3039, 2911, 1720, 1609, 1512, 1172, 1031, 972 cm-1. 
 
Diethyl ((cinnamyloxy)(furan-2-yl)methyl)phosphonate (179j') 
 
Molecular formula: C18H23O5P MW = 350.35 g.mol-1 
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Following a modified version of general procedure H, the synthesis was carried out 
with hydroxyphosphonate 179j (272 mg, 1.00 mmol) with phenylallyl methyl 
carbonate (192 mg, 1.00 mmol) instead of allyl methyl carbonate. The mixture was 
then stirred for 30 minutes at 50 °C. The crude product was purified by flash column 
chromatography over silica gel (CH2Cl2/EtOAc, 100:0 to 80:20) to afford the title 
compound as a yellow oil (210 mg, 0.60 mmol, 60%). 
1H NMR (400 MHz, CDCl3) δ 7.47 (m, 1H), 7.38-7.25 (m, 5H), 6.58 (d, J = 16.0 Hz, 1H), 
6.57 (d, J = 3.0 Hz, 1H), 6.41 (m, 1H), 6.23 (ddd, J = 16.0, 7.0, 5.7 Hz, 1H), 4.84 (d, 
J = 16.9 Hz, 1H), 4.31 (ddd, J = 12.6, 5.6, 1.0 Hz, 1H), 4.23-4.06 (m, 5H), 1.32 (t, 
J = 7.1 Hz, 3H), 1.27 (t, J = 7.1 Hz, 3H). 
13C NMR (CDCl3, 100.6 MHz) δ 148.6, 143.5 (d, J = 2.4 Hz), 136.5, 134.1, 128.7 (2C), 
128.1 (2C), 126.7, 124.8, 111.3 (d, J = 6.5 Hz), 111.0 (d, J = 1.8 Hz), 70.9 (d, J = 12.7 Hz), 
70.3 (d, J = 176.2 Hz), 63.4 (d, J = 7.3 Hz), 63.3 (d, J = 7.2 Hz), 16.6 (d, J = 5.8 Hz), 16.5 
(d, J = 5.8 Hz). 
HRMS: calculated for [C18H24O5P-PhCHCHCH2O]: 218.0708; found: 218.0703. 
IR: 3591, 2997, 2912, 1730, 1239, 1027, 979 cm-1. 
 
Diethyl (E)-(3-(4-methoxyphenyl)-1-((2-methylallyl)oxy)allyl)phosphonate (179k') 
 
Molecular formula: C18H27O5P MW = 354.38 g.mol-1 
Following the general procedure H, the synthesis was carried out with 
3-([allyloxy][diethoxyphosphoryl]methyl)phenyl non-8-enoate 180k (200 mg, 
0.67 mmol) and methyl (2-methylallyl) carbonate (87 mg, 0.67 mmol). The mixture was 
then stirred for 2 h at 50 °C. The crude product was purified by flash chromatography 
over silica gel (CH2Cl2/EtOAc, 90:10 to 60:40) to afford the title compound as a yellow 
oil (208 mg, 0.59 mmol, 88%). 
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1H NMR (400 MHz, CDCl3) δ 7.39-7.31 (m, 2H), 6.90-6.83 (m, 2H), 6.64 (ddd, J = 15.9, 
4.5, 1.2 Hz, 1H), 6.07 (ddd, J = 15.9, 7.7, 5.3 Hz, 1H), 4.99 (s, 1H), 4.94 (s, 1H), 4.30 
(ddd, J = 15.5, 7.7, 1.2 Hz, 1H), 4.24-4.12 (m, 4H), 4.11 (d, J = 12.7 Hz, 1H), 3.97 (d, 
J = 12.7 Hz, 1H), 3.81 (s, 3H), 1.76 (s, 3H), 1.31 (td, J = 7.1, 3.5 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 159.8, 141.5, 134.5 (d, J = 13.5 Hz), 129.1 (d, J = 2.6 Hz), 
128.1 (d, J = 1.8 Hz, 2C), 120.2 (d, J = 4.4 Hz), 114.2 (2C), 113.6, 75.9 (d, J = 170.8 Hz), 
73.8 (d, J = 12.1 Hz), 63.2 (d, J = 7.0 Hz), 62.9 (d, J = 6.9 Hz), 55.5, 19.7, 16.7 (t, J = 5.5 
Hz, 2C). 
31P NMR (162 MHz, CDCl3) δ 20.0. 
 
4.4.4. Additional allylation products 
Diethyl (hydroxy(4-nitrophenyl)methyl)phosphonate (180u) 
 
Molecular formula: C11H16NO6P MW = 289.22 g.mol-1 
A mixture of aldehyde (774 mg, 5.12 mmol, 1.10 equiv.), diethyl phosphite (600 µL, 
4.66 mmol, 1.0 equiv.) and triethylamine (65 µL, 0.47 mmol, 10 mol%) in toluene 
(4.7 mL) was stirred at 50 °C for 3 h. The reaction mixture was then concentrated 
under reduced pressure to a volume of ca. 2 mL. Purification by flash chromatography 
over silica gel (CH2Cl2/EtOAc 80:20 to 60:40) afforded the title compound as a yellow 
oil (1.05 g, 3.63 mmol, 78%). 
1H NMR (400 MHz, CDCl3) δ 8.22 (d, J = 8.7 Hz, 2H), 7.67 (d, J = 8.7 Hz, 2H), 5.17 (d, 
J = 12.2 Hz, 1H), 4.17-4.02 (m, 4H), 1.29 (t, J = 7.1 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 147.7 (d, J = 3.5 Hz), 144.3 (d, J = 2.5 Hz), 127.8 (d, 
J = 5.1 Hz, 2C), 123.4 (2C), 70.3 (d, J = 158.0 Hz), 64.1 (d, J = 7.1 Hz), 63.5 (d, J = 7.5 Hz), 
16.6 (d, J = 4.8 Hz), 16.5 (d, J = 4.8 Hz). 
31P NMR (162 MHz, CDCl3) δ 19.7. 
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Diethyl (1-(allyloxy)-1-(4-nitrophenyl)but-3-en-1-yl)phosphonate (179u) 
 
Molecular formula: C17H24NO6P MW = 369.35 g.mol-1 
Following a modified version of general procedure H, diethyl (hydroxyl[4-
nitrophenyl]methyl)phosphonate (100 mg, 0.35 mmol, 1.0 equiv.) was charged in a vial 
with allyl methyl carbonate (39 μL, 0.35 mmol, 1.0 equiv.), Pd2(dba)3 (7.9 mg, 8.6 µmol, 
0.025 equiv.), triphenylphosphine (9.1 mg, 0.035 mmol, 0.10 equiv.), cesium carbonate 
(17.0 mg, 0.086 mmol, 0.25 equiv.) and toluene (0.4 mL). The reaction mixture was 
stirred for 30 min at 50 °C. Allyl methyl carbonate (78.6 μL, 0.69 mmol, 2 equiv.) were 
then added and the resulting mixture was stirred at 100 °C for 12 h. Upon completion, 
the mixture was filtered over a pad of Celite and purified by flash column 
chromatography over silica gel (CH2Cl2/EtOAc 90:10 to 70:30) to afford the bis-allylated 
product as a yellow oil (54 mg, 0.14 mmol, 40 %) of sufficient purity to be used in the 
next step. 
1H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 8.2 Hz, 2H), 7.80-7.72 (m, 2H), 5.96 (ddt, 
J = 17.3, 10.5, 5.2 Hz, 1H), 5.63 (ddt, J = 17.0, 10.3, 6.7 Hz, 1H), 5.36 (dq, J = 17.3, 
1.7 Hz, 1H), 5.20 (dq, J = 10.3, 1.6 Hz, 1H), 5.11 (dq, J = 17.0, 1.6 Hz, 1H), 5.08-5.02 (m, 
1H), 4.48-4.40 (m, 1H), 4.20-4.07 (m, 3H), 4.03-3.88 (m, 2H), 3.36-3.25 (m, 1H), 
3.06-2.94 (m, 1H), 1.28 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 147.3 (d, J = 3.2 Hz), 146.3, 134.3, 131.4 (d, J = 11.2 Hz), 
128.6 (d, J = 4.1 Hz, 2C), 123.0 (d, J = 2.5 Hz, 2C), 119.4, 116.6, 81.2 (d, J = 159.5 Hz), 
65.8 (d, J = 4.2 Hz), 63.6 (d, J = 7.4 Hz), 63.2 (d, J = 7.5 Hz), 37.2 (d, J = 4.0 Hz), 16.6 (d, 
J = 5.5 Hz), 16.4 (d, J = 5.6 Hz). 
31P NMR (162 MHz, CDCl3) δ 19.8. 
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Diethyl ((4-(benzylamino)phenyl)(hydroxy)methyl)phosphonate (193) 
 
Molecular formula: C18H24NO4P MW = 349.37 g.mol-1 
4-Chlorobenzaldehyde (200 mg, 1.42 mmol, 1.0 equiv.), benzyl amine (155 µL, 
1.42 mmol, 1.0 equiv.), diethyl phosphite (183 µL, 1.42 mmol, 1.0 equiv) and CH2Cl2 
(1 mL) were charged in a microwave tube. The reaction mixture was stirred at 80 °C for 
45 min under microwave irradiation then at 90 °C for 30 min. Purification by flash 
chromatography over silica gel (CH2Cl2/Et2O 50:50) afforded the title compound as a 
yellow oil (290 mg, 0.69 mmol, 55%). 
1H NMR (400 MHz, CDCl3) δ 7.34-7.22 (m, 5H), 7.19-7.14 (m, 2H), 6.72-6.66 (m, 2H), 
4.17-4.07 (m, 2H), 4.02-3.90 (m, 2H), 3.88-3.79 (m, 2H), 3.55 (d, J = 13.3 Hz, 1H), 1.31 
(t, J = 7.0 Hz, 3H), 1.17 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 156.9, 139.3, 129.8 (d, J = 6.4 Hz, 2C), 128.6 (2C), 128.5 
(2C), 127.3, 125.50, 116.2 (d, J = 2.5 Hz, 2C), 63.5 (d, J = 7.1 Hz), 63.1 (d, J = 7.2 Hz), 
58.7 (d, J = 156.4 Hz), 51.1 (d, J = 17.1 Hz), 16.6 (d, J = 5.6 Hz), 16.4 (d, J = 5.8 Hz). 
31P NMR (162 MHz, CDCl3) δ 23.6. 
MS-ESI: m/z 350 ([M+H]+), 212 ([M-PO(OEt)2]+). 
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Diethyl ((4-(allyl(benzyl)amino)phenyl)(hydroxy)methyl)phosphonate (194) 
 
Molecular formula: C21H28NO4P MW = 389.43 g.mol-1 
This compound was prepared following general procedure H with 193 (78 mg, 
0.21 mmol). The mixture was stirred for 5 h at 50 °C. The crude product was purified 
by flash chromatography over silica gel (CH2Cl2/EtOAc, 90:10 to 70:30) to afford the 
title compound as a yellow oil (63 mg, 0.21 mmol, quantitative). 
1H NMR (400 MHz, CDCl3) δ 7.31-7.12 (m, 7H), 6.85 (d, J = 8.4 Hz, 2H), 5.99 (ddt, 
J = 17.3, 10.5, 5.3 Hz, 1H), 5.35 (dq, J = 17.3, 1.7 Hz, 1H), 5.21 (dd, J = 10.5, 1.7 Hz, 1H), 
4.47 (d, J = 5.3 Hz, 2H), 4.07-3.94 (m, 2H), 3.94-3.83 (m, 2H), 3.80-3.66 (m, 2H), 3.46 (d, 
J = 13.3 Hz, 1H), 2.32 (br. s, 1H), 1.20 (t, J = 7.1 Hz, 3H), 1.06 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 158.5 (d, J = 3.1 Hz), 139.5, 133.3, 129.9 (d, J = 6.3 Hz, 2C), 
128.4 (4C), 127.8 (d, J = 4.2 Hz), 127.17, 117.8, 114.8 (d, J = 2.4 Hz, 2C), 68.9, 63.0 (d, 
J = 7.1 Hz), 62.8 (d, J = 6.9 Hz), 58.9 (d, J = 155.1 Hz), 51.2 (d, J = 17.4 Hz), 16.6 (d, 
J = 5.9 Hz), 16.4 (d, J = 5.7 Hz). 
31P NMR (162 MHz, CDCl3) δ 23.8. 
MS-ESI: m/z 390 ([M+H]+), 252 ([M-PO(OEt)2]+). 
 
 
  
P(O)(OEt)2
OH
N
  
 
268 
Diethyl ((benzylamino)(4-methoxyphenyl)methyl)phosphonate (195) 
 
Molecular formula: C19H26NO4P MW = 363.39 g.mol-1 
4-Methoxybenzaldehyde (200 mg, 1.47 mmol 1.0 equiv.), benzyl amine (160 µL, 
1.47 mmol, 1.0 equiv.) and diethyl phosphite (189 µL, 1.47 mmol, 1.0 equiv) were 
charged in a microwave tube. The reaction mixture was stirred at 80 °C for 15 min 
under microwave irradiation. Purification by flash chromatography over silica gel 
(CH2Cl2/Et2O 90:10 to 50:50) afforded the title compound as a pale oil (429 mg, 
1.18 mmol, 80%). Spectral data matched those reported in the literature.[355] 
1H NMR (400 MHz, CDCl3) δ 7.38-7.31 (m, 2H), 7.31-7.20 (m, 5H), 6.91 (d, J = 8.5 Hz, 
2H), 4.16-3.90 (m, 4H), 3.89-3.77 (m, 5H), 3.54 (d, J = 13.3 Hz, 1H), 2.04 (br. s, 1H), 1.28 
(t, J = 7.1 Hz, 3H), 1.15 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.5 (d, J = 3.0 Hz), 139.4, 130.0 (d, J = 6.2 Hz, 2C), 128.5 
(4C), 127.5, 127.3, 114.1 (d, J = 2.3 Hz, 2C), 63.0 (d, J = 7.2 Hz), 62.9 (d, J = 6.9 Hz), 58.9 
(d, J = 155.3 Hz), 55.4, 51.2 (d, J = 17.2 Hz), 16.6 (d, J = 5.9 Hz), 16.5 (d, J = 5.9 Hz). 
31P NMR (162 MHz, CDCl3) δ 23.8. 
MS-ESI: m/z 364 ([M+H]+), 226 ([M-PO(OEt)2]+). 
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Diethyl ((allyl(benzyl)amino)(4-methoxyphenyl)methyl)phosphonate (196) 
 
Molecular formula: C22H30NO4P MW = 403.46 g.mol-1 
This compound was prepared following general procedure H with 195 (100 mg, 
0.28 mmol). The mixture was stirred for 12 h at 50 °C. The crude product was purified 
by flash chromatography over silica gel (CH2Cl2/EtOAc, 95:5 to 50:50) to afford the title 
compound as a yellow oil (22 mg, 0.06 mmol, 20%). Further elution afforded remaining 
starting a-aminophosphonate 195 (72 mg, 0.20 mmol, 72%). 
1H NMR (400 MHz, CDCl3) δ 7.43-7.36 (m, 4H), 7.34-7.28 (m, 2H), 7.26-7.21 (m, 1H), 
6.91 (d, J = 8.6 Hz, 2H), 5.85 (dddd, J = 17.3, 10.2, 8.3, 4.2 Hz, 1H), 5.22 (d, J = 17.3 Hz, 
1H), 5.16 (d, J = 10.2 Hz, 1H), 4.33-4.21 (m, 3H), 4.17 (d, J = 26.0 Hz, 1H), 3.90 (dt, 
J = 10.2, 7.1 Hz, 1H), 3.83 (s, 3H), 3.80-3.64 (m, 2H), 3.16 (d, J = 13.8 Hz, 1H), 2.79 (dd, 
J = 14.1, 8.3 Hz, 1H), 1.38 (t, J = 7.1 Hz, 3H), 1.02 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.4, 139.8, 136.9, 132.3 (d, J = 9.0 Hz, 2C), 129.0 (2C), 
128.4 (2C), 127.0, 124.1, 117.7, 113.7 (2C), 62.7 (d, J = 7.0 Hz), 62.3 (d, J = 6.8 Hz), 59.9 
(d, J = 163.4 Hz), 55.4, 55.1 (d, J = 8.8 Hz), 54.3 (d, J = 8.1 Hz), 16.8 (d, J = 6.3 Hz), 16.4 
(d, J = 5.5 Hz). 
31P NMR (162 MHz, CDCl3) δ 23.8. 
MS-ESI: m/z 404 ([M+H]+), 266 ([M-PO(OEt)2]+). 
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Diethyl (1-hydroxy-1-phenylethyl)phosphonate (198) 
 
Molecular formula: C12H19O4P MW = 258.25 g.mol-1 
Diethyl phosphite (822 µL, 6.38 mmol, 1.2 equiv.) and n-BuLi (2.5 M solution in 
hexanes, 2.1 µL, 5.3 µmol, 0.1 mol%) were mixed under dry nitrogen. After stirring for 
5 min, acetophenone (620 µL, 5.32 mmol,  1.0 equiv.) was added at 10 °C and the 
reaction was stirred for 5 min. The reaction was quenched by adding EtOAc (2 mL) and 
H2O (2 mL). The layers were separated and the aqueous phase was extracted with 
EtOAc (2 x 5 mL). The pooled organic layers were dried over anhydrous MgSO4 and 
concentrated. The crude was co-evaporated with toluene several times to remove 
traces of phosphite. Purification by flash chromatography over silica gel (PE/EtOAc 
50:50 to 33:66) afforded the title compound as white crystals (1.3 g, 5.2 mmol, 98%). 
Spectral data matched those reported in the literature.[301] 
1H NMR (400 MHz, CDCl3) δ 7.63-7.58 (m, 2H), 7.35 (t, J = 7.3 Hz, 2H), 7.28 (dd, J = 7.3, 
1.7 Hz, 1H), 4.15-3.80 (m, 4H), 3.66 (br.s, 1H), 1.82 (d, J = 15.5 Hz, 3H), 1.25 (t, 
J = 7.1 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 141.1, 128.1 (d, J = 2.5 Hz, 2C), 127.5 (d, J = 2.9 Hz), 126.0 
(d, J = 4.3 Hz, 2C), 73.6 (d, J = 158.6 Hz), 63.4 (d, J = 4.3 Hz), 63.4 (d, J = 4.4 Hz), 26.1 (d, 
J = 3.9 Hz), 16.5 (d, J = 5.7 Hz), 16.4 (d, J = 6.0 Hz). 
 31P NMR (162 MHz, CDCl3) δ 24.1. 
m.p. = 77-78 °C. 
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Diethyl (1-(allyloxy)-1-phenylethyl)phosphonate (199) 
 
Molecular formula: C15H23O4P MW = 298.32 g.mol-1 
To a solution of 𝛼-hydroxyphosphonate 198 (50 mg, 0.19 mmol, 1.0 equiv.) in Et2O 
(0.5 M solution) were added Pd2(dba)3 (4.4 mg, 4.8 µmol, 2.5 mol%), 
triphenylphosphine (5.6 mg, 21 µmol, 10 mol%) and cesium carbonate (15 mg, 
48 µmol, 25 mol%). Allyl methyl carbonate (1.00 equiv.) was added the resulting 
mixture was stirred at room temperature for 2 h. The reaction mixture was then 
filtered over a pad of Celite and concentrated under reduced pressure. CH2Br2 (14 µL, 
0.20 mmol) was added to the crude solution in CDCl3, and the yield was determined by 
1H NMR analysis to be 27%. An analytically pure sample was obtained by flash 
chromatography over silica gel (CH2Cl2/EtOAc 90:10 to 80:20). 
1H NMR (400 MHz, CDCl3) δ 7.57-7.49 (m, 2H), 7.41-7.33 (m, 2H), 7.33-7.27 (m, 1H), 
5.94 (ddt, J = 17.2, 10.4, 5.2 Hz, 1H), 5.32 (dq, J = 17.2, 1.6 Hz, 1H), 5.15 (ddd, J = 10.4, 
3.0, 1.6 Hz, 1H), 4.16-3.93 (m, 5H), 3.85-3.78 (m, 1H), 1.89 (d, J = 15.9 Hz, 3H), 1.26-
1.18 (m, 6H). 
13C NMR (101 MHz, CDCl3) δ 138.7, 135.0, 128.2 (d, J = 2.4 Hz, 2C), 127.9 (d, J = 3.2 Hz), 
127.8 (d, J = 4.5 Hz, 2C), 116.2, 79.5 (d, J = 169.9 Hz), 64.2 (d, J = 12.7 Hz), 63.4 (d, 
J = 7.1 Hz), 63.3 (d, J = 6.9 Hz), 19.8, 16.5 (d, J = 5.1 Hz), 16.5 (d, J = 5.2 Hz). 
31P NMR (162 MHz, CDCl3) δ 21.7. 
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4.4.5. Synthesis of the oxacycles 
Diethyl (2,5-dihydrofuran-2-yl)phosphonate (178k) 
 
Molecular formula: C8H15O4P MW = 206.18 g.mol-1 
A sealable tube was charged with diene 179k (40.0 mg, 0.170 mmol, 1.00 equiv.) 
dissolved in CH2Cl2 (1.7 mL). Grubbs II catalyst (5.8 mg, 0.010 mmol, 0.04 equiv.) was 
added to the resulting solution and the tube was sealed. The solution was stirred at 
45 °C for 1 h. The solvent was then removed under reduced pressure. The crude was 
purified by flash chromatography over silica gel (CH2Cl2/EtOAc, 90:10 to 60:40) to 
afford the title compound as a yellow oil (33.0 mg, 0.150 mmol, 89%). 
1H NMR (400 MHz, CDCl3) δ 6.08-6.00 (m, 1H, H2), 5.90 (m, 1H, H3), 5.05 (m, 1H, H1), 
4.75 (m, 2H, H4), 4.14 (m, 4H), 1.32 (t, J = 6.2 Hz, 3H), 1.28 (d, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 129.2 (d, J = 11.3 Hz, C2), 123.5 (d, J = 5.0 Hz, C3), 82.3 (d, 
J = 168.0 Hz, C1), 77.0 (C4), 63.1 (d, J = 7.0 Hz), 62.6 (d, J = 7.0 Hz), 16.6 (d, J = 2.5 Hz), 
16.6 (d, J = 2.7 Hz). 
31P NMR (162 MHz, CDCl3) δ 19.0. 
HRMS: calc for [C8H15NaO4P]+: 229.0606; found: 228.9661. 
IR: 2984 (m), 1732 (m), 1463 (m), 1394 (s), 1371 (s), 1236 (s), 1164 (s), 1138 (s), 
1017 (s), 977 (s), 796 (s), 763 (s) cm-1. 
 
Diethyl (2-(4-nitrophenyl)-3,6-dihydro-2H-pyran-2-yl)phosphonate (178u) 
 
Molecular formula: C15H20NO6P MW = 341.30 g.mol-1 
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A sealable tube was charged with diene 179u (30.0 mg, 0.0810 mmol, 1.0 equiv.) 
dissolved in CH2Cl2 (1.6 mL). Grubbs II catalyst (2.8 mg, 0.0030 mmol, 0.04 equiv.) was 
added to the resulting solution and the tube was sealed. The solution was stirred at 
45 °C for 2 h. The solvent was then removed under reduced pressure. The crude was 
purified by flash column chromatography over silica gel (Hexane/Et2O, 50:50) to afford 
the title compound as a colorless oil (24.0 mg, 0.067 mmol, 82%). 
1H NMR (400 MHz, CDCl3) δ 8.21 (d, J = 8.9 Hz, 2H), 7.71 (dd, J = 8.9, 2.3 Hz, 2H), 
5.91-5.82 (m, 1H), 5.57 (d, J = 10.4 Hz, 1H), 4.31 (dq, J = 17.0, 3.0 Hz, 1H), 4.18-3.94 (m, 
5H), 3.15-3.03 (m, 1H), 2.84 (dq, J = 17.7, 6.1, 3.0 Hz, 1H), 1.24 (td, J = 7.1, 3.5 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 147.6 (d, J = 3.6 Hz), 144.6, 129.2 (d, J = 4.5 Hz, 2C), 125.9, 
123.3 (d, J = 2.5 Hz, 2C), 121.4 (d, J = 9.9 Hz), 75.8, 63.7 (t, J = 7.7 Hz, 2C), 61.6 (d, 
J = 10.5 Hz), 27.7, 16.5 (dd, J = 5.7, 2.1 Hz, 2C). 
31P NMR (162 MHz, CDCl3) δ 18.8. 
HRMS: calc for [C15H21NO6P]+: 342.1106; found: 342.1110.  
IR: 2982 (s), 2926 (s), 2851 (s), 1604 (s), 1519 (s), 1444 (s), 1390 (s), 1346 (s), 1252 (s), 
1163 (m), 1017 (m), 967 (s), 855 (s), 794 (s), 742 (s), 693 (m), 660 (s) cm-1. 
 
Diethyl (2,3,4,7-tetrahydrooxepin-2-yl)phosphonate (178m) 
 
Molecular formula: C10H19O4P MW = 234.23 g.mol-1 
A µW tube was charged with diene 178m (50.0 mg, 0.191 mmol, 1.00 equiv.) dissolved 
in CH2Cl2 (3.8 mL). Grubbs II catalyst (8.1 mg, 0.0096 mmol, 0.05 equiv.) was added to 
the resulting solution and the tube was sealed. The solution was stirred at 45 °C for 
1 h. The solvent was then removed under reduced pressure. The crude was purified by 
flash chromatography over silica gel (CH2Cl2/EtOAc, 90:10 to 80:20) to afford the title 
compound as a dark oil (36.4 mg, 0.155 mmol, 81%).  
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1H NMR (400 MHz, CDCl3) δ 5.84-5.74 (m, 1H), 5.66-5.55 (m, 1H), 4.54 (ddq, J = 16.1, 
4.0, 1.8 Hz, 1H), 4.17 (m, 4H), 4.08 (ddq, J = 16.1, 3.7, 1.9 Hz, 1H), 3.92 (ddd, J = 11.7, 
9.3, 4.8 Hz, 1H), 2.59-2.46 (m, 1H), 2.28-2.17 (m, 1H), 2.17-2.04 (m, 2H), 1.33 (td, 
J = 7.1, 1.8 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 131.3, 129.18, 76.9 (d, J = 166.7 Hz), 69.3 (d, J = 12.2 Hz), 
62.8 (d, J = 6.8 Hz), 62.4 (d, J = 6.8 Hz), 28.7 (d, J = 2.1 Hz), 27.0 (d, J = 15.6 Hz), 16.7 (d, 
J = 3.2 Hz), 16.7 (d, J = 3.2 Hz). 
31P NMR (162 MHz, CDCl3) δ 22.4. 
HRMS: calc for [C10H19NaO4P]+: 257.0919; found: 257.0913. 
IR: 2984 (m), 1732 (m), 1463 (m), 1394 (s), 1371 (s), 1236 (s), 1164 (s), 1138 (s), 
1017 (s), 977 (s), 796 (s), 763 (s) cm-1. 
 
Diethyl (1,3-dihydrobenzo[c]oxepin-1-yl)phosphonate (178n) 
 
Molecular formula: C14H19O4P MW = 282.28 g.mol-1 
A µW tube was charged with diene 178n (86.3 mg, 0.306 mmol, 1.00 equiv.) dissolved 
in CH2Cl2 (6.5 mL). Hoveyda-Grubbs II catalyst (10.1 mg, 0.016 mmol, 0.05 equiv.) was 
added to the resulting solution and the tube was sealed. The solution was stirred at 
45 °C for 1 h. The solvent was then removed under reduced pressure. The crude was 
purified by flash chromatography over silica gel (Toluene/EtOAc, 80:20 to 50:50) to 
afford the title compound as a dark oil (80.0 mg, 0.282 mmol, 92%). 
1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 7.6 Hz, 1H), 7.30-7.24 (m, 2H), 7.21 (ddd, 
J = 7.5, 6.0, 2.8 Hz, 1H), 6.53 (dt, J = 12.3, 2.0 Hz, 1H), 5.88 (dt, J = 12.3, 3.0 Hz, 1H), 
4.86 (d, J = 18.1 Hz, 1H), 4.71 (ddd, J = 18.1, 3.0, 2.0 Hz, 1H), 4.60 (ddd, J = 18.1, 3.0, 
2.0 Hz, 1H), 4.35-4.13 (m, 4H), 1.34 (td, J = 7.1, 3.1 Hz, 6H). 
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13C NMR (101 MHz, CDCl3) δ 136.9 (d, J = 14.5 Hz), 135.7 (d, J = 5.0 Hz), 131.9, 131.2 (d, 
J = 1.4 Hz), 129.4, 128.3, 127.4 (d, J = 4.6 Hz), 127.1, 77.0 (d, J = 168.1 Hz), 73.6 (d, 
J = 9.9 Hz), 63.3 (d, J = 6.9 Hz), 62.8 (d, J = 6.7 Hz), 16.7 (dd, J = 5.7, 1.5 Hz, 2C). 
31P NMR (162 MHz, CDCl3) δ 20.0. 
HRMS: calc for [C14H20O4P]+: 283.1099; found: 283.1094. 
IR: 2981 (m), 2870 (s), 1448 (m), 1253 (s), 1095 (m), 1054 (s), 1033 (m), 971 (s), 
780 (s) cm-1. 
 
Diethyl (3,4,5,6,7,10-hexahydro-2H,12H-benzo[b][1,5]dioxacyclotetradecin-12-
yl)phosphonate (178o) 
 
Molecular formula: C20H31O5P MW = 382.44 g.mol-1 
A round-bottomed flask was charged with diene 179o (70 mg, 0.17 mmol, 1.00 equiv.) 
dissolved in CH2Cl2 (170 mL) and the solution was heated at 50 °C. A solution of 
Grubbs II catalyst (8.7 mg, 0.010 mmol, 0.060 equiv.) in CH2Cl2 (4 mL) was added in 
four portions over 4 h. The solution was then concentrated under reduced pressure 
and the crude mixture was purified by flash chromatography over silica gel 
(Hexane/EtOAc, 70:30 to 30:70) to afford a mixture of E/Z products as a brown oil 
(60 mg, 0.16 mmol, E/Z = 83:17, 92%). 
1H NMR (400 MHz, CDCl3) δ 7.61 (dt, J = 7.7, 2.2 Hz, 1H, minor), 7.53 (dt, J = 7.7, 2.2 Hz, 
1H, major), 7.27-7.20 (m, 1H), 6.97 (t, J = 7.5 Hz, 1H), 6.81 (d, J = 8.3 Hz, 1H), 5.56 (d, 
J = 14.8 Hz, 1H, major), 5.53-5.41 (m, 2H), 5.30 (d, J = 17.0 Hz, 1H, minor), 4.35-3.84 (m, 
8H), 2.20-2.02 (m, 2H), 2.02-1.30 (m, 8H), 1.26 (t, J = 7.0 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 156.5 (d, J = 6.4 Hz), 137.5, 129.3 (d, J = 4.3 Hz), 129.1 (d, 
J = 3.4 Hz), 127.1, 123.1 (d, J = 1.9 Hz), 120.4 (d, J = 3.1 Hz), 110.7 (d, J = 2.3 Hz), 69.7 
(d, J = 12.0 Hz), 67.6, 66.1 (d, J = 171.5 Hz), 62.8 (d, J = 6.8 Hz, 2C), 31.0, 27.8, 27.3, 
26.5, 26.0, 16.6 (d, J = 6.0 Hz), 16.5 (d, J = 6.0 Hz). 
P(O)(OEt)2
O
O
  
 
276 
31P NMR (162 MHz, CDCl3) δ 20.5 (major), 19.8 (minor). 
HRMS: calc for [C20H32O5P]+: 383.1987; found: 383.1981. 
IR: 2917 (m), 2849 (s), 1734 (s), 1632 (m), 1463 (s), 1257 (s), 1222 (m), 1054 (s), 
1083 (m), 1019 (s), 747 (s) cm-1. 
 
Diethyl 2,12-dioxa-1(1,3)-benzenacyclotridecaphan-9-en-13-ylphosphonate (178p) 
 
Molecular formula: C20H31O5P MW = 382.44 g.mol-1 
A round-bottomed flask was charged with diene 3s (25.0 mg, 0.061 mmol, 1.00 equiv.) 
dissolved in CH2Cl2 (60 mL) and the solution was heated at 50 °C. A solution of 
Grubbs II catalyst (5.2 mg, 0.006 mmol, 0.10 equiv.) in CH2Cl2 (4 mL) was added in four 
portions over 4 h. The solution was then concentrated under reduced pressure and the 
crude mixture was purified by flash chromatography over silica gel (Toluene/EtOAc, 
70:30) to afford a mixture of E/Z products as a dark oil (16 mg, 0.042 mmol, 
E/Z = 77:23, 69%). 
1H NMR (400 MHz, CDCl3) δ 7.22 (t, J = 7.9 Hz, 1H), 7.13 (dq, J = 4.2, 2.2 Hz, 1H), 6.97 
(d, J = 7.6 Hz, 1H), 6.90-6.80 (m, 1H), 5.66-5.34 (m, 2H), 4.67 (d, J = 16.9 Hz, 1H), 
4.39-4.31 (m, 1H), 4.30-4.21 (m, 1H), 4.16-3.95 (m, 5H), 3.78 (dd, J = 11.9, 5.7 Hz, 1H), 
2.06-1.90 (m, 2H), 1.77-1.64 (m, 2H), 1.47-1.28 (m, 6H), 1.25 (td, J = 7.2, 1.5 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 159.3 (d, J = 2.5 Hz), 137.1, 135.3, 129.3, 127.1, 121.0 (d, 
J = 5.6 Hz), 116.7, 115.0 (d, J = 5.8 Hz), 78.8 (d, J = 168.7 Hz), 73.1 (d, J = 14.8 Hz), 68.2, 
63.3 (d, J = 7.0 Hz), 63.2 (d, J = 6.7 Hz), 31.2, 29.4, 28.2, 27.0, 25.4, 16.6 (t, J = 5.2 Hz, 
2C). 
31P NMR (162 MHz, CDCl3) δ 19.2 (major), 18.8 (minor). 
HRMS: calc for [C20H31NaO5P]+: 405.1807; found: 405.1801. 
O
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IR: 2926 (s), 2856 (s), 1734 (s), 1669 (s), 1601 (m), 1446 (m), 1392 (s), 1255 (s), 
1157 (s), 1022 (m), 964 (s), 787 (s), 725 (m), 694 (s) cm-1. 
 
Diethyl (3-oxo-2,13-dioxa-1(1,3)-benzenacyclotetradecaphan-10-en-14-
yl)phosphonate (178q) 
 
Molecular formula: C21H31O6P MW = 410.45 g.mol-1 
A round-bottomed flask was charged with diene 3t (60 mg, 0.14 mmol, 1.00 equiv.) 
dissolved in CH2Cl2 (135 mL) and the solution was heated at 50 °C. A solution of 
Grubbs II catalyst (7.0 mg, 0.0080 mmol, 0.060 equiv.) in CH2Cl2 (4 mL) was added in 
four portions over 4 h. The solution was then concentrated under reduced pressure 
and the crude mixture was purified by flash chromatography over silica gel 
(Hexane/EtOAc, 70:30 to 30:70) to afford a mixture of E/Z products as a yellow oil 
(56 mg, 0.14 mmol, E/Z = 78:22, quantitative). 
1H NMR (400 MHz, CDCl3) δ 6.97 (m, 4H), 5.64-5.37 (m, 2H), 4.71 (dd, J = 17.6 Hz, 1H, 
major), 4.67 (dd, J = 17.4 Hz, 1H, minor), 4.21-3.91 (m, 5H), 3.69 (m, 1H), 2.57-2.32 (m, 
2H), 2.09-1.90 (m, 2H), 1.87-1.65 (m, 3H), 1.48-1.31 (m, 3H), 1.26-1.12 (m, 8H). 
13C NMR (101 MHz, CDCl3) δ 173.1, 151.1 (d, J = 2.7 Hz), 137.1 (J = 1.9 Hz), 135.0, 129.3 
(d, J = 2.8 Hz), 126.4, 125.7 (d, J = 4.7 Hz), 121.6 (d, J = 3.2 Hz), 120.9 (d, J = 5.8 Hz), 
77.5 (d, J = 168.5 Hz), 71.7 (d, J = 15.1 Hz), 63.5 (d, J = 7.0 Hz), 63.2 (d, J = 6.9 Hz), 35.0, 
32.3, 30.1, 28.7, 28.0, 24.3, 16.5 (d, J = 5.7 Hz, 2C). 
31P NMR (162 MHz, CDCl3) δ 18.5 (major), 18.0 (minor). 
HRMS: calc for [C21H32O6P]+: 411.1937; found: 411.1934. 
IR: 2980 (s), 2929 (s), 2856 (s), 1756 (s), 1589 (s), 1482 (s), 1443 (s), 1390 (m), 1255 (s), 
1217 (s), 1139 (m), 1020 (s), 960 (s), 838 (s), 791 (s), 746 (m), 696 (s) cm-1. 
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4.4.6. Claisen rearrangement 
Diethyl ((1E)-1-(prop-1-en-1-yloxy)prop-1-en-1-yl)phosphonate (202) 
 
Molecular formula: C10H19O4P MW = 234.23 g.mol-1 
To a solution of diene 179k (50 mg, 0.21 mmol, 1.0 equiv.) in THF (0.4 mL) was added 
Ru(PPh3)3(CO)(Cl)H (11 mg, 11 µmol, 5 mol%) and the reaction mixture was stirred at 
130 °C in a sealed tube for 120 min. The mixture was concentrated under reduced 
pressure and purification by flash chromatography over silica gel (CH2Cl2/EtOAc 75:25) 
afforded the title compound as a mixture of Z/E isomers as a yellow oil (22 mg, 
94 µmol, Z/E = 78:22, 44%). The configuration of the vinyl phosphonate was assigned 
based on the 1H-31P coupling constants.[356] 
1H NMR major isomer (400 MHz, CDCl3) δ 6.22-6.17 (m, 1H), 6.08 (dq, J = 5.8, 1.8 Hz, 
1H), 4.57 (qd, J = 6.9, 5.8 Hz, 1H), 4.16-4.03 (m, 4H), 1.76 (dd, J = 7.1, 3.0 Hz, 3H), 1.65 
(dd, J = 6.9, 1.8 Hz, 3H), 1.32 (t, J = 7.1 Hz, 6H). 
1H NMR minor isomer (400 MHz, CDCl3) δ 6.24 (dq, J = 10.1, 7.0 Hz, 1H), 6.22-6.17 (m, 
1H), 5.06 (dq, J = 12.2, 6.9 Hz, 1H), 4.16-4.03 (m, 4H), 1.73 (dd, J = 7.0, 3.0 Hz, 3H), 1.55 
(dd, J = 6.9, 1.7 Hz, 3H), 1.32 (t, J = 7.1 Hz, 6H). 
13C NMR major isomer (101 MHz, CDCl3) δ. 145.7 (d, J = 221.7 Hz), 144.1 (d, J = 2.3 Hz), 
129.2 (d, J = 31.8 Hz), 103.6, 62.6 (d, J = 5.7 Hz, 2C), 16.4 (d, J = 6.2 Hz, 2C), 11.3 (d, 
J = 13.1 Hz), 9.1. 
13C NMR minor isomer (101 MHz, CDCl3) δ 144.4 (d, J = 223.3 Hz), 144.4 (d, J = 2.0 Hz), 
130.2 (d, J = 31.8 Hz), 103.3, 62.4 (d, J = 5.6 Hz, 2C), 16.4 (d, J = 6.2 Hz, 2C), 12.1, 11.5 
(d, J = 13.3 Hz).  
31P NMR (162 MHz, CDCl3) δ 10.4 (minor), 10.2 (major). 
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Diethyl (E)-(3-(4-methoxyphenyl)-4-methyl-5-oxopent-1-en-1-yl)phosphonate (203k) 
 
Molecular formula: C17H25O5P MW = 340.36 g.mol-1 
Allyloxyphosphonate 179k (50 mg, 0.15 mmol, 1.0 equiv.) and Ru(PPh3)3(CO)(Cl)H 
(7.0 mg, 7.3 µmol, 5 mol%) were charged in a sealable tube. The tube was evacuated 
under high-vacuum and back-filled with nitrogen (3 times), then toluene (0.7 mL) was 
added and the tube was sealed. The reaction mixture was stirred at 115 °C for 30 min 
under microwave irradiation. The resulting solution was concentrated under reduced 
pressure. Purification by flash chromatography over silica gel (CH2Cl2/EtOAc 90:10 to 
60:40) afforded the title compound as a mixture of diastereoisomers in a 2:1 ratio 
(27 mg, 76% purity, 0.060 mmol, 41%). 
1H NMR (400 MHz, CDCl3) δ 9.68 (d, J = 2.3 Hz, 1H, minor), 9.50 (d, J = 2.3 Hz, 1H, 
major), 7.13-7.03 (m, 2H), 6.95-6.77 (m, 3H), 5.65 (dddd, J = 19.4, 17.1, 8.4, 1.3 Hz, 1H), 
4.11-3.91 (m, 4H), 3.78 (d, J = 4.8 Hz, 3H), 3.69-3.57 (m, 1H), 2.91-2.77 (m, 1H), 
1.35-1.21 (m, 6H), 1.14 (d, J = 7.0 Hz, 3H, major), 0.94 (d, J = 7.1 Hz, 3H, minor). 
31P NMR (162 MHz, CDCl3) δ 17.9 (minor), 17.8 (major). 
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